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The principal purpose of this study was to identify, develop and trial a new 
warfarin education program to enhance warfarin knowledge, management and 
compliance in a wider patient population, inclusive of the ‘high risk’ group. This 
‘high risk’ group included patients who were elderly, had low literacy skills and 
came from non-English speaking backgrounds.  
Effective patient education is a central part of the practice of all health 
professionals because it helps to ensure safe and effective warfarin management. 
With recent increases in warfarin prescribing and warfarin-related adverse drug 
events the need for an effective patient warfarin education program is more 
apparent.  
The study aims to improve currently available warfarin education programs 
delivered to warfarin prescribed patients in a home-based setting. The new 
program is conceptually based on five key elements: improved health 
professional/patient communication and partnerships; improved warfarin 
compliance; simple, easy-to-read warfarin information, improved continuity of care 
between hospital and community settings; and improved patient follow-up. 
Unfortunately, during the course of the study, many similar strategies and 
interventions targeting these key elements were incorporated into the customary 
program, as well as the new program, which may have impacted on the final 
results of the study. 
The study was conducted from February 2003 to February 2004, on consenting 
patients who were prescribed warfarin and admitted to Illawarra Health’s The 
Ambulatory Care Team (TACT). This prospective study included 50 intervention 
patients receiving the new warfarin education program, and 52 control patients 
receiving the customary warfarin education program offered to TACT patients. 
Many of these patient participants also came from the ‘high risk’ group, which 
included; the elderly, those with low literacy skills and those from non-English 
speaking backgrounds.  
The evaluation phase of the study involved comparing and contrasting the 
effectiveness of the new warfarin education program against the customary 
 iv 
warfarin education program, in terms of the patients’ warfarin knowledge, 
management and compliance. The patients’ satisfaction with the information 
received and their therapeutic outcomes (therapeutic INR scores, healthcare visits 
and warfarin-related adverse drug events) were also compared and contrasted 
between the two programs.  
The findings of this study suggest that the new warfarin information booklet 
(APPENDIX 12) was written in a better quality, easier-to-read format, than was the 
Boots warfarin information booklet (2003). Overall, the trend in the results 
suggested that the new warfarin education program more effectively educated 
patients, including the ‘high risk’ patients, about their warfarin therapy, as 
compared to the customary warfarin education program. The patients receiving the 
new warfarin education program were more knowledgeable about their warfarin, 
more confidently managed and complied with their warfarin therapy at home, and 
achieved better therapeutic outcomes, than did patients who received the 
customary warfarin education program. Interestingly, both the new and the 
customary warfarin education programs used in this study appeared to be more 
effective than other available warfarin education programs, achieving better 
warfarin knowledge scores and therapeutic outcomes, with fewer warfarin-related 
adverse drug events and healthcare visits.  
The implications of this study are that by targeting the five key elements of an 
effective warfarin education program we can help to improve warfarin knowledge, 
management and compliance in many patients, including those from the ‘high risk’ 
group. Education based on the five key elements empowers patients to make 
educated decisions about their warfarin therapy; which in turn help to optimise their 
warfarin-related therapeutic outcomes and minimise warfarin-related adverse drug 
events.  
One of the major benefits of this research, is that the five key elements of an 
effective patient education program, used in this new warfarin education program, 
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 Medication-related errors are the major cause of adverse events within the 
healthcare system both in Australia and overseas, causing an estimated 10-20 
percent of all medically related adverse events (Bates 1999; Dartnell, Anderson, 
Chohan, Galbraith, Lyon, Nestor and Moulds 1996; Leape, Kabcenell, Berwick 
and Roessner 1998). Australian research has shown that between 2 and 4 
percent of all hospital admissions are due to adverse drug events, with an 
estimated cost of at least $350 million per annum (Australian Council for Safety 
and Quality in Health Care 2002; Roughead 1999; Runciman, Roughead, 
Semple and Adams 2003). A large proportion of these adverse events could be 
prevented by improving patient education and communication (Forster, Asmis, 
Clark and Saied 2004; Wilson, Runciman, Gibberd, Harrison, Newby and 
Hamilton 1995). The ‘Improving Medication Safety Workshop’ (Australian Council 
for Safety and Quality in Health Care 2001) recommended a national approach to 
reducing adverse drug events by targeting specific medications such as warfarin. 
 Inadequate patient education has been identified as a major cause of 
adverse drug events involving warfarin in hospital and community settings 
(Bhasale, Miller, Britt and Reid 1996). For ‘high risk’ groups which include the 
elderly, those with low literacy skills and people from non-English speaking 
backgrounds, the lack of literacy can be a major obstacle to effective healthcare, 
communication and education (Doak, Doak, Friedell and Meade 1998). Written 
patient medication information, including warfarin information, is often pitched at 
a level beyond the comprehension of patients with low literacy skills, who, without 
adequate education, face unnecessary health risks and possible hospitalisation 
(Baker, Parker, Williams and Clark 1998; Baker 1997; Estrada, Barnes, Martin-
Hryniewicz, Collins and Byrd 1999; Estrada, Hryniewicz, Barnes-Higgs, Collins 
and Byrd 2000).  
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 This thesis reports the development, implementation and evaluation of a 
new warfarin education program. The new program is founded on a conceptual 
framework targeting five key elements: 
 health professional/patient communication and partnerships 
 warfarin compliance 
 simple, easy-to-read warfarin information 
 the continuity of care between hospital and community settings 
 patient follow-up.  
The thesis contends that by incorporating strategies and interventions to target 
and improve these five key elements, there will be an improvement in the 
patients’ warfarin knowledge, management and compliance which will ultimately 
lead to optimal therapeutic outcomes and minimal adverse drug events. Special 
consideration in the development of the new program was given to the ‘high risk’ 
patient population, which include the elderly, those with low literacy skills and 
those from non-English speaking background.  
The following two chapters discuss the literary sources used to support 
the need for a new warfarin education program, inclusive of simple, easy-to-read 
warfarin information. They also provide the evidence for the five key elements, 
which need to be targeted when producing an effective warfarin education 
program.  
The fourth chapter describes the conceptual framework used to develop 
the new warfarin education program and the fifth chapter deals with the 
methodology used to target the key elements. Processes used to develop the 
new, simple and easy-to-read warfarin information booklet are described, as are 
interventions and strategies to improve health professional/patient 
communication and partnerships, warfarin compliance, continuity of care 
between hospital and community settings and patient follow-up. Chapter five also 
describes how evaluation questionnaires and outcome data were used to 
compare and contrast the new warfarin education program against the customary 
warfarin education program delivered to the patients admitted to Illawarra 
Health’s The Ambulatory Care Team (TACT). 
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The results of this research study and an analysis of the data collected for 
the 102 patient participants during the evaluation phase are summarised in 
Chapter 6. Information is provided about the improved readability, quality and 
suitability of the new warfarin booklet (APPENDIX 12), as compared to the Boots 
warfarin information booklet (2003) and other available written warfarin 
information. Data regarding the patients’ warfarin knowledge, management and 
compliance was evaluated to compare the effectiveness of the new program 
against the customary warfarin education program delivered to The Ambulatory 
Care Team (TACT) patients. The data was also used to compare the patients’ 
satisfaction with the information they received and their therapeutic outcomes 
(i.e. therapeutic International Normalised Ratio (INR) scores and healthcare 
visits) over the three month follow-up period between the two groups.  
The final chapter provides an overview of the study with discussions about 
the results, limitations, recommendations and implications for both current 
practice in warfarin education and future research. Detailed description is 
provided about the improved warfarin knowledge, management and compliance, 
as well as improved satisfaction and therapeutic outcomes for the patients 
receiving the new warfarin education program as compared to the customary 
warfarin education program. Acknowledgement is made about the fact that many 
similar strategies and interventions targeting the five key elements incorporated 
into the new warfarin education program were also incorporated into the 
customary warfarin education program. This certainly impacted on the final 
results making them less significantly different than initially expected. However 
based on the overall improvement in the warfarin education for all patients 
receiving the new warfarin education program, including the ‘high risk’ group, it is 
recommended that all home-based warfarin education programs adapt the new 
program as a best practice model for an effective warfarin education program. 
Based on the success of the results in this study, the final chapter concludes with 
a recommendation that to be effective all patient medication education programs 
need to target improving the following five key elements; health 
professional/patient communication and partnerships; medication compliance; 
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simple, easier-to-read medication information; continuity of care between hospital 
and community settings; and patient follow-up. 
 
 
1.2 ABOUT THIS STUDY 
 The focus of this research is the development and evaluation of a new 
warfarin education program for a home-based ambulatory care service. The 
objective of the new program was to improve warfarin knowledge, management 
and compliance in a wider patient population, inclusive of the ‘high risk’ group.  
The literature has identified inadequacies in current patient medication 
education practices, especially with regard to warfarin, in both hospital and 
community based settings. The researcher has witnessed first hand the impact of 
these inadequacies both professionally and personally. Professionally, through 
20 years of experience as a hospital and community pharmacist, and personally, 
through her parents, who come from a non-English speaking background.  
The patient populations who have the most problems with their 
medications and knowing how to manage them include the elderly, those with 
low literacy skills and those from non-English speaking backgrounds (Baker, 
Parker, Williams, Pitkin, Parikh, Coates and Imara 1996; Forster, Asmis et al. 
2004; Nadar, Begum, Kaur, Sandhu and Lip 2003). Unfortunately, with limited 
time and resources during busy working schedules of health professionals who 
treat them, these patients are often poorly educated resulting in an increased 
incidence of poor therapeutic outcomes and adverse drug events (Australian 
Council for Safety and Quality in Health Care 2002). This research is important 
because it seeks to provide effective warfarin education to a patient population, 
inclusive of this ‘high risk’ group, which will help to reduce the large incidence of 
poor warfarin-related therapeutic outcomes and adverse drug events reported in 
the literature (Halstead, Roughead, Rigby, Clark and Gallus 1999).  
This thesis contends that the improved warfarin knowledge and 
understanding acquired by patients from the new warfarin education program will 
empower them to make confident, informed decisions about their warfarin 
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management and compliance. The objective is to help optimise warfarin-related 
therapeutic outcomes and minimise warfarin-related adverse drug events 
(Australian Council for Safety and Quality in Health Care 2002).  
 
 
1.3 OVERVIEW OF THE STUDY  
  The principal purpose of this study was to identify, develop and trial a new 
warfarin education program to enhance warfarin knowledge, management and 
compliance in a wider patient population. In order to achieve this several stages 
were included in the study: 
 
 The first stage of the study involved the development of a new warfarin 
education program and a new warfarin information booklet, based on the 
best evidence with regard to effective patient medication education 
programs. 
 The second stage of the study involved a 10-person ‘pilot test’ of the new 
warfarin education program to ensure that the new booklet, education 
session and evaluation questionnaires could be readily understood and 
answered by the pilot sample typical of the study population. 
 The third stage of the study involved a comparative analysis of the new 
warfarin education program against the customary warfarin education 
program delivered to patients admitted to Illawarra Health’s, The 
Ambulatory Care Team (TACT). Comparing and contrasting the two 
programs, immediately and three months after the initial warfarin 
education session involved comparing the participating patients’ warfarin 
knowledge, management and compliance, as well as their satisfaction with 
the warfarin education programs. Outcome measures included: the 
proportion of therapeutic International Normalised Ratio (INR) scores; the 
number of general practitioner, emergency department and hospital visits; 
and the number of warfarin-related adverse drug events. 
 
 6 
1.4 VALUE OF THIS RESEARCH  
 Warfarin is an oral anticoagulant which, until recently, has been mainly 
prescribed for deep venous thrombosis, pulmonary embolus, prosthetic heart 
valves, post hip surgery or to prevent the recurrence of myocardial infarction 
(Ansell, Buttaro, Thomas, Knowlton and The Anticoagulation Guidelines Task 
Force 1997; Gallus 1999). Recently, it has been found that warfarin dramatically 
reduces the risk of embolic stroke in patients with atrial fibrillation (AF) and that 
treatment benefits significantly outweigh the risks in these patients (Campbell, 
Roberts, Eaton, Coghlan and Gallus 2001; Tillman, Charland and Witt 2000). 
These new indications will increase the number of patients being prescribed 
warfarin (Cruickshank, Ragg and Eddey 2001; The Newcastle Anticoagulation 
Study Group 1998) and almost certainly increase the incidence of warfarin-
related adverse events, based on current educational practices (Gurwitz, Field, 
Harrold, Rothschild, Debellis, Seger, Cadoret, Fish, Garber, Kelleher and Bates 
2003; Halstead, Roughead et al. 1999).  
 Historically, patient warfarin education has been inadequate (Connor 
1998) and the amount of information given possibly even overwhelming (Ansell, 
Buttaro et al. 1997). A lack of patient education has been identified as a major 
cause of poor warfarin-related therapeutic outcomes and adverse drug events in 
both hospital and community settings (Bhasale, Miller et al. 1996; Halstead, 
Roughead et al. 1999). It is timely therefore, to develop a more systematic 
approach to the delivery of warfarin education, which addresses the needs of a 
wider patient population, inclusive of elderly, low literacy and non-English 
speaking background patients. Such a program should aim to improve warfarin-
related therapeutic outcomes and minimise adverse drug events by empowering 
patients to successfully comply with and manage their warfarin therapy at home, 






1.5 THE SIGNIFICANCE OF THIS RESEARCH 
 Patient education is a central part of the practice of all health professionals 
and is a very important way in which to ensure safe and effective warfarin 
management. To date, warfarin education programs have been identified as 
primarily unstructured and inadequate (Bhasale,Miller et al 1996; Ansell Buttaro 
et al 1997; Connor 1998 and Halstead, Roughead et al 1999). This research 
assesses whether the way in which the warfarin education program is structured, 
the presentation of the written warfarin information and improved collaboration 
between patients, carers and relevant health professionals will have an impact on 
the effectiveness of the education program.  
The new warfarin education program, which is delivered to patients in a 
home-based setting, is based on a conceptual framework incorporating the five 
key elements of an effective warfarin education program. The strategies and 
interventions introduced in the new program also address the needs of the ‘high 
risk’ patient population, in an attempt to ensure that they also benefit from the 
program and achieve optimal therapeutic outcomes with minimum adverse drug 
events. 
One of the major benefits of this research is that the five key elements of 
an effective patient education program used in this new warfarin education 
program can also be generically applied to other patient medication education 




IDENTIFYING THE KEY ELEMENTS IN THE LITERATURE WHICH 
CONTRIBUTE TO ADVERSE DRUG EVENTS, INCLUDING 
WARFARIN-RELATED ADVERSE DRUG EVENTS 
 
 
2.1 INTRODUCTION  
 In 1995, the use of medications in Australia was reported to be the most 
common health-related action taken by people suffering from illness or injury 
(ABS 1999). With that salient fact in mind, the purpose of this study was to 
promote improved warfarin medication education in a wider patient population, to 
help optimise therapeutic outcomes and minimise adverse drug events. The oral 
anticoagulant, warfarin, is the focus of this study because its inappropriate use is 
a large and unresolved problem (Halstead, Roughead et al. 1999). Warfarin also 
has the potential of becoming an even bigger problem with recent increases in 
prescribing for patients suffering from atrial fibrillation (Cruickshank, Ragg et al. 
2001; Ezekowitz and Falk 2004). 
 This chapter commences with an introduction to patient education and its 
potential impact on therapeutic outcomes and adverse drug events. Further it 
reviews adverse drug events and their impact on healthcare costs by way of 
hospital admissions and general practitioner encounters. Medication-related 
adverse event terms are defined and the incidence of adverse drug events in 
Australia, are discussed. Key factors which contribute to adverse drug events are 
identified and include: poor health professional/patient communication and 
partnerships; poor medication compliance; inappropriate written medicine 
information; poor continuity of care between hospital and community settings; 
and poor patient follow-up (Australian Council for Safety and Quality in Health 
Care 2002; Roughead and Gilbert 2002). Consideration in this chapter is given to 
 9 
implementing strategies and interventions to target each of these key elements, 
with a view to developing an effective warfarin education program. 
 The chapter concludes with an overview of the increasing problem of 
warfarin-related adverse drug events (Campbell, Roberts et al. 2001; Hirri and 
Green 2002), which may in part be due to the increase in warfarin prescribing 
(Elliott, Woodward and Oborne 2002; Gallus, Baker, Chong, Ockelford and Street 
2000; Peterson, Jackson and Bereznicki 2002), as well as inadequacies in the 
currently available warfarin education programs (Connor 1998). This increasing 
incidence of warfarin-related adverse drug events and warfarin knowledge 
deficits in many patients (Cheah and Martens 2003; Nadar, Begum et al. 2003; 
Tang, Lai, Lee, Wong, Cheng and Chan 2003) highlight the need for a new, 
effective warfarin education program. Importantly, this new warfarin education 
program should be designed to address the needs of the ‘high risk’ patient 
population (the elderly, those with low literacy skills and those from non-English 
speaking backgrounds) who are more likely to experience poor warfarin-related 
outcomes (Estrada, Martin-Hryniewicz, Peek, Collins and Byrd 2004; Lambert 
and Wynne 2003; Nadar, Begum et al. 2003). When used in conjunction with the 
home healthcare delivery services (McGuire, Stowasser and Collins 1997), it is 
envisaged that this new education program will help to improve warfarin-related 
therapeutic outcomes and reduce the incidence of warfarin-related adverse drug 
events.  
 
2.2 RATIONALE FOR THE SEARCH STRATEGY  
 Serious limitations in available warfarin education programs became 
increasingly apparent to the researcher through her 20 years’ experience as a 
hospital and community pharmacist, and through her elderly migrant parents. 
The researcher was also involved in developing and writing medication 
information leaflets over many years, and attempted, unsuccessfully, to persuade 
Boots Healthcare to rewrite its information booklet, ‘Warfarin: important 
instructions for patients’ (2002, 2003) in a simpler, more accessible format. The 
researcher then became interested in reviewing the home-based warfarin 
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education program delivered to Illawarra Health’s The Ambulatory Care Team 
(TACT) patients, including the development of a new simple, easy-to-read 
information booklet, leading to the study presented in this thesis.  
The literature reviewed for this study focused on available patient 
medication information and in particular, warfarin information written in English. 
They also focused on ways in which to educate patients effectively about their 
medications, including improving their medication knowledge and understanding, 
management and compliance.  
 
2.2.1 The search strategy  
 A number of sources were used to search the literature about factors 
possibly affecting patient medication education, medication compliance, 
therapeutic outcomes and adverse drug events. Pubmed (1966-present), 
CINAHL (1996-2004; 1966-present) and MEDLINE (1996-2004; 1966-present) 
were among the most commonly used databases. Proquest 5000 (Health and 
Medical), Expanded Academic Index (1980-Present), Australian Medical Index 
(AMI), Synergy (1999-present), Science Direct, Embase and the Cochrane 
Database of Systematic Reviews were also frequently accessed. The AUSTATS 
database was used to search Australian Bureau of Statistics (ABS) information, 
the Australian Institute of Health and Welfare (AIHW) website, the TGA website 
and the Web of Science database (1975-present) provided useful citation 
indices, which then could be further investigated. Finally, the First Search 
database and other Australian University sites were accessed to scan for any 
relevant theses, which may have been published about similar research studies. 
Only materials published in the English language or translated into English were 
accessed for the literature review.  
The initial relevant search terms were quite broad and included: adverse 
drug events; medication compliance and/or concordance; community based 
patient compliance with drug therapy; medication self-management; patient 
education and teaching; medication information; continuity-of-care; patient follow-
up; evaluation of education programs; hospital-in-the-home programs; 
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literacy/culture/non-English speaking backgrounds; and medication. The search 
was then narrowed down to: oral anticoagulants; warfarin (coumadin); warfarin-
related adverse drug events; warfarin compliance; warfarin education programs; 
warfarin information; the evaluation of warfarin education programs; the effects of 
literacy, culture and non-English speaking backgrounds on warfarin knowledge 
and understanding. Warfarin, adverse drug events, medication compliance and 
patient warfarin education programs proved to be the most useful terms for the 
search strategy. Nevertheless, each of these terms introduced the researcher to 
many articles that were subsequently excluded as they dealt with hospital 
inpatient medication education programs, health behaviour change models and 
medication self-management programs rather than the patients’ anticoagulation 
management and education by a multidisciplinary team in their own home, which 
became an important criterion for inclusion. 
 During the three year study, Medline and Cinahl alerts via 
Autorun@ovid.com were also organised to scan for weekly updates on the 
following search terms; ‘warfarin’, ‘medication compliance’, ’medication 
education’, ‘communication barriers’ and ‘ethnic and cultural barriers’. As was 
expected there was a great deal of duplication among these databases. Even 
though over 200 sources were used in the literature review, there were very few 
papers found which explored the key elements of an effective patient medication 
education program, and in particular a patient warfarin education program. There 
were many sources, which discussed the need to improve patient warfarin 
knowledge and understanding as a means to optimise therapeutic outcomes and 
minimise adverse drug events.  
Inadequacies in acquiring sufficient information from the databases were 
countered by accessing a variety of sources including books on the subject, 
reports and government documents. These were obtained through library 
catalogues, interlibrary loans, pertinent web sites and searching the 




2.3 THE IMPACT OF PATIENT EDUCATION ON THERAPEUTIC OUTCOMES 
AND ADVERSE DRUG EVENTS 
 
Patient education improves health outcomes by promoting healthy 
behaviour and involving patients in their own health care decisions (JCAHO 
1998). The process begins with the imparting of information, but it also includes 
interpretation and integration of information to bring about attitudinal or 
behavioural changes that benefit a person’s health status (Rankin and Duffy 
Stallings 2000). Verbal communication, patient involvement, the readability of 
written information and an evaluation of the learning outcomes have all been 
identified as important issues to consider when providing patient education 
(Webber 1990).  
During recent times the notion of patient-centred care with patient 
education as the central focus has been incorporated worldwide in strategies to 
help achieve better therapeutic outcomes and reduce the incidence of adverse 
drug events. Strategies which encourage patients to become active participants 
in the decision making process about their care are the basis of the Joint 
Commission on the Accreditation of Healthcare Organization (JCAHO) Standards 
for Patient Education (JCAHO 1993) in the United States, the Medicines 
Partnership Task Force (The Royal Pharmaceutical Society of Great Britain 
1997) in the United Kingdom, and the recent ‘Consumer Engagement in Health 
Care’ (Australian Government Department of Health and Ageing 2005) initiatives 
supported by the Australian Government. Even though these initiatives are 
becoming commonplace worldwide, there is very little evidence about their 
impact reported in the literature, which often gives a largely one-sided view. The 
common position is that if a medication and/or therapeutic regimen is not 
followed as prescribed, then the problem must somehow be with the patient. 
Neither the behaviour nor the attitude of the health professional, or the structure 
of the education program, are taken into consideration when evaluating the 
effectiveness of such initiatives. It is important therefore, to consider this point 
when reading through the evidence available in the literature. 
 13 
There are very few data in the literature about the impact of patient 
education alone on the medication related therapeutic outcomes and incidence of 
adverse drug events. Typically patient education is discussed as one of several 
interventions including counselling, familial support, follow-up, compliance aids 
(Roter, Hall, Merisca, Nordstrom, Cretin and Svarstad 1998) used to promote 
medication compliance, thereby improving therapeutic outcomes and reducing 
adverse drug events.  
A recent systematic review, found that interventions delivered by 
pharmacists (e.g. medication education and counselling, written information, 
medication review etc) directed toward hypertensive, hypercholesterolemic, 
chronic heart failure, or diabetic patients improved therapeutic outcomes and 
decreased the use and/or cost of health services, compared to patients not 
receiving the interventions (Beney, Bero and Bond 2004). Pharmacist provided 
videotapes, booklets, educational newsletters and follow-up have all been found 
to improve medication compliance, especially amongst elderly patients (Poston, 
Loh and Dunham 1998). There is also evidence in the literature that elderly 
patients who received home based pharmacy counselling, medication review and 
education services were more likely to be compliant with their medication than 
were patients who only received a home visit (Lowe, Raynor, Purvis, Farrin and 
Hudson 2000).  
Esposito (1995) evaluated four educational programs to see which would 
be more effective in increasing medication compliance amongst elderly patients. 
He found that elderly patients were less likely to be compliant if they were 
provided with (i) a medication fact sheet and a discharge summary sheet, or (ii) a 
medication fact sheet with 30 minutes of verbal instruction on discharge from 
hospital, as compared to the patients who received (iii) a medication schedule 
written in large dark lettering, with a list of side effects and a dosage schedule, or 
(iv) a medication schedule and 30 minutes of verbal instruction. Even though the 
patient population was small in this study (n = 42) and hence the findings could 
not be reported statistically. It is noteworthy that the patients given a medication 
schedule, also known as a medication regimen, were more likely to be compliant 
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with their medications and less likely to suffer from any adverse drug events. 
These results support the earlier work of Ascione and Shimp (1984) who also 
found that a reminder aid (e.g. written information, a medication reminder 
calendar, or a medication reminder package) with verbal reinforcement improved 
medication knowledge and compliance in 158 ambulatory cardiovascular 
patients. These studies and a preponderance of information available in the 
literature suggest that both written and verbal information given together, 
compared to being given alone, help to improve the patients and/or carers 
knowledge and satisfaction, resulting in better patient outcomes and fewer visits 
to health care providers (Forster, Smith, Young, Knapp, House and Wright 2004; 
Issacman, Purvis, Gyuro, Anderson and Smith 1992; Jenkins, Blank, Miller, 
Turner and Stanwick 1996).  
 In summary, patient education has been found to improve therapeutic 
outcomes and reduce the incidence of adverse drug events by promoting good 
medication compliance. During recent times, worldwide organizations have taken 
patient education one step further by encouraging patients to become active 
participants in the decision making process. According to the evidence in the 
literature successful patient medication interventions include: the provision of 
medication information (verbal and written), medication counselling, medication 
reviews and home based follow-up by all healthcare professionals and especially 
the pharmacist.  
 
2.4 ADVERSE EVENTS 
 
2.4.1 Background 
 Adverse events are a major concern to the healthcare system, causing 
significant personal burden and healthcare costs. Medication incidents are 
recognised as a leading cause of adverse events both in Australia and 
internationally (Forster, Murff, Peterson, Gandhi and Bates 2003; Kohn, Corrigan 
and Donaldson 1999; Leape, Brennan, Laird, Lawthers, Localio, Barnes, Herbert, 
Newhouse, Weiler and Hiatt 1991; Wilson, Runciman et al. 1995). Many of these 
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adverse drug events are considered to be potentially preventable (Forster, Murff 
et al. 2003; Wilson, Runciman et al. 1995) through effectively educating patients 
about their medications and empowering them to make informed decisions about 
their medication management and compliance (Australian Council for Safety and 
Quality in Health Care 2002; Bhasale, Miller, Reid and Britt 1998; Mullen, 
Simons-Morton, Ramirez, Frankowski, Green and Mains 1997).  
Patient populations deemed to be at particularly ‘high risk’ of experiencing 
adverse drug events include: the elderly (Forster, Asmis et al. 2004; Gurwitz, 
Field et al. 2003); those with low literacy skills (Baker, Parker et al. 1996; Doak, 
Doak et al. 1985; Feifer 2003); and patients from non-English speaking 
backgrounds (Nadar, Begum et al. 2003; Shaw, Hemming, Hobson, Nieman and 
Naismith 1977). Elderly patients (aged 65 years and over) are more likely to 
experience adverse drug events because they generally take more medications 
(Australian Council for Safety and Quality in Health Care 2002) and often suffer 
from cognitive and/or physical limitations (Stewart and Caranasos 1989). 
Patients with low literacy skills are more susceptible to adverse drug events 
(Feifer 2003) because they know significantly less about their disease and how to 
manage their medications (Williams, Baker, Parker and Nurss 1998). These 
deficits in medication knowledge and understanding have also been found to 
exist among the non-English speaking background (NESB) patients (Nadar, 
Begum et al. 2003; Wilson, Racine, Tekieli and Williams 2003). An Australian 
study found that a considerable proportion (35 percent) of their 257 NESB patient 
participants had little or no understanding about their drug therapy (dose, 
frequency and drug function) (Shaw, Hemming et al. 1977), which almost 
certainly predisposed them to adverse drug events and poor compliance.  
It is important, therefore, to examine what is known about adverse drug 
events and how their incidence can be reduced or even potentially prevented by 
way of improved patient medication education. It is also important to note that 
interventions and strategies which target improved patient medication education, 





 Due to the varying use of terms in the literature and throughout this 
chapter, specific definitions of medication related adverse events are listed 
below. The terms ‘adverse event’, ‘medication incident’, ‘adverse drug event’, 
‘adverse drug reaction’ and ‘medication error’ are all used to describe medication 
related problems (Australian Council for Safety and Quality in Health Care 2002). 
 An Adverse Event (AE) is an incident in which harm resulted to a person 
receiving healthcare (Australian Council for Safety and Quality in Health 
Care 2001). 
 Medication incidents are problems which occur in the prescription, 
dispensing and administration of medicines (Australian Council for Safety 
and Quality in Health Care 2002). 
 An Adverse Drug Event (ADE) is a medication incident which leads to 
patient harm (Australian Council for Safety and Quality in Health Care 
2002). 
 An Adverse Drug Reaction (ADR) is a side effect caused by a medication 
on its own or in combination with other drugs (Australian Council for 
Safety and Quality in Health Care 2002). 
 A medication error is a failure in the (drug) treatment process that leads to, 
or has the potential to, harm the patient (Ferner and Aronson 2000) and 
includes an act of omission or commission (Australian Council for Safety 
and Quality in Health Care 2001). 
 Preventability of an adverse event is an error in management due to 
failure to follow accepted practice at an individual or system level (Wilson, 
Runciman et al. 1995) 
 Potentially preventable includes the adverse events with a preventability 






2.4.3 Incidence of adverse drug events 
 Australian data indicate that adverse drug events make a significant 
contribution to unplanned hospital admissions. The Australian national hospital 
morbidity database shows that for a twelve month period from 1999 to 2000, 
69,766 hospital separations were due to adverse drug events (Australian Council 
for Safety and Quality in Health Care 2002; Runciman, Roughead et al. 2003). 
Between 2 and 4 percent of all Australian hospital admissions have been 
identified to be medication related (Australian Council for Safety and Quality in 
Health Care 2002; Runciman, Roughead et al. 2003). This translates to 140,000 
hospital admissions with an estimated cost in Australia of at least $350 million 
dollars per annum, in the public hospital system alone (Australian Council for 
Safety and Quality in Health Care 2002; Roughead 1999). The literature also 
confirms that the elderly are more likely to be admitted to hospital because of 
medication-related adverse drug events (Chan, Nicklason and Vial 2001; Hagan 
and Cooper 1999). Twenty percent of patients aged 65 years and over 
(Australian Council for Safety and Quality in Health Care 2002) and 30 percent of 
patients aged 75 years and over (Chan, Nicklason et al. 2001) are believed to 
experience unplanned medication-related hospital admissions.  
 Adverse drug events are not confined to hospital settings. They are also a 
major problem in community settings as reported in the BEACH survey (Bettering 
the Evaluation and Care of Health)(Runciman, Roughead et al. 2003). During 
1999 - 2000, there were 4.1 adverse drug events recorded for every 1,000 
general practice visits (Hargreaves 2001). The Australian incident-monitoring 
study which collected reports from 673 general practitioners from 1996 - 1998 
found that adverse drug events, were responsible for 1,556 (60 percent) of the 
2,582 adverse events reported (Steven, Malpass, Moller, Runciman and Helps 
1999). Analysis of 805 incident reports from another Australian general practice 
study (October 1993 - June 1994) also found that adverse drug events (51 
percent) were the most frequently reported adverse events, especially involving 
patients aged 65 years and over (Bhasale, Miller et al. 1998). It could be argued 
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that the data collected from these few general practice studies are not truly 
representative of the incidence of adverse drug events Australia wide. They do, 
however, provide a snapshot of the potential impact that adverse drug events 
can have on general practice encounters and healthcare costs in the community 
setting.  
 Although adverse drug events may be a common occurrence in both the 
hospital and community settings, they should not be considered to be 
unavoidable outcomes associated with medication use. Evidence in the literature 
suggests that a large proportion of these adverse drug events are potentially 
preventable (Gurwitz, Field et al. 2003; Rigby, Clark and Runciman 1999; 
Roughead, Gilbert, Primrose and Sansom 1998). A Canadian prospective cohort 
study of 400 patients discharged from hospital found that a majority of the 50 
adverse drug events experienced by the 400 discharged patients could have 
been prevented with improved patient education, communication, continuity of 
care and patient follow-up (Forster, Murff et al. 2003). These claims are 
consistent with other reports which also found that potentially preventable 
adverse drug events could be reduced by improving patient medication education 
and communication (Dartnell, Anderson et al. 1996; Forster, Asmis et al. 2004; 
Forster, Clark, Menard, Dupuis and al 2004; Gandhi, Weingart, Borus, Seger, 
Peterson, Burdick, Seger, Shu, Federico, Leape and Bates 2003; Roberts and 
Stokes 1998). Similarly, an Australian study which reviewed the medical records 
of over 14,000 admissions to 28 hospitals during 1992, suggested that 43 
percent of the reported adverse drug events could have been potentially 
prevented, identifying improved medication education and communication as 
potential areas for improvement (Wilson, Runciman et al. 1995). From a 
community perspective, an observational Australian study (October 1993 - June 
1994) asserted that 322 (79 percent) of the 407 adverse drug events reported by 
324 general practitioners could have been prevented by improving patient 
education, patient and health professional communication, as well as the 
continuity of care between hospital and community settings (Bhasale, Miller et al. 
1998). Certainly each of these studies varied markedly in their estimate of how 
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many adverse drug events were potentially preventable. Importantly however, 
they all made the same claims that a significant proportion of the adverse drug 
events could be potentially prevented by improved patient education, 
patient/health professional communication and the continuity of care between 
hospital and community settings. Clearly these are factors consistently 
considered important in effective patient compliance to medication regimens. 
 In summary, it has been established that adverse drug events are leading 
causes of adverse events both in Australia and overseas. They contribute to an 
increase in healthcare costs by causing unplanned hospital admissions and 
general practitioner encounters. There are studies reported in the literature, 
which suggest that many of these adverse drug events could be potentially 
prevented by improving patient education, patient/health professional 




2.4.4 Key elements which contribute to adverse drug events 
 
2.4.4.1 Introduction 
 Adverse drug events are a persistent and important problem of public 
health in terms of morbidity, mortality and cost (Peyriere, Cassan, Floutard, 
Riviere, Blayac, Hillaire-Buys, Quellec and Hansel 2003). Work in this area has 
only been underway in Australia for approximately 10 years, with an emphasis on 
medication safety and the reduction of adverse drug events in the past five years 
(Australian Council for Safety and Quality in Health Care 2001). Following the 
1999 report by the National Expert Advisory Group on Safety and Quality in 
Australian Health Care, the Australian Council for Safety and Quality in Health 
Care was established in January 2000 to prioritise medication safety in Australia 
(Australian Council for Safety and Quality in Health Care 2002; Commonwealth 
Department of Health and Aged Care 2000). One of the major strategies 
identified by the council to minimise these potentially preventable adverse drug 
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events was to improve patient medication knowledge and understanding by 
effectively educating them about their medications (Australian Council for Safety 
and Quality in Health Care 2002). 
 Key elements identified in the literature as contributing to adverse drug 
events include: poor health professional/patient communication and partnerships; 
poor medication compliance; inappropriate written medication information; poor 
continuity of care between hospital and community settings; and poor patient 
follow-up (Australian Council for Safety and Quality in Health Care 2001). In 
order to help reduce the potentially preventable adverse drug events, it is 
therefore important to target each of these key elements, as well as addressing 
the needs of the ‘high risk’ patient population, in the development of patient 
education programs. 
 
2.4.4.2 Poor health professional/patient communication and partnerships 
 Poor health professional/patient communication and partnerships have 
been identified by Bhasale, Miller et al (1998) and Elwyn, Edwards and Britten 
(2003) as important factors which contribute to adverse drug events and poor 
therapeutic outcomes. More recently Cox, Stevenson, Britten and Dunbar (2004) 
identified that these factors result in patients having poor knowledge and 
understanding of their medications, subsequently causing an inability to 
appropriately manage them at home. 
 DiMatteo (1997) claimed that poor communication could result in as many 
as half the number of all patients leaving their doctors’ offices not knowing what 
they have been told or how to follow their therapeutic regimens. Patients 
contributed to this poor communication through their unwillingness to ask 
questions and/or challenge the health professional’s authority, being 
overwhelmed with the information provided and misunderstanding medical 
jargon. Becker and Maiman (1980) also found that patients often feel that they 
are wasting the doctors’ valuable time and omit details which they deem 
unimportant or are too embarrassed to mention.   
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 Ineffective patient/health professional partnerships are important as they 
can precipitate adverse drug events because patients may not know enough 
about their medications to manage them appropriately (Bhasale, Miller et al. 
1998). Patients may feel unsupported in their attempts to become actively 
involved and to ask questions about their medications and therapeutic regimens 
(Cox, Stevenson et al. 2004; Elwyn, Edwards et al. 2003). 
Patient populations most likely to experience poor therapeutic outcomes 
and adverse drug events because of poor health professional/patient 
communication and partnerships include the ‘high risk’ group. Elderly patients 
(aged 65 years and over) have been found to have problems communicating and 
forming partnerships with their health professionals (Stewart and Caranasos 
1989). They typically take many medications and are overwhelmed with the 
information received (Col, Fanale and Kronholm 1990; Ryan 1999). Reports in 
the literature have identified that the proportion of people who use medications 
increases with age, from 42 percent of those aged less than 15 years, to 86 
percent of those aged 65 years and over (ABS 1999).  
Patients with low literacy skills, which may include the elderly, also 
experience poor health professional/patient communication and partnerships 
because their health professionals are often unaware of their communication 
problems which they seldom voluntarily admit and often try to conceal (Doak, 
Doak et al. 1985). Similarly, the language, social and cultural barriers for non-
English speaking background (NESB) patients make it difficult for health 
professionals to assess how effectively they have communicated with these 
NESB patients (Davidhizar and Brownson 1999; Minas, Lambert, Kostov and 
Boranga 1996).  
Strategies to improve health professional/patient communication and 
partnerships should also address the needs of each of these ‘high risk’ patient 
groups. Two major elements of effective communication between the health 
professional and the patient identified by DiMatteo (1997) are accurate 
transmission of information to and from the health professional and the patient, 
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as well as the health professionals’ emotional support and understanding of the 
patient as a unique individual.  
Reports in the literature have identified that communication improved 
when health professionals offered patients encouragement, reinforcement of key 
points by using repetition, reassurance and feedback (Clark, Gong, Schork, 
Evans, Roloff, Hurwitz, Maiman and Mellins 1998; Estrada, Hryniewicz et al. 
2000). A meta-analysis on the effectiveness of health education and health 
promotion undertaken by Kok, van den Borne and Mullen (1997) concluded that 
the effectiveness of health education is promoted by systematic planning and the 
use of learning principles in the intervention, including relevance, 
individualisation, feedback, rewards and facilitation. Providing environments 
which encourage patients to listen, feel confident enough to ask questions and 
participate in the decision making process have also been found to be important 
ways in which to improve communication and partnerships (Elwyn, Edwards et 
al. 2003; The Royal Pharmaceutical Society of Great Britain 1997). The 
incorporation of such strategies into patient education programs are believed to 
contribute to not only improved health professional/patient communication and 
partnerships (Cox, Stevenson et al. 2004), but also improved therapeutic 
outcomes (DiMatteo 1997; Elwyn, Edwards et al. 2003) and reduced incidence of 
adverse drug events (Ascione and Shimp 1984; Esposito 1995). 
A number of principles for improved health professional/patient 
communication have been developed based on a large randomised control trial 
involving 472 asthma patients, their parents and 69 paediatricians (Clark, Gong 
et al. 1998). Positive outcomes from the trial were identified as successful 
therapeutic outcomes of patients, improved parents’ knowledge about how to 
manage their children’s asthma and a reduction in health care utilisation. The 
investigators recommended that the following communication principles be 
included in patient education programs.  
 Attend to the patient (eye contact, sit closely with the patient slightly 
leaning forward 
 Elicit the patient’s underlying concerns about the condition 
 23 
 Construct reassuring messages that alleviate fears 
 Address any immediate concerns that the family expresses 
 Engage the patient in interactive conversation through use of open 
ended questions, simple language, and analogies to teach 
important concepts 
 Tailor the treatment regimens by eliciting and addressing potential 
problems in the timing, dose or side effects of the drugs 
recommended 
 Use appropriate non-verbal encouragement (pat on the shoulder, 
nodding) and verbal praise when the patient reports using correct 
disease managements strategies 
 Elicit the patient’s immediate objective related to controlling the 
disease and reach agreement with the family on a short term goal 
 Review the long term plan for the patient’s treatment so the patient 
knows what to expect over time, knows the situation under which 
the physician will modify treatment, and knows the criteria for 
judging the success of the treatment plan 
 Help the patient plan in advance for decision making about chronic 
condition (such as using diary information or guidelines for handling 
potential problems and exploring contingencies in managing the 
disease) 
This is the only study that has approached the issue of health 
professional/patient communication in such a systematic manner. Other studies 
have identified some of these issues, for example DiMatteo (1997) identified that 
the accurate transmission of information, emotional support and understanding 
between the health professional and the patient were important in effective 
communication, but none have drawn the issues together in such a 
comprehensive fashion. 
Extending the concept of communication, fostering and developing good 
health professional/patient partnerships are also considered to be important in 
medication education programs. Partnerships can empower patients to know and 
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understand more about their medication, enabling them to make better educated 
therapeutic decisions (Lorig, Sobel, Ritter, Laurent and Hobbs 2001; Mullen, 
Simons-Morton et al. 1997). In a study of 952 patients with chronic disease, by 
Lorig et al (1999), it was found that a structured self-management education 
program improved health status and reduced hospitalisation rates over a 6-
month period. As compared with control group, the treatment group 
demonstrated significant improvement in five of the health status variables (self-
rated health, disability, social/role activities limitation, energy/fatigue, and health 
distress; p< 0.02). The treatment group, as compared with the control group, also 
had fewer hospitalisations (p<0.05) and spent, on average, 0.8 fewer nights in 
the hospital (p = 0.01). The study concluded that these results were due to a 
number of factors including the patients improved knowledge and understanding 
about how to manage their medications and disease therapy at home, as well as 
their improved communications with their physicians.  
The importance of good patient/health professional partnerships in helping 
to achieve optimal medication outcomes has only been recognised over the last 
10 years with the promotion of the concept of patient concordance (Aslani and 
Du Pasquier 2002; The Royal Pharmaceutical Society of Great Britain 1997). 
Concordance describes the process whereby health professionals and patients 
exchange their views on treatment and come to an agreement about the need (or 
not) for a particular treatment (Elwyn, Edwards et al. 2003). In the United 
Kingdom the role of the Medicines Partnership Task Force (1997) is to support 
the national strategy through the promotion of concordance between the health 
professionals and their patients. In the absence of any evaluation data 
concerning the effectiveness of these collaborative strategies on the patients 
medication related therapeutic outcomes and adverse drug events it is only 
possible to speculate that such initiatives should produce positive effects.  
 Since poor communication and partnerships between health professionals 
and their patients are believed to contribute to poor therapeutic outcomes and 
adverse drug events (Elwyn, Edwards et al. 2003) it would seem reasonable to 
suggest that patient education programs should incorporate strategies which 
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target improved health professional/patient communication and partnerships. 
Offering encouragement, reinforcement, reassurance and feedback (Clark, Gong 
et al. 1998), as well as making patients feel confident to ask questions and be 
part of the decision making process (The Royal Pharmaceutical Society of Great 
Britain 1997) are amongst the factors reported in the literature to promote good 
health professional/patient communication and partnerships. These factors need 
to be considered in the development of patient medication education programs, 
especially for the ‘high risk’ group of patients.  
 
2.4.4.3 Poor medication compliance 
 Medication compliance is a key indicator of the success of patient 
medication education programs. Current estimates of non compliance range from 
20 to 70 percent for all medications (Barat, Andreasen and Damsgaard 2001; 
Stewart and Caranasos 1989) and 50 to 65 percent for long-term medications 
(Haynes, McKibbon and Kanani 1996), indicating there is much room for 
improvement through patient medication education. Further, patient populations 
most likely to encounter adverse drug events because of poor compliance, and 
hence are high priorities for improved education initiatives, include the elderly 
(Col, Fanale et al. 1990; Ryan 1999), those with low literacy skills (Feifer 2003) 
and patients from non-English speaking backgrounds (Davidhizar and Brownson 
1999).  
Medication compliance, synonymous with medication adherence and 
concordance, is defined as the extent to which patients follow the instructions 
they are given for prescribed treatments. There are several methods which can 
be used to measure compliance and these include pill counts, patients’ self-
report, pharmacy dispensing records, electronic monitoring systems, as well as 
blood and urine assays. Some of the strengths and weaknesses of these 
different methods are summarised in the following  
 
 





Pill count - quick and easy 
- the number of tablets can be 
quickly inspected to see how many 
have been taken from the pack 
 
- cannot identify the number of days 
missed 
- patients can manipulate tablet 
numbers  
- can be time consuming if conducted 
in a home setting  
-patients may resent having their pills 
counted 
 
Self-reporting - patients do their own reporting 
- quick and easy  
-  - subjective measurement  
- patient recall may be inaccurate 
- patients may be reluctant to admit 
‘noncompliance’ 
- patients may have a tendency to 
over-report compliance 
- researchers may allocate different 
scores to self-reporting claims 
- possible ‘Hawthorne effect’ because 
patients are aware of being monitored 





- objective measure of compliance 
- quick and easy 
- can produce population based 
analyses 
- can generate reports from days to 
years 
- can be inaccurate if several 
pharmacies are involved 
- can prove to be timely and expensive 
if several pharmacies are involved 
- can lead to errors if patients stockpile 








- provide a good record of the 
number of times a patient 
remembers to take their medication 
- provide a good record of the 
interval between doses  
- expensive and cumbersome when the 
electronic device does not fit the 
prescription medication bottle 
- can causes problems if the device 
becomes faulty 
- patients who are used to using 
reminder dosing units (e.g. blister 
packs, dosette boxes etc) cannot use 
them with the electronic monitoring 
device 
 
Blood or urine 
assays 
- effective and accurate for 
appropriate medications 
- expensive and may not be routinely 
available for many medications  
- may be invasive 
- some blood tests can be affected by 
the timing of the last dose which can 
cause misleading results 
 
According to this summary it would be true to say that each compliance 
measurement method is limited to some degree. These limitations have also 
been highlighted in different reports which have found that self-reporting can 
overestimate compliance (Haynes, McKibbon et al. 1996; Shalansky 2004), pill 
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counts can underestimate compliance (Grymonpre, Didur, Montgomery and Sitar 
1998), electronic monitoring devices are useless if they become faulty or lost 
(Turner and Hecht 2001) and only complete pharmacy prescription data records 
can be used to correctly estimate medication compliance (Grymonpre, Didur et 
al. 1998).   
There is no gold standard for measuring medication compliance, which is 
why different researchers have used different methods over time. Earlier studies 
typically used pill counts, whereas in recent times electronic monitoring devices 
such as the Medication Event Monitoring System (MEMS) have replaced pill 
counts as the reference standard (Farmer 1999). Reviewing the strengths and 
weaknesses of the different compliance measurements listed above it could be 
argued that no one single method is more reliable or superior to the other. 
Perhaps the best way to deal with these shortcomings is to use at least two or 
more of the most convenient and available compliance measurement methods, 
which can be used to achieve the study’s goals. A good example of this, is a 
recent study which compared the compliance of HIV protease inhibitors for 108 
HIV infected adults over an 8 week period (Liu, Golin, Miller, Hays, Beck, 
Sanandaji, Christian, Maldonado, Duran, Kaplan and Wenger 2001). The 
researchers used a medication event monitoring system (MEMS), a pill count, a 
self-report interview and a combination of all these results known as the 
composite adherence score (CAS) to measure medication compliance which was 
then compared to the HIV viral load in the blood. They found that the composite 
score showed the strongest predictive relationship with the HIV viral load, 
suggesting that a composite score of more than one compliance measurement 
method is a more reliable way in which to predict medication compliance. In light 
of this, it could be speculated that other studies which used two compliance 
measurements such as self-reports and pill counts (Esposito 1995), as well as 
pill count and electronic monitoring (Bansberg, Hecht, Charlebois, Chesney and 
Moss 2001; Girvin, McDermott and Johnston 1999) more accurately predicted 
medication compliance than did the studies which used only one medication 
compliance measurement such as; self-reporting (Katon, Rutter, Ludman, Von 
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Korff, Lin, Simon, Bush, Walker and Unutzer 2001), pill counts (Haynes, Sackett, 
Gibson, Taylor, Hackett, Roberts and Johnson 1976) and urine tests (Colcher 
and Bass 1972). 
The implications of the work to date are that at least two compliance 
measures should be used when and if appropriate. In the absence of information 
about the best way in which to measure warfarin compliance in a community 
setting it could be argued that the two most appropriate methods include blood 
assays known as the international normalised ratio blood tests, INR blood tests, 
and self-reporting. The INR blood tests alone are not ideal because the tests can 
be done at varying time intervals depending on how often they are ordered by the 
health professionals thereby possibly distorting the overall results. The pill counts 
would be difficult and time consuming to conduct in a community setting, the 
electronic monitoring devices would need to be attached to each of the different 
warfarin strengths which could also distort the results if certain strengths were 
not always required during the research study, and pharmacy dispensing records 
would not be ideal when and if participants were using multiple pharmacies. In 
summary therefore, even though using the INR blood test and self-reporting are 
not ideal, they are a step forward in the way warfarin compliance data can be 
collected and evaluated. 
Researchers have found that many factors can contribute to poor 
medication compliance. These factors include poor knowledge and 
understanding (Fineman and DeFelice 1992; Fitten, Coleman, Siembieda, Yu 
and Ganzell 1995); cognitive and/or physical limitations such as failing eyesight 
and hearing complications (Stewart and Caranasos 1989), misinterpretation of 
instructions (Ruzicki, Bettesworth and Steele 1986); side effects (Ferguson, 
Ziedins, West, Richardson and Michocki 1996), visiting numerous medical 
practitioners, as well as having complex drug regimens which interfere with their 
daily living (Pendleton 1992).  
Reports in the literature have identified that these factors especially 
contribute to poor medication compliance in the ‘high risk’ group (Ryan 1999; 
Schlenk, Dunbar-Jacob and Engberg 2004). In a study of elderly patients, aged 
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65 years and over, Col et al (1990) interviewed 315 patients admitted to hospital 
and found that of the 89 patients admitted because of adverse drug events, 36 
(11.4 percent) were due to non compliance. The authors identified that having 
multiple medications, poor recall and seeing numerous physicians were amongst 
the many contributing factors for non compliance. Similarly, patients with low 
literacy skills may be non compliant because they cannot understand the 
information provided to them by their health professionals (Feifer 2003; Mayeaux 
Jr, Murphy, Arnold, Davis, Jackson and Sentell 1996; Roter, Rudd and Comings 
1998). This may also be the case with non-English speaking background patients 
(Ziguras, Klimidis, Lambert and Jackson 2001; Ziguras, Lambert, McKenzie and 
Pennella 1998). Unfortunately, there is very limited evidence in the literature 
about factors, which contribute to poor compliance in the non-English speaking 
background patients. A major factor contributing to the poor representation of 
studies with these populations in the literature is the subjects’ lack of the English 
language, often used as ineligibility criterion for inclusion into studies. It may be 
fair to assume, however, that they would also experience poor compliance based 
on factors already discussed.  
A recent systematic review of randomised trials of interventions to assist 
patients follow prescriptions for medications (Haynes, Montague, Oliver, 
McKibbon, Brouwers and Kanani 2001) identified that only 33 of the 1806 
citations met the stringent criteria set by the reviewers. The criteria included that 
(i) both compliance and treatment effects were measured, (ii) there was at least 
80% follow-up of each group studied; and (iii) for long-term treatments, the 
follow-up period was at least 6 months. The reviewers concluded that simplifying 
the medication regimen could improve compliance and treatment outcomes for 
both short and long term medications. However, to improve the compliance and 
therapeutic outcomes of long term medications the interventions needed to be 
more complex and include combinations of: more thorough patient education and 
counselling; reminders; close follow-up; reinforcement; supervised self-
monitoring; family support and rewards for success. Surprisingly, given its 
simplicity, they specified that the single most important intervention was recalling 
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patients and making every effort to keep them in care. It is noteworthy that even 
though there is evidence to support the positive influence of both social and 
behavioural factors to improve compliance and therapeutic outcomes (Col, 
Fanale et al. 1990), these were not targeted by any of the randomised control 
trials evaluated in this review by Haynes et al (2001).  
Similar results were also found in a meta-analysis (Roter, Hall et al. 1998) 
which summarised the results of 153 studies published between 1977 to 1994 
evaluating the effectiveness of interventions to improve patient compliance with 
medical regimens. Inclusion criteria for the meta-analysis included: (i) an 
intervention to influence or improve compliance; (ii) a control group and an 
intervention group; (iii) compliance with a therapeutic recommendation; (iv) an 
association with compliance and at least one intervention variable; (v) sample 
size no less than 10 and (vi) a study published in English. This meta-analysis, 
similar to the systematic review by Haynes, McDonald, Garg and Montague 
(2002a), concluded that a mixed programmatic focus was much more effective at 
improving medication compliance and therapeutic outcomes than was a single 
programmatic focus. These mixed programmatic focus interventions included 
patient education, familial support, heath professional/patient communication and 
partnerships, as well as emotional support. Unfortunately, the effectiveness of 
such mixed interventions, in patients with low literacy skills and from non-English 
speaking backgrounds, have not been evaluated to date. It would be reasonable 
to assume however, that such mixed focus interventions would also help to 
promote medication compliance and therapeutic outcomes in these patient 
populations. 
Other interventions shown to improve medication compliance include the 
use of compliance aids such as dosette boxes, reminders and blister packs 
(Roter, Hall et al. 1998; Wong and Norman 1987). A review of the 52 medication 
errors involving dosette boxes by Levings et al (1999) found that the problems 
were associated with incorrectly filling the dosette box and/or incorrect use of the 
dosette box. Even though this study concluded that more appropriate patient 
selection and more care with filling the dosette boxes would minimise these 
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adverse events, such compliance aids are not always the perfect solution to 
compliance problems. Not only are they expensive but they are also 
inappropriate for patients with significant cognitive impairment who cannot 
remember when and if they took their last dose of medications. This may 
subsequently result in patients either taking too many medications or not taking 
enough and therefore contributing to poor compliance and possible adverse drug 
events. 
Stewart and Caranasos (1989) also have made recommendations to help 
improve medication compliance, especially in the elderly patients. Their 
recommendations include the following: 
 Simple, clear instructions repeated periodically 
 Written instructions 
 Assessment of the cognitive function of the patient prior to the 
education, and tailoring the education to their ability 
 Development of a routine for taking medications 
 Construction of a chart when multiple medications were used. 
 
There is little doubt that improved medication compliance will help to 
optimise therapeutic outcomes and minimise adverse drug events  
(Haynes, McDonald et al. 2002a). Reports in the literature suggest that to 
improve medication compliance a mixed programmatic intervention approach 
rather than a single-focus intervention approach would be more successful for 
both short and long term medications (Haynes, McDonald and Garg 2002b; 
Roter, Hall et al. 1998). Since it is not possible at this stage to identify which 
combination of factors would be most useful, patient medication education 
programs should target the factors know to contribute to improved medication 
compliance. These factors include patient education and counselling, reminders, 
close follow-up, reinforcement, family support and where appropriate the use of 




2.4.4.4 Inappropriate written medication information 
 It is difficult for patients to optimise their therapeutic outcomes and avoid 
adverse drug events if they receive insufficient and inappropriate medication 
information. This may result in errors in judgment, failure to recognise important 
signs and symptoms of side effects, and possibly completely misunderstanding 
therapeutic regimens and treatment plans (Bhasale, Miller et al. 1998).  
Baker (1997) and Estrada, Hryniewicz et al (2000) have found that much 
of the currently available written medication information cannot be read or 
understood by a large proportion of the population. This is because it is written 
between grade 9 and grade 14 levels, well beyond the comprehension of those 
educated at or below a grade six level (Rolland 2000). It has also been identified 
that written information often contains a lot of medical jargon and terminology 
which cannot be read or understood by many patients, especially those with low 
literacy skills (DiMatteo 1997; Murphy and Davis 1997). Written medication 
information available in Australia, known as consumer medicine information 
(CMI), has been found to include such complex terms (Baker 1997; Koo, Krass 
and Aslani 2001).  
Since 1995 it has been mandatory that all prescription medicines in 
Australia be given to patients with the appropriate CMI, as outlined in the 
Therapeutic Goods Regulations (1990). These CMIs are available as package 
inserts, loose leaflets and in electronic format. The current legislation includes 
regulations about the content and presentation of CMIs but these regulations are 
not based on scientific evidence regarding how to communicate medicines 
information effectively to consumers. It has been reported that patients find CMIs 
difficult to read because of their font size, sheer volume of pages and their 
common inclusion of medical jargon (Koo, Krass et al. 2001). 
In an attempt to improve medication-related therapeutic outcomes, the 
literature identifies the need to provide simple and easy-to-comprehend 
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medication information (Esposito 1995). This information should be appropriate 
for all patient populations, including the ‘high risk’ group. Poor literacy skills and 
written patient medication information will be discussed in much greater detail in 
the next chapter.  
 
2.4.4.5 Poor continuity of care between hospital and community settings 
 Poor continuity of care between hospital and community settings has also 
been recognised as an important contributor to adverse drug events (Australian 
Council for Safety and Quality in Health Care 2002; Forster, Murff et al. 2003). 
Recently the Australian Pharmaceutical Advisory Council (APAC) introduced the 
‘Guidelines on the continuum of care of quality use of medicines between 
hospital and community’ (Australian Pharmaceutical Advisory Council 1998) with 
the aim to improve communication between both settings. Even though there are 
no evaluation data available on the impact of adhering to these guidelines, based 
on the fact that they were initially introduced to address the communication 
problems between hospital and community settings it would be fair to suggest 
that their effects would be positive. In other words, adherence to these guidelines 
could help to optimise therapeutic outcomes and reduce adverse drug events by 
promoting the timely transfer of information, not only to the patient and/or their 
carer, but also to the patients’ health professionals working in the community 
setting (Thornton, Simon and Mathew 1999). 
 Unlike typical hospital inpatient healthcare delivery services, Illawarra 
Health’s The Ambulatory Care Team (TACT) is a multidisciplinary team, which 
provides home healthcare delivery services to Illawarra residents aged 16 years 
and over who would otherwise be hospitalised. TACT is similar to the 
proliferating number of ‘Hospital in the Home’ (HITH) services available in 
Australia since 1995 (Duke and Street 2003), which have provided home 
healthcare delivery for medical conditions requiring anticoagulation management 
and intravenous antibiotics. TACT differs to many other Australian HITH services 
in that it provides a pharmacist to deliver home-based medication education 
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which is a new and emerging philosophy in patient medication education (Mullan 
1999; Stowasser 1999; Stowasser, Collins and Stowasser 2002).  
In the absence of good continuity of care between hospital and 
community-based settings (Balla and Jamieson 1994; Bolton, Mira, Kennedy and 
Moses-Lahra 1998), TACT is well placed to promote the continuity of care by 
incorporating the APAC guidelines (1998) into its everyday practice. There is an 
implication that adhering to these guidelines will help to optimise therapeutic 
outcomes and minimise adverse drug events.  
 
2.4.4.6 Patient follow-up 
 Patient follow-up, including telephone follow-up, has been identified as an 
important strategy to help optimise therapeutic outcomes and minimise adverse 
drug events. Patient follow-up has the potential to improve health 
professional/patient communication and partnerships, medication compliance, 
medication information and the continuity of care because it directly impacts on 
each of these factors (Haynes, McDonald et al. 2002a). 
 Evidence to support the positive influence of telephone follow-up on health 
professional/patient communication and partnerships can be found in a study 
conducted by an American telephone anticoagulation service, which managed 
between 300 and 400 patients. Following a 12-month surveillance period, this 
service found that its patients, all of whom received telephone follow-up, were 
more proactive with their warfarin therapy and more likely to have therapeutic 
blood tests results, than were patients who did not receive the follow-up service 
(Waterman, Milligan, Banet, Gatchel and Gage 2001). Another study, which 
involved 30 African American men with type 2 diabetes, also found that 
telephone follow-up, accompanying a structured education program, contributed 
to favourable diabetes health outcomes and improved patient/health professional 
partnerships (Hendricks and Hendricks 2000). While these studies examine 
actions of patients with different health problems, it appears that the importance 
of patient follow-up is common to successfully managed community therapeutic 
programs. 
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 A meta-analysis on the effectiveness of interventions to improve patient 
compliance and education concluded that telephone follow-up was an integral 
part of the essential mixed programmatic focus interventions (Roter, Hall et al. 
1998). This meta-analysis included a study, which compared the effectiveness of 
improving medication compliance in 82 patients for a 10 to 14 day course of 
antibiotic therapy. The study found that the mean compliance for the telephone 
follow-up patients who also received written and oral counselling was significantly 
better than for the control patients who received neither telephone follow-up nor 
counselling. Those in the former group achieved 85.4 percent mean compliance 
while those in the latter just 76.6 percent mean compliance (Garnett, Davis, 
McKenney and Steiner 1981). Similarly, another study within the same meta-
analysis, observing 60 Non Insulin Dependent Diabetes Mellitus (NIDDM) 
patients found that patients who received the follow-up intervention (by telephone 
calls and home visits) were more compliant with their diabetes management plan 
than were patients who received the standard educational program with no 
follow-up intervention (Estey, Tan and Mann 1990). Regardless of the fact that 
the medications were for both short and long-term use, the studies indicate that 
patient follow-up, including telephone follow-up, helped to improve medication 
compliance. 
 Regular follow-up in long-term self-management programs have been 
found to enhance outcomes for asthmatic children (Gebert, Hummelink, Konning, 
Staab, Schmidt, Szczepanski, Runde and Wahn 1998), as well as other chronic 
disease states (Lorig 1996). A recent Australian study found that home-based 
follow-up of patients discharged from hospital on warfarin therapy resulted in 
significant reductions in the number of haemorrhagic complications (Jackson, 
Peterson, Vial and Jupe 2004). An American study which evaluated the impact of 
a 12-month follow-up telephone call service provided by a pharmacist to 221 
patients discharged from a general hospital found that fewer patients from the 
telephone call group returned to the emergency department within 30 days (10 
percent phone call compared to 24 percent no phone call). This study found that 
not only did the follow-up telephone service reduce the incidence of adverse drug 
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events but it also increased patient satisfaction (Dudas, Bookwalter, Kerr and 
Pantilat 2001). 
 Based on the evidence in the literature it can be concluded that follow-up 
is an essential component for effective medication education. Patient follow-up, 
including telephone follow-up, can be used to specifically target and reinforce 
other factors such as; health professional/patient communication and 
partnerships, medication compliance and management, patient education and 
improved patient satisfaction, all of which help to optimise therapeutic outcomes 
and minimise adverse drug events. 
 
2.4.4.7 Summary  
 In order to optimise therapeutic outcomes and minimise adverse drug 
events it is important to target key elements known to contribute to such events. 
These key elements have been found to include improving health 
professional/patient communication and partnerships, improving medication 
compliance, providing simple, easy-to-read written medication information, 
improving the continuity of care between hospital and community settings, and 
offering patient follow-up. Effective medication education should not only target 







 The focus of the discussion will now turn to the oral anticoagulant warfarin. 
Warfarin has been identified as a major medication causing adverse drug events, 
both in Australia and overseas (Australian Council for Safety and Quality in 
Health Care 2002; Forster, Murff et al. 2003; Hirri and Green 2002). To date, 
warfarin-related adverse drug events have been identified as a large and 
unresolved problem (Campbell, Roberts et al. 2001). This problem has the 
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potential to grow and escalate with continually emerging research findings 
demonstrating its benefits in patients with different disease states such as atrial 
fibrillation (Ezekowitz and Falk 2004; Gallus, Baker et al. 2000; Peterson, 
Jackson et al. 2002). Consistent with previous discussions of the ‘high risk’ 
patient population, those most likely to experience warfarin-related adverse drug 
events include the elderly, those with low literacy skills (Estrada, Martin-
Hryniewicz et al. 2004; Lambert and Wynne 2003; Tang, Lai et al. 2003) and 
those from non-English speaking backgrounds (Nadar, Begum et al. 2003).  
 It could be argued that inadequate warfarin education programs (Connor 
1998) and patient warfarin knowledge deficiencies (Cheah and Martens 2003; 
Lambert and Wynne 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 2003) 
support the need for a new effective warfarin education program. This thesis 
promotes the development and implementation of a new warfarin education 
program, which acknowledges and averts the historical inadequacies, offering a 
considered approach to effective patient education. This improved patient 
education will in turn empower patients to make informed decisions about their 
warfarin therapy, helping to optimise their therapeutic outcomes and minimise 
adverse drug events (Ansell, Buttaro et al. 1997; Kagansky, Knobler, Rimon, 




 To understand why warfarin is being prescribed more frequently today, it 
is essential to know its function. Warfarin, which is derived from clover (Catania 
1994), works by limiting the availability of vitamin K, a necessary component in 
the formation of coagulation factors II (prothrombin), VII, IX and X, and the 
anticoagulant proteins C and S. Warfarin prevents new clots from forming and 
existing clots from getting bigger (Catania 1994). The extent of the warfarin-
induced blood coagulation defect, expressed as an International Normalised 
Ratio (INR), is the major determinant of treatment success or failure. 
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 To achieve safe and effective warfarin treatment, patients need to be 
effectively educated about the most important considerations in managing their 
warfarin therapy. These considerations include: indications for therapy; how and 
when to take their warfarin; the importance of regular blood tests; target 
International Normalised Ratio (INR) levels; possible warfarin-related side effects 
and drug-to-drug interactions; and exercise, dietary and alcohol restrictions 
required to optimise therapy (Gallus 1999). 
 Until recently the use of warfarin has been limited to the treatment of 
venous thrombosis or pulmonary embolism, the prevention of systemic embolism 
caused by prosthetic heart valves and the recurrence of embolic stroke (Gallus 
1999). Less frequently, warfarin has been used to prevent systemic embolism in 
refractory heart failure or when atrial fibrillation complicates cardiac valvular 
stenosis or incompetence. There has also been limited usage of warfarin to 
prevent venous thrombo-embolism after hip surgery, or to prevent a recurrence 
of myocardial infarction (Gallus, Baker et al. 2000).  
More recently, it has been found that warfarin dramatically reduces the 
risk of embolic stroke in patients with atrial fibrillation (AF) and that treatment 
benefits significantly outweigh the risks (Ansell, Buttaro et al. 1997; Gallus, Baker 
et al. 2000). Despite these benefits in patients with atrial fibrillation, warfarin is 
underused, especially in elderly patients (DeBray, Couturier and Siguret 2003; 
Peterson, Jackson et al. 2002; Whittle, Wickenheiser and Venditti 1997), 
primarily because physicians perceive the risk of poor compliance and a lack of 
warfarin knowledge and understanding as being unacceptably high among these 
patient populations (Man-Son-Hing and Laupacis 2003). With an increased 
pressure to prescribe, however, and with the possibility of improving patient 
warfarin education, this situation may change in the near future. 
 
2.5.3 Incidence of warfarin-related adverse drug events  
 The literature identifies that warfarin is responsible for a high incidence of 
adverse drug events (Australian Council for Safety and Quality in Health Care 
2001; Forster, Murff et al. 2003; Runciman, Roughead et al. 2003). With recent 
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increases in warfarin prescribing (Cruickshank, Ragg et al. 2001) and the 
likelihood that prescribing will further increase for patients diagnosed with atrial 
fibrillation (Gallus, Baker et al. 2000), warfarin-related adverse drug events will 
almost certainly grow in magnitude.  
 Australian data support the evidence that warfarin-related adverse events 
are a large and unresolved problem (AIHW 2003), causing an estimated cost of 
$100 million per annum for hospitalisation alone in 1992 (Rigby, Clark et al. 
1999). From 1999 to 2000, warfarin was associated with 5,080 adverse drug 
events requiring admission to Australian hospitals, 7.3 percent of the total 
adverse drug events (AIHW 2002). Data from the Australian Institute of Health 
and Welfare (AIHW 2003), indicates that there has been a steady increase in the 
number of warfarin-related hospital admissions over the past few years. 
According to these data, hospital admissions with diagnosis code ICD-10-AM 
T455 (anticoagulant poisoning) increased from 434 in 1998/99, to 449 in 1999/00 
and then to 471 in 2000/01, an increase of 8.5 percent over the three year period 
from 1998 to 2001. Similarly, hospital admissions for the external cause code 
ICD-10-AM Y442 (anticoagulants primarily affecting blood constituents), 
increased from 4,378 in 1998/99, to 5,080 in 1999/2000 and then to 5,228 in 
2000/2001 (AIHW 2003), an increase of 19 percent over the three year period 
from 1998 to 2001. Unfortunately, there are no data available about the incidence 
of warfarin-related adverse drug events and the number of general practice 
encounters over the past few years. However, based on the hospital data and the 
evidence that patients can be successfully treated for warfarin induced bleeding 
in an outpatient setting (Brigden, Kay, Le, Graydon and Mcleod 1998), as well as 
the availability of guidelines to treat warfarin-related adverse events in both 
community and hospital settings (Gallus, Baker et al. 2000) it could be assumed 
that similar increases are being experienced in the community sector. 
Data available from the Australian Therapeutic Goods Administration 
(TGA) Adverse Drug Reactions Advisory Committee (ADRAC 2005) also indicate 
that the reporting of suspected warfarin-related adverse drug events has 
increased progressively over the past few years, from 47 reports in 1992, to 103 
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reports in 1999 and then to 115 reports in 2004. Even though a significant portion 
of these reports relate to the loss of anticoagulant control either because of 
dose/compliance or interactions with other co-administered drugs and are not a 
true indication of the total number of warfarin-related adverse drug events their 
increase in number over the past few years supports the evidence that warfarin-
related adverse drug events are on the rise in Australia. 
 It could be argued that this steady increase in warfarin-related adverse 
drug events could be attributed to the increase in warfarin prescribing (Arnsten, 
Gelfand and Singer 1997; Elliott, Woodward et al. 2002; Peterson, Jackson et al. 
2002), rising from 1.673 million warfarin prescriptions in 1999 (Commonwealth 
Department of Health and Aged Care 2003) to 1.897 million warfarin 
prescriptions in 2002 (Commonwealth Department of Health and Aged Care 
2004). However, many other factors have been found to contribute to adverse 
drug events. These factors include; poor health professional/patient 
communication and partnerships (Bhasale, Miller et al. 1996), poor warfarin 
compliance (Campbell, Roberts et al. 2001), poor and inappropriate written 
warfarin information (Estrada, Hryniewicz et al. 2000; Estrada, Martin-Hryniewicz 
et al. 2004), poor continuity of care between hospital and community settings 
(Bramley-Moore, Dwyer, Perlman and Sucic 1996) and poor patient follow-up 
(Pickette 2002). Importantly, warfarin-related adverse events are a major concern 
for the ‘high risk’ patient population which include the elderly and those with low 
literacy skills (Lambert and Wynne 2003; Tang, Lai et al. 2003), as well as the 
non-English speaking background patients (Nadar, Begum et al. 2003). 
In summary, the incidence of warfarin-related adverse drug events is on 
the increase and will continue to rise with recent recommendations to prescribe 
warfarin for diseases such as atrial fibrillation (Elliott, Woodward et al. 2002; 
Peterson, Jackson et al. 2002). Strategies need to be put in place to improve 
patient warfarin education (Hirri and Green 2002; Kagansky, Knobler et al. 2004) 
by targeting the elements known to contribute to poor warfarin-related 
therapeutic outcomes and adverse drug events.  
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2.5.4 Inadequacies in currently available warfarin education programs  
 Effective patient education is paramount to the success of warfarin 
therapy (Kagansky, Knobler et al. 2004; Pubentz, Calcagno and Teeters 1998; 
Roche-Nagle, Chambers, Nanra, Bouchier-Hayes and Young 2003). Literature 
spanning 20 years suggests that most warfarin education programs are based on 
content, without demonstrating any structured framework, program design or 
outcome evaluation (Wyness 1989). It appears that over the years, warfarin 
education programs have evolved relying on the health professionals’ intuition, 
convenience and habit as the use of warfarin has increased. The literature 
suggests that many of these education programs are inadequate (Connor 1998), 
presenting too much information and overwhelming patients (Ansell, Buttaro et 
al. 1997). 
There is almost no reporting of current available warfarin education 
programs in the literature and as a consequence little evidence regarding 
effectiveness of such programs. A review by Wyness (1989) some 15 years ago 
provided evidence regarding 15 different warfarin education programs available 
at the time. The major emphasis for each of the programs was content rather 
than stating any education objectives or evaluation outcomes. The programs 
mainly used written information sheets and/or booklets as teaching aids, with two 
of the programs providing audiovisual videos. The points emphasized during the 
education programs were based on the individual choice of the educator rather 
than being based on any structural framework. The other important issue about 
these warfarin education programs was that none of them were evaluated which 
means that it is not possible to compare the effectiveness of the different 
programs.  
The primary warfarin-related focus in the literature today is on the 
important warfarin information for health professionals (Deblinger 2000; Gibbar-
Clements, Shirrell, Dooley and Smiley 2000; Hirsh, Dalen, Deykin, Poller and 
Bussey 1995). Evidence regarding the effectiveness of current warfarin 
education programs is almost nonexistent. Interestingly however, for anyone with 
access to a computer or the internet, there is a proliferation of information about 
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warfarin. This electronically available information primarily is not based on any 
systematic educational approach and is often devoid of scientific evidence. 
Examples of these include the Clever Clog – anticoagulation education software 
for use in the primary care setting, as well as the plethora of warfarin websites 








Shortcomings in current warfarin education programs are borne out by 
reports of deficiencies in patients’ warfarin knowledge, which can predispose 
them to poor therapeutic control and adverse drug events (Lambert and Wynne 
2003; Nadar, Begum et al. 2003; Wilson, Racine et al. 2003). Recent American 
(Cheah and Martens 2003) and English (Taylor, Ramsay, Tan, Gabbay and 
Cohen 1994) studies which evaluated patient warfarin knowledge, found that 
overall most patients exhibited warfarin knowledge deficits, even after they had 
received warfarin education. Cheah and Martens (2003) study of 50 hospital 
inpatients, found that although 68 percent were satisfied with the education they 
received, there was an overall warfarin knowledge deficit, with knowledge scores 
ranging from 6.3 percent to 87.5 percent, out of a possible 100 percent (Mean, 
46.9; Standard Deviation 20.9). Taylor et al (1994) evaluated the warfarin 
knowledge scores for 70 outpatients using a different warfarin knowledge 
questionnaire. They also found that overall warfarin knowledge was poor, with 
only half the patients being able to identify adverse events associated with poor 
anticoagulant control, a safe level of alcohol consumption and possible drug-to-
drug interactions with non-prescription drugs and warfarin therapy. Unfortunately, 
because these studies did not use the same warfarin education programs or the 
same questionnaire to analyse warfarin knowledge they cannot be directly 
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compared. They do suggest however, that currently used warfarin education 
programs are not effective in ensuring that the patients have adequate warfarin 
knowledge and understanding to safely manage their warfarin therapy at home. 
 Many studies have confirmed that the patients most likely to experience 
poor therapeutic outcomes and adverse drug events because of their warfarin 
knowledge deficits are the elderly (Tang, Lai et al. 2003), those with low literacy 
skills (Estrada, Martin-Hryniewicz et al. 2004) and patients from non-English 
speaking backgrounds (Nadar, Begum et al. 2003). Tang et al (2003) conducted 
a study in Hong Kong from January to March 1999 and found that overall 
warfarin knowledge was poor in the 122 patients evaluated, especially amongst 
the elderly and those with low literacy skills. Only 40 - 45 percent of the patients 
knew the strengths of their warfarin tablets, the reason for taking their warfarin 
and its effects on the body. The 60 patients who had read the written warfarin 
information had a better warfarin knowledge than those who did not, and illiteracy 
was noted as the main reason for not having read the written information. In this 
study not only were the elderly patients and those with low literacy skills found to 
have the poorest warfarin knowledge and understanding they were also found to 
have poorer anticoagulant control. Similarly, a study by Estrada et al (2004) 
found that of the 143 American patient participants over the age of 50, those with 
poor literacy skills had poorer than average warfarin knowledge and 
anticoagulant control. The study by Nadar et al (2003) on 180 non-English 
speaking background (NESB) patients attending a United Kingdom 
anticoagulation clinic, used different warfarin knowledge questionnaires to 
evaluate their warfarin knowledge data, but interestingly they also found that on 
average warfarin knowledge was poor with an average score of 5.5 (61.1 
percent) out of a total score of 9 for the NESB and elderly patients. The results of 
these studies highlight that current warfarin education programs do not effectively 
educate patients, especially those at ‘high risk,’ about their warfarin therapy. This 
predisposes patients to poor therapeutic outcomes and warfarin-related adverse 
drug events. In addition, these studies also identify a limitation in the area of 
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warfarin education research, as there appears to be a lack in common validated 
instruments to determine the levels of warfarin knowledge and understanding.  
There is also an absence of the descriptions and/or evaluations of 
Australian based warfarin education programs in the literature. It must be 
presumed therefore, that warfarin education in Australian hospital and community 
settings is based on an ad hoc set of messages decided upon by the health 
professionals. In the absence of consensus guidelines for warfarin education, the 
health professionals themselves decide what information about warfarin they 
should deliver to their patients. Concerns are mainly focused on the maintenance 
of an appropriate International Normalised Ratio (INR). It is only when these 
results are not within normal range that the health professionals question their 
patients in an attempt to discover what it is that they may be doing to cause their 
INR results to be outside therapeutic range.  
As well as presenting the warfarin education on a seemingly ad hoc basis, 
other idiosyncrasies regarding warfarin education exist. Rather than use the 
warfarin consumer medicine information, CMI, many of the Australian health 
professionals delivering warfarin education either develop and use their own 
written patient warfarin information or alternatively use the Boots warfarin 
information booklets (2002; 2003). Unfortunately, much of this information is 
written at a level (Baker 1997; Estrada, Hryniewicz et al. 2000) beyond the 
comprehension of many patients and hence inappropriate as a written 
information resource. 
Inadequacies in patient knowledge resulting from the currently available 
warfarin education programs highlight the need for a new more systematic 
approach to the delivery of warfarin education. Such a program should target the 
key elements believed to contribute to poor therapeutic outcomes and adverse 
drug events. During the development and implementation of this new program, 
special consideration should be directed to the development and/or use of 
validated instruments to determine if possible, the contribution of various 




2.5.5 The impact of improved warfarin education of warfarin-related 
therapeutic outcomes and adverse drug events 
A well-organised structured education program should enable patients to 
learn the necessary skills to achieve optimal therapeutic outcomes and minimise 
adverse drug events. Kagansky et al (2004) reported a combined retrospective 
and prospective cohort study on 323 patients, aged 80 years and older who were 
discharged from hospital on an oral anticoagulant. After following up these 
patients for approximately two to three years, the researchers found that the rate 
of major bleeds was highest amongst the patients who received poor quality 
warfarin education, which had been performed by the medical staff. The 
education programs consisted of an explanation about the purposes of the oral 
anticoagulant, the risk of complications and information about INR values. The 
poor quality of such education was found to be the most significant risk factor 
associated with bleeding complications in this elderly patient population. The 
results of this study like many others (Arnsten, Gelfand et al. 1997; Nadar, 
Begum et al. 2003; Roche-Nagle, Chambers et al. 2003) suggest that a good 
quality warfarin education program could help to reduce the incidence of bleeding 
complications associated with poor warfarin management. 
Patients who have a poor understanding of the indications for warfarin use 
and its potential adverse effects are more likely to be non compliant than are 
those who receive warfarin education (Arnsten, Gelfand et al. 1997). Barcellona 
et al (2002) found that the time spent within therapeutic range was improved for 
patients who knew why they were taking their oral anticoagulant, as compared to 
those who did not, significantly more so for the elderly patients aged 65 years 
and over (89 percent versus 76 percent, p = 0.04). This study also found that 
patients’ anticoagulation control could be improved by simply answering a 
warfarin knowledge questionnaire.  
Evidence exists that poor compliance with anticoagulant treatment occurs 
in 10 – 26% of cases, especially among the elderly patients (Arnsten, Gelfand et 
al. 1997). An audit of hospital admissions over a 3 month period found that poor 
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anticoagulant compliance was the major contributing factor causing over-
anticoagulation in 29 patients (Hirri and Green 2002). Similarly, Brigden et al 
(1998) also found that along with drug-to-drug interactions, poor compliance was 
a significant contributor to poor anticoagulation control in 65 patients admitted to 
hospital.  
Comprehensive patient education about warfarin should also target 
improved patient education about drug-to-drug interactions with warfarin, which 
has been found to be responsible for many warfarin-related adverse drug events 
(Barcellona, Contu and Marongiu 2002; Brigden, Kay et al. 1998). Barcellona et 
al (2002) found that patients who knew more about potential food and warfarin 
interactions spent more time within therapeutic range than did those who did not. 
Similarly, Wilson et al (2003) identified that more than half of the 65 African 
American patients, aged 50 years and over in their study, could not read or 
understand the culturally inappropriate written information given to them, and 
were therefore more susceptible to warfarin related adverse drug events based 
on possible drug-food interactions.  
 Thus patients’ knowledge abut warfarin is still generally poor, especially 
for patients in the ‘high risk’ group (Cheah and Martens 2003; Lambert and 
Wynne 2003; Nadar, Begum et al. 2003), highlighting the need for a more 
effective warfarin education program. This new program would need to target the 
many interventions found to help improve medication compliance (Haynes, 
McDonald et al. 2002a; Roter, Hall et al. 1998), as well as the many other factors 
believed to contribute to improved warfarin anticoagulation control. Such factors 
include encouraging patients to be involved in the decision making process 
(Dantas, Thompson, Manson, Tracy and Upshur 2004), promoting good health 
professional communication and partnerships (Barcellona, Contu, Sorano and 
Marongiu 2000), and providing easy-to-read culturally appropriate written 
warfarin information (Estrada, Hryniewicz et al. 2000; Wilson, Racine et al. 2003). 
Dantas et al 2004 conducted 21 face-to-face interviews with older patients and 
found that even though satisfaction was high amongst all patients, those who 
were more involved with the decision making process had a better warfarin 
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knowledge and understanding than those who were not. Further evidence to 
support the need to promote health professional/patient communication and 
partnerships can be seen in the 96 percent response rate from the 264 patients 
attending two Italian anticoagulation clinics, indicating that doctor-patient 
relationships were very important to them (Barcellona, Contu et al. 2002). The 
importance of easy-to-read culturally appropriate written warfarin information will 




 Warfarin is one of the major medications causing adverse drug events, 
both in Australia and overseas (Australian Council for Safety and Quality in 
Health Care 2002; Forster, Murff et al. 2003). The incidence of warfarin-related 
adverse drug events is on the rise with recent recommendations for increased 
warfarin prescribing in atrial fibrillation (Cruickshank, Ragg et al. 2001). 
Inadequacies in the currently available warfarin education programs (Connor 
1998) and patient warfarin knowledge deficiencies (Cheah and Martens 2003; 
Nadar, Begum et al. 2003; Tang, Lai et al. 2003), highlight the need for a new 
patient warfarin education program to help improve the patients’ warfarin 
knowledge and understanding (Hirri and Green 2002). This new warfarin patient 
education program should target the key elements believed to contribute to poor 
warfarin-related therapeutic outcomes and warfarin-related adverse drug events, 
as well as the needs of the ‘high risk’ patient population.  
 
 
 2.6 CONCLUSION 
 This chapter has identified that many adverse drug events, including 
warfarin-related adverse drug events, which are potentially preventable, have a 
major impact on health, healthcare and healthcare costs, both in Australia and 
overseas. Improved patient medication education has been recognised as an 
important intervention, which can be used to help optimise therapeutic outcomes 
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and reduce the potentially preventable adverse drug events. Recent and ongoing 
increases in warfarin prescribing are likely to lead to a further increase in the 
incidence of warfarin-related adverse drug events.  
 The literature has identified that current warfarin education programs are 
not as effective as they should be, because many patients, and especially ‘high 
risk’ patients, have deficits in their warfarin knowledge. This highlights the need 
for a new more systematic approach to the delivery of warfarin education 
targeting the key elements believed to contribute to poor therapeutic outcomes 
and adverse drug events, while addressing the needs of ‘high risk’ patients. The 
key elements which should be targeted include: improved health 
professional/patient communication and partnerships; warfarin compliance; 
simple, easy-to-read written warfarin information; continuity of care between 
hospital and community settings; and patient follow-up.  
 The next chapter focuses on the problems associated with patients having 
poor literacy skills and their inability to read and understand typically available 
written medication information, including warfarin information. The chapter 
recommends the use of a number of simple tests and instruments to assess and 
ensure that written patient medication information can be read and understood by 
a wider patient population, inclusive of those with low literacy skills. The chapter 
also recommends a number of simple instruments, which can be used to ensure 
that the patient medication education program is of a suitable, good quality 




LOW LITERACY SKILLS, WRITTEN PATIENT MEDICATION 





The previous chapter highlighted the need to target key elements which 
contribute to adverse drug events, in order to improve patient medication 
education, including patient warfarin education, and to help optimise therapeutic 
outcomes. Several interventions which focus on these key elements were 
discussed, with an emphasis on the need to accommodate the ‘high risk’ patient 
population. This chapter focuses on problems associated with low literacy skills 
and the readability of currently available written patient information, including 
warfarin information. It also highlights the importance of evaluation, which is often 
neglected in medication education programs. 
Prior to developing and implementing any new patient medication 
education programs, however, it is important to consider the problems associated 
with patients having poor literacy skills. Unfortunately, poor literacy skills which 
can contribute to poor patient knowledge and understanding (Davis, Crouch, 
Wills, Miller and Abdehou 1990; Winslow 2001) can also aggravate the problems 
associated with poor medication compliance, poor therapeutic outcomes (Horner, 
Surratt and Juliusson 2000) and the increased incidence of adverse drug events 
(Feifer 2003). Research indicates that much of the currently available written 
patient medication information, used as an adjunct to verbal instruction, is written 
at levels beyond the comprehension of many patients, and especially those with 
low literacy skills (Koo, Krass and Aslani 2003; Mayeaux Jr, Murphy et al. 1996; 
Rutledge and Donaldson 1998). This chapter considers some of the readability 
tests, guidelines and evaluation instruments which can be used to ensure that 
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written patient medication information can be read and understood by a wider 
patient population, inclusive of those with low literacy skills. 
 Finally, the significance of evaluation cannot be overlooked and should be 
identified as an important intervention for an effective patient medication 
education program. Process, impact and outcome evaluation are invaluable ways 
in which to ascertain the suitability and quality of an education program. The 
patient’s satisfaction with the program is an important factor and assessing 
whether or not it achieves its goals and objectives are important ways in which to 
assess the success of the program. 
 
 
3.2 LOW LITERACY SKILLS AND WRITTEN PATIENT MEDICATION 
INFORMATION  
 
3.2.1 The problem of low literacy in healthcare 
Low literacy is a pervasive and under-recognised problem in healthcare, 
both in Australia and overseas (Baker 1997; Mayeaux Jr, Murphy et al. 1996). 
Low literacy skills have been found to contribute to increased healthcare costs, 
adverse drug events, poor compliance (Feifer 2003) and an increase in hospital 
admissions (Baker, Parker et al. 1998; Winslow 2001). For many patients, a lack 
of literacy is a major obstacle to effective healthcare (Doak, Doak et al. 1998) 
because they lack sufficient knowledge to effectively manage their medications 
(Williams, Baker et al. 1998) and simply cannot read or understand the 
commonly used written information (Council on Scientific Affairs 1999; Davis, 
Michielutte, Askov, Williams and Weiss 1998; Roter, Rudd et al. 1998). 
People with low literacy skills include not only the poorly educated but also 
the elderly (aged 65 years and over) and immigrants who speak English as a 
second language (Doak, Doak et al. 1996b). Based on data from the Australian 
Bureau of Statistics (ABS), a large proportion of the Australian population has 
low literacy skills. The 1996 Australian literacy survey identified that 20 percent of 
Australians aged 15 to 65 years, and 41 to 46 percent aged 65 to 74 years, have 
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very poor literacy skills (level 1) (Australian Bureau of Statistics 1996). Another 
investigation has also found that of the 20 percent of Australians who are from 
non-English speaking backgrounds (NESB), 2.5 percent speak little or no English 
(McLennan 1998). These patient populations cannot read or comprehend the 
typically available written medication information (Albright, Guzman, Acebo, 
Paiva, Faulkner and Swanson 1996; Baker 1997; Davis, Michielutte et al. 1998). 
 
3.2.2 Written patient medication information 
 
3.2.2.1 Background  
Written educational materials are convenient, economical and very useful 
for providing medication information to patients and/or their carers (Bernier and 
Yasko 1991; Clark, AbuSabha, von Eye and Achterberg 1999). Research has 
identified that by adding simple and easy-to-read medication information to 
verbal instruction there is an increase in patient knowledge, compliance and 
satisfaction with therapeutic regimens (Baker, Roberts, Newcombe and Fox 
1991; Roter, Hall et al. 1998). Evidence to support this is reported in a recent 
Cochrane collaborative review of 33 randomised clinical trials which concluded 
that combination strategies, including written medication information and 
counselling, improve compliance and clinical outcomes for both short-term (less 
than two weeks) and long-term treatments (Haynes, McDonald et al. 2002a).  
Presently, the reading grade levels of written medication information, 
including warfarin information, available in Australia and overseas have been 
assessed to range from grade 9 to grade 14 (Baker 1997; Estrada, Hryniewicz et 
al. 2000; Weiss 1997). These are considerably higher than the average reading 
grade ability of many patients with low literacy skills, which is deemed to be 
below a grade 6 readability level (Davis, Crouch et al. 1990; Rolland 2000). 
Studies in America (Baker, Parker et al. 1998; Estrada, Martin-Hryniewicz et al. 
2004; Gazmararian, Baker, Williams, Parker, Scott, Green, Fehrenbach, Ren and 
Koplan 1999) and in Australia (Baker 1997) confirm that these patients have 
difficulty reading currently available written medication information. The 
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readability of 30 consumer product information (CPI) leaflets, currently known as 
consumer medicine information (CMI), available in Australia (Baker 1997), using 
the Flesch Reading Ease (FRE) formula (Flesch 1948) (APPENDIX One) 
identified that only 40 percent or less of the patient population could read or 
understand these leaflets. Koo et al (2001) also identified that in an Australian 
study with 38 focus group participants over the age of 18, many of them were not 
only dissatisfied with the font size and volume, but they were also dissatisfied 
with the amount of medical jargon included in their CMI information. 
Patients with low literacy skills are often too embarrassed to admit that 
they cannot read or understand commonly used written patient information 
(Mayeaux Jr, Murphy et al. 1996). They are more likely therefore to experience 
poorer therapeutic outcomes and adverse drug events than are patients from the 
general patient population (Baker, Parker et al. 1998; Consumers' Health Forum 
of Australia 2000; Winslow 2001). Given that a sizeable proportion of the 
Australian population has low literacy skills (Australian Bureau of Statistics 1996), 
it has been recommended that written medication information should be available 
at or below the average reading ability of an Australian, estimated to be grade 8 
(Buchbinder, Hall, Grant, Mylvaganam and Patrick 2001). Indeed others like 
Doak et al (1996) recommend that all written patient medication information 
should be available at or below a grade 6 reading level, which arguably would be 
more suitable for patients with low literacy skills. In some situations this may be 
possible, unfortunately however because of medication names and related 
terminology this may not always be possible.  
Multiculturalism is identified as an important factor which affects the 
comprehension of written patient medication information (Voelker 1995; Westby 
1995; Wilson, Racine et al. 2003). This is especially true in Australia where much 
of the information is almost exclusively written in English (Bajramovic and Tett 
2000). Having the information translated into another language is not always an 
easy solution because many non-English speaking patients are illiterate in their 
native language, as well as in English. Ideally these patients need to be verbally 
educated about their medications in their own languages with the assistance of 
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an interpreter (Williamson, Stecchi, Allen and Coppens 1997). This would help to 
reduce the communication barrier and improve medication education, 
compliance and therapeutic outcomes for these non-English speaking 
background patient populations (Lambert and Minas 1998; Minas, Lambert et al. 
1996).  
 In summary, a large proportion of the Australian population has low 
literacy skills and cannot read or understand the currently available written 
patient medication information, including warfarin information. The time has come 
to address this problem. All written patient medication information, including 
warfarin information, should be presented in a simple and easy-to-read format, 
written at or below a grade 8 to grade 6 reading level (Doak, Doak et al. 1996b). 
The inclusion of these factors into written medication information would help to 
ensure their readability and comprehension by a wider patient population, 
inclusive of those with low literacy skills (Butow, Brindle, McConnell, Boakes and 
Tattersall 1998).  
 
3.2.2.2 Preparation of written patient medication information   
A patient’s understanding and satisfaction with written information has 
also been found to be influenced by factors such as format, colour, text, print size 
and the use of illustrations (Clark, AbuSabha et al. 1999; Klug Redman 2001). It 
is important, therefore, to address these factors which help to engage the interest 
of most patient populations, including patients with low literacy skills (Koo, Krass 
et al. 2003).  
There are a number of tools and guidelines available to assist with 
addressing factors such as format, colour, text, print size and illustrations. The 
United Kingdom Department of Health recently produced the ‘Toolkit for 
Producing Patient Information’ (2002) (APPENDIX 2) which is simple and easy to 
use. Alternatively, the ‘Guidelines for Writing Patient Information’ (Doak, Doak et 
al. 1996b) (APPENDIX 3) provide useful recommendations on how to ensure that 
these factors are addressed for patients with low literacy skills. The impact of 
both the ‘Toolkit for Producing Patient Information’ (2002) and the ‘Guidelines for 
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Writing Patient Information’ (1996) on the quality and suitability of health 
information have yet to be formally evaluated, however, they are functional, 
practical and easy to use.  
When preparing written information for distribution to patients from non-
English speaking backgrounds it is important to ensure that the information and 
illustrations are culturally sensitive. Seeking the advice of cultural group 
members and health professionals who are from these cultural groups during the 
planning and development stage helps to ensure that the information is in fact 
culturally-sensitive (Doak, Doak et al. 1996b). In most circumstances, when 
money and time permits, written patient information should be translated from 
English into the patients’ language, when and if required. This of course would 
only benefit the non-English speaking background patients who are literate in 
their native language (Williamson, Stecchi et al. 1997).  
For the many health professionals who are involved in the preparation of 
written patient medication information, it is important to acknowledge that the 
patients’ understanding and satisfaction with the information can be influenced by 
factors such as format, colour, text, print size and illustrations (Clark, AbuSabha 
et al. 1999; Klug Redman 2001). Health professionals should therefore use 
simple tools and guidelines such as the ‘Toolkit for Producing Patient Information’ 
(The United Kingdom Department of Health 2002) and the ‘Guidelines for Writing 
Patient Information’ (Doak, Doak et al. 1996b) when preparing and developing 
written patient information.  
 
3.2.2.3 Assessing the readability of written patient medication information 
The goal of written patient medication information is to increase patient 
understanding and comprehension and to serve as resource material for the 
patient and/or their carer. It is the responsibility of health professionals to ensure 
that the available written medication information can be read and understood by 
the majority of patients, including those with low literacy skills. There are two 
methods which can be used to assess understanding and readability. The first 
method involves assessing the patient’s health literacy level to ensure that s/he 
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can understand the information. The second method involves assessing the 
readability level of the written patient medication information.  
A number of tests are available to assess patients’ health literacy levels. 
These include simple word recognition tests such as the Wide Range 
Achievement Test-Revised (WRAT-R) (Jastak and Wilkinson 1993), the Rapid 
Estimate of Adult Literacy in Medicine (REALM)(Murphy, Davis, Long, Jackson 
and Decker 1993) and the Slosson Oral Reading Test-Revised (SORT-R) 
(Slosson 1990). For research purposes, the Test of Functional Health Literacy in 
Adults (TOFHLA)(Nurrs, Parker, Williams and Baker 1995) is currently 
considered the most useful health literacy comprehension test because it has 
been found to have good content validity and it uses text from real healthcare 
settings (Davis, Michielutte et al. 1998). Overall, these tests tend to be time 
consuming to administer and busy health professionals might derive more benefit 
from assessing the readability of the written patient medication information, as 
opposed to assessing each patient’s health literacy level.  
Readability formulae are designed to make quick and easy assessments 
of readability and to estimate the reading grade level a patient requires to 
understand written information. Some of the well-known formulae include SMOG 
(McLauglin 1969) (APPENDIX 4), the Fry Readability Formula (FRY) (Fry 1968) 
(APPENDIX 5) and the Flesch Reading Ease (FRE) formula (Flesch 1948) 
(APPENDIX 1). Alternatively, there is the convenient and easy to use 
computerised Flesch-Kincaid program available on Microsoft Office Word 2000. 
Each of these readability formulae have a high correlation (Spadaro, Robinson 
and Smith 1980) which means that they can all be readily used and interchanged 
to assess the readability of written information. The major limitation for each of 
these formulae, as far as written patient information is concerned, is that they are 
not healthcare specific. Recently, an instrument called ‘The Readability 
Assessment Instrument’ (RAIN) (Singh 1994) was developed to estimate the 
readability and patient comprehension of written patient information. 
Unfortunately to date, the validity and the ease with which this instrument can be 
used is difficult to assess because its use has been limited to only one American 
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study analysing the readability of seven different patient ‘phenytoin’ information 
leaflets (Kirkpatrick and Mohler 1999).  
In summary, there are two ways in which to assess whether or not written 
medication information can be read and understood by patients. The first way, 
which is considered more time consuming and less practical, is to assess the 
individual patient’s health literacy levels by using tests such as: Wide Range 
Achievement Test-Revised (WRAT-R) (Jastak and Wilkinson 1993); Rapid 
Estimate of Adult Literacy in Medicine (REALM)(Murphy, Davis et al. 1993); 
Slosson Oral Reading Test-Revised (SORT-R)(Slosson 1990); and the Test of 
Functional Health Literacy in Adults (TOFLA)(Nurrs, Parker et al. 1995). The 
second way is to assess the readability of the written medication information by 
using readability formulae such as SMOG (McLauglin 1969), the Fry Readability 
Formula (FRY) (Fry 1968), the Flesch Reading Ease (FRE) formula (Flesch 
1948) and the computerised Flesch-Kincaid instrument on the Microsoft Office 
Word 2000 program, keeping in mind that they are not healthcare specific. In 
terms of convenience and efficiency, the latter is probably most suitable for busy 
health professionals to ensure that the information they are providing can be read 
and understood by the majority of their patients. 
 
3.2.2.3.1 Assessing the readability of written warfarin information 
 Warfarin information available in Australia and internationally, has been 
assessed as being written at a level beyond the comprehension of patients with 
low literacy skills (Baker 1997; Estrada, Hryniewicz et al. 2000; Tang, Lai et al. 
2003). An American study which used the Flesch-Kincaid Grade Level formula to 
determine the readability of 50 brochures commonly used in anticoagulation 
management units, found that all the brochures were written at levels beyond the 
comprehension of patients with low literacy skills, educated at or below a grade 6 
level. This study found that the mean readability level of the brochures was grade 
10.7 (95 percent; CI 10.1 to 11.2). No brochures had a readability level of grade 
6 or below; 12 percent (n=6) had readability scores at grade 7 to 8 levels; 74 
percent (n=37) had readability scores at grade 9 to 12 levels; and 14 percent 
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(n=7) were written at levels above grade 12 (Estrada, Hryniewicz et al. 2000). 
Another study conducted in Hong Kong found that poor literacy skills were the 
main reason for poor warfarin knowledge in 62 patients (50.8 percent) of the 122 
patients studied. These patients were not able to read and understand the written 
warfarin information provided to them (Tang, Lai et al. 2003). Finally, the most 
recent American study conducted by Estrada et al (2004) found that 68 (47.6 
percent) of the 143 patient participants over the age of 60 could not read health-
related words written at or above grade 8 levels and were more likely to 
experience poor anticoagulant control over a three month period. Similar studies 
have not yet been conducted in Australia, nor have studies focused on patients’ 
use and/or satisfaction with their warfarin consumer medicine information (CMI) 
or the commonly used Boots warfarin information booklets (2002, 2003). In the 
absence of such data a computerised Microsoft Office Word 2000 Flesch-Kincaid 
test was carried out on the commonly used Boots warfarin information booklet 
(2002) which was found to be written at a grade 9.4 reading level and a grade 8.9 
reading level for the more recent 2003 edition. Both booklets, therefore, which 
are commonly used by Australian health professionals, are written at grade levels 
well above the reading ability of patients with low literacy skills.  
 There appears to be an obvious lack of suitable written warfarin 
information, especially for patients with low literacy skills, both in Australia and 
overseas. This highlights the need to develop and produce a new warfarin 
information booklet written at or below a grade 8 level (Buchbinder, Hall et al. 
2001), or preferably even below a grade 6 level (Estrada, Hryniewicz et al. 2000). 
Such a booklet should also adhere to recommended guidelines ensuring that it 
appeals to the patients’ understanding and satisfaction based on factors such as 
format, colour, text, print size and illustrations.  
 
3.2.3 Summary 
 Written patient medication information is an efficient, relatively inexpensive 
adjunct to verbal instruction. Unfortunately, currently available written medication 
information, including warfarin information, is typically written at levels beyond 
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the comprehension of many patients, especially those with low literacy skills 
(Baker 1997; Estrada, Martin-Hryniewicz et al. 2004; Weiss 1997). Health 
professionals who have the responsibility of preparing and providing written 
patient medication information, including warfarin information, should 
acknowledge that a large proportion of the population has low literacy skills and 
should therefore ensure that the information is available at or below a grade 8 
reading level (Buchbinder, Hall et al. 2001) or better still a grade 6 reading level 
(Estrada, Hryniewicz et al. 2000). There are many simple readability tests such 
as SMOG (McLauglin 1969), the Fry Readability Formula (FRY) (Fry 1968), the 
Flesch Reading Ease (FRE) formula (Flesch 1948) and the computerised Flesch-
Kincaid instrument on the Microsoft Office Word 2000 program which can be 
used to ensure that information is written at an appropriate level. 
 
 
3.3. EVALUATION OF PATIENT EDUCATION PROGRAMS 
 Evaluation is an essential component of an effective patient education 
program because it ensures that the program is suitable, effective and satisfies 
the patient’s needs. Evaluation can be classified in three different ways. The first 
is process evaluation, which measures the activities of the program, the quality of 
the program and assesses whom the program is reaching. The second is impact 
evaluation which measures the immediate effect of the program and the third is 
outcome evaluation which measures the long-term effects of the program (Hawe, 
Degeling and Hall 1990). 
 Process evaluation, which measures the activities of the program, 
assesses the quality of the program and the suitability of the program to reach 
target populations, can involve the use of readability, suitability, quality and 
patient satisfaction instruments. Examples of some readability tests which have 
already been discussed in this chapter, include the SMOG Formula (McLauglin 
1969)(APPENDIX 4) and the Fry Readability Formula (Fry 1968)(APPENDIX 5). 
Several instruments are available to assess the suitability and the quality of the 
written patient information. One example of such an instrument is the ‘Suitability 
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Assessment of Materials instrument’ (SAM) (Doak, Doak et al. 
1996b)(APPENDIX 6). SAM is a useful validated tool, which evaluates the 
content, literacy demands, graphics, layout and typography, as well as the 
learning stimulation, motivation and cultural appropriateness of the written 
information for patient populations, inclusive of the low literacy skilled 
populations. A second instrument is the ‘Bernier Instructional Design Scale’ 
(BIDS)(Bernier 1996)(APPENDIX 7) which is a useful instrument for identifying 
and measuring the presence (or absence) of instructional design and learning 
principles within the written information. A third quick and easy-to-use instrument 
is the ‘Checklist for print materials’(Bidford Maine Area Health Education Center 
1996) (APPENDIX 8) which assesses the appropriateness of the written material 
for patients. All of these instruments can be used to evaluate the quality and the 
suitability of the written medication information, including warfarin information, for 
both the general and low literacy skilled patient populations. The results of these 
evaluations can also uncover deficiencies within the written medication 
information which may need to be addressed to improve its suitability and quality. 
An important arbiter of the quality of medication information is the extent to 
which individuals perceive that the information has satisfied their needs (Horne, 
Hankins and Jenkins 2001). Assessing patients’ satisfaction with the amount of 
medication information provided is a prerequisite for developing partnerships in 
the quality use of medicines and the optimisation of therapeutic outcomes (Cox, 
Stevenson et al. 2004). It is important therefore to use tools such as the 
‘Satisfaction with Information about Medicines Scale’ (SIMS)(Horne, Hankins et 
al. 2001)(APPENDIX 20) which assesses the patients’ satisfaction and/or 
dissatisfaction with the information they have received. Even though patient 
dissatisfaction can be a disappointment to the health professional, it gives them a 
chance to improve educational practices and hopefully remedy the situation.  
 Impact evaluation assesses whether or not the program has met its 
objectives by evaluating patient knowledge and understanding, and their 
adherence to recommended health behaviours such as medication management 
and compliance. Changes in patients’ medication knowledge and understanding, 
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as well as their medication management and compliance are measures of the 
impact of the medication education programs, including warfarin education 
programs. In the past, evaluation of warfarin education programs have been poor 
(Wyness 1990), with recent studies identifying that even though patients received 
warfarin education, they had deficits in their warfarin knowledge, often resulting 
in poor warfarin management and compliance (Cheah and Martens 2003; 
Lambert and Wynne 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 2003). The 
results of these recent studies highlight the need to evaluate the impact of 
warfarin education programs on the patients’ warfarin knowledge and 
understanding. 
 Finally, outcome evaluation assesses whether or not the program has met 
its aims and objectives. Program outcome indicators need to translate into health 
status measurements, which can include blood test results and healthcare 
utilisation (for example; number of general practitioner, hospital and/or 
emergency department visits). These are important indicators of the long-term 
effectiveness of the education program and patients’ abilities to manage their 
own medications (Lorig and associates 1996). These outcome evaluations would 
be especially important for patients taking warfarin therapy, and in particular 
those suffering from atrial fibrillation, a recently promoted indication for lifelong 
warfarin therapy (Elliott, Woodward et al. 2002; Peterson, Jackson et al. 2002) . 
 Evaluation is therefore an important component of an effective patient 
medication education program, including a warfarin education program, because 
it assesses the quality and suitability of the program, patients’ satisfaction with 
the program and the overall impact of the program in terms of patient knowledge 
and understanding, medication management and compliance. Finally, outcome 
evaluation measures the long-term effectiveness of the medication education 
program. Evaluation not only ensures that the program appeals to the patients 
and achieves its goals and objectives, but it also helps to identify possible 
inadequacies within the program which may need to be addressed to improve its 




  Effective warfarin education is invaluable for patients to be able to manage 
their warfarin therapy and to make confident educated decisions about warfarin 
management which may affect their anticoagulant control and health status 
(Gibbar-Clements, Shirrell et al. 2000; Moore 1977). With recent increases in 
warfarin prescribing (Elliott, Woodward et al. 2002) deficits in patient  warfarin 
knowledge (Cheah and Martens 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 
2003) and the rising incidence of warfarin-related adverse drug events (AIHW 
2003), there is an obvious need to develop and implement a new and effective 
patient warfarin education program.  
 This chapter has discussed the difficulties faced by patients with low 
literacy skills in reading and understanding typically available written patient 
information, including warfarin information. These difficulties can negatively 
impact upon their therapeutic outcomes and in some cases lead to adverse drug 
events. Written patient warfarin information should therefore be available at no 
higher than a reading grade 8 level (Buchbinder, Hall et al. 2001), or preferably at 
or below a grade 6 level (Estrada, Hryniewicz et al. 2000). This would ensure that 
the warfarin information could be easily read and understood by a wider patient 
population, inclusive of those with low literacy skills.  
Since factors such as format, colour, text, print size and the use of 
illustrations can impact upon a patient’s understanding and satisfaction with 
written patient information (Clark, AbuSabha et al. 1999; Klug Redman 2001), it 
is important to address each of these factors by adhering to simple guidelines 
when developing and producing written patient medication information. Examples 
of these guidelines include the ‘Toolkit for Producing Patient Information’ (The 
United Kingdom Department of Health 2002) and the ‘Guidelines for Writing 
Patient Information’ (Doak, Doak et al. 1996b). Adhering to these simple 
guidelines helps to ensure that the written information engages the interest of 
many patient populations, inclusive of those with low literacy skills (Koo, Krass et 
al. 2003).  
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This chapter has also discussed the importance of evaluation to ensure 
that medication education programs, including those for warfarin, are of good 
quality and are effective. Process, impact and outcome evaluation can be used to 
assess the suitability of the program to reach target populations, its effectiveness 
to improve patients’ medication knowledge, management and compliance and its 
long-term effectiveness to achieve aims and objectives. 
 The next chapter will discuss in detail the conceptual framework used to 
develop and design a new patient warfarin education program. The advantage of 
using a conceptual framework is that it provides a blueprint to replicate 
successful key interventions and strategies and offers a systematic process to 
analyse success or failure of the program (Doak, Doak et al. 1996b). It is also 
noted in the literature that educational programs most likely to succeed are those 
developed and managed using structural frameworks (National Institutes of 
Health 2001). One of the most significant aspects of this research study is that 
even though there is a focus on developing an effective patient warfarin 
education program, the conceptual framework can be generically applied to any 
effective patient medication education program. 
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CHAPTER 4  
CONCEPTUAL FRAMEWORK FOR AN EFFECTIVE PATIENT 





  Historically, warfarin patient education programs have been inadequate 
(Connor 1998), overwhelming (Ansell, Buttaro et al. 1997) and not properly 
evaluated (Wyness 1989). Recent studies by Cheah et al (2003), Nadar et al 
(2003) and Lambert et al (2003) have all found that patients, and especially those 
from the ‘high risk’ group, have deficits in their warfarin knowledge after receiving 
warfarin education. These studies and others published within recent years 
(Barcellona, Contu et al. 2002; de Felipe Medina 2003; Roche-Nagle, Chambers 
et al. 2003) highlight the need for more effective warfarin education programs to 
reduce these warfarin knowledge deficits and to improve warfarin management 
and compliance in a wider patient population, inclusive of the ‘high risk’ group.  
The new warfarin education program developed and trialed for this study 
was based on a conceptual framework which reflects ‘best evidence’ with regard 
to patient medication education programs. The new program targeted the five 
key elements identified in the literature which contribute to improved therapeutic 
outcomes and reduced incidence of adverse drug events. These five key 
elements were: improved health professional/patient communication and 
partnerships; warfarin compliance; simple, easy-to-read written warfarin 
information; continuity of care between hospital and community settings; and 
patient follow-up. 
A full evaluation of the new program, which will be discussed in the next 
chapter, was also undertaken during the course of the study. During the 
evaluation phase the new program was compared to and contrasted to the 
customary warfarin education program delivered to The Ambulatory Care Team 
(TACT) patients prescribed warfarin. 
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 This chapter outlines the conceptual underpinnings of these five key 
elements and describes how they link to form the basis of an effective warfarin 
education program. Importantly, using this conceptual framework to plan 
interventions and strategies which target improved patient education provides a 
blueprint to develop other much needed medication education programs.  
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4.3 INTERVENTIONS USED TO TARGET THE FIVE KEY ELEMENTS OF THE 
CONCEPTUAL FRAMEWORK IN THE NEW WARFARIN EDUCATION 
PROGRAM. 
 
4.3.1 Health professional/patient communication and partnerships  
 Poor health professional/patient communication and partnerships have 
been identified as major contributors to poor therapeutic outcomes and adverse 
drug events (Bhasale, Miller et al. 1998; Cox, Stevenson et al. 2004; Elwyn, 
Edwards et al. 2003). Interventions which target this key element are recognised 
as important ways in which to improve patient knowledge and understanding and 
to empower patients to make confident, educated decisions about their 
medication management. The literature provides a range of strategies to help 
improve health professional/patient communication and partnerships.  
Health professionals should focus on promoting their roles as good 
educators by developing good communication skills and collaborating more 
effectively with their patients (Aslani and Du Pasquier 2002; Rankin and Duffy 
Stallings 2000). Good communication and collaboration involves encouraging 
their patients to become part of the education process by asking questions, 
making comments and not being afraid to express their opinions (Dantas, 
Thompson et al. 2004). Health professionals need to ensure their manner is 
always encouraging, reinforcing, reassuring and approachable, especially when 
accepting feedback (Clark, Gong et al. 1998; Kok, van den Borne et al. 1997). 
They also need to seek the respect of their patients and in turn offer them 
respect for their beliefs, assumptions and attitudes (The Royal Pharmaceutical 
Society of Great Britain 1997). This study aimed to incorporate each of these 
strategies into the new warfarin education program in an attempt to maximise 
communication and collaborative interchange between the health professional 
(who is also the researcher/pharmacist) and the patient.  
The establishment of effective partnerships is reliant on learning 
environments which encourage patients to listen, access information and to seek 
reassurance about their knowledge and understanding (Australian Council for 
 66 
Safety and Quality in Health Care 2002). For the purposes of this study, 
therefore, the initial warfarin education sessions were delivered to patient 
participants in their own homes or at an alternate venue chosen by themselves.  
Simple guidelines need to be adhered to by health professionals when 
establishing good communication and partnerships with the ‘high risk’ patient 
population. These simple guidelines, which were incorporated into the new 
warfarin education program, include: using simple language; speaking slowly; 
repeating and underlining key points; and not giving too many directives during 
the education session (Doak, Doak et al. 1996b; Mayeaux Jr, Murphy et al. 
1996). It is also important to urge carers and/or family members to attend the 
education sessions (Doak, Doak et al. 1998) and ensure that interpreters are 
made available for non-English speaking background patients (Williamson, 
Stecchi et al. 1997). 
In summary, interventions and strategies which promote good health 
professional/patient communication and partnerships are essential components 
of an effective warfarin education program because they help to optimise 
therapeutic outcomes and minimise adverse drug events (Cox, Stevenson et al. 
2004; Elwyn, Edwards et al. 2003). These interventions and strategies need to 
target encouragement, reinforcement, reassurance and feedback (Clark, Gong et 
al. 1998; Kok, van den Borne et al. 1997) in an environment which encourages 
the patients, including those from the ‘high risk group’, to listen, access 
information and seek reassurance about their knowledge and understanding 
(Australian Council for Safety and Quality in Health Care 2002),  
 
4.3.2 Warfarin compliance 
Poor warfarin compliance is also a significant contributor to poor 
anticoagulation control (Arnsten, Gelfand et al. 1997) and warfarin-related 
adverse events (Brigden, Kay et al. 1998; Hirri and Green 2002). Knowing that 
the ‘high risk’ patient population, including the elderly and those with low literacy 
skills (Lambert and Wynne 2003; Tang, Lai et al. 2003), as well as the non-
English speaking background patients (Nadar, Begum et al. 2003) are most likely 
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to experience poor warfarin-related therapeutic outcomes, it would be reasonable 
to assume that this is significantly contributed to by poor warfarin compliance. 
Targeting ways in which to improve warfarin compliance, especially in the ‘high 
risk’ group, is therefore a key element of an effective warfarin education program.  
According to the literature, however, improved medication compliance can 
only be effectively achieved by including several interventions at the one time 
(Haynes, McDonald et al. 2002a; McDonald, Garg and Haynes 2002; Roter, Hall 
et al. 1998). These interventions include: educating the patients, carers and/or 
family members about the importance of regular medication compliance; 
explaining the implications of not complying with regular therapy; recommending 
compliance aids when and if required; offering encouragement, reinforcement, 
reassurance and follow-up; as well as undertaking medication reviews.  
Good warfarin compliance can be encouraged by effectively educating the 
patient, their carer and/or family member about warfarin therapy (Barcellona, 
Contu et al. 2002). Several studies have highlighted the essential warfarin 
information, which needs to be understood. This includes: how warfarin works; 
the importance of taking warfarin appropriately and why regular monitoring is 
necessary; appropriate dosing schedules; possible side effects and drug-to-drug 
interactions; as well as possible necessary behaviour changes, for example; 
exercise, dietary and alcohol restrictions (Gibbar-Clements, Shirrell et al. 2000; 
Hirsh, Dalen et al. 1995). Carers and family members should always be urged to 
attend warfarin education sessions to promote information recall and encourage 
good patient warfarin compliance (Doak, Doak et al. 1996b). 
Compliance aids such as blister packs, dosette boxes, medication alarms 
and medication cards help to improve medication compliance for all patient 
populations (Roter, Hall et al. 1998; Wong and Norman 1987), including the ‘high 
risk’ patients (Levings, Szep et al. 1999). They have been found to be especially 
useful for patients suffering from cognitive and/or physical limitations (poor eye 
sight, hearing impairment) (Barat, Andreasen et al. 2001; Wong and Norman 
1987). For the purpose of this study, even though all patients were informed 
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about compliance aids, the ‘high risk’ patients were strongly encouraged to use 
compliance aids. 
Offering the patients encouragement, reinforcement, reassurance and 
feedback promotes both good health professional/patient communication, 
partnerships and good medication compliance (Kok, van den Borne et al. 1997). 
These interventions in combination with patient follow-up, which will be discussed 
later in this chapter, were all used in the new warfarin education program to help 
promote warfarin compliance.  
Patient medication reviews are an essential part of the practice of all 
pharmacists because they can reduce inappropriate prescribing and adverse 
drug events (Hanlon, Weinberger, Samsa, Schmader, Uttech, Lewis, Cowper, 
Landsman, Cohen and Feussner 1996). They also help to improve medication 
compliance in patients who suffer from any cognitive and/or physical limitations 
(Stewart and Caranasos 1989), as well as those taking multiple medications, 
including warfarin (Fulmer, Hollander-Feldman, Sook Kim, Carty, Beers, Molina 
and Putnam 1999). Medication reviews not only help to simplify the medication 
regimen for these patients but they also help to minimise possible drug-to-drug 
interactions with warfarin (Becker and Maiman 1980; Haynes, McDonald et al. 
2002a). For the purposes of this study, the researcher/TACT pharmacist 
reviewed all the intervention patients’ medications, including their complementary 
medications, to ensure that they were taken appropriately in an easy-to-follow 
regimen. In the event of possible drug-to-drug interactions, the researcher/TACT 
pharmacist collaborated with the patients’ healthcare providers to ensure that the 
interacting drugs were ceased, changed or carefully monitored while taken in 
combination with the warfarin therapy. 
In summary, targeting interventions to improve medication compliance and 
in this instance warfarin compliance is a key element of an effective education 
program. Several interventions were included in the new warfarin education 
program to help optimise warfarin compliance. These interventions included: 
educating the patients, carers and/or family members about their warfarin 
therapy; recommending compliance aids; offering encouragement, 
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reinforcement, reassurance and follow-up; as well as undertaking medication 
reviews. These interventions were especially important to help promote warfarin 
compliance in the ‘high risk’ patient population.  
 
4.3.3 Simple, easy-to-read warfarin information 
Evidence suggests that patients who receive insufficient and inappropriate 
medication information are more likely to experience poor therapeutic outcomes 
and adverse drug events (Bhasale, Miller et al. 1998). Therefore, it is important to 
provide simple and easy-to-read medication information (Esposito 1995; Houts, 
Witmer, Egeth, Loscalzo and Zabora 2001) which is appropriate, readily available 
and understood by all patients including those in the ‘high risk’ group (Doak, 
Doak et al. 1996b).  
There are many tools, instruments and guidelines available, which can be 
used to ensure that warfarin information is written in a simple, easy-to-read 
format with culturally sensitive illustrations. Readability tools such as the SMOG 
test (McLauglin 1969)(APPENDIX 4), the Fry Readability Fry Readability Formula 
(Fry 1968) (APPENDIX 5) and the computerized Flesch-Kincaid Instrument 
available on the Microsoft Office Word 2000 program can be used to ensure that 
the information is written at a suitable level. While, the ‘Toolkit for producing 
patient information’ (The United Kingdom Department of Health 
2002)(APPENDIX 2) and the ‘Guidelines for writing patient information’ (Doak, 
Doak et al. 1996b) (APPENDIX 3), can be used to ensure that the information is 
written in a simple, easy-to read format with attention to colour, text, print size 
and graphics. Finally, the ‘Suitability Assessment of Materials” (SAM) instrument 
(Doak, Doak et al. 1996b) (APPENDIX 6), the ‘Bernier Instructional Design Scale’ 
(BIDS)(Bernier 1996)(APPENDIX 7) and the ‘Checklist for print materials’ 
(Bidford Maine Area Health Education Center 1996) (APPENDIX 8) can all be 
used to ensure the quality and the suitability of the written information, especially 
for the ‘high risk’ patient population. 
In the absence of available suitable written warfarin information (Estrada, 
Hryniewicz et al. 2000) the researcher/TACT pharmacist used all of the tools, 
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instruments and guidelines described above to develop the new warfarin 
information booklet (APPENDIX 12). They were all deemed to be important 
because of the evidence that patients’ use and satisfaction with written 
information is dependent upon its readability, presentation and quality (Clark, 
AbuSabha et al. 1999; Koo, Krass et al. 2003).  
In summary, to improve warfarin-related therapeutic outcomes and 
minimise adverse drug events, patients must be given sufficient and appropriate 
written information. Good quality, simple, easy-to-read information, available in a 
suitable format with culturally sensitive illustrations is therefore necessary to 
effectively educate patients about their warfarin. Consequently, several tools, 
instruments and guidelines were used in the development of the new warfarin 
information booklet (APPENDIX 12) to ensure its readability, quality and 
suitability for a wider patient population, inclusive of the ‘high risk’ group. 
 
4.3.4 Continuity of care between hospital and community settings 
Poor continuity of care between hospital and community settings has been 
recognised as an important contributor to poor therapeutic outcomes and 
adverse drug events (Bhasale 1998; Forster, Murff et al. 2003). The need to 
focus on interventions which target the improvement of continuity of care with 
regard to medication and medication information, has only become a priority in 
Australia in the past few years. Many medication errors and adverse drug events 
have arisen due to inadequacies in the transfer of relevant medication and 
medication information between hospital and community settings (Clark, Graham 
and Williamson 1999; Dartnell, Anderson et al. 1996). Misadventures occur 
because patients, carers and community-based healthcare providers are often ill-
informed about medication changes which took place while the patients were 
admitted to the healthcare services (Bhasale 1998) . 
The recently prepared Australian Pharmaceutical Advisory Council 
(APAC) ‘Guidelines on the continuum of care of quality use of medicines 
between hospital and community’ (Australian Pharmaceutical Advisory Council 
1998) (APPENDIX 9) provide useful strategies to improve this continuum of care 
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between hospital and community settings for medication management, including 
warfarin management. These APAC guidelines focus on the need to ensure that 
an accurate medication history and review is carried out for each patient, that 
patients are given medication and medication information in a timely manner and 
that their nominated healthcare providers are informed about the new 
medications and/or changes once patients have been discharged from the 
healthcare service. 
Improved continuity of care between hospital and community settings are 
known to improve overall therapeutic outcomes and reduce adverse drug events 
(Australian Council for Safety and Quality in Health Care 2002), which is why the 
APAC ‘Guidelines on the continuum of care of quality use of medicines between 
hospital and community’ (1998) were incorporated into the new warfarin 
education program. All the patients’ medications were reviewed, warfarin 
medication, information and education was delivered to the patients, their carers 
and their general practitioners in a timely manner, upon admission and discharge 
from Illawarra Health’s The Ambulatory Care Team (TACT).  
 
4.3.5 Patient follow-up 
Patient follow-up has also been shown to improve therapeutic outcomes 
and reduce the incidence of adverse drug events (Dudas, Bookwalter et al. 
2001). Patient follow-up can be achieved in several ways including: written 
communication; face-to-face interviews; group sessions; and telephone follow-
up. All of these patient follow-up methods are useful and effective because they 
offer reassurance and reinforcement to the patients, encouraging them to be 
proactive with their treatment regimens (Hendricks and Hendricks 2000; 
Waterman, Milligan et al. 2001), while improving their satisfaction and reducing 
the number of medication-related problems (Dudas, Bookwalter et al. 2001).  
Patient follow-up is therefore an essential component of an effective 
warfarin education program because not only does it have benefits of its own but 
it also positively impacts upon some of the other key elements which include: 
health professional/patient communication and partnerships; medication 
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compliance; and the continuity of care (Haynes, McDonald et al. 2002a). Based 
on limited time, resources and the fact that telephone follow-up appears to be 
equally as effective as the other follow-up methods in improving health 
professional/patient communication and partnerships (Hendricks and Hendricks 
2000), medication compliance (Roter, Hall et al. 1998), patient education (Estey, 
Tan et al. 1990) and medication self-management (Dudas, Bookwalter et al. 
2001), it was concluded that telephone follow-up is a suitable way in which to 
follow up patients and it was the method used in the study. 
 
 
4.4 SUMMARY  
 In summary, having reviewed the literature, five key elements were 
identified which need to be targeted when developing an effective medication 
education program. These include: improved health professional/patient 
communication and partnerships; medication compliance; simple, easy-to-read 
medication information; the continuity of care between hospital and community 
settings; and patient follow-up. As well as targeting these key elements it is also 
necessary for effective programs to address the needs of the ‘high risk’ patient 
population, which include the elderly, those with low literacy skills, and those 
from non-English speaking backgrounds.  
By introducing several interventions and strategies to target these five key 
elements, it was intended that the new warfarin education program would 
promote good health professional/patient communication and partnerships, 
encourage optimal warfarin compliance and provide simple, easy-to-read written 
warfarin information for the patients. Processes were also put in place for the 
new program to achieve improved continuity of care between hospital and 
community settings by adhering to the APAC guidelines (1998) and by providing 
patient telephone follow-up. 
This chapter has discussed the conceptual underpinnings of the five key 
elements, which form the basis of an effective medication education program, 
and in this instance a new warfarin education program. Strategies and 
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interventions used to target these key elements in the new warfarin education 
program, developed for this study, were also identified and described.  
The next chapter will outline the methodology used to incorporate this 
conceptual framework into the new warfarin education program, which will then 
be compared to and contrasted with the customary warfarin education program 
presented to patients prescribed warfarin, who are admitted to Illawarra Health’s 








 The methods used in this study to develop, implement and evaluate the 
new warfarin education program are described in depth throughout this chapter. 
Initially, there is a description of the study design and how the five key elements 
reflecting ‘best evidence’ are incorporated into the new program. The actual 
program itself and the evaluation instruments used in the study are schematically 
described in section 5.4, which then goes on to discuss the results of the pilot 
study and the necessary ethical considerations. The chapter concludes with 
information about how eligible patient participants were recruited, which 
documentation they needed to complete and the questionnaires that were used 
for evaluation purposes. A tabled summary of the methodological process and a 
flowchart of the research study are also provided as an overview of the study 
process and design. 
It is important to note that for the purposes of this study, when referral is 
made to the word ‘patient’ this also includes the primary ‘carer’ or ‘family 
member’ who was responsible for managing and administering warfarin 
medication, when patients did not do so themselves. 
 
5.2 OVERVIEW OF THE STUDY  
The purpose of the study was to develop and implement a new warfarin 
education program, to help improve warfarin knowledge, compliance and 
management in a wider patient population, inclusive of the ‘high risk’ patients. 
This ‘high risk’ group of patients included the elderly, those with low literacy skills 
and those from non-English speaking backgrounds. The study was conducted on 
patients who were admitted to Illawarra Health’s The Ambulatory Care Team 
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(TACT) and prescribed warfarin for either the first time, or after a period of no 
less than 15 years. Even though TACT operates from within Wollongong 
hospital, it is a community-based healthcare service, which visits, treats and 
educates patients in their own homes.  
The study was a prospective study involving all patients newly prescribed 
warfarin and admitted to the Illawarra Health Ambulatory Care Team over a 12- 
month period from February 2003 to February 2004. A prospective study was 
considered reasonable because it looked forward in time and involved one group 
being exposed and the other group not being exposed to the new warfarin 
education program. Also, because outcome data such as warfarin knowledge 
and understanding, satisfaction with the education program, medication 
management and therapeutic data (e.g. warfarin levels) were to be collected after 
the exposure to the education program. After consultation with Dr Pam Davy, a 
statistician at the University of Wollongong, it was agreed that in order to detect a 
difference in warfarin knowledge and understanding between the two groups, at 
a power of 70% using the 5% level of significance, at least 100 participants - 50 
control and 50 intervention - would be required for the study.  
Power calculation is a statistical method used in the estimation of the 
sample size needed to increase the likelihood of demonstrating genuine 
differences within a study. A powerful study is very likely to find genuine 
differences if any exist, and a weak study could easily miss them (Hassard 
1991). To ensure that a difference is in fact genuine and not merely a random 
occurrence, the level of significance or  level is usually set to 0.05 or less. 
Generally speaking a power of 80% is the preferred level for a study thereby 
providing a  level of 0.2. It is more appropriate to relax the  level rather than 
the  level in a study because  errors (i.e. missing a genuinely better program or 
treatment and hence continuing with an established reasonable program or 
treatment), has less detrimental effects than  errors (i.e. switching from an 
established effective program or treatment to a new relatively, unknown program 
or treatment that is not actually any better)(Hassard 1991).  
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In this study, a  level of 0.2 was assessed not to be practical because it 
required a large sample size which could not be managed within the duration and 
resources available for this PhD study. The  level was relaxed and a power of 
70% was used in the calculation of sample size. The participants’ warfarin 
knowledge was considered the most important variable because it was expected 
to impact on the other variables being investigated (i.e. self-management, 
medication-taking-measures, satisfaction with information, and health care 
related outcome measures). The calculation was therefore based on this 
variable, using a power of 70% and a 5% level of significance.  
The main implication of the power calculation is that it would only be 
expected to identify a statistically significant difference in the warfarin knowledge 
variable for both groups within the time and resource constraints of this study. A 
sample size of 100 with equal allocation to each arm was deemed adequate to 
identify an improvement of one point for the mean warfarin knowledge 
questionnaire scores attributable to the new warfarin education program 
intervention. This calculation was based on a standard deviation of 4.5, a power 
of 70%, a 5% significance level and a one sided test. 
For the purposes of this study the group of patients receiving the new 
warfarin education program are referred to as the intervention patients and the 
group of patients receiving the customary warfarin education program are 
referred to as the control patients. The new warfarin education program, was 
conceptually based on the five key elements of an effective patient medication 
education program, also included a newly developed warfarin information booklet 
(APPENDIX 12). This new booklet was derived from a review of the literature and 
written in a simple, easy-to-read format, whereas the customary warfarin 
education program involved the TACT pharmacist reading through the Boots 
warfarin information booklet (2003) with the patient in their own home.  
Evaluation was incorporated into the study at three levels: process, impact 
and outcome evaluation. This enabled the researcher/TACT pharmacist to 
analyse and assess the suitability, quality and effectiveness of the new program 
as compared to the customary program, in terms of the patients’ warfarin 
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knowledge, compliance and management. The patients’ satisfaction with the 
program and their long-term outcomes (therapeutic INR scores, as well as 
general practitioner, hospital and emergency department visits) were also 
compared and contrasted between the two programs. Unfortunately, customary 
practice did not remain static during the study period due to the continuously 
evolving professional practice of the TACT service. This is acknowledged as a 
limiting factor of the research study and will be discussed in the final chapters of 
this thesis. 
The overall purpose of the study was to develop and implement a new 
warfarin education program to help improve warfarin knowledge, compliance and 
management in a wider patient population, inclusive of ‘high risk’ patients. The 
conceptual framework of this new program, which incorporated five key elements 
of an effective patient medication education program, can be readily used as a 
blueprint for any other medication education program, in both community and 
hospital settings. 
 
5.3 THE PROCESS FOR THE DESIGN AND DEVELOPMENT OF THE NEW 




The design of the research study involved several important components. 
Firstly, the new warfarin education program incorporated interventions and 
strategies to target the five key elements of an effective patient medication 
education program which included: improved health professional/patient 
communication and partnerships; warfarin compliance; simple, easy-to-read 
warfarin information; the continuity of care between hospital and community 
settings; and patient follow-up.  
Secondly, evaluation was incorporated to compare and contrast the new 
warfarin education program against the customary warfarin education program 
delivered to TACT patients prescribed warfarin. Important components of the 
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evaluation process included assessing the readability, suitability and quality of 
the new written warfarin information booklet (APPENDIX 12) against the Boots 
warfarin information booklet (2003). In addition, analysis of the patients’ warfarin 
self-management, compliance, knowledge and understanding, as well as their 
satisfaction with the warfarin education program, provided important data to 
compare and contrast the two education programs.  
Finally, reviewing the patients’ International Normalised Ratio (INR) blood 
test results, the number of healthcare visits and side effects experienced, helped 
to assess and compare the long-term effectiveness of both education programs. 
These results provided data to compare the warfarin-related therapeutic 





















The following diagram provides an overview of the methods used to 
design, develop and evaluate the new warfarin education program, including the 
new warfarin information booklet (APPENDIX 12).  
 
Figure 2: Overview of the methods used to design, develop and evaluate 
the new warfarin education program, including the new warfarin 
information booklet (APPENDIX 12). 






























The chapter will now discuss how the five key elements and evaluation 
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5.3.2 Health professional/patient communication and partnerships 
 Several measures were incorporated into the new warfarin education 
program design to promote good health professional/patient communication and 
partnerships. The measures introduced by the health professional included: 
offering the patient encouragement, reinforcement, reassurance and feedback; 
delivering the initial education session in a home environment; urging carers 
and/or family members to attend the education session; providing interpreters for 
non-English speaking background patients; and always using simple and easy-
to-understand language 
Encouragement was given to patients by asking lots of questions, inviting 
them to make comments (Kok, van den Borne et al. 1997), and respecting their 
opinions (The Royal Pharmaceutical Society of Great Britain 1997). Examples of 
the questions asked to offer encouragement can be found in the ‘Transcript of 
the new warfarin education session’ (APPENDIX 11). During the education 
sessions, the patients were also urged to become active participants in their own 
healthcare by recording their own INR results, warfarin doses and appointment 
times in the new warfarin information booklet (APPENDIX 12).  
Reinforcement was provided by using the new written warfarin information 
booklet (APPENDIX 12), underlining the main points and referring to the 
illustrations as visual aids (Doak, Doak and Lorig 1996a). The ‘Warfarin 
Counselling Checklist ’ (APPENDIX 13) was used to ensure that all the main 
points had been discussed and reinforced. Typical questions asked to reinforce 
patients’ understanding of the warfarin information included:  
 “Why do you believe that the warfarin has been prescribed for you?” 
  “Which brand of warfarin has been prescribed for you?”  
 “What dose should you take today?”  
Reassurance throughout the program was promoted by ensuring that the 
patients were comfortable and confident enough to seek reassurance by 
addressing them in a positive, caring and motivating manner (The Royal 
Pharmaceutical Society of Great Britain 1997). Even when the patients had 
completely misunderstood or misinterpreted instructions, they were politely 
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corrected and positively reassured about their ability to safely and successfully 
manage their own warfarin therapy at home. 
Informal feedback was received before, during and after the initial warfarin 
education sessions, as well as during the follow-up phone calls and on 
completion of the evaluation questionnaires after three months of warfarin 
therapy. Positive and negative comments, as well as opinions, were perceived to 
be of benefit because they could be used to improve the patient warfarin 
education program. The patients’ beliefs, opinions, assumptions and attitudes 
were always treated with utmost respect (The Royal Pharmaceutical Society of 
Great Britain 1997). A typical example included patients perceiving that they 
were endangering their lives by taking warfarin, known to them as rat poison. In 
these instances, it was acknowledged that even though warfarin was rat poison 
it did have many therapeutic advantages, which were then explained to the 
patients. 
The initial education sessions took place in the patients’ homes or in an 
alternative place specified by the patients, where it was ensured that they were 
relaxed and comfortable. Environments conducive to learning were sought by 
recommending that all radios, televisions, computers and stereos were turned 
off. Carers and family members were also positively encouraged to attend the 
education sessions and to ask questions and make comments.  
For patients from non-English speaking backgrounds, Illawarra Health 
interpreters were made available during the education sessions to translate the 
information into their native language. In an attempt to improve communication 
with these patients it was always necessary to make direct eye contact with 
them, rather than directing all the conversation toward the interpreters 
(Williamson, Stecchi et al. 1997).  
The information was presented slowly, using simple and easy-to 
understand language, especially when educating the ‘high risk’ patient 
population (Mayeaux Jr, Murphy et al. 1996). Main points were emphasized 
using the ‘Warfarin Counselling Checklist ’ (APPENDIX 13) and the ‘New 
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Warfarin Information Booklet’ (APPENDIX 12) as guides to ensure that important 
points were covered. 
In summary, developing good health professional/patient communication 
and partnerships was a key element targeted by several interventions in the new 
warfarin education program. These interventions included promoting 
encouragement, reinforcement, reassurance and patient feedback, supporting a 
collaborative approach by valuing the patients’ opinions and comments and 
inviting them to be active participants in their own healthcare. Education 
sessions were conducted in the comfort of the patients’ home and often in the 
presence of carers and/or family members who were also urged to attend. Non-
English speaking background patients were provided with an interpreter, and the 
language used during the education session was always simple and easy-to-
understand, which was especially beneficial for the ‘high risk’ patient population.  
 
5.3.3 Warfarin compliance 
 Good warfarin compliance was another key element targeted in the new 
warfarin education program (Haynes, McDonald et al. 2002a). Interventions, 
such as improving the patients’ understanding of their warfarin therapy in 
treating their disease, encouraging family support and compliance aids, as well 
as minimising the complexity of their medication regimens, were considered 
priorities in the new warfarin education program. These interventions were 
particularly important for the ‘high risk’ patient population. 
 Patients were educated about how warfarin works to treat their disease, 
how to take it appropriately and how to monitor their warfarin therapy, as per the 
‘New warfarin Education Program Objectives’ (APPENDIX 14). Examples of 
patients successfully treated with warfarin were given, as per the ‘Transcript of 
the new warfarin education session’ (APPENDIX 11), to try to encourage optimal 
warfarin compliance. Some examples of the questions patients were asked to 
ensure that they had a good understanding about why they had to comply with 
their warfarin therapy, included: 
 “Do you understand why you have been given warfarin tablets?”  
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 “When is the best time to take your warfarin tablets?” 
 
Family members and carers were contacted by telephone prior to the 
education session and strongly urged to attend the session. Not only did they 
provide the necessary support and encouragement to help optimise warfarin 
compliance, especially among the ‘high risk’ patients, but they also helped 
patients with information recall (Doak, Doak et al. 1996b). 
 Compliance aids such as blister packs, dosette boxes, medication alarms 
and medication cards identified to improve medication compliance (Levings, 
Szep et al. 1999; Wong and Norman 1987), were recommended to all patients. 
They were especially recommended to the elderly living alone and to those 
suspected to be suffering from cognitive and/or physical limitations (for example 
poor eye sight, hearing impairment). Medication alert bracelets were also 
recommended to these patients. 
Minimising the complexity of the patients’ medication regimen was another 
intervention used in the new program to help improve warfarin compliance. 
Medication reviews were carried out to develop a simple, easy-to-follow dosage 
regimen for the patients. They were asked to physically show the 
researcher/TACT pharmacist all their prescribed, non-prescribed and 
complementary medicines, which they took in addition to their warfarin therapy. 
The medication review ascertained the importance of all the patients’ 
medications and helped to identify any potential drug-to-drug interactions, 
especially between warfarin and complementary medicine, which were acted 
upon in collaboration with the patients’ healthcare providers. Typical examples of 
medication review recommendations included: 
 suggesting that other medications, when and if possible, be taken in the 
morning and warfarin be taken alone in the evening. 
 advising patients to stop taking prophylactic Aspirin. 
 recommending that interacting complementary medications be 
discontinued until after the warfarin therapy was complete. 
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 In summary, improving warfarin compliance was one of the key elements 
targeted in the new warfarin education program. Improving the patients’ warfarin 
knowledge and understanding, encouraging family support and the use of 
compliance aids, as well as conducting medication reviews were all used as 
interventions in the new program to help improve warfarin compliance. Several 
of these interventions, which included familial support and compliance aids, were 
especially recommended for the ‘high risk’ patients. 
 
5.3.4 Simple, easy-to-read written warfarin information 
 Several interventions incorporated in the new program aimed to improve 
patient comprehension, especially among patients with low literacy skills. These 
interventions included designing the booklet in a simple and easy-to-read format 
with culturally sensitive illustrations and adhering to recommended guidelines 
ensuring its good quality and suitability. As already mentioned in this chapter, it 
was important to ensure that the language used during the education sessions 
was simple and easy-to-understand, particularly when educating the patients 
with low literacy skills (Mayeaux Jr, Murphy et al. 1996). 
The new booklet (APPENDIX 12) was written in a simple and easy-to-read 
format so that it could be read and understood by a wider warfarin prescribed 
population, inclusive of those with low literacy skills. Several available tools, 
guidelines and principles were used to ensure that the booklet was written in a 
format to help improve knowledge, understanding and information recall (Houts, 
Witmer et al. 2001). The manual SMOG test (McLauglin 1969) (APPENDIX 4), 
the Fry Readability Formula (Fry 1968) (APPENDIX 5) and the computerized 
Flesch-Kincaid instrument available on the Microsoft Office Word 2000 program 
were used to ensure that the booklet was written below a grade 8 reading level.  
The ‘Toolkit for producing patient information’ (The United Kingdom 
Department of Health 2002) (APPENDIX 2) and the ‘Guidelines for writing 
patient information’ (Doak, Doak et al. 1996a) (APPENDIX 3) were used to 
ensure that the information was presented in a simple, easy-to-read format with 
attention to colour, text and print size. Consequently, the booklet was written in a 
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large 12 font print size, with bulleted points and ample white spaces to avoid 
looking too cluttered. These modifications were especially useful for elderly 
patients who have problems seeing and reading currently available written 
patient information (Rutledge and Donaldson 1998). 
Visual images and illustrations were included in the new booklet because 
research has shown that memory has many more access points for visuals than 
for words and letters (Doak, Doak et al. 1996b). The illustrations were used to 
highlight important concepts (Rutledge and Donaldson 1998) and to help 
encourage desired behaviour (Davidhizar and Brownson 1999), such as using 
an electric razor or a soft bristle toothbrush. Twenty Illawarra Health interpreters 
from different cultural backgrounds were also asked to comment on whether or 
not the visual images and illustrations were culturally appropriate. 
The quality and the suitability of the new warfarin booklet was assessed 
by the researcher/TACT pharmacist and two of her colleagues, using the 
validated ‘Suitability Assessment of Materials’ (SAM) instrument (Doak, Doak et 
al. 1985)(APPENDIX 6), the ‘Bernier Instructional Design 
Scale’(BIDS)(APPENDIX 7), and the ‘Checklist for print materials’ (Bidford Maine 
Area Health Education Center 1996)(APPENDIX 8). The SAM instrument was 
especially useful in assessing and evaluating the suitability of the booklet for 
patients with limited literacy skills (Doak, Doak et al. 1985), while the BIDS 
instrument identified the presence (or absence) of instructional design/learning 
principles, and the Checklist  provided an assessment for the appropriateness of 
the written material for patients.  
On completion of the first draft of the new warfarin information booklet 
(APPENDIX 12), comments were sought from two literacy and educational 
experts from the University of Wollongong (Professor Brian Ferry and Professor 
Brian Cambourne). They were asked to give their expert opinions about the 
suitability and the quality of the booklet for the general population, inclusive of 
those with low literacy skills and from non-English speaking backgrounds. 
Comments and opinions were also sought from ten pharmacists working in 
community and hospital settings, as well as allied health colleagues from ‘The 
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Ambulatory Care Team’ (TACT). All of these comments, including those made 
by the Illawarra Health interpreters, were collated and, where appropriate, 
changes were made to the new warfarin information booklet prior to the research 
study. These changes are comprehensively detailed in the pilot study section of 
this chapter. 
In summary, the new warfarin information booklet was written in a simple, 
easy-to-read format to ensure that a wider warfarin prescribed population, 
including those with low literacy skills, could read and understand the booklet. 
Several validated tests, guidelines and instruments were used to design and 
develop the new booklet and to evaluate its quality and suitability. The language 
used during the education sessions was simple and easy-to-understand, once 
again targeting a wider patient population, inclusive of those with low literacy 
skills.  
 
5.3.5 The continuity of care between hospital and community settings 
 Improved continuity of care between hospital and community settings was 
also specifically targeted in the new warfarin education program. The ‘Guidelines 
on the continuum of care of quality use of medicines between hospital and 
community’ (Australian Pharmaceutical Advisory Council 1998)(APPENDIX 9), 
known as the APAC guidelines, were used. These guidelines were incorporated 
in the new warfarin education program from the beginning. The customary 
warfarin education program did not include these guidelines at the beginning of 
the study.  However, it is important to note that since TACT is a new service 
undergoing continuous development, some of the interventions recommended 
by the APAC guidelines were incorporated into the customary TACT program 
during the study period, following directions from area health service 
management. Typical examples include: faxing the patients’ general practitioner 
with the details of their admission and subsequent discharge from the TACT 
service; encouraging the patients to record their INR results, warfarin doses and 
appointment times in their booklets; and giving patients information sheets about 
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potential warfarin interactions with other drugs, including complementary 
medicines (APPENDIX 27). 
Each of the seven APAC principles will now be discussed with a brief 
explanation of the interventions used to target these principles in the new 
warfarin education program. Many of these interventions such as; medication 
reviews, family support and interpreter services, have already been discussed 
elsewhere in this chapter because they also target some of the other key 
elements. 
 
Principle 1: It is the responsibility of the admitting institution to ensure the 
development and coordination of a medication discharge plan for each patient. 
The person responsible for coordinating the development, implementation, and 
monitoring of the medication discharge plan, including medication supply and 
medication information, should be identified as soon as practicable after 
admission. 
New consenting patients requiring warfarin therapy had the details of their 
admission to TACT and proposed warfarin management faxed to their general 
practitioners. These patients were then placed in either the control or intervention 
groups by the TACT pharmacists and educated within four days of their 
admission to TACT. Non-consenting patients were not part of the study, but still 
received the customary warfarin education program. 
 
 Principle 2: Hospital staff should obtain an accurate medication history, 
including prescription and over-the-counter medicines and other therapies such 
as herbal products, at the time of admission. 
 After admission to TACT and during the initial education session the 
researcher/TACT pharmacist carried out a thorough medication review of all the 




Principle 3: Hospital staff should evaluate the current medication at the 
time of admission, in consultation with the patient’s general practitioner, with a 
view to;          
 -identifying the appropriateness and effectiveness of current medication, 
 and rationalising current medications if appropriate 
-paying particular attention to any problems associated with current  drug 
 therapy, including any possible relationship with the current medical 
 condition, and  
 -documenting allergies and any previous adverse drug reactions 
The purpose of the medication review was to identify the appropriateness 
of all the patient’s medications, to review the times that they were taken and to 
minimise potential drug-to-drug interactions, side effects and/or adverse drug 
events such as allergies. When changes to prescribed medications were 
necessary, the researcher/TACT pharmacist collaborated with the patient’s 
medical practitioners and other members of TACT staff, prior to recommending 
the changes. For simple recommendations such as the timing of the warfarin 
doses, the type of analgesic and/or self-prescribed complementary medicines 
used, the researcher/TACT pharmacist spoke directly to the patient and/or carers 
without involving any of the other healthcare practitioners.  
 
Principle 4:  During the hospital stay, treatment plans relating to the 
probable medication management during the stay and, where applicable, at 
discharge, should be developed in consultation with the patient and/or carer. 
Hospital staff should negotiate with the patient issues relating to treatment and 
the development of a discharge plan, and these discussions should be 
documented in the patient’s notes. This plan should form part of the overall care 
plan or critical pathway. 
-The use of interpreters may be required to ensure good communication 
 with people from non-English speaking backgrounds. 
 89 
-To enable the discharge process to be successful, there needs to be 
 effective communication and coordination between all relevant parties in 
 the hospital environment. 
-Where appropriate, community health providers, especially the patient’s 
 general practitioner, should be consulted. 
-Carers should also be consulted where appropriate. 
 During the initial warfarin education session the researcher/TACT 
pharmacist informed the patients about their warfarin management plan using the 
new warfarin education program.  
Non-English speaking patients were provided with accredited Illawarra 
Health interpreters to translate all the relevant information to them in their native 
language. 
All patients were informed that after their discharge from TACT, they 
would be expected to promptly visit their general practitioners who would then be 
responsible for monitoring their warfarin therapy. All patients, including those 
from the ‘high risk’ patient population, were encouraged to visit only one general 
practitioner and one local community pharmacist, in an attempt to minimise poor 
therapeutic outcomes and adverse drug events (Pendleton 1992), and to improve 
the continuity of care. 
On discharge from TACT the patient’s general practitioner was faxed with 
the details about his/her discharge, warfarin dose and INR results. When it was 
appropriate, other healthcare providers who cared for the patient in the 
community setting were also informed about their discharge from the service (for 
example palliative care nurse). 
 
Principle 5: Prior to discharge, pre-discharge medication review and 
dispensing of adequate medication should take place in a planned and timely 
fashion. Adequate medication means sufficient medication to carry the patient 
through to the next arranged review (by their general practitioner, outpatient 
clinic, or some other arrangement), or to complete the course of treatment.  
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If patients are discharged with inadequate supplies of medication, this can 
compromise quality of care for the patient. Supply of the medication from the 
hospital facility must be adequate to ensure continuity of medication is not 
interrupted by the inability to obtain further ongoing supplies if required, within a 
reasonable timeframe. 
On admission to TACT, patients were supplied with sufficient 1mg, 2mg 
and 5mg warfarin tablets to maintain their warfarin therapy appropriately. Upon 
discharge from TACT, only five days’ supply of the warfarin tablets were 
dispensed to patients to encourage them to promptly visit their general 
practitioners. In the event of a public holiday or the possibility that general 
practitioner appointments could not be arranged within the five-day period, either 
the patient continued to be monitored by TACT or more warfarin tablets were 
provided. 
 
Principle 6: At the time of discharge, each patient should be provided with 
a discharge folio containing relevant information such as Consumer Medicine 
Information, a medication record, patient/carer plan, and information on the 
availability and future supply of medication. 
After the initial warfarin education session patients were given the new 
warfarin information booklet (APPENDIX 12) to keep as a resource and they 
were instructed during the session on how to record their own INR results, 
warfarin doses and appointment times in the back of the booklet. They were told 
that their warfarin supplies and warfarin monitoring after their discharge from 
TACT would be the responsibility of their general practitioners. 
 
Principle 7: No patient should be discharged from hospital until the details 
of the admission, medication changes (including additions/deletions) and 
arrangements for follow-up have been communicated to the healthcare 
provider(s) nominated by the patient as being responsible for his or her ongoing 
care. 
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 As already discussed, once the patient had been discharged from the 
TACT service, his/her general practitioners were sent a fax outlining their 
warfarin management, warfarin dose and INR results upon discharge. Other 
health practitioners caring for the patient were also notified of their discharge, 
when and if it was appropriate to do so. 
Improving the continuity of care between hospital and community settings 
was a key element incorporated into the new warfarin education program. 
Several interventions were included in the new program to accommodate each of 
the seven APAC guidelines, which aimed to improve this continuum of care. 
These interventions included: the timely transfer of both warfarin medication and 
information to the patients, their carers and their healthcare practitioners; 
conducting medication reviews; and effectively educating the patients about their 
warfarin management. Some of these interventions, which were deemed to have 
a positive impact and complied with the APAC guidelines, were also incorporated 
into the customary warfarin education program during the course of the research 
study. The possible impact of this on the study design and outcomes will be 
discussed in the later chapters of this thesis. 
 
5.3.6 Patient follow-up 
Patient follow-up is the last of the key elements of an effective patient 
warfarin education program targeted in the new warfarin education program. 
Patient follow-up was incorporated as follow-up telephone calls, which took place 
both one week and three months after the initial warfarin education session.  
The follow-up telephone calls one week after the initial education session 
encouraged patient feedback. Patients were asked whether or not they had any 
problems or concerns with the warfarin therapy and/or information. These calls 
were also used to reinforce and reassure the main points of warfarin information 
to the patient, as per the ‘Warfarin Counselling Checklist ’ (APPENDIX 13). 
The main objectives of the follow-up phone calls three months after the 
initial warfarin education session were to reassure and reinforce warfarin 
information to the patients and to collect evaluation data. The evaluation data 
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pertained to questionnaires about their warfarin management; compliance; 
knowledge and understanding; as well as their satisfaction with the warfarin 
information provided, and possible warfarin-related therapeutic outcomes (Refer 
to Appendices 17-21). The ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) 
was a particularly useful follow-up educational tool, because if patients answered 
questions incorrectly, their answers were documented and they were then given 
the correct answer. In other words, this questionnaire helped to reinforce correct 
warfarin information to the patients. 
In summary, the follow-up telephone calls allowed the patients to have 
their warfarin knowledge and understanding reinforced. They also encouraged 
the patients to provide feedback and to discuss any queries or concerns they 
may have experienced. During the study period, the three-month follow-up 
telephone calls were also used to complete patient questionnaires, which were 
used for evaluation purposes. 
 
5.3.7 Evaluation  
Evaluation was incorporated into the new warfarin education program, at the 
three levels of: process, impact, and outcome. These different evaluation 
modalities were used to assess and analyse the readability, quality and suitability 
of the new booklet (APPENDIX 12) used in the new program, and to evaluate 
patient’s warfarin management, compliance, knowledge and understanding, 
satisfaction with the warfarin information provided and their health outcomes. 
Analysis and assessment of the evaluation information was used to compare the 
new warfarin education program to the customary warfarin education program 
delivered to TACT patients.  
Process evaluation was used to compare the readability, quality and the 
suitability of the new warfarin education program to the customary program. 
Instruments used to assess the readability and the suitability of the written 
warfarin information in both programs have already been described in this 
chapter. These instruments included the following readability formulae: the 
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SMOG test (McLauglin 1969) (APPENDIX 4); the Fry Readability Formula ((Fry 
1968) (APPENDIX 5); and the computerized Flesch-Kincaid instrument available 
on the Microsoft Office Word 2000 program. Quality and suitability instruments 
used during the process evaluation phase included: the ‘Suitability Assessment 
of Materials’ (SAM) (Doak, Doak et al. 1985)(APPENDIX 6); the ‘Bernier 
Instructional Design Scale’(BIDS)(Bernier 1996) (APPENDIX 7);and the 
‘Checklist for print materials’ (Bidford Maine Area Health Education Center 
1996)(APPENDIX 8). Process evaluation was also used to contrast the patients’ 
satisfaction with both programs by using the validated ‘Satisfaction with 
Information about Medicines Scale’ (SIMS) (Horne, Hankins et al. 2001) 
(APPENDIX 20), immediately and three months after the initial warfarin 
education session. 
Impact evaluation assessed whether or not the program had met its 
objectives by evaluating patient knowledge and understanding, as well as 
adherence to recommended health behaviour changes, such as warfarin 
management and compliance. In the absence of a validated warfarin knowledge 
questionnaire, a series of questions were drafted for the ‘Warfarin Knowledge’ 
questionnaire (APPENDIX 19) based on several different warfarin studies 
conducted over the past three decades by Scalley et al (1979), Witte et al (1980) 
and Wyness (1989), as well as the ‘Warfarin Education Program Objectives’ 
(APPENDIX 14) and the contents of the new warfarin information booklet 
(APPENDIX 12). In addition to the ‘Warfarin Knowledge’ questionnaire 
(APPENDIX 19), patients were asked to complete the ‘Self-Management’ 
questionnaire (APPENDIX 17) adapted from Lorig et al ‘Self-Efficacy 
Questionnaire’ (1996 page 41-44) and the ‘Medication-Taking-Measures’ (MTM) 
questionnaire (Morisky, Green and Levine 1986)(APPENDIX 18), immediately 
and three months after the initial education session. These latter questionnaires 
were used to assess and compare their warfarin-related management and 
compliance behaviours.  
Outcome evaluation assessed whether or not the program had worked 
toward achieving its goals within a three-month period, and to compare the new 
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warfarin education program to the customary warfarin education program. The 
‘Outcome Measures of the Warfarin Education Program’ questionnaire 
(APPENDIX 21) was adapted from Lorig et al (1996 pages 53-55) ‘Health 
Outcome Measures for Health Care Utilization’ and was completed over the 
telephone, three months after the initial warfarin education session. Information 
collected from this questionnaire included the number of healthcare provider 
visits (general practitioner, hospital and/or emergency department), the number 
of warfarin-related adverse drug events experienced and the patient’s INR blood 
test results. When patients had neglected to record their own INR results, the 
researcher/TACT pharmacist obtained their results from the relevant pathology 
services.  
Process evaluation data were used to assess and compare the readability, 
quality and the suitability of the written warfarin information used in both 
education programs. Impact evaluation data were used to contrast the patient’s 
satisfaction with each of the education programs, as well as their impact on 
patients’ warfarin knowledge and understanding, and his/her adherence to 
recommended warfarin management and compliance behaviours. Finally, 
outcome evaluation data were used to compare the effects that both programs 
had on the patients’ health outcomes, which included warfarin blood test results 
and healthcare utilisation (for example; the number of general practitioner visits 
and/or hospital visits).  
 
5.3.8 Summary  
In summary, the new warfarin program was based on introducing 
interventions and strategies to target the five key elements of an effective patient 
medication education program. These five key elements were: health 
professional/patient communication and partnerships, warfarin compliance, 
simple, easy-to-read written warfarin information, the continuity of care between 
hospital and community settings and patient follow-up. As well as targeting each 
of these key elements the new warfarin education program also addressed the 
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needs of the ‘high risk’ patient population, to ensure that they too would be 
effectively educated about their warfarin therapy.  
Evaluation was incorporated into the research study to compare the 
readability, quality and suitability of the new warfarin information booklet 
(APPENDIX 12) to the Boots warfarin information booklet (2003) used in the 
customary warfarin education program. Data collected from the ‘Self-
Management,’ ‘Medication-Taking Measures’ and ‘Warfarin Knowledge’ 
questionnaires (Appendices 17-19), as well as the ‘Satisfaction with Information 
about Medicines Scale’ (SIMS) and ‘Outcome Measures of the Warfarin 
Education Program’ questionnaires (Appendices 20-21) were all used to 
compare and contrast the overall effectiveness of the new warfarin education 
program, with the customary warfarin education program delivered to TACT 
patients.  
 
5.4 THE NEW WARFARIN EDUCATION PROGRAM 
The new warfarin education program and the new warfarin information 
booklet (APPENDIX 12) were founded on the ‘Warfarin education program 
objectives’ (APPENDIX 14). These objectives were identified in the literature as 
‘best evidence’ for educating patients about their warfarin therapy (Haines 1998; 
Witte, Gurwich et al. 1980; Wyness 1989) and provided well-defined and 
measurable instructional aims for the education program. Not only were the 
contents of the new warfarin information booklet founded on these objectives, but 
they were also based on information derived from the Boots Healthcare ‘Warfarin 
important instructions for patients’ (2000) and Beata Bajorek’s ‘Warfarin 
medication information booklet for patients and their carers’ developed for use in 
her Ph.D. study; ‘Stroke prevention in elderly patients with atrial fibrillation’ 
(Bajorek 2002). 
The new warfarin education program consisted of an initial home- based 
one-to-one verbal warfarin education session, during which the new warfarin 
information booklet (APPENDIX 12) was used as a written and visual aid. At the 
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end of the session the patients were given the booklet as a written information 
resource and were asked to complete the first set of evaluation questionnaires 
(Appendices 17-20). Follow-up phone calls for the new program were made both 
one week and three months after the initial warfarin education session to offer 
encouragement, reassurance, reinforcement and to promote feedback. The 
three-month follow-up evaluation questionnaires (Appendices 17-21) were also 
completed over the telephone.  
A typical transcript of the initial warfarin education session used in the new 
warfarin education program can be found in APPENDIX 11 and a complete 
schematic representation of the new warfarin education program will now follow. 
The new warfarin education program was based on a conceptual 
framework, which incorporated interventions and strategies targeting the five key 
elements of an effective patient medication education program. These 
interventions and strategies were not chronologically added to the program and 
often targeted more than one of the key elements. The following symbols will 
therefore be used to represent the key elements targeted by the different 
interventions and strategies in the new warfarin education program. 
 Patient/health professional communication and partnerships 
 ♥ Warfarin compliance  
  Simple, easy-to read written warfarin information 
  Continuity of care between hospital and community settings 
  Patient follow-up 
 
Prior to arriving at the patient’s home  
 An appointment for the initial education session was made over the 
telephone and the appropriate information, checklists and 
questionnaires, as per APPENDIX 10, were packed (). 
 The patient’s general practitioner was faxed about their patient’s 
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admission to TACT and their proposed warfarin therapy (). 
 Carers and family members were encouraged to attend the 
education session (, ♥, ). 
 For non-English speaking background patients, Illawarra Health 
interpreters were booked for the education sessions (, ♥, ). 
 
On arrival at the patient’s home 
 The researcher/TACT pharmacist identified herself and reminded 
the patients about the follow-up phone calls, one week and three 
months after the initial education session (, ). 
 The researcher/ pharmacist ensured that the environment was 
conducive to learning, (for example TVs, radios etc were asked to 
be turned off) and it was ensured that the patients were relaxed and 
comfortable)().  
 The researcher/TACT pharmacist completed the patients’ 
‘Demographic Data Sheet’ (APPENDIX 16) and the ‘Warfarin 
Pretest Questionnaire’(APPENDIX 15). The pretest questionnaire 
ascertained the patient’s previous experience(s), if any, with 
warfarin and whether or not they had any preconceptions, feelings 
or fears concerning their warfarin therapy. Each of these issues 
was dealt with in a positive, reinforcing and reassuring manner (, 
). 
 The researcher/TACT pharmacist enquired about the patient’s past 
and present illnesses, as well as their current treatment, to ensure 
that they would not impact upon their warfarin therapy (for example 
patients with cancer receiving cytotoxic therapy would have had 
problems stabilizing their INR results and warfarin therapy) (, 
). 
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During the Initial Warfarin Education Session (refer to APPENDIX 11 for a typical 
transcript of the education session) 
 Encouragement, reassurance, reinforcement and positive feedback 
were always used by the researcher/TACT pharmacist in an 
attempt to promote collaboration and active patient participation 
(, ♥). 
 The researcher/TACT pharmacist remained friendly, approachable 
and supportive throughout the education session. Speaking in a 
clear, positive, interested and enthusiastic manner, trying to help 
motivate the patients to learn and comprehend the information 
given to them (). 
 The researcher/TACT pharmacist always used simple, easy-to-
understand language, the ‘New Warfarin Information Booklet’ 
(APPENDIX 12) and the ‘Warfarin Counselling Checklist ’ 
(APPENDIX 13) to ensure that all the main points had been 
carefully explained to the patients and/or their carers (, , ♥). 
 The new warfarin information booklet (APPENDIX 12) was written 
in a simple, easy-to-read format using validated tests, guidelines 
and instructions to ensure that it could be read by a wider patient 
population, inclusive of those with low literacy skills (). 
 The new warfarin information booklet (APPENDIX 12) was used as 
a written and visual aide for the verbal education session. The 
researcher/TACT pharmacist underlined main points within the 
booklet, referring to the illustrations as visual aids to reinforce the 
information (, ). 
 Information provided during the education program was based on 
the ‘The New Warfarin Education Program Objectives’ (APPENDIX 
14) and focused on improving the patients’ knowledge and 
understanding about how warfarin works, how to take it safely, what 
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the INR blood test results mean, possible side effects and the 
effects other medications, diet, alcohol and lifestyles can have on 
warfarin therapy (♥). 
 Patients were given limited supplies of 5mg, 2mg and 1mg warfarin 
tablets during their admission to TACT. They were asked to show 
the researcher/TACT pharmacist which combinations of warfarin 
tablets they would use to provide a dose equivalent to 9mg, 8mg, 
4mg and 3mg of warfarin. This exercise helped to educate and 
reinforce patients about how to calculate their appropriate warfarin 
dose (♥, ). 
 The researcher/TACT pharmacist performed a medication review 
on all the patient’s medications, including their complementary 
medicines, to ensure that there were no drug- to-drug interactions 
with their warfarin therapy. Recommendations were subsequently 
given about suitable times to take their medications and when 
necessary to cease or change medications which interacted with 
their warfarin after collaborating with their healthcare providers (♥, 
). 
 Patients taking complementary medicines were reminded about the 
‘Patient information on potential drug-to-drug warfarin interactions’ 
leaflet (APPENDIX 27) and asked, if necessary, to cease the 
interacting complementary medications or to discuss them with 
their healthcare providers (). 
 Patients were shown how to keep a record of their INR results, 
warfarin doses and appointment times on pages 18-21 of the new 
warfarin information booklet (APPENDIX 12). They were 
encouraged to continuously record this information as a valuable 
resource for themselves and all their healthcare providers (, , 
). 
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 All patients and especially elderly patients living alone, who 
suffered from any cognitive and/or physical limitations, were 
strongly encouraged to use compliance aids (for example dosette 
boxes, blister packs, alarms, calendars) (♥). 
 Patients were continuously asked questions throughout the 
education session to verify their comprehension of the warfarin 
information (for example Why do you think that you been started on 
warfarin tablets? What is your target INR?)(, ♥).  
 Patients were informed that their general practitioners would be 
responsible for their warfarin monitoring and further warfarin 
prescriptions after their discharge from TACT (). 
 Patients were encouraged to use the new warfarin information 
booklet (APPENDIX 12) as a simple, easy-to-read written 
information resource (). 
 Patients were advised about other reliable warfarin information 
resources such as; the TACT office, their healthcare providers, the 
National Prescribing Service (NPS) (they were given a fridge 
magnet with the NPS telephone number) and the internet sites 
available in the back of the new warfarin information booklet 
(APPENDIX 12)(, ).  
 Patient feedback, which included their comments and opinions, was 
encouraged not only during the follow-up phone calls but also 
throughout the education program ().  
 At the conclusion of the initial warfarin education session, patients 
were encouraged to ask questions and were reassured that if they 
complied with the recommendations, as per the education session, 
they would be able to effectively manage their warfarin therapy at 
home (, ♥). 
 When patients were discharged from TACT, their general 
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practitioners were faxed the details of their discharge, warfarin dose 
and INR values during their admission to TACT (). 
 
Telephone Follow-up Calls (one week and three months after the initial warfarin 
education session)  
 Patients received follow-up phone calls, one week and three 
months after the initial warfarin education session. During these phone 
calls warfarin information was reinforced according to the ‘Warfarin 
Counselling Checklist ’ (APPENDIX 13) (, ♥, ). 
 The patients were also encouraged to discuss any queries or 
concerns, and to express their comments and opinions about the 
warfarin education program (, ♥, ). 
 
Evaluation  
The following is a summary of the evaluation instruments, tools and 
questionnaires used in the new warfarin education program. 
 The readability, quality and the suitability of the new warfarin information 
booklet was assessed using the following 
 SMOG test (McLauglin 1969) (APPENDIX 4) 
 The Fry Readability Formula (Fry 1968) (APPENDIX 5) 
 The computerized Flesch-Kincaid instrument available on 
the Microsoft Office Word 2000 program 
 The ‘Suitability Assessment of Materials’ (SAM) (Doak, Doak 
et al. 1985) (APPENDIX 6) 
 The ‘Bernier Instructional Design Scale’ (BIDS) (Bernier 
1996)(APPENDIX 7) 
 The ‘Checklist for print materials’ (Bidford Maine Area Health 
Education Center 1996) (APPENDIX 8) 
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 The patients were asked to complete the following questionnaires, 
immediately and three months after the initial warfarin education session.  
 ‘Self-Management’ questionnaire (APPENDIX 17) 
 ‘Medication-Taking- Measures’ questionnaire (APPENDIX 18) 
 ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) 
 ‘Satisfaction with Information about Medicines Scale’ (SIMS)  
       (APPENDIX 20) 
 
 Three months after the initial education session patients were also asked 
to complete the ‘Outcome Measures of the Warfarin Education Program’ 




5.5 ETHICAL CONSIDERATIONS 
Prior to the commencement of the pilot study and the research study, 
ethics approval had to be sought from the following:  
 The University of Wollongong Ethics Committee 
 The Management of the Illawarra Health Service  
 The TACT medical director  
 The Illawarra Health interpreter service 
 Patients participating in the research study  
An ethics approval request to conduct the research study was submitted 
by the researcher/TACT pharmacist to the University of Wollongong Ethics 
Committee in November 2002. Illawarra Health’s upper management officials, 
The Ambulatory Care Team’s (TACT) medical director and the Illawarra health 
interpreter service were all informed about the research study and also asked for 
their written consent. Once permission and written consent were received from 
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each of these committees and/or persons, the researcher/TACT pharmacist 
continued with the pilot study and then the research study. 
During the course of the research study there were several ethical issues, 
which needed to be considered and addressed. TACT staff members were 
informed about the research study in an education session presented by the 
researcher/TACT pharmacist, where they also received the ‘Research 
information sheet for Illawarra Health staff’ (APPENDIX 23). During this 
education session, they were informed that a patient’s refusal to participate in the 
study would in no way detrimentally affect their TACT healthcare service. They 
were given the ‘Suggested dialogue for patient recruitment and obtaining 
consent’ (APPENDIX 24) as a guide to help them approach and recruit patient 
participants for the study. TACT staff members were also told that they were 
under no obligation to approach and recruit patients for the study and that their 
decision to do so was purely on a voluntary basis.  
The researcher/TACT pharmacist was a TACT employee prior to the 
study, which meant that she had ready access to the patient’s medical notes and 
hospital data. The patient participants were informed about the study and the 
researcher/TACT pharmacist’s access to this information in the ‘Patient 
participant information sheet’ (APPENDIX 25). The patients consented to 
participate in the study and granted their permission for the researcher/TACT 
pharmacist to access their medical information by signing the ‘Patient participant 
consent form’ (APPENDIX 26).  
Written confirmation about patient confidentiality and the de-identification 
of patient details was made available to all participants through the ‘Patient 
participant consent form’ (APPENDIX 26). The patients were also verbally 
informed about these confidentiality issues during the recruitment phase of the 
study. The ‘Patient participant information sheet’ (APPENDIX 25), the ‘Patient 
participant consent form’ (APPENDIX 26) and the TACT staff, reassured patients 
that their refusal to participate and/or to withdraw from the study at any time 
would in no way impact detrimentally on their TACT healthcare service. 
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As already mentioned in this chapter, when interventions incorporated into 
the new warfarin education program were perceived to be best practice and 
complied with the APAC guidelines, they were also at times incorporated into the 
customary warfarin education program, during the course of the study. These 
changes were based on recommendations from area health service management 
and were out of the control of the researcher. The implications of these changes 
on the study results will be discussed in a later chapter.  
 
 5.6 THE PILOT STUDY 
Prior to the research study being conducted, a pilot study was completed 
to trial the new warfarin education program. Ten pilot group participants were 
educated using the new program as a ‘one off’ education session, including 
being given the new warfarin information booklet (APPENDIX 12). The 10 pilot 
group participants had similar demographic variables such as age, social status 
and educational backgrounds to the eligible TACT patient participants, ensuring 
that their answers to the evaluation questionnaires, their comments and opinions 
would benefit the eligible patient participants (Doak, Doak et al. 1996b). The 10 
pilot group participants had never been prescribed warfarin but they volunteered 
to take part in the trial warfarin education session.  
At the end of their single education session, each of the pilot participants 
was asked to complete the same four evaluation questionnaires which were to 
be used in the research study. These questionnaires included the ‘Self-
Management’, ‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’ 
questionnaires (Appendices17-19), as well as the ‘Satisfaction with Information 
about Medicines Scale’ (SIMS) questionnaire (APPENDIX 20). As an added 
measure, they were also asked to complete the DISCERN questionnaire 
(Charnock, Shepperd, Needham and Gann 1998) (APPENDIX 22) which would 
help to identify their perception about the reliability and the quality of the new 
warfarin information booklet. At the completion of their individual education 
sessions, they were asked for their opinions and/or comments about the warfarin 
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education session, the booklet and the questionnaires. The results of the pilot 
group study will now be briefly discussed.  
There were five male and five female pilot group participants, ranging in 
age from 38 to 70 years. Their educational status varied from a grade 4 level to 
a tertiary level, with four of the participants coming from non-English speaking 
backgrounds. All of the participants were able to readily answer each of the 
questionnaires, except for the ‘Warfarin Knowledge’ questionnaire (APPENDIX 
19). A few of the participants found some of the knowledge questions to be 
ambiguous and confusing, which is why these questions were revised after the 
pilot study. The changes made to the ‘Warfarin Knowledge’ questionnaire prior 
to it being used in the research study as per APPENDIX 19, included: 
Question 1:  “What is your medicine called (generic and brand name)?” 
Revised Q1:  “Which brand of warfarin is prescribed for you?” 
 
Question 9  “What are the appropriate levels for an INR blood test?”  
Revised Q 9 “What is your target INR blood test range?”  
 
Question 17  “Do you need to make any modifications to your daily   
   activities while you are taking warfarin?”  
Revised Q 17 ”Name TWO activities or things you need to be careful  
    doing while taking warfarin.”  
 
The warfarin education session was not changed after the pilot study 
because over 80 percent of the pilot group participants were satisfied with the 
information given to them, according to the results of the ‘Satisfaction with 
Information About Medicines Scale’ (SIMS) (APPENDIX 20) and their positive 
comments. Overall, the new warfarin information booklet remained largely 
unchanged after the pilot study, because the results of the DISCERN 
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questionnaire (APPENDIX 22) indicated that 90 percent of the pilot group 
participants perceived the booklet to be of a ‘high’ to ‘very high’ quality with 
minimal short comings. The minor changes made to the booklet, based on the 
pilot participants’ comments and opinions, included: having a bright front cover 
on the booklet; showing people living a normal life while taking warfarin; a 
contents page for easy access to page numbers; and making the MedicAlert 
bracelets an ‘optional’ alternative for the patient. 
At the conclusion of the pilot study and once the minor changes had been 
made, the researcher/TACT pharmacist then collated the comments and 
opinions about the draft version of the new warfarin information booklet from the 
literacy experts at the University of Wollongong, her work colleagues and the 
Illawarra Health interpreters. Once again, a few minor changes were made to the 
booklet, prior to it being printed in its final version as per APPENDIX 12. These 
minor changes included: 
Page 2:  ‘This booklet will help you lead a normal life whilst on this 
therapy. This booklet will help you understand….’ was replaced with ‘The 
purpose of this book is to help you understand:’ 
Page 8:  ‘Have the INR test done every time your doctor orders one’ was 
replaced with ‘Follow your doctor’s orders for INR testing’ 
Page 10: ‘ To help let people know, you can order a MedicAlert bracelet 
from your pharmacist’ was replaced with ‘You can also wear a MedicAlert 
bracelet (which you can buy from your pharmacist) to let people know that 
you take warfarin’ 
Page 15 ‘Additional things to remember’ was replaced with ‘Other factors 
to consider’ 
Other changes throughout the booklet also involved replacing the term 
“healthcarers” with “healthcare providers”, clearly labelling illustrations and 
deleting those which were deemed unnecessary, as well as altering some 
of the formatting in the booklet. 
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On the completion of these changes to the new warfarin information 
booklet and the questionnaires, based on the results of the pilot study as well as 
the comments and opinions of the literacy experts, work colleagues and 
interpreters, the booklets were printed and the research study commenced in 
January 2003. The methodological process of this research study will now be 
discussed.   
 
5.7 THE RESEARCH STUDY 
 
5.7.1 Background 
Illawarra Health’s The Ambulatory Care Team (TACT) is a 
multidisciplinary team consisting of medical practitioners, pharmacists, 
physiotherapists and registered nurses. TACT provides a home-based outpatient 
management service for conditions that would otherwise be managed in hospital 
including; intravenous antibiotics, subcutaneous enoxaparin injections and 
warfarin management, pre- and post-operative care, as well as wound 
management. Patients who are treated with the oral anticoagulant warfarin and 
educated in their own homes are focused upon for the purpose of this research 
study. It is also important to note that both the educators involved in this study 
were pharmacists employed by the TACT team for at least four years. 
 
5.7.2 Eligible participants, informed consent and confidentiality  
Once permission to conduct the research study was received from the 
University of Wollongong Ethics Committee, the Illawarra Health management, 
the TACT medical director and the Illawarra Health interpreter service, the 
researcher/TACT pharmacist conducted an education session to inform the other 
TACT staff members about the study. During this education session, the TACT 
staff members were given the ‘Research information sheet for Illawarra Health 
staff’ (APPENDIX 23) and the step-by-step guide on how to go about recruiting 
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patients on a voluntary basis, as per the ‘Suggested dialogue for patient 
recruitment and obtaining consent’ (APPENDIX 24).  
All patients accepted for admission to The Ambulatory Care Team (TACT) 
during the study period who were over 18 years of age, resided in the Illawarra 
Health area and were newly prescribed warfarin, or those who were 
recommencing warfarin therapy after at least 15 years, were considered eligible 
for the research study. For the purposes of this study patient participants aged 65 
years and over were referred to as elderly, and those educated at or below a 
grade 6 level were referred to as having low literacy skills, as deemed by Davis 
et al (1990) and Rolland (2000). Patients from non-English speaking 
backgrounds were also considered eligible for the research study because 
Illawarra Health interpreters were made available to translate all the relevant 
information to them. On admission to TACT eligible patients were verbally 
informed about the study as detailed below and asked to consent to becoming 
patient participants by signing the ‘Patient participant consent form’ (APPENDIX 
26).  
Informed consent is an ethical obligation fundamental to research. 
Obtaining informed consent and maintaining confidentiality are critical to the way 
we deliver healthcare and remain a crucial part of our medico legal responsibility 
to the patient and to society (Betancourt and Jacobs 2000). Thus, eligible patient 
participants were informed about the study by having the ‘Patient participant 
information sheet’ (APPENDIX 25) read out to them by either a TACT pharmacist 
or another TACT staff member during one of their initial home visits. 
Subsequently, after reading through the ‘Patient participant consent form’ 
(APPENDIX 26), consenting patients were asked to sign the consent form and 
reminded about their right to withdraw from the study at any time.  
All data collected during the course of the research study were processed 
in a way that protected the patients’ confidentiality and anonymity, with only the 
data containing fully completed evaluation questionnaires (Appendices 15-21), 
immediately and after three months, being used for analysis. Patient participant 
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details and consent forms were securely stored separately from the other data 
and coding was used during data collection. Patient participants were given 
sufficient time, prior to and following education and evaluation sessions, to raise 
any questions or concerns they may have had in relation to the research study 
and/or the data collection process. 
 
5.7.3 Research participants and the study 
For the purposes of this research, over 100 consenting patient participants 
were recruited for the study, with the intention to allocate 50 patient participants 
to the control group and 50 patient participants to the intervention group. Patient 
recruitment continued until there were at least 50 control patients and 50 
intervention patients who had completed all questionnaires, inclusive of the three 
month follow-up questionnaires. To ensure consistency, the control group 
patients were educated by a TACT pharmacist using the customary warfarin 
education program and the Boots warfarin information booklet (2003).The 
intervention group patients, on the other hand, were educated by the TACT 
researcher/pharmacist, using the new warfarin education program and the new 
warfarin information booklet (APPENDIX 12). Typical transcripts for both the 
customary and the new warfarin education sessions can be found in APPENDIX 
28 and APPENDIX 11, respectively. 
The patient participants in the study were allocated into the control or the 
intervention group depending on what day of the week they were admitted to 
TACT and which TACT pharmacist, the researcher - referred to as the 
researcher/TACT pharmacist - using the new warfarin education program or the 
non-researcher pharmacist – referred to as the TACT pharmacist - using the 
customary warfarin education program was available at work. It was an allocation 
by convenience because the non-researcher TACT pharmacist worked with 
TACT on a Monday and the researcher/TACT pharmacist worked with TACT on 
a Thursday and it was common practice that all new warfarin prescribed patients 
admitted to TACT received warfarin education within four days. As a result, the 
 110 
patient participants who consented between Friday and Sunday were allocated 
into the control group, for the TACT pharmacist to educate with the customary 
warfarin education program. The patient participants who consented between 
Monday and Thursday, on the other hand, were allocated to the intervention 
group, for the researcher/TACT pharmacist to educate with the new warfarin 
education program. The allocation of patients to the control or intervention 
groups could be problematic if there were different referral patterns over different 
days of the week. From experience with TACT referral patterns this was not 
expected to occur, however referral and other patient data were collected for 
each patient and compared as part of the data analysis to confirm that this 
method of patient allocation resulted in comparable patient samples for both 
groups.  
Non-English speaking background patients were also recruited by inviting 
an Illawarra Health interpreter to translate all the relevant information to the 
patients. The researcher/TACT pharmacist was especially interested in the non-
English speaking background patients because they are often excluded from 
similar studies based on their language barriers, and yet they are in the ‘high risk’ 
group, which we know little about. 
Demographic variables such as age, nationality, sex, educational level 
and morbidities were recorded on the ‘Patient Demographic Data’ (APPENDIX 
16). Demographic data were collected by the pharmacists from the patients, their 
inpatient notes and/or the Illawarra Health DRACIS database. These 
demographic data were used in the analysis to investigate their possible effects 
on the patients’ warfarin knowledge and understanding, self-management and 
compliance, as well as to compare their effects on the two different warfarin 
education programs. 
Evaluation questionnaires were completed in the patients’ homes, 
immediately after the initial warfarin education sessions, and then over the 
telephone during the three-month follow-up. The purpose of the evaluation 
questionnaires was to assess and analyse the effectiveness of the new warfarin 
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education program, and to compare and contrast it with the customary warfarin 
education program, given to TACT patients receiving warfarin therapy.  
Data collected from the ‘Self-Management’ (APPENDIX 17) and 
‘Medication-Taking-Measures’ (APPENDIX 18) questionnaires from both 
intervention and control patients helped to compare the impact of the two 
programs on the patients’ perception about warfarin self-management and 
compliance. Comparing the results of the data collected from the ‘Warfarin 
Knowledge’ questionnaires (APPENDIX 19) assisted with analysing which 
program - the new or the customary - was superior in terms of improving warfarin 
knowledge and understanding. Reviewing the ‘Satisfaction with Information about 
Medicines Scale’ (SIMS)(APPENDIX 20) established whether or not the patients 
were more or less satisfied with either of the two education programs. Finally, 
data collected from the ‘Outcome Measures of the Warfarin Education Program’ 
questionnaire (APPENDIX 21) was used to compare the therapeutic outcomes of 
both education programs over the three-month period. The outcomes reviewed 
included; therapeutic INR blood test results, visits to general practitioners, 
hospitals and emergency departments, as well as possible warfarin-related 
adverse drug events.  
 
5.7.4 Data processing and analysis 
All information gathered from patient participants for the purposes of this 
study, including personal details and questionnaires, was de-identified and 
secured in a locked cabinet at the University of Wollongong. No personal details 
were provided to other patient participants nor were they identified in any of the 
journal articles, conference presentations and thesis publications resulting from 
this research study. Clinical data collected from patient participants were kept by 
Illawarra Health’s medical records department and stored according to its 
standard record keeping practices. No information was left on the network 
computer that could be accessed by anyone other than the researcher/TACT 
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pharmacist herself. On completion of the research study and after the required 
time all identifying details will be appropriately destroyed.  
On completion of the research study, a period of approximately 12 
months, all the information was collected and collated by the researcher/TACT 
pharmacist. The information collected from the questionnaires was quantitatively 
coded and entered into a JMP database created for the study by the 
researcher/TACT pharmacist in the JMP statistical computer program (Sall 
2000). The ‘Self-Management,’ ‘Medication-Taking- Measures’ and the 
‘Satisfaction with Information about Medicines Scale’ (SIMS) questionnaires 
(APPENDIX 17, 18 and 20) are all scale form questions which are readily 
entered quantitatively into the database. On the other hand, the ‘Warfarin 
Knowledge’ questionnaire (APPENDIX 19), which consisted of open-ended 
questions, was coded ‘post facto’ by the researcher/TACT pharmacist following 
the pilot phase, and also entered quantitatively into the database. The ‘Outcome 
Measures of the Warfarin Education Program’ questionnaire’ (APPENDIX 21) 
had a combination of numerical values, pre-coded answers and open-ended 
questions. The numerical values and pre-coded answers were quantitatively 
added to the database, whereas the answers to the open-ended questions were 
typed into the database for thematic analysis. Similarly, any comments that were 
made by the patients and/or their carers during the three-month follow-up period 
were also typed into the database for thematic analysis. 
On completion of data entry, the quantitative data were analysed by the 
researcher/TACT pharmacist with the assistance of a qualified statistician at the 
University of Wollongong. Several statistical tests were used to compare the new 
warfarin education program against the customary warfarin education program. 
These tests included: t-tests to determine whether or not mean scores for the 
different questionnaires were significantly different for the two programs; paired t-
test to compare immediate scores and follow-up scores within the same groups 
of patients; ANOVA tests to compare the mean scores for both groups taking into 
account several variables at once; correlation coefficients to analyse the 
relationships between the mean scores for each of the questionnaires and the 
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number of healthcare visits, as well as the percentage of International 
Normalised Ratio (INR) blood test results within therapeutic range; and chi-
squared tests to evaluate whether or not there were any relationships between 
two variables such as category (i.e. intervention or control) and education level. 
The results of these tests and analyses will be discussed at length in the 
following chapter. 
 
5.7.5 Summary of the methodological process of the research study 
The following is a summary of the methodological processes of the study. 
Table 1 gives an overview of the differences between the new warfarin education 
program given to the intervention group patients and the customary warfarin 
education program given to the control group patients.  
 










TACT staff member will invite eligible patients 
to participate in the research study as per 
APPENDIX 24. If they agree to participate they 
will be given the ‘Patient participant 
information sheet’ (APPENDIX 25) and asked 
to sign the ‘Patient participant consent form’ 
(APPENDIX 26). The consent form will then be 
filed in a secured cabinet in the TACT office.  
 
Note: For non-English speaking background 
patients an Illawarra Health interpreter will be 




















Consenting patient participants will be 
allocated to the intervention or control groups 
and then telephoned by the TACT pharmacists 
to make a suitable appointment time for the 
initial education session to take place. They 
will also be reminded about the evaluation 









Carers and/or family members will be strongly 






Initial warfarin education sessions will be 
delivered in the patient’s home or an 






A collaborative approach to the education 
session will be highly promoted, using 
encouragement, reassurance, reinforcement 





Intervention patients will be asked many 
questions and will be encouraged to make 
comments and given their opinions throughout 





An Illawarra Health interpreter will be in 







Researcher/TACT pharmacist will ensure that 
the environment is conducive to learning i.e. 
turn off any televisions, radios etc, and ensure 





All patient participants will have their 
‘Demographic Data’ (APPENDIX 16) recorded 






Patient participants will be pre-tested for their 















Researcher/TACT pharmacist will educate the 
intervention patient participants with the new 
warfarin education program using the 
‘Transcript of the new warfarin education 
session’ (APPENDIX 11), the ‘New warfarin 
information booklet’ (APPENDIX 12), the 
‘Warfarin Counselling Checklist ’(APPENDIX 
13) and the ‘New Warfarin Education 
Objectives’ (APPENDIX 14) to ensure that all 







Researcher/TACT pharmacist will speak in 
simple, easy-to-understand language, 
underlining key points in the new warfarin 
information booklet (APPENDIX 12), which will 





TACT pharmacist will educate the control 
patient participants with the customary 
warfarin education program as per the 
‘Transcript for the customary warfarin 
education program’ (APPENDIX 28) using the 




Intervention patients will be encouraged to 
disclose the use of all other medicines 
including complementary medicines in order to 
check for drug-to-drug interactions, by way of 






Control patients will be asked to disclose other 
prescribed medication  
  
‘Patient information on potential drug-to-drug 
warfarin interactions’ (APPENDIX 27) will be 






Intervention patients will be encouraged to 
record their INR blood test results, warfarin 
doses and appointment times in the back of 
















Compliance aids will be highly recommended 
for ‘high risk’ patients living alone or believed 






Intervention patients will be asked to show the 
researcher/TACT pharmacist how to make up 
warfarin doses equivalent to 9mg, 8mg, 4mg 





The National Prescribing Service ‘Medicines 
Line’ 1300 888 763 (given as a fridge magnet) 
and other suitable websites available in the 
new warfarin information booklet will be 
recommended to intervention patients as 






TACT office number 42 225 328 will be made 






Intervention patients will be given telephone 
reinforcement, reassurance and follow-up, one 






All patient participants will be given evaluation 
questionnaires (Appendices 17-20) to 
complete, immediately and three months after 
the initial warfarin education session. The 
immediate questionnaires will be completed in 
the patient’s home, and the three-month 
follow-up questionnaires will be completed 






All patient participants will complete the 
‘Outcome Measures of the Warfarin Education 
Program’ questionnaire (APPENDIX 21) over 










A simplified version of this table is presented on the following page, as a 
flowchart of the research study 
 





























100 Consenting patient 















(immediately and three-month follow-up) 
 ‘Self-Management’ 
 ‘Medication-Taking-Measures’ 




(immediately and three-month follow-up) 
 ‘Self-Management’ 
 ‘Medication-Taking-Measures’ 




Three months after initial 
warfarin education session 
 ‘Outcome Measures of 
the Warfarin Education 
Program’ questionnaire 
(APPENDIX 21) 
Three months after initial 
warfarin education session 
 ‘Outcome Measures of 




5. 8 SUMMARY 
 This chapter has provided an overview of the process for the design, 
implementation and the development of the new warfarin education program 
including the new warfarin information booklet (APPENDIX 12). The new warfarin 
education program has been discussed at length detailing which of the 
interventions and strategies have been used to target the five key elements of an 
effective medication education program. Evaluation has also been incorporated 
as a major component of the research study. Data collected from the evaluation 
questionnaires, as well as the tools, instruments and guidelines used to assess 
the new booklet (APPENDIX 12) and the Boots warfarin information booklet 
(2003) will be used to compare and contrast the process, impact and the 
outcomes of the new and customary warfarin education programs.  
Ethical considerations were reported on, as were the changes made to the 
new program and the booklet based on the results of the pilot study and the 
comments made by the literacy experts from the University of Wollongong, the 
researcher/pharmacist’s colleagues, the Illawarra Health interpreters and the pilot 
group participants. Finally, the methodological process of the research study 
itself was discussed and summarised as a table and a flowchart. 
The time has now come to analyse the data and discuss the findings of 
the different evaluation modalities used in this research study. These analyses 








The analysis of the findings is presented in this chapter. Initially, there is a 
discussion about the results of the tests used to assess the readability of the new 
warfarin information booklet compared with the typically used Boots warfarin 
information booklet (2003). The readability tests used included the SMOG test 
(McLauglin 1969), the Fry test (Fry 1968)(See Appendices 4-5), and the 
computerised Flesch-Kincaid instrument available on the Windows 2000 Word 
program. The chapter then discusses the results of the ‘Suitability Assessment of 
Materials’ (SAM)(Doak, Doak et al. 1985) instrument, the ‘Bernier Instructional 
Design Scale’(BIDS) (Bernier 1996) (See APPENDIX 6-7) and the ‘Checklist for 
print materials’ (Bidford Maine Area Health Education Center 1996), used to 
compare the quality and the suitability of the new booklet to the Boots warfarin 
information booklet (2003).  
Throughout the rest of the chapter, discussion focuses on comparing and 
contrasting data collected from evaluation questionnaires and the outcome 
measures of the new warfarin education program against the same evaluation 
questionnaires collected for the customary warfarin education program. Data 
were collected using the ‘Self-Management’ questionnaire (APPENDIX 17); the 
‘Medication-Taking Measures’ questionnaire (APPENDIX 18); the ‘Warfarin 
Knowledge’ questionnaire (APPENDIX 19) and the ‘Satisfaction with Information 
about Medicines Scale’ (APPENDIX 20). These questionnaires were completed 
immediately and then three months after the initial warfarin education sessions. 
Analysis of the ‘Patient Demographic Data’ (APPENDIX 16) and the ‘Outcome 
Measures of the Warfarin Education Program’ questionnaire’ (APPENDIX 21) 
were also used to compare the new warfarin education program to the customary 
warfarin education program. 
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6.2 COMPARING AND CONTRASTING THE READABILITY OF THE NEW 
WARFARIN INFORMATION BOOKLET WITH THE BOOTS WARFARIN 
INFORMATION BOOKLET (2003). 
 Readability scores for the new warfarin information booklet (APPENDIX 
12) and the Boots warfarin information booklet (2003) were derived from the 
SMOG test (McLauglin 1969), the Fry test (1968) and the Microsoft Word 2000 
computeriSed Flesch-Kincaid test. These test results are presented below. 
The SMOG test (McLauglin 1969) was performed twice on 30 sentences 
from the new booklet. The first test was performed on 10 consecutive sentences 
taken from pages 3, 8 and 14 - 15 of the new booklet, and the second test was 
conducted on the contents page, as well as pages 7 - 8 and 15 of the booklet. 
These pages were chosen because they provided 10 consecutive sentences for 
testing from the beginning, middle and end of the booklet as per the test 
instructions. In both instances, the SMOG test results indicated that the new 
booklet was written at a grade 8 reading level. In comparison, the two SMOG 
tests carried out on the Boots warfarin information booklet (2003) analysing 10 
consecutive sentences from pages 2, 10 and 17; as well as pages 3 - 4,10 and 
18 of the booklet, indicated that it was written at a grade 10 - 11 reading level.  
The Fry Readability Formula (1968) otherwise known as the Fry test, was 
performed on three 100 word passages from the text, omitting the headings. 
Specific pages from each booklet were chosen and tested. According to the Fry 
test (1968), carried out on 100 words from pages 3, 8 and 10, the new warfarin 
information booklet was written at a grade 6 reading level. The following is a 
summary of these Fry test results: 
Page 3 (100 words) 8.3 sentences; 149 syllables 
Page 8 (100 words) 7.7 sentences; 125 syllables 
Page 10 (100 words) 13 sentences; 151 syllables. 
In contrast, the results of the Fry test (1968) conducted on pages 2, 8 and 14 of 
the Boots warfarin information booklet (2003) found that it was written at a grade 
14 reading level. The following is a summary of these Fry test results: 
Page 2 (100 words) 6.5 sentences; 155 syllables 
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Page 8 (100 words) 4 sentences; 180 syllables 
Page 14 (100 words) 8. 3 sentences; 185 syllables 
The Fry test results indicate that, on average, the readability scores for the new 
warfarin information booklet (APPENDIX 12) were 8 grades lower than the Boots 
warfarin information booklet (2003). Also, the new booklet had, on average, a 
larger number of sentences per page and a smaller number of multi-syllable 
words, implying that it was easier to read than the Boots booklet. 
 The last readability test used to compare the two booklets was the 
Microsoft Word 2000 computerised Flesch-Kincaid test. This test also calculated 
reading ease level, which was based on the average number of syllables per 
word and the average number of words per sentence. Scores for the reading 
ease level range from 0 (zero) to 100 and the higher the score, the greater the 
number of people who can readily understand the written information (Flesch 
1974).This final test found the new warfarin information booklet had been written 
at a grade 6.7 reading level, with a 62 percent reading ease level. The results for 
the Boots warfarin information booklet (2003) on the other hand, indicated that it 
had been written at a grade 8.9 reading level with a 58.5 percent reading ease 
level. Once again, these results found that the reading grade level of the new 
warfarin information booklet was lower than the Boots warfarin information 
booklet. This test also found that the new warfarin information booklet had a 
slightly higher reading ease level than the Boots warfarin booklet, suggesting that 
it could be read and understood by a greater proportion of the population. 
 The scores for each of the different readability tests indicated that the new 
warfarin information booklet (APPENDIX 12) was written between a grade 6 - 8 
level and that the Boots warfarin information booklet (2003) was written between 
a grade 8.9 –14 level. Thus, the new booklet was written at a reading level at 
least 2 - 3 grades lower than the Boots booklet (2003) used in the customary 
warfarin education program. The researcher/TACT pharmacist chose the actual 
sentences and words used in the readability tests but the potential for bias was 
small, as the choices of sentences were limited within each of the booklets. 
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6.3. COMPARING AND CONTRASTING THE QUALITY AND THE 
SUITABILITY OF THE NEW WARFARIN INFORMATION BOOKLET WITH 
THE BOOTS WARFARIN INFORMATION BOOKLET (2003). 
 In order to compare the quality and the suitability of the new warfarin 
information booklet to the Boots warfarin information booklet, the 
researcher/TACT pharmacist and two of her colleagues completed the following 
tests on both booklets; the ‘Suitability Assessment Materials’ (SAM) (Doak, Doak 
et al. 1985), the ‘Bernier Instructional Design Scale’ (BIDS) (Bernier 1996) and 
the ‘Checklist for print materials’ (Bidford Maine Area Health Education Center 
1996) (Appendices 6 - 8). The results for each of these tests, which are 
especially useful for assessing the quality and the suitability of the written 
information for patients with low literacy skills, will now be presented.  
  The ‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 
1985)(APPENDIX 6) is an instrument used to obtain a numerical rating for 
suitability factors other than readability. SAM addresses suitability in terms of 
content, literacy, demand, graphics, layout, learning stimulation/motivation, and 
the culture of the intended audience. The SAM ratings were analysed as 
percentage ratings according to the following criteria: superior material = 70 -100 
percent; adequate material = 40 - 69 percent; and not suitable material = 0 - 39 
percent. 
  The SAM scores for the new warfarin information booklet completed by 
the researcher/TACT pharmacist and two of her colleagues were 92 percent, 
95.2 percent and 83 percent. Each of the raters indicated that the new booklet 
was well within the superior rating (70 -100 percent) for the SAM instrument. 
None of the raters gave the new booklet a ‘not suitable’ rating (0 – 39 percent) for 
any of the factors in the SAM instrument. In contrast however, two of the raters 
assigned SAM scores of 55 percent and 44.7 percent within the adequate rating 
range (40 – 69 percent) and one rater assigned 33.3 percent within the not 
suitable rating range (0 – 39 percent) for the Boots warfarin information booklet 
(2003). Thus, according to the SAM scores, the new warfarin information booklet 
was superior to the Boots warfarin information booklet (2003) in terms of quality 
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and suitability. It could therefore be suggested that the new booklet was more 
suitable than the Boots booklet especially for patients with low literacy skills. 
The ‘Bernier Instructional Design Scale’ (BIDS)(1996) (APPENDIX 7) is an 
instrument used to identify the presence (or absence) of instructional design and 
learning principles contained in printed educational materials (Bernier 1996). The 
rating scale for the BIDS instrument is based on the following numerical scores 
given to each of the 35 items in the instrument: 0 = not met; 1 = partially met;  
2 = met; and, NA= Not Applicable.  
Based on the same results for all three raters, analysis of the BIDS 
instrument on the new booklet, using the criteria discussed above, found that 26 
items met the instructional design and learning principles and that no items were 
found not to meet the instructional design and learning principles. For the Boots 
warfarin information booklet (2003) on the other hand, all three raters found that 
only 8 items met the instructional design and learning principles and that the 
following four items did not meet the instructional design and learning principles 
(BIDS score= 0); 
 Q.4 Drawings/illustrations are recognisable to the target group 
with or without explanatory text. 
 Q.5 Drawings/illustrations are labelled clearly. 
 Q.6 Drawings/illustrations represent racial and ethnic groups 
appropriate to the target audience. 
 
Therefore, according to the three raters and the results of the BIDS 
instrument, the new warfarin information booklet met the instructional design and 
learning principles much more so than did the Boots warfarin information booklet 
(2003). Unlike the new booklet, the Boots booklet (2003) was found not to meet 
the instructional design and learning principles for drawings, illustrations and their 
cultural sensitivity. All in all, therefore, the new booklet appeared to suit the 
needs of the wider patient population, much more so than did the Boots booklet 
(2003), because of its adherence to instructional design and learning principles. 
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 The third and last instrument used by the three raters to compare the 
quality and the suitability of the two booklets was the ‘Checklist for print 
materials’ (Bidford Maine Area Health Education Center 1996) (APPENDIX 8). 
This 17-item checklist provided a quick and easy way in which to assess the 
appropriateness of the written material for patients. Points in the checklist which 
were not ticked and identified as missing by all three raters, were recorded as 
potential deficiencies in the suitability of the written information within the 
booklets. 
According to the results of the ‘Checklist for print materials’ (Bidford Maine 
Area Health Education Center 1996) (APPENDIX 8) there were no potential 
deficiencies in the suitability of the new warfarin information booklet because 
each of the 17 items in the checklist was ticked by at least two of the raters. The 
Boots warfarin information booklet (2003), however, was found to have potential 
deficiencies in 7 of the 17-item checklist because they were not ticked by any of 
the three raters. These items included: 
 1. The cover is attractive. It indicates the core content and intended 
audience. 
 5. A summary that stresses what to do is included. 
 8. Text is vivid and interesting. Tone is friendly. 
 9. Pages or sections appear uncluttered. Ample white spaces. 
 13. Illustrations are simple - preferably line drawings. 
 14. Illustrations serve to amplify text. 
 17. Interaction is invited via questions, responses, suggested action, etc. 
In other words, the Boots booklet was found not to have an attractive cover, it did 
not include summaries and interesting text, the pages appeared cluttered and 
there was a lack of illustrations and invitations for patients to interact. Once again 
the new warfarin information booklet was found to have fewer potential 
deficiencies in appropriateness and suitability than the Boots warfarin information 
booklet (2003).  
In summary, the results of the ‘Suitability Assessment Materials’ (SAM) 
(Doak, Doak et al. 1985), the ‘Bernier Instructional Design Scale’ (BIDS) (Bernier 
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1996) and the ‘Checklist for print materials’ (Bidford Maine Area Health 
Education Center 1996) independently performed by the researcher/TACT 
pharmacist and two of her colleagues, indicated that the new warfarin information 
booklet was considered to be superior in terms of quality and suitability, as 
compared to the Boots warfarin information booklet (2003). The new booklet was 
also found to comply with instructional design, learning principles and have fewer 
potential deficiencies in terms of appropriateness and suitability than the Boots 
booklet. These results imply that the new booklet in terms of quality and 
suitability, as compared to the Boots booklet, would better suit the needs of a 
wider patient population, inclusive of those with low literacy skills. 
 
 
6.4 COMPARING AND CONTRASTING THE NEW WARFARIN EDUCATION 
PROGRAM WITH THE CUSTOMARY WARFARIN EDUCATION PROGRAM. 
 
6.4.1 Patient participants and demographic variables 
 
6.4.1.1 Introduction 
Data collection was conducted from February 2003 to February 2004. All 
consenting patients who were admitted to The Ambulatory Care Team (TACT) 
and commenced warfarin therapy for the first time, or recommenced warfarin 
after a period of at least 15 years, were included. Of the 114 patients who 
consented to participate, five patients could not be contacted for the three month 
follow-up evaluations, five patients had their warfarin therapy discontinued by 
their general practitioners, one died from cancer-related illness and one withdrew 
from the study. Consequently, complete data were collected from 102 patient 
participants, 55 females and 47 males. Fifty intervention patients had received 
the new warfarin education program and 52 control patients had received the 
customary warfarin education program delivered to Illawarra Health’s The 
Ambulatory Care Team (TACT) warfarin prescribed patients.  
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This next section of the chapter compares and contrasts the intervention 
and control patient participants’ demographic variables including: gender, age, 
educational level, ethnicity, source of referral and referral diagnosis. The last 
demographic variable reported in this section is the percentage of patient 
participants who had a carer and/or a family member present during the initial 
warfarin education session. 
 
6.4.1.2 Gender 
The results in table 2 indicate that there was a reasonable balance of 
males and females in the research sample population (N=102). Forty-six percent 
(47) of the patient participants were male and 54 percent (55) were females. The 
intervention group had a smaller percentage of male participants, 38 percent 
(19), than did the control group, 54 percent (28). Consequently, the female 
participants in the intervention group outnumbered those in the control group, 62 
percent (31) as compared to 46 percent (24). A Pearson’s correlation chi-square 
test, p-value equal to 0.1085, indicates that there were no significant differences 
in the gender between the intervention and control group participants. 
 
Table 2: Gender of patient participants. 
Patient Participant Male Female 
Intervention (n=50) 38% (19) 62% (31) 
Control (n=52) 54% (28)  46% (24) 




Table 3 shows that the ages of the patient participants were similar for 
both groups, with patients aged between 65-74 years being the most common 
age group. Interestingly, 62.8 percent (64) of all participating patients were aged 
65 years and over, which means that they were elderly and in the ‘high risk’ 
group. This elderly population can be further subdivided into 68 percent (34) of 
the intervention patients and 57.7 percent (30) of the control patients. A 
Pearson’s correlation chi-square test, p-value equal to 0.3715, indicates that 
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there were no significant differences in the ages between the intervention and 
control group participants. 
 









Percentage of total 
patient population 
(N=102) 
>85 2.0% (1) 5.77% (3) 3.92% (4) 
75-84 22% (11) 25.0% (13) 23.53% (24) 
65-74 44% (22) 26.9% (14) 35.29% (36) 
55-64 18% (9) 17.3% (9) 17.64% (18) 
45-54 10% (5) 11.53% (6) 10.78% (11) 
<44 4% (2) 13.47% (7) 8.82% (9) 
 
 
6.4.1.4 Education level 
As shown in table 4, the intervention group patients had been educated 
from between grade 1 and tertiary levels, and the control group patients had 
been educated between grade 4 and tertiary level. These results suggest that 
the intervention group patients experienced a wider range of educational levels 
than did the control group patients.  
Table 4 also shows that 36 percent (18) of the intervention group patients 
and 30.8 percent (16) of the control group patients were educated at or above a 
grade 10 level. Thirty-two percent (16) of the intervention group patients and 50 
percent (32) of the control group patients were educated between grades 7 and 
9. Finally, and most importantly, 32 percent (16) of the intervention group 
patients and 19.23 percent (10) of the control group patients were educated at or 
below a grade 6 level, which, according to the literature means they are 
classified as patients with low literacy skills (Doak, Doak et al. 1996b). These 
results indicate, therefore, that similar percentages of patients in both groups 
were educated at or above a grade 10 level. Whereas more control group 
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patients were educated between grade 7-9 levels, and considerably more 
intervention group patients were educated at or below a grade 6 level. In other 
words, the intervention group had a larger proportion of ‘high risk’ patients with 
low literacy skills than did the control group.  
 
 











Percentage of total 
patient participants 
(N=102) 
Grade 1 2.00% (1) 0.00% (0) 0.98% (1) 
Grade 2 6.00% (3) 0.00% (0) 2.94% (3) 
Grade 3 4.00% (2) 0.00% (0) 1.96% (2) 
Grade 4 8.00% (4) 1.92% (1) 4.90% (5) 
Grade 5 4.00% (2) 1.92% (1) 2.94% (3) 
Grade 6 8.00% (4) 15.38% (8) 11.76% (12) 
Grade 7 8.00% (4)  3.85 % (2)  5.88% (6) 
Grade 8 12.0% (6) 23.08% (12) 17.65% (18) 
Grade 9 12.0% (6) 23.08% (12) 17.65% (18) 
Grade 10 20.0% (10) 15.38% (8) 17.65% (18) 
Tertiary 16% (8) 15.38% (8) 15.69% (16) 
 
According to the data in table 4, the median grade educational level for the 
intervention group was grade 8, and grade 9 for the control group. The mean 
grade level for the intervention group was grade 7.94, and grade 8.83 for the 
control group, assuming that patients educated at a tertiary level were educated 
to an equivalent of a grade 13 level. The mode level of education for the 
intervention group was grade 10, and grade 8 and 9 for the control group. It is 
important to note, that 20 percent (10) of the intervention group patients, as 
opposed to 46.16 percent (24) of the control group patients, achieved the modal 
level of education. Even though the mode level of education was higher in the 
intervention group than that for the control group, a much smaller percentage of 
intervention group patients achieved the mode level of education than did the 
control group patients.  
A chi-squared test was used to analyse whether or not there was a 
relationship between the two groups (i.e. intervention and control) and the 
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patients’ level of education. The results of this chi-squared test found no 
significant difference (p-value 0.2992), suggesting that there was no difference in 
the patients’ level of education between the two groups. While these results 
were found to be insignificant, a larger proportion of the intervention group 
patients, as compared to the control group patients, were educated at or below a 
grade 6 level (32 percent compared to 19.2 percent, respectively). 
 
6.4.1.5 Ethnicity 
Table 5 indicates that 14.7 percent (15) of the patient participants were 
from non-English speaking backgrounds (NESB). Both the intervention (18 
percent (9) and control (11.5 percent (6) groups had similar small numbers of 
NESB patients. The nationalities represented by these NESB patients (n=15) 
were: Greek, 20 percent (3); Croatian, 13.3 percent (2); Italian, 13.3 percent (2); 
Turkish, 13.3 percent (2); German, 6.7 percent (1); Lebanese, 6.7 percent (1); 
Macedonian, 6.7 percent (1); Maltese, 6.7 percent (1); Serbian, 6.7 percent (1) 
and Spanish, 6.7 percent (1). No single nationality significantly outnumbered 
another within the two groups.  
Interestingly, seven of the nine NESB intervention group patients were 
educated at or below a grade 4 level, whereas only one of the six NESB control 
group patients was educated at or below grade 4 level. Overall, therefore, even 
though both groups had similar numbers of NESB patients, the NESB 
intervention group patients were less educated than the NESB control group 
patients. 
 
Table 5: Percentage of patient participants from non-English speaking 
backgrounds.  




Intervention (n=50) 18% (9) 82% (41) 
Control (n=52) 11.5% (6) 88.5% (46) 









6.4.1.6 Source of referral  
The results in table 6 show that the sources of referral for the patient 
participants in both groups were similar. The hospital ward referrals to The 
Ambulatory Care Team (TACT) for both groups significantly outnumbered the 
emergency department and general practitioner referrals.  
 









Intervention (n=50) 26% (13) 20% (10) 54% (27) 
Control (n=52) 19.2% (10) 17.3% (9) 63.5 % (33) 
Total number 
(N=102) 
22.6 % (23) 18.6% (19) 58.8 % (60) 
 
 
6.4.1.7 Referral diagnosis 
The results in table 7 indicate that the most common referral diagnosis for 
both the intervention and control group patients was deep venous thrombosis, 
followed by atrial fibrillation. The table also shows that similar percentages of 
patients in both groups were diagnosed with deep venous thrombosis, atrial 
fibrillation and pulmonary embolus.  
 




















Cardiac Valve, Leg Stent) 
Intervention 
(n=50) 
46% (23) 24% (12) 16% (8) 14% (7) 
Control 
(n=52) 
36.5% (19) 32.7% (17) 9.6% (5) 21.2% (11) 
Total number 
(N=102) 





6.4.1.8 Carers and/or family members 
Over half the participating patient population had a carer and/or family 
member present during the initial warfarin education session (60 percent 
intervention and 52 percent control). Interestingly, only five of the nine NESB 
intervention group patients, as compared to five of the six NESB control group 
patients, had a carer present during the education sessions.  
 
6.4.1.9 Summary 
 In summary, the results of the demographic data indicate that overall the 
intervention and control group patients had similar demographic variables. There 
was an even distribution of males and females in the participating patient 
population, with a large proportion of the patients classified as ‘high risk’ because 
they were aged 65 years and over (62.8 percent), educated at or below grade 6 
levels (25.5 percent) and/or came from non-English speaking backgrounds (14.7 
percent). The patients in both groups were referred to The Ambulatory Care 
Team (TACT) mainly from the hospital ward, with a variety of diagnoses, the 
most common of which was deep venous thrombosis. Interestingly, over half of 
the participating patient population had a carer and/or family member present 
during the initial warfarin education session.  
 
6.4.2 ‘Self-Management’ questionnaire (APPENDIX 17) results 
 The ‘Self-Management’ questionnaire (APPENDIX 17) adapted from Lorig 
et al ‘Self-Efficacy Questionnaire’ (1996 page 41- 44), was used to evaluate the 
patient participants’ perception about their ability to manage their warfarin 
therapy at home, and to compare the scores between the intervention and 
control groups. The scores for this questionnaire, which were completed 
immediately and three months after the initial warfarin education session, were 
combined to give a score out of 20. A score between 16 and 20 suggested that 
the patient was highly confident, a score between 8 and 15 suggested that the 
patient was moderately confident, and a score below 8 suggested that the patient 
was not confident about managing their own warfarin therapy at home. 
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 To assess whether or not there was a difference in the ‘Self-Management’ 
questionnaire scores between the intervention and control groups, a mean score 
for the ‘Self-Management’ questionnaire was calculated and then t-tests were 
performed on these mean scores. As shown in table 8, the mean ‘Self-
Management’ questionnaire scores were higher for the intervention group 
patients than the control group patients, immediately and after three months. 
Results of the t-tests for the immediate scores (p-value 0.1727), and for the 
three-month follow-up scores (p-value 0.207), indicate that they did not differ 
significantly. In other words, both groups perceived that they were highly 
confident about managing their warfarin therapy at home, immediately and three 
months after the commencement of their warfarin therapy. 
 
Table 8: t-test results comparing intervention and control group patients’ 
mean ‘Self-Management’ questionnaire scores immediately and three 




mean SM score 
(n=50) 
Control patients 




Immediate 19.08 18.44 0.1727 
Three-month 
follow-up 
19.90 19.73 0.2007 
(In the table ‘immediate’ = questionnaire completed immediately after the initial warfarin 
education session; ‘three-month follow up’ = questionnaire completed three months later; SM = 
Self-Management) 
 
 The results in table 8 also indicate that the mean ‘Self-Management’ 
questionnaire scores for both groups improved over the three-month period. 
Paired t-tests were used to analyse whether or not the mean three-month follow-
up ‘Self-Management’ questionnaire scores differed to the immediate mean 
scores for each of the groups.  
Table 9 shows that the mean ‘Self-Management’ questionnaire scores 
were significantly different for both groups three months after the initial warfarin 
education session, with a p-value equal to 0.0009*** for the intervention group 
patients and a p-value equal to 0.0024** for the control group patients. Although, 
the mean scores were not significantly different between the two groups, they 
both significantly increased after three months of warfarin therapy. The 
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intervention group patients’ scores increased by approximately 0.82 and the 
control group patients’ scores increased by 1.288. Both groups therefore, 
perceived that their warfarin management at home had improved over the three-
month period. 
 
Table 9: Paired t-test results comparing intervention and control group 
patients’ ‘Self-Management’ mean scores immediately and three months 
after the initial warfarin education session. 
Difference between 














Intervention group  
(SM1-SM2) 
-1.285 -0.82 -0.355 49 -3.54 0.0009*** 
Control group 
(SM1-SM2) 
-2.097 -1.29 -0.479 51 -3.20 0.0024** 
(In the table: SM1 = immediate ‘Self-Management’ questionnaire score; SM2 = three-month follow-
up ‘Self-Management’ questionnaire score; CL = 95% confidence interval of the difference) 
 
Upon completion of their ‘Self-Management’ questionnaire (APPENDIX 17), 
all participating patients were asked to make comments about whether or not 
they were worried about taking warfarin tablets. Similar comments were made by 
patients in both groups expressing their concerns. These concerns related to 
having to adjust their lifestyle behaviours (diet, alcohol intake and sporting 
activities), recognising serious side effects, having to take the warfarin regularly 
and undergoing regular blood tests. Examples of some of these immediate 
comments included:  
 Intervention 4 “..worried about side effects and blood tests…” 
 Intervention 97 “ I’m worried because it is a heavy duty drug…” 
 Control 5 “Worried about restrictions…” 
 Control 113: “A little worried about adjusting habits…” 
Other examples of comments made three months after the commencement of 
warfarin therapy included:  
 Intervention 97 “Don’t like taking warfarin…” 
 Control 5 “Don’t want restrictive lifestyle…” 
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Importantly, some of the initial concerns relating to lifestyle behaviours appear to 
have been maintained over the three-month period. 
 In summary, even though the intervention group patients achieved higher 
mean scores for their ‘Self-Management’ questionnaire, immediately and after 
three months, t-tests found that these mean scores were not significantly 
different. Paired t-test results, however, found that the mean scores for the ‘Self-
Management’ questionnaires for both groups improved significantly over the 
three month period. This indicates that the patients in both groups perceived that 
their warfarin management at home improved over time. Interestingly, the 
comments expressed by patients in both groups reflected their concerns about 
having to adjust their lifestyle behaviours while on warfarin medication, and these 
concerns persisted over the three-month period. 
  
6.4.3 ‘Medication-Taking Measures’ questionnaire (APPENDIX 18) results 
 The ‘Medication-Taking-Measures’ (MTM) questionnaire (APPENDIX 18) 
is a validated scale designed to test medication compliance. A score of 4 is 
considered high compliance, 3 moderate compliance, and 2 or less is low 
compliance.  
A summary of the ‘Medication-Taking-Measures’ (MTM) scores for the 
questionnaires, completed immediately and three months after the initial warfarin 
education session, is presented in table 10. The results in this table suggest that 
even though similar trends in the MTM questionnaire scores were found for both 
groups, the actual percentages and numbers of patients with low, moderate and 
high compliance scores differ between the two groups. A higher proportion of the 
intervention group patients, rather than the control group patients, achieved high 
compliance scores for the immediate (62 percent versus 53.85 percent) and the 
three month follow-up (80 percent versus 71.15 percent) MTM questionnaires. 
These results imply that the new warfarin education program encouraged 
patients to be more confident about their warfarin compliance, than did the 
customary warfarin education program. 
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Table 10: ‘Medication-Taking-Measures’ questionnaire scores for 
intervention and control group patients immediately and three months after 
the initial warfarin education session. 
 
(In the table: MTM Score = ‘Medication-Taking-Measures’ questionnaire score; immediate = 
immediate scores after the initial warfarin education session; and 3-month follow-up = scores 
achieved three months after the initial warfarin education session) 
 
To ascertain whether or not there was a significant difference in the mean 
MTM questionnaire scores for both groups, t-tests were performed. Table 11 
shows the results of these t-tests. P-values equal to 0.7389 and 0.2592 
respectively, for the immediate and the three-month follow-up scores, suggest 
that the mean scores were not significantly different. Although the compliance 
scores for both groups appeared to differ in table 10, the results in table 11 
suggest that they were not significantly different. This means that the new 
warfarin education program appeared to be equally as effective as the customary 





























(MTM Score  2) 
30% (15) 23.08% 
(12) 




8% (4) 23.08% 
(12) 




62% (31) 53.85% 
(28) 
80% (40) 71.15% (37) 
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Table 11: t-test results comparing intervention and control group patients’ 
mean ‘Medication-Taking-Measures’ questionnaires scores immediately 
and three months after the initial warfarin education session. 
Patient 
participants 
Mean MTM score  
intervention patients 
(n=50) 





Immediate 2.92 3.0192 0.7389 
Three-month 
follow-up 
3.7 3.5192 0.2592 
(In the table: Immediate = questionnaire completed immediately after the initial warfarin education 
session; Three-month follow-up = questionnaire completed three months after initial warfarin 
education session; MTM = ‘Medication-Taking-Measures’ questionnaire) 
 The results in table 11 also indicate that the MTM questionnaire scores 
increased for both groups after three months of warfarin therapy. To assess 
whether or not this increase over the three-month period was statistically 
significant, a paired t-test was performed comparing the mean scores for each 
group. The results of the paired t-tests are summarised in table 12 and indicate 
that there was a significant difference between the immediate and three-month 
follow-up mean MTM questionnaire scores for both groups. The p-value for the 
intervention group patients was 0.0017** and the p-value for the control group 
patients was 0.0243*. On average, the three-month follow-up mean MTM 
questionnaire scores increased by 0.78 for the intervention group patients and 
0.5 for the control group patients. Therefore, the paired t-tests for both groups 
suggest that there was a significant improvement in the MTM questionnaire 
scores over the three-month period. This means that the patients in both groups 
became significantly more confident about their warfarin compliance over time.  
Table 12: Paired t-test results comparing intervention and control group 
patients’ ‘Medication-Taking-Measures’ mean scores immediately and three 
months after the initial warfarin education session. 
Difference between 






















-0.50 -0.068 51 -2.32 0.0243* 
(In the table: MTM1 = immediate ‘Medication-Taking-Measures’ questionnaire score; MTM2 
=three-month follow-up ‘Medication-Taking-Measures’ questionnaire score; CL = 95% confidence 
interval of the difference) 
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Comments made by the patients in both groups on the completion of their 
‘Medication-Taking-Measures’ questionnaire (APPENDIX 18) were also 
comparable. Initially, the comments reflected their carelessness toward 
medication compliance, especially when they had never taken regular medication 
before. Some of these initial comments included: 
 Intervention 19 “I’m a little careless and forgetful…” 
 Intervention 28 “Have never had to take regular medicines before…” 
 Control 9 “Never really taken medication before…” 
 Control 54 “Always do what the doctor tells me to…” 
  
The comments made three months later were mainly about forgetting to take 
their warfarin tablets on a few occasions. Eighteen percent (9) of the intervention 
group patients and 32.7 percent (17) of the control group patients commented on 
how many times they had forgotten to take their warfarin during the three-month 
period. These comments may be an indication that both groups of patients 
understood the importance of good warfarin compliance and may have been 
more diligent about their warfarin compliance. From their initial education 
sessions, they also knew that they would be followed-up and that their INR blood 
test results would be an objective measure of their true warfarin compliance 
rates. 
In summary, even though the trends for the ‘Medication-Taking-Measures’ 
(MTM) questionnaire (APPENDIX 18) scores were higher for the intervention 
group patients than for the control group patients, both immediately and after 
three months of therapy, t-tests ascertained that these scores were not 
significantly different. There was, however, a significant improvement in the 
‘Medication-Taking Measures’ (MTM) questionnaire scores for both groups over 
the three-month period, suggesting that they had become significantly more 
confident with their warfarin compliance over time. The patients’ comments 
received during this time mainly reflected their fears about being careless or 
forgetting to take their warfarin medication, which may also be representative of 
their improved understanding about the importance of good warfarin compliance. 
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6.4.4 ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) results.  
 
6.4.4.1 Introduction 
 The ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) was used to 
estimate the patients’ warfarin knowledge and understanding following the 
education sessions. In the absence of a validated or reliable instrument in the 
literature this questionnaire was drafted from several different warfarin studies 
performed over the past three decades (Scalley, Kearney et al. 1979; Witte, 
Gurwich et al. 1980; Wyness 1989), the ‘Warfarin Education Program Objectives’ 
(APPENDIX 14) and the contents of the new warfarin information booklet 
(APPENDIX 12). The answers to the ‘Warfarin Knowledge’ questionnaire 
(APPENDIX 19) were coded as True (for correct answers) and False (for 
incorrect answers). Adding the number of correct responses in the questionnaire 
gave a score out of 26. The ‘Warfarin Knowledge’ questionnaire scores were 
then further subdivided into the following categories (score  22.0 excellent; 19.0-
21.9 good; 16.0-18.9 average; 15.9 poor) to allow for a more meaningful 
analysis and discussion.  
 
6.4.4.2 t-test used to compare the mean ‘Warfarin Knowledge’ questionnaire 
scores for the intervention and control groups 
To establish whether or not there was a difference in the warfarin 
knowledge scores between the intervention and the control groups, a t-test was 
performed on the mean ‘Warfarin Knowledge’ questionnaire scores recorded 
immediately and three months after initiation of warfarin therapy. The mean score 
for the immediate ‘Warfarin Knowledge’ questionnaire for the intervention group 
was 21.0 (80.8 percent) and 19.0 (73.0 percent) for the control group, both of 
which were classified as good warfarin knowledge scores. A t-test indicated that 
there was a significant difference in the scores between the groups with a p-
value equal to 0.0173*. This result identified that the intervention group patients 
had a significantly higher immediate ‘Warfarin Knowledge’ questionnaire score 
than did the control group patients. In other words, the new program improved 
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the patients’ warfarin knowledge and understanding more so than did the 
customary program, immediately after the initial warfarin education session. 
The mean ‘Warfarin Knowledge’ questionnaire scores three months after 
the initial warfarin education session was 18.04 (69.4 percent) for the intervention 
group, and 17.04 (65.5 percent) for the control group. These results show a 
deterioration in the mean ‘Warfarin Knowledge’ scores for both groups over the 
three month period. Both the intervention and control group mean scores were 
therefore reclassified, falling from good to average. A p-value equal to 0.1805 for 
the t-test, used to compare the mean scores for both groups, indicated that there 
was no significant difference between scores achieved by both groups after three 
months. This demonstrates that, the initial positive influence of the new warfarin 
education program on the patients’ warfarin knowledge and understanding had 
become less significant over time. 
 
6.4.4.3 Chi-Squared tests used to assess whether or not there was a relationship 
between the patient group and the correct answer to questions in the ‘Warfarin 
Knowledge’ questionnaire. 
 A chi-squared test was used to assess whether or not there was a 
relationship between the patient group (intervention or control group) and the 
correct answers for each of the questions in the ‘Warfarin Knowledge’ 
questionnaire (APPENDIX 19). The chi-squared test performed on the ‘Warfarin 
Knowledge’ questionnaire completed immediately after the initial warfarin 
education session produced p-values below 0.05 for the following six questions, 
suggesting a relationship between the patient group (intervention or control) and 
the correct answers to these questions. 
 Q.1 Which brand of warfarin is prescribed for you? (p-value 0.0049**) 
 Q.2. Why is the warfarin prescribed for you? (p-value 0.0262*) 
 Q.7a. What should you do if you forget to take a dose of warfarin?  
 (p-value 0.0045**) 
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 Q.8b. Can you suggest two things, which you could use to remind you 
 about taking your warfarin tablets (if necessary)?    
 (p-value 0.0012**) 
 Q.11a What are FOUR signs of bleeding from too much warfarin?  
 (p-value 0.0149*) 
 Q.15 Are there any foods which can affect how warfarin works?  
 (p-value 0.0122*) 
 
The direction of the relationship between these questions and the patient 
group is summarised in table 13, which shows that a larger proportion of the 
intervention group patients correctly answered Questions 2, 7a, 8b, 11a and 15, 
as compared to the control group patients. A greater proportion of the control 
group patients, however, correctly answered Question 1. Initially, therefore, the 
intervention group patients had a better understanding about: why warfarin was 
prescribed for them; what to do if they forgot to take a dose of warfarin; how to 
remind themselves about their warfarin dose; what side effects to look out for as 
a result of too much warfarin; and which foods could interact with their warfarin 
medication. The control group patients, on the other hand, were more 
knowledgeable about the brand name of their warfarin medication. 
 
Table 13 Percentage of intervention and control group patients to correctly 
answer ‘Warfarin Knowledge’ (APPENDIX 19) questions 1, 2, 7a, 8b, 11a 
and 15 immediately after the initial warfarin education session. 





(n=50) who answered 
question correctly 
Control patients 
(n=52) who answered 
question correctly 
Q.1 30% (15) 57.7% (30) 
Q.2 94% (47) 76.9% (40) 
Q.7a 72% (36) 42.3% (22) 
Q.8b. 52% (26) 19.2% (10) 
Q.11a 94% (47) 75% (39) 





The chi-squared tests performed on the questions in the ‘Warfarin 
Knowledge’ questionnaire completed after three months, found that only the 
correct answer to one question differed significantly between the two groups. 
This was Question 10 “What is your target INR blood test range?” with a p-value 
of 0.008*. For this particular question, 72 percent (36) of the intervention group 
patients, as compared to 44.2 percent (23) of the control group patients, 
answered the question correctly. This means that a significantly greater 
proportion of the intervention group patients knew what their therapeutic 
International Normalised Ratio (INR) blood test ranges should be during their 
warfarin treatment, as compared to the control group patients.  
 
6.4.4.4 Two-way ANOVA test to assess whether or not there was a relationship 
between the patients’ group, educational level and ‘Warfarin Knowledge’ 
questionnaire score. 
 Two-way ANOVA tests were used to determine whether or not the 
patients’ warfarin knowledge scores, immediately and after three months were 
affected by their group (i.e. intervention or control) and educational level. The 
ANOVA test was used in place of the t-test because three variables; group, 
educational level and warfarin knowledge score were being assessed in place of 
two variables. The ANOVA test is more appropriate in this instance because it 
can compare means between the two groups taking into account several factors. 
The results from the two-way ANOVA tests produced a p-value equal to 0.0058* 
immediately, and a p-value equal to 0.0278* for the three-month follow-up 
scores. These results suggest that there was a significant difference between the 
mean ‘Warfarin Knowledge’ questionnaire scores (calculated from the General 
Linear Models (GLM) procedure for the Least Square Means), taking into 
account their group (intervention or control) and their educational level, as per 
Table 14. In other words, the more educated patients in both the intervention and 




Table 14: Summary of intervention and control group patients’ mean GLM 
‘Warfarin Knowledge’ questionnaire scores immediately and three months 

































≤ Grade 6  19.8 (16) 17.7 (10) 16.6 (16) 15.0 (10) 
Grade 7-9 21.1 (16) 18.2 (26) 18.3 (16) 16.0 (26) 
≥ Grade 10 22.0 (18) 21.5 (16) 19.1 (18) 20.0 (16) 
(In the table: Mean scores were calculated from the General Linear Models (GLM) procedure for 
the Least Square Means; WK = ‘Warfarin Knowledge’ questionnaire; immediate = WK scores 
achieved immediately after the initial warfarin education session; 3-month follow-up= WK scores 
achieved three months after the initial warfarin education session)  
  
Based on the warfarin knowledge score classifications (WK scores  22.0 
excellent; 19.0-21.9 good; 16.0-18.9 average; 15.9 poor), the results in table 14 
indicate that immediately after the initial warfarin education session, the 
intervention group patients educated at all three levels (i.e. ≤ grade 6, between 
grade 7-9, and, ≥ grade 10) achieved higher mean scores than did the control 
group patients educated at the same levels. The immediate score for the 
intervention group patients educated at or below 9 levels, including those 
educated at or below grade 6 levels, were good, compared to average for control 
group patients educated at the same level. Similarly, the immediate mean score 
for intervention group patients educated at or above grade 10 levels was 
excellent, compared to good for control group patients in the same education 
category. This indicates that the new warfarin education program was initially 
more effective than the customary education program in educating patients from 
all different educational backgrounds about their warfarin therapy and improving 
their warfarin knowledge and understanding.  
Table 14 also shows that after three months of warfarin therapy the mean 
‘Warfarin Knowledge’ scores were much lower than the initial scores for both 
groups. The mean scores for the intervention group patients educated at or 
below grade 6 levels, and between grade 7-9 deteriorated to average scores, 
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and the scores for those educated at or above grade 10 levels deteriorated to 
good scores. The mean scores for the control group patients educated at the 
different levels also deteriorated, with those educated at or below grade 6 levels 
achieving poor scores, the lowest recorded for all patient participants. It could be 
argued, therefore, that the customary warfarin education program did not 
appropriately cater for the needs of the patients with low literacy skills (educated 
at or below a grade 6 level), which is why their warfarin knowledge scores were 
the lowest recorded. 
Interestingly, the only mean scores for the ‘Warfarin Knowledge’ 
questionnaire achieved by the control group patients which were higher than 
those achieved by the intervention group patients, were the three-month follow-
up scores achieved by patients educated at or above grade 10 level (20.0 versus 
19.1). Importantly, however, these scores were not significantly different which 
means that both programs were equally effective at educating patients with 
educational levels at or above grade 10 about their warfarin therapy.  
Overall, therefore, the intervention group patients achieved higher mean 
‘Warfarin Knowledge’ questionnaire scores than did the control group patients, 
immediately and three months after the commencement of warfarin therapy. In 
fact, the immediate scores were significantly higher for the intervention group 
patients than they were for the control group patients. Not surprisingly, the more 
educated patients in both groups achieved the higher mean warfarin knowledge 
scores and those educated at or below a grade 6 level achieved the lowest mean 
scores. The control group patients educated at or below a grade 6 level achieved 
the lowest mean ‘Warfarin Knowledge’ questionnaire scores. 
 
6.4.4.5 Paired t-tests used to compare the immediate ‘Warfarin Knowledge’ 
questionnaire score against the three-month follow-up ‘Warfarin Knowledge’ 
questionnaire score.  
 Paired t-tests were used to assess whether or not the deterioration in the 
‘Warfarin Knowledge’ (WK) questionnaire scores over the three-month period for 
both groups was significant. Table 15 provides a summary of the paired t-test 
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results and suggests that there was a significant difference between the 
immediate and three-month follow-up scores for both groups. The three-month 
follow-up ‘Warfarin Knowledge’ questionnaire scores for the intervention group 
patients were on average 2.9 marks lower than the immediate scores (p-value 
less than 0.0001***). Similarly, the three-month follow-up scores for the control 
group patients were on average 2.12 marks lower than the immediate scores (p-
value 0.0019*). Thus there was a significant deterioration in the mean ‘Warfarin 
Knowledge’ questionnaire scores over the three-month period for both groups. 
This deterioration in warfarin knowledge and understanding could have serious 
implications for patients on long-term warfarin therapy. 
 
Table 15: Paired t-test results comparing intervention and control group 
patients ‘Warfarin Knowledge’ mean scores immediately and three months 
after the initial warfarin education session. 
Difference between 

















1.76 2.9 4.04 49 5.10 <0.0001*** 
Control group  
(WK1-WK2) 
0.82 2.12 3.41 51 3.28 0.0019** 
(In the table: WK = ‘Warfarin Knowledge’ questionnaire; WK1 = immediate mean ‘Warfarin 
Knowledge’ questionnaire score; WK2 = three-month follow-up mean ‘Warfarin Knowledge’ 




 In summary, a number of tests were performed to evaluate the results of 
the ‘Warfarin Knowledge’ questionnaire (APPENDIX 19). The results of t-tests 
indicated that the new warfarin education program, used to educate the 
intervention group patients, significantly improved warfarin knowledge and 
understanding immediately after the initial warfarin education session, as 
compared to the customary warfarin education program used to educate the 
control group patients. This significant improvement, however, was not 
maintained because there was no significant difference identified between the 
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‘Warfarin Knowledge’ questionnaire scores achieved by both groups after three 
months of warfarin therapy.  
Chi-squared tests identified relationships between the patient group 
(intervention or control) and the correct answers to several questions in the initial, 
and only one question in the three-month follow-up ‘Warfarin Knowledge’ 
questionnaire. Compared to control group patients more intervention group 
patients had a better understanding about: why warfarin was prescribed; how to 
manage and improve warfarin compliance; how to recognise serious side effects; 
and possible food interactions. A two-way ANOVA test also identified that the 
more educated patients in both groups achieved higher mean scores for their 
‘Warfarin Knowledge’ questionnaires. Finally, paired t-tests confirmed that the 
three-month follow-up ‘Warfarin Knowledge’ questionnaire scores for both groups 
were significantly lower than their immediate scores, suggesting that warfarin 
knowledge had deteriorated over time.  
Overall, therefore, the new warfarin education program improved the 
patients’ warfarin knowledge and understanding, especially immediately after the 
initial warfarin education session, more so than did the customary warfarin 
education program. Notably, the low literacy skilled patients educated at or below 
a grade 6 level, who received the customary warfarin education program, 
achieved the lowest mean ‘Warfarin Knowledge’ questionnaire scores after three 
months of warfarin therapy. This suggests that the new warfarin education 
program, as compared to the customary warfarin education program, more 
effectively improved warfarin knowledge and understanding in all patients, 
including those with low literacy skills. 
 
6.4.5 t-tests to compare the mean scores for the ‘Self-Management,’ 
‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’ 
questionnaires 
6.4.5.1 Introduction 
 t-tests were used to evaluate whether or not a number of different factors 
affected the mean scores for the ‘Self-Management’, ’Medication-Taking-
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Measures’ and ‘Warfarin Knowledge’ questionnaires (Appendices 17-19) 
immediately and three months after the initial warfarin education session. The 
factors assessed included patient participants: having prior warfarin knowledge; 
coming from non-English speaking backgrounds; being elderly (aged 65 years 
and over); having a carer and/or family member present during the initial warfarin 
education session; and seeking more warfarin information. The results of these t-
tests will now be discussed. 
 
6.4.5.2 Comparing mean scores for the various questionnaires for participating 
patients with and without prior warfarin knowledge 
 In order to establish whether or not prior warfarin knowledge affected the 
mean ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin 
Knowledge’ questionnaire scores immediately and three months after the initial 
warfarin education session, t-tests were performed on each of these scores. The 
t-tests were carried out on the scores of intervention and control group patients 
with and without prior warfarin knowledge.  
The results of these t-tests for the intervention group patients’ mean 
questionnaire scores are summarised in table 16, which shows that no p-values 
were below 0.05. Thirty percent (15) of the intervention group patients who had 
prior warfarin knowledge, achieved mean scores for the ‘Self-Management’, the 
‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’ questionnaires 
which were not significantly different to the mean scores achieved by the 70 
percent (35) of the intervention group patients who had no prior warfarin 
knowledge. Thus, the intervention group patients with and without prior warfarin 
knowledge were equally confident about their warfarin management and 









Table 16: t-test results comparing mean scores for the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of 
intervention group patients with and without prior warfarin knowledge 




Mean score for 
intervention patients 
with prior warfarin 
knowledge (n=15) 
Mean score for 
intervention patients 






19.133 19.057 0.8615 
SM score  
(3-month follow-up) 
19.933 19.886 0.6488 
MTM score 
(immediate) 
2.6 3.0571 0.3603 
MTM score  
(3-month follow-up) 
3.8 3.6571 0.5002 
WK score 
(immediate) 
20.333 21.229 0.4022 
WK score  
(3-month follow-up) 
18 18.086 0.9418 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire 
completed immediately after the initial warfarin education session and 3-month follow-up = 
questionnaire completed three months after the initial warfarin education session) 
 
 
Table 17 also shows that there were no p-values below 0.05 for the t-tests 
carried out on mean scores for the control group patients with and without prior 
warfarin knowledge. The 48.1 percent (25) of control group patients with prior 
warfarin knowledge did not achieve significantly different mean scores to the 
51.9 percent (27) of control group patients with no prior warfarin knowledge. 
Therefore, the mean scores for the ‘Self-Management ’, ‘Medication-Taking-
Measures’ and ‘Warfarin Knowledge’ questionnaires, completed immediately 
and three months after the initial warfarin education session, were similar for the 
control group patients with and without prior warfarin knowledge. Here again, the 
control group patients with and without prior warfarin knowledge were equally 
confident about their warfarin management and compliance at home, and they 




Table 17: t-test results comparing mean scores for the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of 
control group patients with and without prior warfarin knowledge 




Mean score for 
control patients with 
prior warfarin 
knowledge (n=25) 
Mean score for control 







18.96 17.963 0.2022 
SM score  
(3-mth follow-up) 
19.56 19.889 0.1904 
MTM score 
(immediate) 
3.2 2.8519 0.3663 
MTM score  
(3-mth follow-up) 
3.68 3.3704 0.2278 
WK score 
(immediate) 
20 18.333 0.1492 
WK score  
(3-mth follow-up) 
17.16 16.889 0.8115 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire 
completed immediately after the initial warfarin education session and 3-month follow-up = 
questionnaire completed three months after the initial warfarin education session) 
 
 
The combined results for both groups, as shown in tables 16 and 17, 
indicate that patients who had prior warfarin knowledge did not achieve 
significantly different mean scores for any of the questionnaires, as compared to 
the patients without prior warfarin knowledge. Hence, prior warfarin knowledge 
did not seem to positively impact upon the patients’ confidence to manage or 
comply with their warfarin therapy at home, nor did it improve warfarin 
knowledge and understanding. Possibly the most important aspect of these 
results is that even though the participating patients’ confidence about their 
warfarin management and compliance improved over time, their warfarin 




6.4.5.3 Comparing mean scores for the ‘Self-Management’ ‘Medication-Taking-
Measures’ and the ‘Warfarin Knowledge’ questionnaires for participating patients 
from English and non-English speaking backgrounds. 
 t-tests were used to evaluate whether or not coming from an English 
speaking background or a non-English speaking background affected the mean 
scores for the ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin 
Knowledge’ questionnaires completed immediately and three months after the 
initial warfarin education session. The t-test results for the intervention group 
patients are summarised in table 18 and in table 19 for the control group patients. 
 As shown in table 18, the English speaking background intervention group 
patients, as opposed to the non-English speaking background intervention group 
patients, achieved higher mean scores for each of the ‘Self-Management’, 
’Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires. The 
only significant differences between the two were achieved for the immediate 
‘Self-Management’ questionnaire score with a p-value of 0.0047**, and the 
immediate ‘Warfarin Knowledge’ questionnaire score with a p-value of 0.0248*. 
The English speaking background intervention group patients, as compared to 
the non-English speaking background intervention patients, appeared to be more 
confident about their warfarin management at home and had a better warfarin 
knowledge and understanding immediately after their initial warfarin education 
session. Notably, even though these results were expected, the small number of 
non-English speaking background intervention group patients in this sample 














Table 18: t-test results comparing mean scores for the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of 
intervention group patients from English and non-English speaking 



















19.4 17.7 0.0047** 
SM score  
(3-month follow-up) 
19.9 19.8 0.3361 
MTM score 
(immediate) 
3.1 2.3 0.229 
MTM score  
(3-month follow-up) 
3.7 3.6 0.4857 
WK score 
(immediate) 
21.5 18.67 0.0248* 
WK score  
(3-month follow-up) 
18.3 16.8 0.2608 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire 
completed immediately after the initial warfarin education session and 3-month follow-up = 
questionnaire completed three months after the initial warfarin education session) 
 
 
Table 19 summarises the results for the control group patients. Again, the 
English speaking background control group patients achieved higher mean 
scores overall for each of the ‘Self-Management’, ’Medication-Taking-Measures’ 
and ‘Warfarin Knowledge’ questionnaires, than did the non-English speaking 
background control group patients. In this instance, none of these questionnaire 
mean scores were significantly different between the English speaking and the 
non-English speaking background control patients. Based on the small number of 
control group patients from non-English speaking backgrounds (n=6) however, 






Table 19: t-test results comparing mean scores for the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of 
control group patients from English and non-English speaking 





Mean score for 
control patients from 
English speaking 
backgrounds (n=46) 








18.6 17.5 0.396 
SM score  
(3-month follow-up) 
19.8 19.2 0.0899 
MTM score 
(immediate) 
3.1 2.5 0.337 
MTM score  
(3-month follow-up) 
3.5 3.8 0.3781 
WK score 
(immediate) 
19.33 17.67 0.3614 
WK score  
(3-month follow-up) 
17.4 14.0 0.0504 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire 
completed immediately after the initial warfarin education session and 3-month follow-up = 
questionnaire completed three months after the initial warfarin education session.) 
 
In summary, tables 18 and 19 showed that English speaking background 
patients in both the intervention and control groups achieved higher mean 
scores overall for each of the questionnaires (Appendices 17-19), than did the 
non-English speaking background patients. When tables 18 and 19 were 
compared to each other, it was also identified that the non-English speaking 
backgrounds intervention group patients, as compared to the non-English 
speaking backgrounds control group patients, achieved higher mean scores for 
the ‘Self-Management’ and ‘Warfarin Knowledge’ questionnaires (Appendices 17 
and 19), immediately and after three months of warfarin therapy. On the other 
hand, the non-English speaking background control group patients achieved 
slightly higher mean scores for the immediate and three-month follow-up 
‘Medication-Taking-Measures’ questionnaire scores. These results suggest that 
the new warfarin education program improved the non-English speaking 
background patients’ confidence about their warfarin management at home, as 
 152 
well as their warfarin knowledge and understanding, whereas the customary 
warfarin education program improved the non-English speaking background 
patients’ confidence with their warfarin compliance. Unfortunately, the number of 
non-English speaking background patients, in both groups, was too small to 
analyse statistically and conclusively. 
  
6.4.5.4 Comparing mean scores for the ‘Self-Management’, ‘Medication-Taking-
Measures’ and the ‘Warfarin Knowledge’ questionnaires for participating patients 
aged above and below 65 years. 
 t-tests were used to analyse whether or not being elderly (aged 65 years 
and over) affected the mean scores for the ‘Self-Management’, ‘Medication-
Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires. At first, the t-tests 
were conducted on the mean scores achieved by all the patient participants in 
both groups aged 65 years and over, and compared to the scores achieved by 
all patient participants in both groups aged below 65 years. There were no 
significant differences found for the mean scores of the ‘Self-Management’ and 
‘Medication-taking-Measures’ questionnaires. However, there were significant 
differences in the immediate and three-month follow-up ‘Warfarin Knowledge’ 
questionnaire mean scores.  
The participating patients aged 65 years and over achieved an immediate 
‘Warfarin Knowledge’ mean score of 19.16 (73.7 percent) and a three-month 
follow-up score of 16.59 (63.8 percent). On the other hand, participating patients 
aged below 65 years achieved an immediate mean score of 21.5 (82.7 percent) 
and a three-month follow-up mean score of 19.105 (73.5 percent). The results of 
the t-tests found a p-value equal to 0.0012** for the immediate scores, and a p-
value equal to 0.0014** for the three-month follow-up scores. These results are 
indicative of the fact that the warfarin knowledge and understanding was poorer 
in all participating patients aged 65 years and over, as compared to those aged 
65 years and under. 
To investigate possible differences in the questionnaire mean scores 
within the two groups (intervention and control), further t-tests were performed. 
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Firstly, t-tests were conducted on the mean scores of the intervention group 
patients aged above and below 65 years of age and the results of these tests 
are summarised in table 20. Secondly, t-tests were performed on the mean 
scores of the control group patients aged above and below 65 years and the 
results of this test are summarised in table 21.  
 
Table 20: t-test results comparing mean scores for the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of 
intervention patients aged above and below 65 years immediately and 




Mean score for 
intervention 
patients aged 65 
years and over 
(n=34) 
Mean score for 
intervention patients 






19.088 19.063 0.9608 
SM score  
(3-month follow-up) 
19.912 19.875 0.7743 
MTM score 
(immediate) 
2.971 2.813 0.7484 
MTM score  
(3-month follow-up) 
3.735 3.625 0.5965 
WK score 
(immediate) 
20.412 22.125 0.0991 
WK score  
(3-month follow-up) 
17.0 20.313 0.0026** 
 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire 
completed immediately after the initial warfarin education session and 3-month follow-up = 
questionnaire completed three months after the initial warfarin education session.) 
 
 Table 20 shows that between intervention group patients aged above and 
below 65 years, the only significant difference in scores was in the three-month 
follow-up ‘Warfarin Knowledge’ questionnaire scores (p-value 0.0026**). In this 
questionnaire, the results show that elderly intervention group patients (aged 65 
years and over) achieved significantly lower scores than those intervention 
group patients aged less than 65 years. This demonstrates that after three 
months of warfarin therapy, elderly patients who have received the new warfarin 
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education program had significantly less warfarin knowledge and understanding 
than did their younger counterparts. 
 
Table 21: t-test results comparing mean scores for the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of 
control patients aged above and below 65 years immediately and three 




Mean score for 
control patients aged 
65 years and over 
(n=30) 
Mean score for 
control patients aged 






18.967 17.727 0.1236 
SM score  
(3-month follow-up) 
19.633 19.864 0.3484 
MTM score 
(immediate) 
3.233 2.727 0.1986 
MTM score  
(3-month follow-up) 
3.6 3.409 0.4642 
WK score 
(immediate) 
17.733 21.045 0.0034** 
WK score  
(3-month follow-up) 
16.133 18.227 0.0640 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire 
completed immediately after the initial warfarin education session and 3-month follow-up = 
questionnaire completed three months after the initial warfarin education session.) 
 
Table 21 shows that between control group patients aged above and 
below 65 years, the only significant difference was in the immediate ‘Warfarin 
Knowledge’ questionnaire’ (p-value 0.0034**). These results suggest that the 
elderly control group patients (aged 65 years and over) achieved significantly 
lower mean scores than those control group patients aged below 65 years, 
immediately after the initial warfarin education session. This demonstrates that 
the elderly patients who received the customary warfarin education program had 
significantly less warfarin knowledge and understanding than did the younger 
patients from the initiation of their warfarin therapy. 
Comparing tables 20 and 21 also identified that the mean scores achieved 
by the elderly intervention group patients were, on the whole, higher than the 
average mean scores achieved by the elderly control group patients. According 
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to t-tests results, however, only the immediate ‘Warfarin Knowledge’ 
questionnaire scores were significantly higher for the elderly intervention group 
patients compared to the elderly control group patients (p-value 0.0092**). This 
demonstrates that the new warfarin education program, as compared to the 
customary warfarin education program, significantly improved the elderly 
patients’ warfarin knowledge and understanding immediately after the initial 
warfarin education program. The higher mean scores achieved by the elderly 
intervention group patients compared to the elderly control group patients for the 
‘Self-Management’ and ‘Medication-Taking-Measures’ questionnaires, also 
suggests that the new program was more effective than the customary program, 
in promoting warfarin self-management and compliance at home for elderly 
patients. 
In summary, the elderly patient participants (aged 65 years and over) 
achieved lower overall mean scores for the ‘Self-Management’, ‘Medication-
Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires, than did the patient 
participants aged below 65 years. Statistical analysis, however, found that only 
the elderly patient participants’ ‘Warfarin Knowledge’ questionnaire scores were 
significantly lower than those of the younger patient participants. These results 
demonstrate, that the customary warfarin education program was less effective 
at educating the elderly patients than the younger patients from the beginning, 
whereas the new warfarin education program lost its initial benefit over time. 
Interestingly, the new warfarin education program, as compared to the customary 
warfarin education program, was more effective at improving elderly patients’ 
warfarin knowledge and understanding, as well as their overall confidence with 








6.4.5.5 Comparing mean scores for the ‘Self-Management’, ‘Medication-Taking-
Measures’ and the ‘Warfarin Knowledge’ questionnaires for participating patients 
with and without the presence of a carer and/or family member during the initial 
warfarin education session. 
t-tests were used to analyse whether or not having a carer and/or family 
member present during the education session had an effect on the patients’ 
mean scores for the ‘Self-Management’, ‘Medication-Taking-Measures’ and 
‘Warfarin Knowledge’ questionnaires (Appendices 17-19), completed 
immediately and three months after the initial warfarin education session. P-
values for both the intervention and the control groups were all above 0.05 
indicating that there was no difference in results based on having a carer and/or 
family member present during the initial warfarin education session. Nor did it 
have an apparent effect on the patients’ confidence to manage and comply with 
their warfarin therapy at home, or affect their warfarin knowledge and 
understanding. However, this result does not provide any indication of the role of 
the carer – whether those with a carer present were better off than those without 
a carer present. It was not possible to address this question in the present study.  
 
6.4.5.6 Comparing mean scores for the three-month follow-up ‘Self-
Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ 
questionnaires for patients seeking more warfarin information from their general 
practitioners, medicines information telephone lines, the internet, etc. 
 In order to analyse whether or not the patients who had sought more 
warfarin information achieved different mean scores for their ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires 
(Appendices 17-19) compared to those who did not, t-tests were performed. 
These t-tests were performed on the mean scores for each of these 
questionnaires completed after three months of warfarin therapy (it was assumed 
that they did not seek information before their initial warfarin education sessions). 
The results for the intervention and control group patients, who did and didn’t 
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seek more warfarin information, are summarised in tables 22 and 23, 
respectively.  
As shown in table 22 the only mean score which was significantly different 
for the intervention group patients who sought more warfarin information 
compared to those who did not was the ‘Warfarin Knowledge’ questionnaire (p-
value 0.0072**). Arguably the most interesting point to make here is that the 
average mean ‘Warfarin Knowledge’ questionnaire score for the intervention 
group patients who had sought more information was lower than the mean score 
achieved by intervention group patients who did not. In reality, this result may 
not be considered conclusive because of the small number of intervention group 
patients who sought more warfarin information, 16 percent (8). Alternatively, it 
may also reflect that the quality and readability of the warfarin information 
available from these other sources is poor and/or incomprehensible, making 
them more confused about their warfarin therapy. 
 
Table 22: t-test results comparing the mean scores for the ‘Self-
Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ 
questionnaires of intervention group patients who sought more warfarin 




Mean scores for 
intervention patients 
who sought more 
warfarin information 
(n=8) 
Mean scores for 
intervention patients 





SM score  
(3-month follow-up) 
19.75 19.929 0.5053 
MTM score  
(3-month follow-up) 
3.75 3.6905 0.8226 
WK score  
(3-month follow-up) 
17.452 21.25 0.0072** 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4) and WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26))  
 
Table 23 shows that the only significant difference in any of the mean 
scores for the questionnaires completed by the control group patients, who did 
and did not seek more warfarin information, was the ‘Medication-Taking-
Measures’ (MTM) questionnaire (p-value 0.0004***). In this case, all 7.7 percent 
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(4) of the control group patients who sought more warfarin information had a 
perfect MTM score equal to 4, as compared to the mean MTM score of 3.4792 
for the 92.3 percent (48) control group patients who did not seek more warfarin 
information. Once again, given that only a small number of control group patients 
actually sought more warfarin information and that the MTM mean scores were 
representative of ‘high’ compliance scores in both instances, it cannot be 
concluded that the patients who sought more warfarin information were truly 
more confident about their warfarin compliance, than were patients who did not.  
  
Table 23: t-test results comparing the mean scores for the ‘Self-
Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ 
questionnaires of control group patients who sought more warfarin 




Mean scores for 
control patients who 
sought more warfarin 
information 
(n=4) 
Mean scores for 
control patients who 





SM score  
(3-mth follow-up) 
19 19.792 0.4874 
MTM score  
(3-month follow-up) 
4 3.4792 0.0004*** 
WK score  
(3-month follow-up) 
20.75 16.708 0.0534 
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM 
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4) and WK score = 
‘Warfarin Knowledge’ questionnaire score (maximum score= 26))  
 
Importantly, tables 22 and 23 indicate that only a small proportion of the 
intervention group patients (16 percent (8)) and control group patients (7.7 
percent (4)), actually sought more warfarin information. Therefore, it is not 
possible to generalise that the results in these data are representative of the 
general warfarin prescribed patient population. It could be argued, however, that 
because both of the education programs were so effective and informative, 






In summary, the results of the t-tests did not show a significant difference 
in either of the groups for the ‘Self-Management’, ‘Medication-Taking-Measures’ 
or the ‘Warfarin Knowledge’ questionnaire scores when patient participants’ had 
prior warfarin knowledge or when they had a carer and/or family member present 
during the initial warfarin education session. Compared to English speaking 
background patient participants, non-English speaking background patient 
participants were found to have poorer warfarin knowledge and less confidence 
with their warfarin management and compliance. The data indicated, however, 
that the non-English speaking background patients who received the new 
warfarin education program had a better understanding of their warfarin 
knowledge and were more confident about their warfarin management, than were 
the non-English speaking background patients who received the customary 
warfarin education program. Similarly elderly patient participants (aged 65 years 
and over) had poorer warfarin knowledge and less confidence with their warfarin 
management and compliance, than did the younger patients. Here again, the 
elderly intervention group patients who received the new warfarin education 
program had a better understanding of their warfarin knowledge and were, 
overall, more confident about their warfarin management and compliance, than 
were elderly control group patients who received the customary warfarin 
education program. The new warfarin education program, therefore, seemed to 
be more effective than the customary warfarin education program at improving 
these ‘high risk’ participating patients’ warfarin knowledge and understanding, as 
well as confidence with their warfarin management and compliance.  
Given the small number of patient participants who sought more warfarin 
information, it is difficult to draw and real conclusions from the data. However, the 
fact that so few patient participants did actually seek more warfarin information 
may be an indication that both the new and the customary warfarin education 




6.4.6 ‘Satisfaction with Information about Medicines Scale’ (SIMS) 
(APPENDIX 20) results 
 
6.4.6.1 Introduction 
 The patients’ satisfaction with the warfarin information they were given 
was measured with the established and validated ‘Satisfaction with Information 
about Medicines Scale’ (SIMS) (APPENDIX 20)(Horne, Hankins et al. 2001). 
Questions 1 - 9 were used to analyse the patients’ satisfaction with the 
information they received about warfarin’s action and usage and questions 10 - 
17 were used to analyse their response to the information they received about 
warfarin’s potential problems. The following rating criteria were used: 
a) too much 
b) about right 
c) too little 
d) none received  
e) none needed 
 
6.4.6.2 Analysis of questions 1-9 of the ‘Satisfaction with Information about 
Medicines Scale’ (SIMS) questionnaire. 
Analysis of questions 1-9 of the SIMS data collected immediately after the 
initial warfarin education session showed that both groups rated highly the 
information they received for questions 1- 4, 6 and 8 of the scale, as per 
APPENDIX 20. These questions refer to warfarin’s name, indication, action, and 
duration of therapy. More than 90 percent of both groups rated the information 
they received for these questions as about right (b). The ratings for questions 5, 
7 and 9 of the questionnaire, however, varied somewhat and a summary of the 
findings is listed below. 
 
 Question 5 How long warfarin will take to act. 
100 percent (50) of the intervention group patients and 86.5 percent (45) of 
the control group patients felt that the information they received about 
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question 5 was about right (b). However, 11.54 percent (6) of the control 
group patients felt that too little information (c) was received, and 1.92 percent 
(1) felt that no information had been received (d). 
These results show that the intervention group patients were more 
satisfied with the information they received about how long it takes for 
warfarin to act. 
 
 Question 7 How long you will need to be on your medicine. 
92 percent (46) of the intervention group patients and 88.46 percent (46) of 
the control group patients felt that they had received the right amount of 
information (b) for question 7. However, 8 percent (4) of the intervention 
group patients and 7.69 percent (4) of the control group patients felt that they 
had received too little information (c), and, 3.85 percent (2) of the control 
group patients felt that they had not received any information (d). 
This shows that the intervention group patients appeared to be more 
satisfied than the control group patients about the information received 
regarding how long they would need to be on warfarin therapy. 
 
 Question 9 How to get a further supply 
86 percent (43) of the intervention group patients and 67.31 percent (35) of 
the control group patients felt that they had received the right amount of 
information (b) for question 9. However, 8 percent (4) of the intervention 
group patients and 21.15 percent (11) of the control group patients felt that 
they had received too little information (c), whereas 9.4 percent (2) of the 
intervention group patients and 7.69 percent (4) of the control group patients 
felt that they had received no information (d). Interestingly, 2 percent (1) of 
the intervention and 3.85 percent (2) of the control group patients felt that 
they hadn’t needed any information (e) about question 9. 
Intervention group patients therefore appeared to be much more satisfied 
than control group patients with the information about how to obtain further 
supplies of warfarin tablets. 
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Overall, for each of these initial SIMS (APPENDIX 20) warfarin action and 
usage questions, the intervention group patients were more satisfied than the 
control group patients about the information they received. It would be fair to say 
however, that even though the satisfaction scores were high for both groups, 
educating patients about: how long warfarin takes to work; how long warfarin 
needs to be taken; and where to get further supplies, would help to improve 
patients’ satisfaction with the current customary warfarin education program 
given to TACT patients.  
The three-month follow-up SIMS data found that 96 percent (98) of the 102 
participating patients in both groups felt that all the information given to them 
about warfarin’s action and usage (Questions 1-9 of APPENDIX 20) was about 
right (b). This demonstrates that their satisfaction scores improved over time. 
 
6.4.6.3 Analysis of questions 10-17 of the ‘Satisfaction with Information about 
Medicines Scale’ (SIMS) questionnaire 
Focus will now turn to Questions 10 - 17 of the data, which analysed 
patients’ satisfaction with information they received about warfarin’s potential 
problems. Once again, the overall results were high with over 90 percent of the 
participating patients immediately - and over 95 percent of patients after three 
months - describing the information they received for Question 12 to 15 in 
APPENDIX 20 was about right (b). These questions referred to their satisfaction 
with the information they received about: what to do if they experienced 
unwanted side effects; whether or not they could drink alcohol while on warfarin 
therapy; whether or not other medicines interacted with warfarin; and what they 
should do if they forgot to take a dose.  
The questions which did not highly satisfy the participating patients were 
questions 10 and 11 initially, and questions 16 and 17 both initially and after 
three months of warfarin therapy. The following is a brief summary of the 




 Question 10 Whether the medicine has any unwanted effects (side 
effects). 
Ninety-eight percent (49) of intervention group patients and 88.46 percent 
(46) of control group patients felt that they had received the right amount of 
information (b) about side effects. However, 2 percent (1) of the intervention 
and 9.62 percent (5) of the control group patients felt that they had received 
too little information (c), and only one control patient or 1.92 percent, 
indicated that no information had been received (d). 
Intervention group patients were slightly more satisfied than the control 
group patients with the initial information they received about warfarin’s side 
effects. 
 
 Question 11 What are the risks of you getting side effects? 
Ninety-two percent (46) of the intervention group patients and 76.92 percent 
(40) of the control group patients felt that they received the right amount of 
information (b) about their risks of suffering side effects. However, 6 percent 
(3) of the intervention group patients and 21.15 percent (11) of the control 
group patients felt that they had received too little information (c), and one 
intervention patient, or 2 percent, and one control patient, 1.92 percent, 
indicated that they had not received any information (d) about the risk of side 
effects. 
Once again, intervention group patients appeared more satisfied than 
control group patients about the information they received concerning the risk 
of suffering from warfarin-related side effects. 
 
More than 60 percent (72) of the participating patients were not satisfied with 
the information referred to in Questions 15 and 16 of the SIMS questionnaire 
(APPENDIX 20), either immediately or after three months of warfarin. The 
satisfaction results were low, primarily because warfarin has no major effects on 
drowsiness or normal heterosexual sexual behaviour and hence these issues 
were not discussed during the education sessions. These results are not 
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surprising because prior to the research study it was decided to use the SIMS 
questionnaire (APPENDIX 20) in its entirety inclusive of these two questions 
which were not considered to be highly relevant to warfarin therapy. 
 
6.4.6.4 Chi-square test results and patient comments used to compare and 
contrast the ‘Satisfaction with Information about Medicines Scale’ (SIMS) 
questionnaire scores for both groups. 
Chi-squared tests, in place of the inappropriate t-tests, were used to 
identify significant differences between the two groups’ satisfaction scores for 
questions 5, 7, 9, 10,11, 16 and 17 of the ‘Satisfaction with Information about 
Medicines Scale’ (SIMS)(APPENDIX 20), identified above. A significant 
difference in the scores was only identified for Question 5 with a p-value of 
0.027*. Therefore, the intervention group patients’ satisfaction with the 
information they received about how long it takes for warfarin to act was 
significantly better than the control group patients’ satisfaction with this 
information. It should be noted however, that this satisfaction score was 
significantly better immediately, as compared to three months after the initial 
warfarin education session. This shows that patients in the new warfarin 
education program were more satisfied than those in the customary program with 
information provided in the first education session about how long warfarin takes 
to act.  
Patients’ comments were once again encouraged during this data 
collection period and, as a result, several comments were documented. These 
comments were similar for both groups and reflected their satisfaction with being 
educated at home and having the information reinforced in a simple and easy-to-
understand manner. Some examples of these comments included: 
 Intervention 2 “Good to get info at home…” 
 Intervention 28 “I like the simplicity of the booklet…” 
 Control 16 “Boots booklet and information from TACT is extremely   
   useful and easy to understand…” 
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 Control 16 “I found answering the questions reassured my    
  knowledge ..” 
 
6.4.6.5 Summary 
In summary, a key arbiter of the quality of medicines information given to 
patients is the extent to which individuals perceive that it has met their needs and 
they are satisfied (Horne, Hankins et al. 2001). Overall, the satisfaction scores 
were high for both groups in relation to the information provided about warfarin’s 
action, usage and potential problems. The ‘Satisfaction with Information about 
Medicines Scale’ (SIMS)(APPENDIX 20) data however identified that the new 
warfarin education program addressed the information about how long warfarin 
will take to act significantly better than did the customary warfarin education 
program.  
 
6.4.7 ‘Outcome Measures of the Warfarin Education Program’ questionnaire 
(APPENDIX 21) results 
 
6.4.7.1 General practitioner visits 
To identify whether or not general practitioner visits affected patients’ 
‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ 
questionnaire scores, a correlation coefficient test was used. The correlation 
coefficient test calculated whether or not there was a relationship between the 
mean three-month follow-up questionnaire scores and the number of general 
practitioner visits (a coefficient of 0 indicates no linear relationship between two 
variables, whereas a coefficient of 1 indicates a linear relationship between two 
variables). The general practitioner visits averaged about 7 visits per patient for 
both the intervention and the control group patients. Interestingly however, the 
general practitioner visits varied between 0 to 30 visits for the intervention 
patients, and 2 to 16 visits for the control patients. The results of the correlation 
coefficient test scores are summarised in table 24. 
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Table 24: Pearson correlation coefficient scores assessing any relationship 
between ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin 
Knowledge’ questionnaire scores and the number of general practitioner 




Intervention Group  
(n=50) 












SM score  
(3-month follow-up) 
-0.14704 0.3082 -0.30512 0.0278* 
MTM score  
(3-month follow-up) 
0.01807 0.9009 0.17809 0.2065 
WK score  
(3-month follow-up) 
-0.04010 0.7822 -0.43277 0.0014** 
(In this table: SM score = ‘Self-Management’ questionnaire score; MTM score = ‘Medication-
Taking-Measures’ questionnaire score and WK score = ’Warfarin Knowledge’ questionnaire 
score; 3-month follow-up = questionnaires scores three months after the initial warfarin education 
session) 
 
According to the results in table 24, only the control group’s ‘Self-
Management’ (SM) questionnaire scores (p-value 0.0278*) and ‘Warfarin 
Knowledge’ questionnaire (WK) scores (p-value 0.0014**) had coefficients 
significantly different to zero, three months after the initial warfarin education 
session. In both these cases, even though correlations were poor, there was a 
direct relationship between the ‘Self-Management’ and ‘Warfarin Knowledge’ 
questionnaire scores and the number of general practitioner visits. Interestingly, 
the coefficients for both of these scores were negative, indicating a negative 
relationship or a reduction in the mean scores for both questionnaires as the 
number of general practitioner visits increased. In other words, as the number of 
general practitioner visits increased for the control group patients, their 
confidence with their warfarin management and their warfarin knowledge 
deteriorated. A possible implication of this finding is that the control group 
patients who had poor self-management skills and poorer warfarin knowledge 
visited their general practitioners more frequently during the initial three months 




6.4.7.2 Hospital visits 
Eighteen percent (9) of the intervention group patients and 21.2 percent 
(11) of the control group patients visited hospital within the first three months of 
their warfarin therapy. The reasons for hospital visits are listed below, with the 
number of patients who presented from each group shown in brackets; 
Intervention Patients (n=9)   Control Patients (n=11) 
 Atrial fibrillation (1)    Heart key hole surgery (1) 
 Chemotherapy (1)    Chemotherapy (2) 
Chest pain (3)    Shortness of breath (1) 
Osteomyelitis (1)    Surgical procedures (5) 
Pain management (1)   Pacemaker inserted (1) 
Surgical procedures (2)   Transient ischaemic attacks (1) 
 
These results suggest that similar proportions of patients from both the 
intervention and control groups visited hospital during their first three months of 
their warfarin therapy for reasons which were not related to poor warfarin 
therapeutic outcomes or warfarin-related adverse drug events.  
 
6.4.7.3 Emergency department visits 
Sixteen percent (8) of the intervention group patients and 11.54 percent 
(6) of the control group patients visited the emergency department during the first 
three months of their warfarin therapy. The reasons for their emergency 
department visits are listed below with the number of patients from each group 
once again represented in brackets; 
Intervention Patients (n=8)   Control Patients (n=6) 
Allergic reaction to antibiotics (1)  Asthma attack (1) 
Atrial fibrillation (1)    Burst blood vessel in eye (1) 
Chest pain (2)    Chest pain (1) 
Minor bleeding (3)    Falls (2) 
 Shortness of breath (1)   Worried post stroke (1) 
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Of the patients in both groups who presented to the emergency department 
during the first three-month period, only 6 percent (3) of the intervention and 1.9 
percent (1) of the control group patients had minor bleeds associated with 
possible warfarin-related adverse events. In total therefore, 3.92 percent (4) of 
the participating patients presented to the emergency department suffering from 
minor bleeds potentially due to warfarin therapy which did not require 
hospitalisation. 
 
6.4.7.4 Warfarin-related adverse drug events  
 Very few patients in both groups reported any possible warfarin-related 
adverse drug events. Six percent (3) of the intervention group patients and 4 
percent (2) of the control group patients reported possible minor bleeding. All of 
the intervention group patients reported to the emergency department for medical 
advice, whereas only one of the two control group patients presented to the 
emergency department for advice. Importantly, only 4.9 percent (5) of the patient 
participants experienced minor possible warfarin-related adverse drug events 
and none of them experienced major possible warfarin-related adverse drug 
events during the three-month follow-up period.  
 
6.4.7.5 Possible drug-to-drug interactions between warfarin and complementary 
medicines  
 Twenty-four percent (12) of the intervention group patients and 19 percent 
(10) of the control group patients were found to be taking complementary 
medicines. Of the 21.6 percent (22) of participating patients who took 
complementary medicines, approximately half of these (10) admitted that their 
general practitioners were unaware of their use of complementary medicines. It 
was only after having been shown the ‘Potential drug-to-drug warfarin interaction 
sheet’ (APPENDIX 27) that they realised the possibility of an interaction and 
agreed to either cease taking the complementary medicines or to continue taking 
them after consultation with their general practitioners. 
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6.4.7.6 International Normalised Ratio (INR) stability  
 The results indicated that there was an inconsistency in the number of 
International Normalised Ratio (INR) blood tests processed per patient during the 
three-month follow-up period. Even though participating patients in both the 
intervention and control groups had an average of 11 INR blood tests, the range 
of INR blood tests processed was between four and 26 over the three-month 
period. 
In order to evaluate the number of patients in both groups who had 
achieved a therapeutic International Normalised Ratio (INR) score (within the 
2.0-3.5 therapeutic range), their therapeutic INR scores were calculated as a 
percentage of their total number of INR blood tests processed during the three-
month period. This calculation was used because of the inconsistent number of 
blood tests processed per patient during the study period. The following formulae 
were used to calculate the percentage of INR scores within therapeutic range 
(INR=2-3.5) and outside therapeutic range (INR = <2 or >3.5). 
  
 
The percentage of INRs = Total number of INR scores between 2 and 3.5 
(within therapeutic range)   Total number of INR scores 
 
 
The percentage of INRs  = Total number of INR scores outside 2 and 3.5 
(outside therapeutic range)  Total number of INR scores 
 
 
Using these formulae it was found that on average, 71.86 percent of the 
intervention group patients’ INR scores, and 69.42 percent of the control group 
patients’ INR scores, were within therapeutic ranges: Thus, 28.14 percent of the 
intervention group patients’ and 30.58 percent of the control group patients’ INR 
scores were outside therapeutic ranges. These results suggest that patients who 
received the new warfarin education program had a slightly higher percentage of 
therapeutic INR scores during the initial three-month period of their warfarin 
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therapy, than did the patients who received the customary warfarin education 
program.  
A t-test was then used to analyse whether or not there was a significant 
difference in the percentage of therapeutic INR scores between the two groups. 
A p-value of 0.5568 suggested that there was no statistically significant 
difference in the percentage of intervention and control group patients’ 
therapeutic INR scores for the first three months of warfarin therapy. 
A Pearson correlation coefficient test was used to investigate whether or 
not there was a relationship between the percentages of INR scores inside and 
outside the therapeutic range (INR=2.0-3.5) and the actual mean scores for the 
‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ 
questionnaires (Appendices 17-19). The results of these correlation coefficient 
tests are summarised in tables 25 and 26 below. 
Table 25 summarises the correlation coefficient test results used to 
identify a relationship between the questionnaire scores and the percentage of 
INR scores within therapeutic range. This table shows that after three months of 
warfarin therapy, only the intervention group patients’ mean ‘Medication-Taking-
Measures’ (MTM) questionnaire score (p-value 0.0328*) had a linear relationship 
with the percentage of therapeutic INR scores (INR = 2.0 - 3.5). The positive 
correlation coefficient for this score suggests that as the MTM questionnaire 
scores increased, so too did the percentage of therapeutic INR scores. In other 
words, as the intervention group patients’ confidence with their warfarin 










Table 25: Pearson correlation coefficient results assessing any relationship 
between the ‘Self-Management’, ‘Medication-Taking-Measures’ and 
‘Warfarin Knowledge’ questionnaire scores and the percentage of 





Percentage INR results within therapeutic range  
(INR = 2.0 - 3.5) 
Intervention Group 
(n=50) 












SM score  
(3-month follow-up) 
0.07542 0.6027 0.10190 0.4768 
MTM score 
(3-month follow-up) 
0.30243 0.0328* -0.14101 0.3237 
WK score 
(3-month follow-up) 
0.00438 0.9759 -0.02418 0.8662 
(In this table: SM score = ‘Self-Management’ questionnaire score; MTM score = ‘Medication -
Taking-Measures’ questionnaire score and WK score = ’Warfarin Knowledge’ questionnaire 
score; the 3-month follow-up = questionnaire results three months after the initial warfarin 
education session; therapeutic INR = 2.0 – 3.5) 
  
Table 26 summarises the correlation coefficient test results used to 
identify a relationship between the questionnaire scores and the percentage of 
INR scores outside the therapeutic range. Not surprisingly, this table shows that 
only the intervention group patients’ ‘Medication-Taking-Measures’ questionnaire 
mean score had a linear relationship with the percentage of INR scores outside 
the therapeutic range (p-value 0.0408*). The negative correlation coefficient in 
this instance, suggested that as MTM questionnaire scores decreased the 
percentage of INR scores outside the therapeutic range increased. Therefore, 
when the intervention group patients’ confidence about their warfarin compliance 
deteriorated, they experienced an increase in the percentage of INR scores 







Table 26: Pearson correlation coefficient results assessing any relationship 
between the ‘Self-Management’, ‘Medication-Taking-Measures’ and 
‘Warfarin Knowledge’ questionnaire scores and the percentage of non-






Percentage INR results outside therapeutic range  
(INR<2.0 or > 3.5) 
Intervention Group 
(n=50) 












SM score  
(3-month follow-up) 
-0.07005 0.6288 -0.10190 0.4768 
MTM score 
(3-month follow-up) 
-0.29040 0.0408* 0.14101 0.3237 
WK score 
(3-month follow-up) 
-0.00747 0.9589 -0.07807 0.5860 
(In this table: SM score = ‘Self-Management’ questionnaire score; MTM score = ‘Medication -
Taking-Measures’ questionnaire score and WK score = ’Warfarin Knowledge’ questionnaire 
score; the 3-month follow-up = questionnaires results three months after the initial warfarin 
education session; non-therapeutic INR = INR< 2.0 or >3.5) 
 
The combined results of the Pearson correlation coefficient tests (Tables 
25 and 26), show that as the intervention group patients’ confidence with their 
warfarin compliance increased so too did their therapeutic INR scores (INR = 
2.0-3.5). Therefore, as expected, the reverse was also true because as the 
intervention group patients’ confidence with their warfarin compliance 
deteriorated there was an increase in their percentage of INR scores outside the 
therapeutic range (INR scores <2 and/or >3.5). Notably, however, the 
percentage of therapeutic INR scores was relatively high for both groups, 71.86 
percent for the intervention group and 69.42 percent for the control group. In 
other words, both warfarin education programs empowered patient participants 








In summary, according to the results of the readability tests the new 
warfarin information booklet (APPENDIX 12) was much easier to read than the 
Boots warfarin information booklet (2003) because it was written between a 
grade 6 - 8 level as compared to a grade 8.9 –14 level. The higher scores for the 
‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier 
Instructional Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print 
materials’ (Bidford Maine Area Health Education Center 1996) also indicated that 
the new warfarin information booklet, as compared to the Boots warfarin 
information booklet (2003), was a better quality booklet, produced at a higher 
standard, catering for the needs of a wider patient population, inclusive of the 
‘high risk’ group.  
Data collection commenced in February 2003 and was completed within 
12 months with a total of 102 of the 114 patient participants providing fully 
completed questionnaires. Fifty intervention patients received the new warfarin 
educational program and 52 control patients received the customary warfarin 
education program delivered to warfarin-prescribed TACT patients. The 
participating patients in both groups were referred to The Ambulatory Care Team 
(TACT) from similar sources and for similar diagnoses, the most common of 
which was deep venous thrombosis. Many of the participating patients came 
from the ‘high risk’ patient population with: 62.8 percent (64) aged 65 years and 
over; 25.5 percent (26) educated at or below a grade 6 level; and 14.71 percent 
(15) coming from non-English speaking backgrounds. 
Although the research data suggest that patients receiving the new 
warfarin education program achieved higher mean scores than patients receiving 
the customary warfarin education program in the ‘Self-Management’, 
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires 
(Appendices 17-19), statistical analysis found that only the immediate ‘Warfarin 
Knowledge’ questionnaire scores were significantly better for those receiving the 
new warfarin education program. The difference in the ‘Warfarin Knowledge’ 
questionnaire scores became less significant over time, with the scores 
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significantly deteriorating for both groups over the three-month period of data 
collection. Interestingly as ‘Warfarin Knowledge’ scores deteriorated in both 
groups ‘Self-Management’ and ‘Medication-taking-Measures’ scores significantly 
improved. This could have serious implications for patients on long-term warfarin 
therapy because they may not have the warfarin knowledge and understanding 
to achieve optimal therapeutic outcomes, even though they may feel confident 
about their warfarin management and compliance at home. 
The ‘high risk’ patients in both groups which included - the elderly (aged 
65 years and over), those with low literacy skills (education at a level ≤ grade 6) 
and those from non-English speaking backgrounds - achieved lower mean 
scores than other participants for the ‘Self-Management’, ‘Medication-Taking-
Measures’ and the ‘Warfarin Knowledge’ questionnaires. However, the trend in 
the data found that intervention group ‘high risk’ patients achieved higher mean 
scores for these questionnaires than did the control group ‘high risk’ patients. 
These results, and especially the higher mean scores for the immediate ‘Warfarin 
Knowledge’ questionnaire, suggest that the new warfarin education program 
more effectively educated the ‘high risk’ patients about their warfarin therapy. 
Although data from the ‘Satisfaction with Information about Medicines 
Scale’ (SIMS) (APPENDIX 20) showed that all patient participants were highly 
satisfied with the warfarin information they received, the intervention group 
patients were more satisfied with the information they received about how long 
warfarin will take to act than were the control group patients.  
Similar results for both groups of patients were achieved for the outcome 
measures during the three-month follow-up period. Both groups had similar 
numbers of general practitioner, hospital, and emergency department visits, with 
only a small percentage of patients (4.9 percent) experiencing minor possible 
warfarin-related adverse drug events. The high percentage of therapeutic INR 
scores (INR = 2 and 3.5) for both groups are indicative of the effectiveness of 
both education programs in empowering the patient participants with the 
knowledge and confidence to achieve good therapeutic control.  
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Overall, therefore, the new warfarin information booklet (APPENDIX 12) 
was written in a better quality, easier-to-read format, than was the Boots warfarin 
information booklet (2003). Comparing and contrasting the new warfarin 
education program against the customary warfarin education program found that 
it was more effective in terms of improving the patients’ warfarin knowledge, 
management and compliance, knowing when to look for medical assistance, as 
well as improving their overall satisfaction with the information received. Similar 
results were also found for the ‘high risk’ patients, including the elderly, those 








For almost two decades, the efficacy of warfarin education programs has 
been the subject of significant debate. Fifteen years ago, Wyness (1989) 
examined the need for clear program design and, some nine years later, Haines 
(1998) proposed a more structured education program for better outpatient 
anticoagulant management. It appears that such calls for a more structured 
education program have been largely ignored. This is evident in the ever-
increasing reports of warfarin knowledge deficiencies in patients prescribed 
warfarin, and particularly the ‘high risk’ patients (Cheah and Martens 2003; 
Lambert and Wynne 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 2003; 
Wilson, Racine et al. 2003).  
The research study, therefore, focused on developing and evaluating a 
new, home based warfarin education program to help improve warfarin 
knowledge, management and compliance in a wider patient population, inclusive 
of the ‘high risk’ group. This ‘high risk’ group includes the elderly, those with low 
literacy skills and those from non-English speaking backgrounds. The conceptual 
framework for the new program incorporated interventions and strategies which 
targeted the five key elements of an effective patient education program. 
Importantly, this framework can be used as a blueprint for other patient 
medication education programs in both hospital and community settings. 
The impact of this new warfarin education program was compared and 
contrasted with the customary home-based warfarin education program used by 
The Ambulatory Care Team (TACT) at Illawarra Health. Evaluations included 
comparing and contrasting the participating patients’ warfarin knowledge and 
understanding, as well as their ability to manage and comply with their warfarin 
therapy at home. Warfarin knowledge was evaluated using the ‘Warfarin 
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Knowledge’ questionnaire (APPENDIX 19) and the participants’ ability to manage 
and comply with warfarin therapy at home was evaluated using the ‘Self-
Management’ and ‘Medication-Taking-Measures’ questionnaires (APPENDIX 17 
and 18). Patient participants’ satisfaction with the warfarin information they 
received was measured by using the ‘Satisfaction with Information About 
Medicines Scale’ (SIMS) (APPENDIX 20), and outcome measures (therapeutic 
INR scores and healthcare visits) were used as objective measures to analyse 
and compare the effectiveness of both programs.  
This chapter discusses the data in relation to the patient participants’ 
warfarin knowledge, management and compliance, as well as their therapeutic 
outcomes based on the interventions and strategies used in the conceptual 
framework. The five key elements targeted by interventions and strategies in the 
conceptual framework included: health professional/patient communication and 
partnerships; warfarin compliance; simple, easy-to-read warfarin information; the 
continuity of care between hospital and community settings; and patient follow-
up. The impact of the new warfarin education program was assessed both 
generally across the wider population and more specifically in respect to the ‘high 
risk’ patient populations. Based on the results of the study recommendations are 
made for both current and future practice in patient warfarin education programs. 
Finally, limitations are acknowledged and conclusions are drawn from the study 
results and, when necessary, from evidence available in the literature.  
The implications of this study are that the incorporation of the five key 
elements of an effective patient education program into a warfarin education 
program will benefit all patients, including those from the ‘high risk’ group. These 
patients will be empowered to confidently manage and comply with their warfarin 
therapy because of their improved warfarin knowledge, which in turn will help 






7.2 OVERVIEW OF THE PARTICIPATING PATIENTS’ WARFARIN 




 From an educational perspective, good knowledge and understanding of 
warfarin therapy underpins optimum therapeutic outcomes (Barcellona, Contu et 
al. 2002) and a reduction in warfarin-related adverse drug events (Kagansky, 
Knobler et al. 2004). Inadequacies in existing warfarin education programs 
(Connor 1998) and consequent patient knowledge deficiencies (Cheah and 
Martens 2003; Tang, Lai et al. 2003), highlight the urgent need for a new more 
effective warfarin education program.  
The new education program developed and tested in this research study 
was based on five aforementioned key elements of education. These methods 
were incorporated with the specific aim of improving warfarin knowledge and 
understanding. However, during the course of the study, several of these specific 
strategies and interventions were also incorporated into the customary warfarin 
education program following directions from the area health service 
management. This unforeseen action was out of the control of the researcher. It 
had the potential to affect findings of the research, particularly the overall 
patients’ warfarin knowledge and understanding results. However, because many 
of these intervention were perceived to be best practice with the potential to 
reduce the incidence of adverse drug events and improve overall therapeutic 
outcomes (Australian Council for Safety and Quality in Health Care 2002; 
Bhasale, Miller et al. 1998; Mullen, Simons-Morton et al. 1997), the area health 
service management recommended that they be included into the customary 






7.2.2 Participating patients’ warfarin knowledge and understanding 
Data from the ‘Warfarin Knowledge’ questionnaires (APPENDIX 19) 
indicate that higher mean scores were achieved by the intervention group 
patients compared to the control group patients. The initial mean scores were 
21.0 (80.8 percent) for the intervention group patients versus 19.0 (73 percent) 
for the control group patients. After three months, the mean scores were 18.04 
(69.4 percent) for the intervention group patients and 17.04 (65.5 percent) for the 
control group patients. These results suggest that the new warfarin education 
program educated patients and improved their warfarin knowledge and 
understanding more effectively than the customary warfarin education program.  
Shortcomings in current warfarin education programs are evident in the 
literature which has identified that patients prescribed warfarin often have 
deficiencies in their warfarin knowledge (Cheah and Martens 2003; Lambert and 
Wynne 2003; Roche-Nagle, Chambers et al. 2003; Tang, Lai et al. 2003). In the 
absence of a validated warfarin knowledge questionnaire, each of these studies 
used a different instrument to measure the patients’ warfarin knowledge, making 
it difficult to compare them against each other and against the data collected in 
this research study. The average percentage of correct warfarin knowledge 
answers achieved by the intervention and control group patients in this study, 
both initially (80.8 percent intervention and 73.0 percent control) and after three 
months (69.4 percent intervention and 65.5 percent control), were higher than the 
46.9 percent achieved by patients in a study by Cheah et al (2003), the 48 
percent achieved in a study by Tang et al (2003) and the 61.1 percent achieved 
in study by Nadar et al (2003). These results suggest that the new warfarin 
education program more effectively educated patients and improved their 
warfarin knowledge and understanding, than not only the customary warfarin 
education program but also many other available warfarin education programs. 
Further studies need to be undertaken, using a common warfarin knowledge 
questionnaire, to contrast the effectiveness of the new warfarin education 
program with other warfarin education programs, available in both Australia and 
overseas. 
 180 
Another explanation for the improved warfarin knowledge and 
understanding of the patient participants in both the intervention and control 
groups of this study is that they had to complete the warfarin knowledge 
questionnaires on two occasions during the study. On both occasions, 
immediately and after three months of warfarin therapy, when and if they 
answered a question incorrectly, their answers were documented and the correct 
answers were reinforced. The higher than average warfarin knowledge scores 
and therapeutic INR scores achieved by patients in both groups, as well as 
comments such as “I found answering the questions reassured my knowledge” 
concur with the results of a recent study (Barcellona, Contu et al. 2002) which 
found that patients who completed a warfarin knowledge questionnaire spent 
more time in the therapeutic range. A recommendation based on these results is 
that a standardised warfarin knowledge questionnaire should be developed and 
completed by all patients receiving warfarin education. Not only would the 
questionnaire help to reinforce warfarin information, it would also help to identify 
deficits in the patients’ knowledge, which could then be addressed by the 
educating health professional. 
Further analysis of the data collected from the initial ‘Warfarin Knowledge’ 
questionnaire found that the intervention group patients had a better knowledge 
and understanding of certain aspects of their warfarin therapy, than did the 
control group patients. These findings suggest that the new program, more so 
than the customary program, improved the intervention patients awareness about 
why their warfarin was prescribed, how to manage missed doses and how to 
recognise side effects and possible drug and/or food interactions with their 
warfarin.  
Pharmacists, nurses, medical practitioners and carers should be aware of 
the difference between the reality of what the patient actually knows and what the 
patient thinks they know (Barat, Andreasen et al. 2001). It is important to 
understand that patients can be overwhelmed by the information they receive 
and often forget what has been communicated to them (Ansell, Buttaro et al. 
1997). The intervention and control group patients’ deterioration in warfarin 
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knowledge over the three-month follow-up period agrees with the literature 
reporting warfarin knowledge deficits following discharge from hospital 
(MacDonald 1998). These results highlight the importance of continuous 
reinforcement of warfarin information (Haynes, McDonald et al. 2002a) which 
according to the data should occur every three months.  
In summary, based on the ‘Warfarin Knowledge’ questionnaire 
(APPENDIX 19) data, it would appear that the new warfarin education program is 
better placed than the customary and other available warfarin education 
programs to improve patients’ warfarin knowledge and understanding. The new 
program has provided patients with a better understanding about why warfarin 
was prescribed for them, possible drug and/or food interactions, how to manage 
missed doses and which side effects to look out for. According to the overall high 
warfarin knowledge scores achieved by all the patient participants, a 
recommendation has been made to develop a standardised warfarin knowledge 
questionnaire to be completed by all patients prescribed warfarin, which will help 
to reinforce and reassure them about their warfarin information. The significant 
deterioration in patients’ warfarin knowledge over time highlights the importance 
of continuous patient follow-up and information reinforcement. 
 
7.2.3 ‘High risk’ patients’ warfarin knowledge and understanding 
 
7.2.3.1 Introduction 
The patient populations at ‘high risk’ of experiencing poor warfarin-related 
therapeutic outcomes and adverse drug events because of poor warfarin 
knowledge and understanding include the elderly, those with low literacy skills 
(Lambert and Wynne 2003; Tang, Lai et al. 2003) and people from non-English 
speaking backgrounds (Nadar, Begum et al. 2003). The research study’s 
participating patient population had a good representation of these ‘high risk’ 
patient population with 62.74 percent (64) of the patients aged 65 years and 
over, 25.5 percent (26) educated at or below grade 6 level, and 14.7 percent (15) 
coming from non-English speaking backgrounds.  
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7.2.3.2 Warfarin knowledge and the elderly patient participants 
Poor quality warfarin education is a common risk factor for poor warfarin-
related therapeutic outcomes and adverse drug events among the elderly 
(Kagansky, Knobler et al. 2004). Current warfarin education programs do not 
cater for elderly patients, aged 65 years and over, who typically score poorly, or 
less than 50 percent for their warfarin knowledge questionnaire scores (Cheah 
and Martens 2003; Lambert and Wynne 2003; Tang, Lai et al. 2003). 
Interestingly, in this study the mean scores for the ‘Warfarin Knowledge’ 
questionnaire achieved by the elderly patient participants in both groups were 
higher than the 50 percent average reported in the literature (Cheah and Martens 
2003; Tang, Lai et al. 2003).  
The elderly intervention group patients initially scored 20.4 (78.5 percent) 
out of a possible 26, compared to the elderly control group patients who scored 
17.7 (68.2 percent) for their ‘Warfarin Knowledge’ questionnaire. After three 
months of therapy, the elderly intervention group patients scored 17.0 (65.4 
percent), compared to the elderly control group patients who scored 16.1 (62.05 
percent). These results suggest that even though the new program more 
effectively improved warfarin knowledge in the elderly patients than did the 
customary program, both programs improved warfarin knowledge and 
understanding in elderly patients more so than did other available warfarin 
education programs. 
Notably, the deterioration in warfarin knowledge scores over the three-
month period in the study was more significant for all the elderly participating 
patients than it was for the younger participating patients, aged below 65 years. 
Not only does this agree with evidence in the literature (Lambert and Wynne 
2003; Taylor, Ramsay et al. 1994) but it also highlights the need to provide 
elderly patients with regular follow-up and reinforcement of their warfarin 
information.  
These results suggest that the new warfarin education program more 
effectively improved warfarin knowledge and understanding in elderly patients, 
than did the customary warfarin education program. Importantly however, both 
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programs appear to be more effective at improving warfarin knowledge and 
understanding in elderly patients compared to other available warfarin education 
programs. To confirm this possibility further studies with a much larger sample 
size of elderly patients would need to conducted, comparing the new warfarin 
education program to other available warfarin education programs.  
 
7.2.3.3 Warfarin knowledge and patient participants with low literacy skills 
According to the literature a significant relationship exists between the 
patients’ literacy level and warfarin knowledge (Barcellona, Contu et al. 2000; 
Estrada, Martin-Hryniewicz et al. 2004; Wilson, Racine et al. 2003). It is not 
surprising therefore, that all patient participants educated at or above grade 10 
levels achieved the highest mean scores for the ‘Warfarin Knowledge’ 
questionnaires and those educated at or below grade 6 levels achieved the 
lowest mean scores.  
Overall, the intervention group participants with low literacy skills 
(educated at or below a grade 6 level) achieved higher mean scores for the 
‘Warfarin Knowledge’ questionnaire, than did the control group patients with low 
literacy skills, both initially (19.8 versus 17.7); and after three months of warfarin 
therapy (16.6 versus 15.0). Importantly, there were more intervention group 
patients with low literacy skills (n = 16) than there were control group patients 
with low literacy skills (n = 10), which may have negatively impacted on the final 
results. This means that the final results may not be a true indication of the 
positive impact of the new warfarin education program on warfarin knowledge of 
patients with low literacy skills. Based on the study results however, it could be 
suggested that the new warfarin education program more effectively educated 
patients with low literacy skills about their warfarin therapy, than did than the 
customary warfarin education program. Further studies examining the impact on 
warfarin knowledge of this new program, for a much larger sample size of 




7.2.3.4 Warfarin knowledge and patient participants from non-English speaking 
backgrounds 
Recent studies have found that non-English speaking background (NESB) 
patients have significant gaps in their warfarin knowledge (Nadar, Begum et al. 
2003; Wilson, Racine et al. 2003). The results of this study suggest that the 
needs of the NESB patients are being met to some degree by the new warfarin 
education program, as compared with the customary warfarin education 
program. The NESB intervention group patients achieved higher mean scores for 
the ‘Warfarin Knowledge’ questionnaire than did the NESB control group 
patients, both initially (18.7 versus 17.7), and after three months of warfarin 
therapy (16.8 versus 14.0). These results suggest that the new program, more so 
than the customary program, improved warfarin knowledge in the NESB patients. 
It cannot be denied, however, that these results were based on a small sample 
size of NESB patient participants (n=14) in total. Further investigations on a 
much larger sample size of NESB patients would therefore need to be conducted 
to assess the true impact of the new warfarin education program on warfarin 
knowledge of NESB patients, as compared to other available warfarin education 
programs. 
Interestingly, only 5 of the 9 NESB intervention group patients, compared 
to 5 of the 6 NESB control group patients, had a carer and/or family member 
present during the initial warfarin education session. In view of the fact that 
carers and/or family members can help with overcoming possible language and 
cultural barriers (Davidhizar and Brownson 1999; Minas, Lambert et al. 1996), it 
is even more impressive that the NESB intervention group patients still managed 
to achieve higher mean warfarin knowledge scores than did the NESB control 
group patients.  
 
7.2.3.5 Summary  
The data implied that compared to the customary warfarin education 
program, the new warfarin education program more effectively improved warfarin 
knowledge in the ‘high risk’ group, which included the elderly, those with low 
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literacy skills and those from non-English speaking backgrounds. The data also 
suggested that the mean warfarin knowledge scores achieved by the ‘high risk’ 
patients in both groups were higher than the mean score of 50 percent achieved 
by patients from the general population in other recent studies (Cheah and 
Martens 2003; Tang, Lai et al. 2003). Unfortunately, this cannot be stated 
conclusively because the other studies used different warfarin knowledge 
questionnaires. Further research is needed, therefore, on a much larger sample 
size of patients from the ‘high risk’ group, to test the effectiveness of the new 
warfarin education program against other available warfarin education programs, 
with regard to improving warfarin knowledge and understanding.  
 
7.2.4 Summary of the participating patients’ warfarin knowledge and 
understanding  
The research study focused on developing a new structured home-based 
warfarin education program to help improve warfarin knowledge and 
understanding in a wider patient population, inclusive of the ‘high risk’ group. This 
new program, based on a conceptual framework targeting five key elements, was 
then compared and contrasted with the customary warfarin education program 
delivered to patients admitted to Illawarra Health’s The Ambulatory Care Team.  
The higher mean scores for the ‘Warfarin Knowledge’ questionnaires 
(APPENDIX 19) achieved by the intervention group patients, compared to the 
control group patients, suggests that the new warfarin education program more 
effectively educated patients, including the ‘high risk’ patients, about their 
warfarin therapy. In fact, based on the high mean scores achieved by all the 
patient participants, it could be argued that both warfarin education programs 
more effectively improved warfarin knowledge and understanding than do other 
available warfarin education programs. Notably, the ‘Warfarin Knowledge’ 
questionnaire used in this study differed to the questionnaires used in other 
studies (Cheah and Martens 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 
2003) making it difficult to state categorically that the new warfarin education 
program was the most effective. Therefore, further research, using a 
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standardised warfarin knowledge questionnaire is recommended to compare and 
contrast the effectiveness of the new program with other available programs.  
An important finding of the research study was the deterioration in warfarin 
knowledge for patients in both groups, and especially elderly patients, over the 
three-month period. This in itself highlights the need to continuously follow-up 
and reassure patients about their warfarin therapy, especially if they are elderly 
and on long-term therapy. Based on the results of this study it is recommended 
that warfarin information be reinforced every three months. 
With the inadequacies in current warfarin education programs (Connor 
1998) leading to gaps in patients knowledge (Cheah and Martens 2003; Lambert, 
Stoll, Singy, Zobel, Molina and Guex 1999; Nadar, Begum et al. 2003), and in the 
absence of a best practice model for home-based warfarin education programs, it 
would be reasonable to recommend the new program as a best practice model 
for an effective warfarin education program. Importantly, this new home-based 
program could be readily adapted to other hospital and community based 
settings. 
 




 Poor health professional/patient communication and partnerships have 
been identified as major contributors to poor warfarin-related therapeutic 
outcomes and adverse drug events (Bhasale, Miller et al. 1996; Gandhi, 
Weingart et al. 2003). The patient populations most likely to have problems with 
communication and establishing partnerships include the elderly, those with low 
literacy skills and patients from non-English speaking backgrounds (Bhasale, 
Miller et al. 1998).  
The new warfarin education program placed special emphasis on the 
improvement of patient/health professional partnerships and communication to 
help patients make educated decisions about their warfarin compliance and 
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management. Interventions of an administrative nature included: one-on-one 
education sessions with the patients and/or their carers at home; follow-up; 
communication directly with the patients, their carers and allied health 
professionals; as well as availing the patients of other important resources (for 
example interpreters for non-English speaking background patients, blister packs 
for the elderly). Other interventions of a more abstract nature included: ensuring 
that the home environment was conducive to learning by making certain that all 
televisions, radios and stereo players were turned off; speaking in an 
encouraging, reinforcing and reassuring manner; asking lots of questions; and 
encouraging feedback from the patients and/or their carers. 
The Ambulatory Care Team (TACT) staff members were also keen to 
incorporate many of these interventions, to help improve health 
professional/patient communication and partnerships, into the customary warfarin 
education program. The very nature of the service provided by TACT and the 
pride of the team members in providing an excellent service, meant that 
professionally it was inevitable that these interventions would be incorporated in 
the customary program. This dynamic made it very difficult to compare the 
customary warfarin education program with the new warfarin education program 
and could be viewed as a limitation of the study. However, in light of recent 
reports identifying that poor health professional/patient communication and 
partnerships contribute to poor warfarin-related therapeutic outcomes and 
adverse events (Dantas, Thompson et al. 2004; Gandhi, Weingart et al. 2003) it 
could be argued that it would have been unconscionable not to have included 
them into the customary program. 
Discussions will now focus on comparing the effectiveness of the new and 
customary warfarin education programs in the area of health professional/patient 




7.3.2 Comparing the effectiveness of the new and customary warfarin 
education programs in the area of health professional/patient 
communication and partnerships 
One of the first indications that good health professional/patient 
communication and partnerships had been established was that all patients 
admitted to TACT for anticoagulation therapy from January 2003 to October 2003 
consented to be part of the study. Of the 114 consenting patients who were 
eligible, only one withdrew from the study voluntarily, while the other 11 were no 
longer eligible because of warfarin cessation, death or simply because they could 
not be re-contacted for evaluation follow-up. In other words, all the patient 
participants who consented to be part of the study initially were happy to continue 
being part of the study, until its completion, without feeling threatened or coerced. 
Data from the ‘Satisfaction with Information about Medicines Scale’ 
(SIMS) (APPENDIX 20) found that most patient participants (over 90 percent) 
were very satisfied with the information they received about warfarin’s action, 
usage and potential problems. Statistical analysis found that only the information 
about how long it takes for warfarin to act significantly satisfied more of the 
intervention group patients than the control group patients (p-value 0.027). It 
could be argued that the similar interventions to improve health 
professional/patient communication and partnerships used in both warfarin 
education programs may have contributed to fewer significant differences 
between the two. Both education programs equally satisfied and met the needs 
of all patient participants who were satisfied with the collaborative interchange 
between themselves and their health professional.  
Improved health professional/patient communication and partnerships for 
both programs can also be inferred from the high mean scores for the ‘Self-
Management’ and ‘Medication-Taking-Measures’ questionnaires (Appendices 17-
18), which will be discussed later in this chapter. Further studies need to be 
conducted to assess the extent to which the new warfarin education program, in 
particular, improves health professional/patient communication and partnerships 
compared to other available warfarin education programs.  
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Another limitation of the study was that several interventions and 
strategies targeting the key elements, which included health professional/patient 
communication and partnerships, were introduced into both warfarin education 
programs at the same time. This makes it difficult to analyse the impact of 
improved health professional/patient communication and partnerships alone. 
Future studies should therefore focus on identifying the impact that improving 
health professional/patient communication and partnerships alone has on 
warfarin knowledge, management and compliance, as well as long-term warfarin-
related therapeutic outcomes and adverse drug events. 
The literature identifies that even though patients were satisfied with the 
information they received there were gaps in their warfarin knowledge (Lambert 
and Wynne 2003; Nadar, Begum et al. 2003). In the present study, data from the 
‘Satisfaction with Information about Medicines Scale’ (SIMS)(APPENDIX 20) and 
the high mean scores in the ‘Warfarin Knowledge’ questionnaire scores 
(APPENDIX 19), suggest that the new warfarin education program, as compared 
to the customary warfarin education program, satisfied more of the patients’ 
needs and improved their level of warfarin knowledge. Further research is 
needed to establish whether or not the new warfarin education program does in 
fact improve patients’ warfarin knowledge and their satisfaction with the 
information provided, as compared to other available warfarin education 
programs. 
Based on the promising results of this study, especially with regard to 
patient satisfaction and improved warfarin knowledge, it could be recommended 
that all warfarin education programs should target improved health 
professional/patient communication and partnerships. In doing so, these 
programs would not only improve patients’ warfarin knowledge, management and 
compliance, but they would also help to promote optimal therapeutic outcomes 





7.3.3 Summary of the effectiveness of health professional/patient 
communication and partnerships in the study  
Several interventions were incorporated into both the new and the 
customary warfarin education programs to help improve health 
professional/patient communication and partnerships. These interventions 
included: home based one-on-one education sessions; offering the patients 
and/or their carers encouragement, reinforcement, reassurance and feedback; 
asking lots of questions; and providing an interpreter when necessary. 
The high mean scores achieved by all participating patients in the ‘Self-
Management’, ‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’ 
questionnaires, as well as the ‘Satisfaction with Information about Medicines 
Scale’ (SIMS) (Appendices 17-20), suggest that both warfarin education 
programs improved patients’ warfarin knowledge, management and compliance 
as well as their satisfaction with the information received. These results imply 
that both programs achieved good health professional/patient communication 
and partnerships which is an improvement on many other available programs 
identified in the literature (Cox, Stevenson et al. 2004; Dantas, Thompson et al. 
2004; Elwyn, Edwards et al. 2003).  
 
 
7.4 WARFARIN COMPLIANCE 
 
7.4.1 Introduction 
Research has shown that poor warfarin compliance contributes 
significantly to poor therapeutic outcomes (Arnsten, Gelfand et al. 1997) and 
adverse drug events (Brigden, Kay et al. 1998; Hirri and Green 2002). Several 
interventions were incorporated into the new warfarin education program based 
on ‘best evidence’ to improve medication compliance (Haynes, McDonald et al. 
2002a). These interventions included: educating the patients, their carers and/or 
family members about the importance of taking warfarin on a regular basis; 
explaining the implications of not complying with regular warfarin dosage; 
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recommending compliance aids when and if required; offering reinforcement, 
reassurance and telephone follow-up; and undertaking medication reviews.  
Data collected from the ‘Self-Management’ (APPENDIX 17) and 
‘Medication-Taking-Measures’ (APPENDIX 18) questionnaires, as well as the 
percentage of therapeutic International Normalised Ratio (INR) scores, were 
used to evaluate the patient participants’ warfarin compliance. These results for 
the intervention and control group patients were compared and contrasted to 
analyse the impact of both warfarin education programs on the patients’ 
compliance.  
 
7.4.2 ‘Self-Management’ questionnaire 
The ‘Self-Management’ questionnaire scores for both the intervention and 
the control group, tested immediately and after three months of therapy, were 
high and well within the highly confident range. These high scores suggest that 
both education programs promoted patient confidence to manage and comply 
with their warfarin therapy at home  
The ‘Self-Management’ questionnaire scores significantly improved over 
the three-month period for both groups (p-value equal to 0.0009*** for the 
intervention group and p-value equal to 0.0024** for the control group), 
suggesting that all patient participants became increasingly confident about their 
warfarin management over time. The trend for the mean ‘Self-Management’ 
questionnaire scores was found to be higher for the intervention group patients 
than the control group patients. Even though these scores were not significantly 
different between the two groups, they do suggest that the new warfarin 
education program encouraged the patients to be more confident about their 
warfarin management, than did the customary warfarin education program.  
The ‘Self-Management’ questionnaire used in this study was adapted from 
Lorig et al’s ‘Self-Efficacy Questionnaire’ (1996 p.41-44), making it difficult to 
directly compare these results with other studies. Indirectly, however, it could be 
argued that both warfarin education programs promoted good warfarin 
management at home, which is known from the literature (Lorig and Gonzales 
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2000; Lorig, Ritter, Stewart, Sobel, Brown, Bandura, Gonzalez, Laurent and 
Holman 2001) to contribute to good therapeutic outcomes in patients with chronic 
disease. Future research should endeavour to test the impact of the new warfarin 
education program against other community and/or warfarin education programs 
for its impact on the patients’ confidence to manage their warfarin therapy at 
home.  
It is worrying that the significant increase in confidence to manage 
warfarin therapy over the three month period was accompanied by a significant 
decrease in the patients’ warfarin knowledge, as per the ‘Warfarin Knowledge’ 
questionnaire scores already discussed. Similar results were also found in other 
studies which showed that even though patients were confident and satisfied with 
the warfarin information they received, they had deficiencies in their warfarin 
knowledge (Lambert and Wynne 2003; Nadar, Begum et al. 2003). This is a 
major concern because deficiencies in warfarin knowledge can predispose 
patients to poor therapeutic outcomes and adverse drug events (Haines 1998; 
Kagansky, Knobler et al. 2004). This research study was too short to investigate 
this anomaly any further, however future research studies should investigate the 
possible impact of such changes over at least a six to 12 month period with a 
view to assessing the importance of regularly following-up patients, as well as 
reassuring them and reinforcing their warfarin information. 
The deterioration in warfarin knowledge accompanied by improved 
confidence in warfarin management over time gives rise to one other possibility 
for further investigation – patient complacency. Certainly the literature identifies 
that poor compliance (Haynes, McDonald et al. 2002a), especially in the ‘high 
risk’ patient population (Barat, Andreasen et al. 2001; Davidhizar and Brownson 
1999; Esposito 1995; Feifer 2003), leads to poor therapeutic outcomes and 
increased adverse drug events. It would be interesting, therefore, to investigate 
whether or not the patients become complacent with their warfarin therapy and 
what impact this could have on their therapeutic outcomes over time. 
In summary, the high mean scores for the ‘Self-Management’ 
questionnaires indicate that both warfarin education programs, and especially the 
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new program, empowered all patients, including those from the ‘high risk’ group, 
to feel confident about managing their warfarin therapy at home. Importantly, 
however, this improved confidence was accompanied by a deterioration in 
warfarin knowledge, highlighting the need to follow-up, reassure and reinforce 
warfarin information on a regular basis. 
 
7.4.3 ‘Medication-Taking-Measures’ questionnaire 
Intervention group patients achieved higher scores in the ‘Medication-
Taking-Measures’ (MTM) questionnaire (APPENDIX 18) than control group 
patients. Intervention group patients achieved more ‘high compliance’ scores 
than control group patients, both initially (62 percent versus 53.85 percent) and 
after three months (80 percent versus 71.15 percent). Although statistical 
analysis did not find these results to be significantly different, they suggest that 
the new warfarin education program promoted better warfarin compliance among 
patients than did the customary warfarin education program. This is also evident 
in the positive correlation coefficient test (p-value equal to 0.0328*), which found 
that as the intervention group patients’ MTM scores increased, so too did their 
percentage of therapeutic INR scores. In other words, as the intervention 
patients’ confidence about their warfarin compliance improved, so too did their 
therapeutic control of warfarin.  
Analysis of the MTM data after a three-month period showed significant 
increases in the scores for both groups (p-value equal to 0.0017** for the 
intervention group and p-value equal to 0.0243* for the control group). In fact, the 
follow-up scores for both groups were approximately 20 percent higher than the 
initial scores, suggesting that, from the patients’ perspective, compliance 
improved over time. The three-month follow-up ‘high compliance’ MTM scores for 
the intervention and control groups (80 percent versus 71.15 percent) were 
considerably higher than the average 50-65 percent medication compliance rates 
reported in the literature for long-term medications (Haynes, McDonald et al. 
2002a; Haynes, McKibbon et al. 1996). These results suggest that both warfarin 
education programs, and especially the new program, were more effective at 
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promoting good compliance than were other available medication education 
programs. Further investigations over a longer period of time, however, would 
need to be carried out to ensure that the patients’ compliance with long-term 
warfarin therapy remained stable. 
It is also worth noting, that the initial comments made by many of the 
patient participants in both groups were that they did not take regular 
medications prior to their warfarin being prescribed. It could be argued, therefore, 
that the significantly higher MTM scores after three months were due in part to 
the effectiveness of both programs in encouraging patients to be compliant with 
their warfarin therapy. The most worrying aspect of the significantly improved 
MTM scores over the three-month period was the concurrent deterioration in the 
patients’ warfarin knowledge. Future studies need to research the effects that this 
deterioration has on the patients’ warfarin compliance over time (at least 6-12 
months). It would also be useful to investigate what elements of ‘warfarin 
knowledge’ are critical to maintain good compliance and which could be left out, 
although this could be difficult to research ethically. 
When the three-month MTM scores were compared to the percentage of 
INR scores within therapeutic range, an interesting observation was made. 
Similar to the findings in a study by Barcellona et al (2002), the intervention 
group patients in this study who were highly compliant also achieved the highest 
therapeutic control, probably because they understood the relationship between 
regular compliance and good therapeutic control. In this study, the intervention 
group patients who declared a high level of compliance (MTM=4) achieved the 
highest mean percentage for therapeutic INR scores (73.7 percent). Whereas, 
the intervention group patients who declared a low level of compliance (MTM=1) 
achieved a lower mean percentage for therapeutic INR scores (64.7 percent). In 
contrast, however, the control group patients who declared a high level of 
compliance (MTM=4) achieved the lowest mean percentage for therapeutic INR 
scores (66.2 percent), and the control group patients who declared a low level of 
compliance (MTM=1) achieved the highest mean percentage of therapeutic INR 
scores (72 percent). These results suggest that the new warfarin education 
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program was more effective than the customary warfarin education program in 
educating patients about the importance of regular warfarin compliance, which 
improved their therapeutic control. Further research is needed, to confirm that the 
new warfarin education program does in fact promote better warfarin compliance 
resulting in improved therapeutic control over prolonged periods of time, as 
compared to other warfarin education programs.  
In addition to the positive impact of both education programs, another 
possible explanation for the significantly higher MTM scores after three months of 
therapy for both groups was that since patient participants knew that they were 
being followed-up, they were more diligent with their warfarin compliance. This 
result is consistent with evidence in the literature which states that patient follow-
up does help to improve medication compliance (Waterman, Milligan et al. 2001). 
There will be more discussion about the impact of patient follow-up later in this 
chapter 
In summary, the ‘Medication-Taking-Measures’ (MTM) questionnaire 
(APPENDIX 18) scores were high for both programs and especially the new 
warfarin education program. These results suggest that even though both 
programs promoted good warfarin compliance, the new program promoted it 
more effectively than did the customary warfarin education program. The 
significantly higher MTM scores after three months indicated that both programs 
continued to effectively promote warfarin compliance over time. Interestingly, the 
intervention group patients who were most confident about their warfarin 
compliance also achieved the highest therapeutic control. Further research is 
needed to analyse the long-term benefits of the new program with regard to 








7.4.4 International Normalised Ratio (INR) scores 
 
7.4.4.1 Discussion of the INR results 
An important aspect of both the ‘Self-Management’ and ‘Medication-
Taking-Measures’ (MTM) questionnaires was that they relied on the patients’ 
own reporting if their confidence levels for management and compliance at 
home. International Normalised Ratio (INR) blood tests, on the other hand, are 
laboratory results, which give an objective measure of the patients’ warfarin 
compliance.  
The high percentage of therapeutic INR scores (69 percent) corresponded 
with the high mean scores for the ‘Self-Management’ and ‘Medication-Taking-
Measures’ questionnaires for both groups. These results imply that patient 
participants who were confident with their warfarin management and compliance 
also achieved good therapeutic control. The association between the MTM 
scores and the INR scores has already been discussed and will not be revisited. 
The association between the ‘Self-Management’ and INR scores will be 
discussed now.  
The data revealed that as the ‘Self-Management’ scores increased for 
both the intervention and control group patients, so too did the percentage of 
therapeutic INR scores. The ‘highly confident’ patients in both groups achieved a 
higher percentage of therapeutic INR scores, 70.9 percent for the intervention 
group and 71.8 percent for the control group, whereas the less confident patients 
in both groups achieved a lower percentage of therapeutic INR scores, 67.8 
percent for the intervention group and 66.7 percent for the control group. These 
results suggest that both the new and the customary warfarin education 
programs effectively empowered a large proportion of the patients to feel 
confident about managing and complying with their warfarin medication, which in 
turn resulted in better therapeutic control. Both programs also appear to be more 
effective than other available programs, based on the fact that they both 
achieved higher than average therapeutic INR scores, 69 percent, as compared 
to the 30 percent to 60 percent average reported in the literature (Gray, 
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Garabedian-Ruffalo and Chretien 1985; Khan, Kamali, Kesteven, Avery and 
Wynne 2004).  
The finding that improved confidence with compliance and management 
promotes improved therapeutic control, is also evident in the literature (Beyth, 
Quinn and Landefeld 2000). This finding emphasises the importance of 
incorporating interventions and strategies to improve patients’ confidence with 
their warfarin compliance and management, which in turn will help to improve 
therapeutic control. Similar results achieved by both the new and customary 
warfarin education programs may have been due to the inclusion of similar 
interventions to target improved warfarin compliance. Further research is needed 
to establish which of the following interventions most effectively improve warfarin 
compliance, especially for elderly patients taking life-long warfarin therapy: 
educating the patients and/or their carers; compliance aids; general 
encouragement, reinforcement, reassurance and follow-up; and/or medication 
reviews. 
 
7.4.4.2 A structured self-management warfarin education program 
Even though therapeutic control for both programs was good overall, there 
still remains the problem of the 30 percent of INR scores which were outside the 
therapeutic range. These are a problem because they could potentially cause 
adverse drug events (Gallus, Baker et al. 2000). One of the ways in which to 
remedy this would be to combine the new warfarin education program with a self-
monitoring program, often referred to as a self-management program. Patients 
could be educated about their warfarin therapy with the new warfarin education 
program and taught how to adjust their own warfarin doses according to their INR 
results. Recent studies examining the therapeutic control of patients performing 
self-monitoring have found that they spend significantly more time within 
therapeutic range compared with patients who do not self-monitor (Ansell, 
Jacobson, Levy, Voller and Hasenkam 2005; McCahon, Fitzmaurice, Murray, 
Fuller, Hobbs, Allan and Raftery 2003; Sawicki 1999). The researcher 
recommends further research into the benefits of combining the new warfarin 
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education program with a structured self-management (self-monitoring) program. 
If the evaluation for this new structured self-management warfarin education 
program was good, it could be recommended as a best practice model for a 
home-based warfarin self-management program. 
 
7.4.4.3 Best practice guidelines for the number of INR blood tests 
Analysis of the INR data revealed that there was no consistency with the 
number of INR blood tests ordered by the patient participants’ general 
practitioners. An average of 11 INR blood tests, ranging from 4 - 26 INR blood 
tests, were ordered by the patient participants’ general practitioners during the 
three month period after their discharge from TACT.  
There is abundant literature which provides information about the 
importance of therapeutic INR monitoring (Ansell, Hirsh, Dalen, Bussey, 
Anderson, Poller, Jacobson, Deykin and Matchar 2001; Dzung The Le 1994). 
However, there is limited information (AMH 2003) about the recommendations for 
the frequency of these blood tests. Evidence suggests that 50 - 60 percent of 
patients will remain within therapeutic range if monitoring of INR occurs monthly, 
77 - 85 percent if monitored weekly and up to 92 percent if monitored every third 
day (Oral Anticoagulation Monitoring Study Group 2001). Best practice 
guidelines about the number of INR blood tests which should be ordered need to 
be developed and distributed to all health professionals prescribing warfarin. 
Also, with the evolving trend for patients to self-monitor their INR at home using 
especially designed devices (Ansell, Jacobson et al. 2005; Fitzmaurice and 
Machin 2001; Koertke, Minami, Bairaktaris, Wagner and Koerfer 2000), 
guidelines need to be given to patients about how often to test their INR. In other 
words, they also need to be provided with best practice guidelines about how 






7.4.5 Carers and/or family members 
 Over 50 percent of both intervention and control group patients, many of 
whom were from the ‘high risk’ group, had a carer and/or family member present 
during the initial warfarin education session. Based on the high proportion of 
therapeutic INR scores (above 70 percent) and the low incidence of minor 
potential warfarin-related adverse drug events (4.9 percent), it could be argued 
that these patients benefited from the assistance of their carers and/or family 
members.  
There is ample evidence to support the benefits of carers and/or family 
members being in attendance during medication education sessions to help 
improve medication compliance (Haynes, McDonald et al. 2002a), memory recall 
(Doak, Doak et al. 1998) and overcoming possible language, cultural, cognitive 
and/or physical barriers (Davidhizar and Brownson 1999; Minas, Lambert et al. 
1996). These benefits, however, are not reflected in higher scores for the three-
month follow-up ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin 
Knowledge’ questionnaires. This suggests that participating patients who had a 
carer present during the initial warfarin education session were not more 
confident about their warfarin management and compliance, nor did they have a 
better warfarin knowledge and understanding than did the participating patients 
without a carer present. One of the possible reasons for these unexpected 
results is that the follow-up questionnaires were completed over the telephone by 
the patients themselves. This could be seen as a limitation of the study because 
if the carer and/or family member had been responsible for the patients’ warfarin 
management then they should have been asked to complete the evaluation 
questionnaires. In order to investigate this further, future research needs to focus 
on the impact that carers and/or family members have on warfarin management, 
by having all the evaluation questionnaires completed by the person responsible 
for administering and managing the warfarin therapy at home, whether it be the 
patient, carer and/or family member. Other important factors to investigate in 
future studies would be whether or not carers and/or family members actually do 
improve warfarin knowledge, management and compliance.  
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Although the literature identifies that carers and/or family support can play 
a significant role in assisting with medication compliance (Schlenk, Dunbar-Jacob 
et al. 2004), very little attention has been paid to the role of families, their 
knowledge and/or expressed emotion toward medication compliance (Sellwood, 
Tarrier, Quinn and Barrowclough 2003). Another recommendation for future 
research would therefore be to compare warfarin management and compliance 
for all patients, especially the ‘high risk’ patients, with and without the physical 
and emotional support of a carer and/or family member. 
 
7.4.6 Compliance aids 
Based on the evidence that compliance aids help to improve medication 
compliance (Levings, Szep et al. 1999; Wong and Norman 1987) several aids, 
including dosette boxes, alarm clocks and calendars, were strongly 
recommended, especially for the ‘high risk’ patients, as part of the new warfarin 
education program. These aids were also recommended in the customary 
warfarin education program, making it difficult to compare and assess their 
effectiveness. 
During data collection, most patient participants could readily suggest two 
aids (for example dosette box, alarm clock) to help them with their warfarin 
compliance. This suggests that both programs effectively increased the patients’ 
awareness of compliance aids, which they could readily use to assist them with 
their warfarin compliance when and if they felt it was necessary. In the past, 
single strategies employed to improve long-term medication compliance such as 
compliance aids have not been found to be very effective (Haynes, McKibbon et 
al. 1996; McDonald, Garg et al. 2002; Roter, Hall et al. 1998), which is why these 
aids were recommended as one of several strategies. This, however, made it 
difficult to evaluate the impact of aids on warfarin compliance in the study. Future 
research should therefore focus on evaluating the impact that a single 
compliance aid such as a dosette box actually has on warfarin compliance, 
especially in the long term for ‘high risk’ patients.  
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7.4.7 Medication reviews 
Complex and complicated medication regimens can impact upon 
medication compliance, especially in patients over 65 years of age (Col, Fanale 
et al. 1990). In this research study, a significant proportion (62.74 percent) of the 
patient participants were aged 65 years and over, and although warfarin itself 
may not be considered a complex and complicated medication regimen, it has 
the potential to be when combined with other medications. Importantly, therefore, 
pharmacists in both groups conducted medication reviews on all patient 
participants, including the elderly, to ensure that medication regimens were 
simplified as much as possible. Home medication reviews became incorporated 
into both programs because they were perceived to be best practice and were 
highly promoted by the local division of general practice (Australian Government 
Department of Health and Ageing 2001). Once again, common practices in both 
programs made it difficult to compare the effect that the medication reviews had 
on the patients’ warfarin compliance for the new and customary warfarin 
education programs.  
Both programs achieved higher than the ‘norm’ warfarin compliance 
scores over the three-month period - above 70 percent as compared with the 50-
60 percent reported in the literature (Haynes, McDonald et al. 2002a; Haynes, 
McKibbon et al. 1996). It could be argued that these results were in part due to 
the benefits of the medication reviews, which ensured that warfarin was taken 
appropriately without any potential drug-to-drug interactions. A recommendation 
for all home-based warfarin education programs, therefore, is to incorporate 
home medication reviews as part of overall strategies to improve warfarin 
compliance.  
 
7.4.8 Summary of the effectiveness of the interventions used to improve 
warfarin compliance 
 
Several interventions were incorporated into both the new and the 
customary warfarin education programs, based on ‘best evidence’ to improve 
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medication compliance (Haynes, McDonald et al. 2002a; McDonald, Garg et al. 
2002). These interventions included: educating the patients, carers and/or family 
members; offering reinforcement, reassurance and follow-up; recommending 
compliance aids; and undertaking medication reviews.  
The high mean scores achieved for the ‘Self-Management’ and 
‘Medication-Taking-Measures’ questionnaires (APPENDIX 17-18), as well as the 
high proportion of therapeutic International Normalised Ratio (INR) scores, 
suggest that these interventions contributed to improving the participating 
patients’ confidence to manage and comply with their warfarin therapy at home, 
resulting in good warfarin therapeutic control. Unfortunately, because several 
interventions were incorporated simultaneously, it was not possible to identify 
which ones were the most effective with regard to improving warfarin compliance 
in both programs.  
Several recommendations arose from the study results. Firstly, there is a 
clear need to develop best practice guidelines for the number of INR blood tests 
required by patients to ensure good therapeutic control. Secondly, given the 
trend towards self-monitoring (often referred to as self-management), there is a 
need to develop a good practice model for a structured warfarin self-
management program, based on the new warfarin education program. Finally, 
medication reviews should be incorporated into all home-based warfarin 
education programs to reduce the risk of drug-to-drug interactions. 
 
 
7.5 SIMPLE, EASY-TO-READ WARFARIN INFORMATION 
 
7.5.1 Introduction 
The amount of information presented to patients beginning anticoagulant 
medication can be overwhelming (Ansell, Buttaro et al. 1997). It has been found 
that on average 40 percent of patients forget the information given to them 
(Prochaska and DeClementi 1986). Based on this knowledge, during the initial 
new warfarin education session the decision was made to verbally communicate 
only the important points as per the ‘Warfarin Counselling Checklist ’ (APPENDIX 
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13) and to provide each patient with the new written warfarin information booklet 
(APPENDIX 12) for written and visual reinforcement. The contents of both the 
checklist and the warfarin information booklet were based on ‘best evidence’ 
about what patients taking warfarin need to know in order to help optimise 
warfarin therapeutic outcomes (Ansell, Buttaro et al. 1997; Gallus, Baker et al. 
2000; Haines 1998; Witte, Gurwich et al. 1980) 
Health professionals have a duty of care to provide information which is 
easy-to-read and understand (Wilson, Racine et al. 2003). A number of 
strategies were used to ensure that the new warfarin information booklet 
(APPENDIX 12) was easily read and understood by most patients, including 
those with low literacy skills. These strategies included using readability 
instruments such as SMOG (McLauglin 1969), the Fry readability formula (Fry 
1968) and the Microsoft Word 2000 computerised Flesch-Kincaid test to ensure 
that the booklet was written at a suitable level. Other strategies included adhering 
to guidelines such as those in the ‘Toolkit for producing patient information’ (The 
United Kingdom Department of Health 2002) (APPENDIX 2) and the ‘Guidelines 
for writing patient information’ (Doak, Doak et al. 1996b) (APPENDIX 3) to 
ensure that the booklet was written in a simple, easy-to-read format with 
culturally-sensitive illustrations. Prior to the commencement of the research 
study, changes were also made to the new booklet, as discussed in chapter 5, 
based on the comments and recommendations made by literacy experts, 
pharmacists, TACT staff, Illawarra Health interpreters and the 10 pilot study 
participants. 
To assess the readability, quality and the patients’ satisfaction with the 
new warfarin information booklet (APPENDIX 12), it was compared and 
contrasted to the Boots warfarin information booklet (2003) used in the 






7.5.2 The overall effectiveness of the new warfarin education program 
compared to the customary program for patients with low literacy  
The literature reports that patients with low literacy skills generally 
experience poor anticoagulation control because they cannot read or understand 
the information given to them (Estrada, Martin-Hryniewicz et al. 2004). The 
participating patients with low literacy skills in this study (educated at or above a 
grade 6 level) achieved a high proportion of therapeutic INR scores (69.5 percent 
intervention group and 69.2 percent control group), as well as high mean scores 
in the ‘Self-Management’ questionnaire (19.9 intervention group and 19.9 control 
group) and the ‘Medication-Taking-Measures’ questionnaire (3.8 intervention 
group and 3.8 control group). These results suggest that both programs equally 
promoted good therapeutic control and instilled confidence in patients with low 
literacy skills to manage and comply with their warfarin therapy at home. 
However, intervention group patients with low literacy skills achieved higher 
mean scores than the control group patients with low literacy skills in the 
‘Warfarin Knowledge’ questionnaire s, both initially (76.2 percent versus 68.1 
percent) and after three months (63.9 percent versus 57.8 percent). As already 
discussed, these results suggest that the new warfarin education program was 
more effective than the customary warfarin education program, as well as other 
programs reported in the literature (Cheah and Martens 2003; Nadar, Begum et 
al. 2003; Tang, Lai et al. 2003) at improving warfarin knowledge in patients with 
low literacy skills.  
Overall therefore, although the new warfarin education program was more 
effective at improving warfarin knowledge in patients with low literacy skills, both 
the new and customary programs equally promoted good therapeutic control and 
encouraged patients with low literacy skills to manage and comply well with their 
warfarin therapy. Interestingly, the high proportion of therapeutic INR scores 
(69.5 percent intervention group and 69.2 percent control group) achieved by the 
patient participants with low literacy skills in this study, were higher than the 30 
percent to 60 percent average reported for the general population in the literature 
(Gray, Garabedian-Ruffalo et al. 1985; Khan, Kamali et al. 2004). A 
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recommendation for future research would be to compare the new warfarin 
education program, inclusive of the new warfarin information booklet (APPENDIX 
12), with other available warfarin education programs and written information, on 
a much larger sample size of patients with low literacy skills. 
 
7.5.3 The effectiveness and readability of the new warfarin information 
booklet (APPENDIX 12) compared to the Boots warfarin information booklet 
(2003)  
Unlike other currently available written warfarin information leaflets and 
booklets (Estrada, Hryniewicz et al. 2000; Tang, Lai et al. 2003), the new 
warfarin information booklet tried to address the needs of ‘high risk’ patient 
population. The ‘Toolkit for producing patient information’ (The United Kingdom 
Department of Health 2002) (APPENDIX 2) and the ‘Guidelines for writing patient 
information’ (Doak, Doak et al. 1996b) (APPENDIX 3) were used to help ensure 
that most patients, including those with low literacy skills, could read and 
understand the information. 
The combined results of the SMOG test (McLauglin 1969)(APPENDIX 4), 
the Fry test (1968) (APPENDIX 5) and the Microsoft Word 2000 computerised 
Flesch-Kincaid test found that the new booklet was written between grade 6 - 8 
reading levels  which complied with the recommendations for reading grade 
levels necessary for patients with low literacy skills (Buchbinder, Hall et al. 2001). 
This new booklet was found to be written at least 2 - 3 grades below the Boots 
warfarin information booklet (2003), as well as several reading grade levels 
below other available written warfarin information (Estrada, Hryniewicz et al. 
2000). It could be argued that because these readability tests are not healthcare 
specific they may not be entirely accurate. In the absence of healthcare specific 
readability tools apart from RAIN (Singh 2002), which is time consuming and 
difficult to use, there were no other tools available for use in the study. The 
development of a healthcare-specific readability instrument would therefore be 
extremely valuable for all health professionals developing written patient 
healthcare information. 
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The patient demographic data collected in the research study indicated 
that 32 percent (16) of the intervention group patients and 19.2 percent (10) of 
the control group patients were educated at or below a grade 6 level. These 
patients with low literacy skills would have been able to read and understand the 
new warfarin information booklet (APPENDIX 12), but would not have been able 
to read and understand the Boots warfarin booklet (2003) or other available 
written warfarin information (Estrada, Hryniewicz et al. 2000; Estrada, Martin-
Hryniewicz et al. 2004).  
These results confirm the need to provide simple, easy-to-read warfarin 
information, which can be read and understood by a wider patient population, 
inclusive of those with low literacy skills. The new warfarin information booklet 
(APPENDIX 12) used in this research study was developed and written with 
these patients in mind. Based on the high evaluation scores for the intervention 
group patients with low literacy skills, the new booklet appears to have 
contributed to the effectiveness of the new program in empowering all patients, 
including those with low literacy skills, to make confident educated decisions 
about their warfarin therapy and management.  
 
7.5.4 The quality and suitability of the new warfarin information booklet 
(APPENDIX 12) compared to the Boots warfarin information booklet (2003). 
 A patient’s understanding and satisfaction with written information is 
influenced by factors such as format, colour, text, print size and the use of 
illustrations (Clark, AbuSabha et al. 1999). In this study the quality and the 
suitability of the two warfarin information booklets were assessed using the 
‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier 
Instructional Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print 
materials’ (Bidford Maine Area Health Education Center 1996)(see Appendices 
6-8).  
The SAM instrument (Doak, Doak et al. 1985) found the new warfarin 
information booklet (APPENDIX 12) to be superior to the Boots booklet (2003) in 
terms of content, literacy, demand, illustrations, layout, learning stimulation and 
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motivation. The BIDS instrument (Bernier 1996) identified that the new booklet 
contained more instructional design and learning principles than did the Boots 
booklet (2003). Also, the ‘Checklist for print materials’ (Bidford Maine Area Health 
Education Center 1996) identified several potential deficiencies within the Boots 
booklet, but none in the new warfarin information booklet. Based on these tests, 
therefore, the new warfarin information booklet could be considered superior in 
terms of quality and suitability to the commonly used Boots warfarin information 
booklet (2003).  
Even though the SAM instrument identified the superiority of the new 
booklet, it also identified some areas in which it could be improved to better meet 
the needs of patients with low literacy skills. The SAM instrument suggested that 
the booklet should limit its scope to essential warfarin information only and to 
develop a subsequent booklet to record blood test results and warfarin doses. 
The SAM instrument also suggested: changing some of the vocabulary (for 
example replace ‘binge eat’ with ‘over eat’); modifying the cover page to 
incorporate people from different cultures; and labelling the illustrations/lists more 
clearly. Unfortunately, the new booklet had already been printed when these 
results were identified which is why they were not incorporated into the booklet. 
These changes, however, have been incorporated in the revised edition of the 
new warfarin information booklet, which will be available in 2005. 
 
7.5.5 The readability, quality and suitability of other written warfarin 
information sought by the patient participants 
The small percentage of intervention group patients (16 percent) who 
sought more warfarin information achieved significantly lower mean scores for 
their ‘Warfarin Knowledge’ questionnaire after three months, than did the 
intervention group patients who did not. On the other hand, the small percentage 
of control group patients (7.7 percent) who sought more information achieved 
slightly higher mean ‘Warfarin Knowledge’ questionnaire scores, than did the 
control patients who did not. Even though these results were based on very small 
numbers of patients within both groups, they suggest that seeking more warfarin 
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information does not always improve warfarin knowledge and understanding. 
One of the reasons for this may be that the information available from these other 
sources is pitched at a level above the comprehension of many patients, as 
identified in the literature (Estrada, Hryniewicz et al. 2000; Estrada, Martin-
Hryniewicz et al. 2004; Wilson, Racine et al. 2003), adding to their warfarin 
knowledge deficits and confusion. An interesting future study would be to 
investigate from where patients, especially those with low literacy skills, seek 
more warfarin information and what impact this information-seeking behaviour 
has on their warfarin knowledge, management and compliance in the long-term. 
 
7.5.6 Non-English speaking background patients and written warfarin 
information 
 Diverse cultural groups interpret written material based on the values, 
rules of behaviour and healthcare practices consistent with their culture 
(Davidhizar and Brownson 1999; Guidry and Fagan 1999). For the purposes of 
this study, both the intervention and control group non-English speaking 
background (NESB) patients were offered a warfarin information booklet written 
in English and an accredited Illawarra Health interpreter to translate the relevant 
warfarin information to them. 
As would be expected (Nadar, Begum et al. 2003), the non-English 
speaking background (NESB) patients achieved lower mean scores for each of 
the evaluation questionnaires, than did the English speaking background patients 
in both groups. Tthe NESB intervention group patients, as compared to the 
NESB control group patients, achieved higher mean scores for the ‘Self-
Management’ and ‘Warfarin Knowledge’ questionnaires. These results suggest 
that compared to the customary warfarin education program, the new warfarin 
education program improved the NESB patients’ knowledge and understanding 
of warfarin and their confidence to manage their therapy. However, the small 
number of NESB patients (9 intervention and 6 control), make it impossible to 
draw meaningful conclusions from these results. A recommendation for future 
research, therefore, would be to compare and contrast the new and customary 
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warfarin education programs on a much larger sample size of NESB patients. 
Also, in the absence of information in the literature, further research needs to be 
done regarding the language and cultural issues pertaining to written warfarin 
information available to patients from non-English speaking backgrounds. 
One obvious limitation of the study was that the written warfarin 
information was only available in English. Unfortunately, restrictions in finances 
and time made it impossible for the information to be translated into the 
appropriate languages during this study. Future studies could evaluate the value 
of translating the new warfarin information booklet into different languages. 
Additionally, the written information needs to be culturally sensitive 
(Wilson, Racine et al. 2003), as does the behaviour of health professionals 
educating patients from non-English speaking backgrounds (Lambert and Minas 
1998; Minas, Lambert et al. 1996; Wilson, Racine et al. 2003). Prior to the study, 
the new warfarin booklet was circulated to Illawarra health service interpreters to 
ensure that it contained culturally sensitive graphics. In future, when the booklet 
is translated into different languages it would be appropriate to include graphics 
and photographs of patients who actually come from the different cultural 
backgrounds. Adherence to culturally-appropriate behaviours should become 
part of the everyday practice of all health professionals dealing with patients from 
diverse cultural communities (Wilson, Racine et al. 2003).  
The researcher/TACT pharmacist providing the new warfarin education 
program had an advantage over the pharmacist providing the customary warfarin 
education program because she comes from a non-English speaking 
background. Even though this could be seen as a limitation of the study it must 
be taken into account that the study area is home to over 100 different 
nationalities, only 10 of which were represented in this research study. Notably, 
the study population did not include either Muslim or indigenous Australian 
patients. These cultures are especially important because Muslim patients often 
change their medication doses and intake time during Ramadan without seeking 
medical advice (Aadil, Houti and Moussamih 2004), and indigenous Australians 
often experience poor therapeutic outcomes based on communication, social and 
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cultural barriers (Morgan, Slade and Morgan 1997; Shannon 1994). In both 
cases, future research could focus on identifying cultural strategies, which could 
be adopted by all health professionals when trying to educate these patients 
about warfarin.  
 
7.5.7 Summary 
 The issues of readability, quality and the suitability of written warfarin 
information were addressed in several ways throughout the research study. 
Several readability tests found the new warfarin information booklet (APPENDIX 
12) to be written in a much simpler, easier-to-read format than the Boots warfarin 
information booklet (2003). Following evaluations with validated instruments, the 
new booklet was also found to be superior to the Boots booklet (2003) in terms of 
quality and suitability for a wider patient population, inclusive of those with low 
literacy skills.  
The high proportion of therapeutic INR scores and the high ‘Warfarin 
Knowledge’ questionnaire scores achieved by the intervention patients with low 
literacy skills, suggests that the new program, including the new warfarin 
education booklet (APPENDIX 12), impacts favourably on warfarin knowledge 
and therapeutic control in patients with low literacy skills. Even though further 
research is needed to confirm this, these promising results imply that all patients 
should receive good quality, simple, easy-to-understand warfarin education 
programs and simple, easy-to-read written warfarin information.  
Other recommendations borne out of the study are that readability tools 
such as SMOG (McLauglin 1969) and Fry Test (Fry 1968)), as well as guidelines 
such as ‘The toolkit for producing patient information’ (The United Kingdom 
Department of Health 2002) and the ‘Guidelines for writing patient information’ 
(Doak, Doak et al. 1996b), should be used when preparing written patient 
information. In doing so, health professionals can ensure that information is 
available in a simple, easy-to-read format, which will appeal to a wider patient 
population. Prior to the distribution of the written patient information its quality 
and suitability should also be assessed by using instruments such as the 
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‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier 
Instructional Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print 
materials’ (Bidford Maine Area Health Education Center 1996) (Appendices 6-8).  
 
 
7.6 THE CONTINUITY OF CARE BETWEEN HOSPITAL AND COMMUNITY 
SETTINGS 
Poor continuity of care between hospital and community settings has been 
reported to negatively impact upon poor therapeutic outcomes and adverse drug 
events (Australian Council for Safety and Quality in Health Care 2002; Balla and 
Jamieson 1994). To improve the continuity of care between hospital (ambulatory 
care in this instance) and community settings, the new warfarin education 
program followed the Australian Pharmaceutical Advisory Council (APAC) 
‘National guidelines to achieve the continuum of quality use of medicines 
between hospital and community’ (1998). The strategies used to incorporate 
these guidelines have already been described in the methodology chapter of this 
thesis and will not be discussed here. It is important to note, however, that these 
guidelines, which can be seen to reflect best practice were also included into the 
customary warfarin education program during the course of the study. This may 
have impacted upon some of the results and made them less significantly 
different than expected. 
The patient participants in the research study were referred to The 
Ambulatory Care Team (TACT) from the following three sources: emergency 
departments, hospital wards and general practitioners. The emergency 
department and hospital ward referrals outnumbered the general practitioner 
referrals at a ratio of 4:1. This highlights the need to prioritise the continuity of 
care between hospital and community settings to ensure that general 
practitioners know how to optimally continue monitoring their patients’ warfarin 
once discharged from the care of TACT.  
Many of the interventions incorporated to improve the continuity of care 
were similar to those used to improve warfarin compliance. These interventions 
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included: encouraging carers and/or family members to be present during the 
initial education sessions; ensuring that an interpreter was available for patients 
from non-English speaking backgrounds; undertaking medication reviews; and 
encouraging the patients to be active participants in their warfarin management. 
 It is difficult, therefore, to accurately assess the impact that the continuity 
of care guidelines had on the therapeutic outcomes of the patient participants in 
this study. However, the high average warfarin knowledge scores (≥73 percent 
initially and ≥65.5 percent after three months), the high proportion of therapeutic 
INR scores (69 percent) and the low incidence of minor potential warfarin-related 
adverse drug events (4.9 percent) achieved by all patient participants in this 
study leaves little doubt about the benefits of adhering to the APAC guidelines. 
These results support the need to always incorporate APAC guidelines into 
ambulatory care services such as TACT because the timely transfer of 
information to patients, carers and/or their health professionals working in the 
community (Thornton, Simon and Mathew 1999) ultimately contributes toward 
optimising therapeutic outcomes and minimising adverse drug events.  
A recommendation for future research would be to evaluate the direct 
impact of the APAC guidelines on ambulatory care services, assessing whether 
or not similar benefits and/or disadvantages are achieved. Some interesting 
aspects to focus on in these future studies would include: assessing the general 
practitioners preferred method of receiving patient information (email, fax, letter); 
their perceptions about the timeliness of the information; as well as the quality of 
the information that they received about their patient.  
In summary, both programs appear to have successfully incorporated the 
APAC guidelines to improve the continuity of care between hospital (ambulatory 
care) and community settings. Even though further research is needed, 
preliminary data from this study indicate that when ambulatory care services like 
TACT adhere to these guidelines there is an improvement in patients achieving 




7.7 PATIENT FOLLOW-UP 
 
7.7.1 Introduction 
Patient follow-up was used in the new warfarin education program 
because it has been identified as a key element of an effective patient education 
program (Dudas, Bookwalter et al. 2001; Haynes, McDonald et al. 2002a). The 
intervention patients received a follow-up telephone call one week after the initial 
warfarin education session. During this initial telephone follow-up they had their 
warfarin information reinforced and they were also encouraged to ask questions 
and make comments about their warfarin therapy. All the participating patients 
(intervention and control) then received telephone follow-up calls after three 
months, and, as initially informed, were asked to complete the evaluation 
questionnaires. During the three-month follow-up telephone calls, all the patient 
participants were also encouraged to ask questions and make any comments 
about their warfarin therapy and education programs. 
 
7.7.2 Impact of patient follow-up on warfarin management and compliance  
As already discussed, patients were possibly more diligent with their 
warfarin management and compliance because they were being monitored in the 
study. Evidence in the literature also supports the positive impact of patient 
follow-up on medication management, compliance and therapeutic control 
(Dudas, Bookwalter et al. 2001; Jackson, Peterson et al. 2004). It would be 
reasonable to conclude, therefore, that the telephone follow-up contributed to all 
patient participants achieving high mean scores for their ‘Self-Management’ and 
‘Medication-Taking-Measures’ questionnaires, as well as the high proportion of 
therapeutic INR scores during the three-month study period. An interesting 
investigation in the future would be to examine the impact that long-term follow-
up (at least 12-24 months) has on patients’ warfarin knowledge and 




7.7.3 Impact of patient follow-up on warfarin-related adverse drug events 
Reports in the literature identify that follow-up after hospital discharge 
significantly reduces the incidence of adverse drug events requiring 
hospitalisation (Dudas, Bookwalter et al. 2001; Jackson, Peterson et al. 2004). 
Therefore, telephone follow-up in this study has almost certainly contributed to 
the very low incidence of minor warfarin-related adverse drug events, none of 
which required hospitalisation. Only 4.9 percent (5) of the patient participants in 
the study experienced minor possible warfarin-related bleeds, as compared with 
the 13.7 percent reported in the literature for other outpatient anticoagulation 
clinics (Wilt, Gums, Amhed and Moore 1995). These results promote the benefits 
of incorporating patient follow-up into a warfarin education program. To identify 
the benefits of patient follow-up alone, future studies would need to identify the 
long-term effects on warfarin-related adverse drug events in patients receiving 
regular follow-up, compared to those receiving no follow-up.  
 
7.7.4 Impact of patient follow-up on warfarin knowledge 
It is notable that even though the intervention group patients received 
follow-up telephone calls one week after their initial warfarin education session, 
their warfarin knowledge deteriorated at a similar rate as that of the control group 
patients during the study. This deterioration in warfarin knowledge could have 
serious implications for patients diagnosed with medical conditions requiring 
potentially lifelong warfarin therapy. Such diagnoses include: atrial fibrillation; 
transient ischaemic attacks; cerebrovascular accidents; and mechanical cardiac 
valves, which were found to exist in 41.2 percent (42) of the patient participants. 
More of a concern is that many of these patients were elderly, aged 65 years and 
over (62.8 percent), and therefore at a potentially greater risk of experiencing 
poor therapeutic outcomes and warfarin-related adverse events (Cheah and 
Martens 2003; Tang, Lai et al. 2003; Taylor, Ramsay et al. 1994; Wilson, Racine 
et al. 2003). A recommendation based on these results is to have regular patient 
follow-up, especially for elderly patients, reassuring them and reinforcing warfarin 
information on a three monthly basis.  
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Based on the three-month follow-up period of this study, it is difficult to 
predict the long-term effects of the warfarin knowledge deficits. Further studies, 
especially on elderly patients, need to investigate whether or not three monthly 
follow-up, reinforcement and reassurance improves warfarin knowledge, 
management, compliance and therapeutic outcomes over time.  
 
7.7.5 Summary of the impact of patient follow-up 
Patient follow-up was believed to contribute to the patient participants’ 
improved warfarin knowledge, management and compliance, as well as their 
good overall therapeutic control and low incidence of warfarin-related bleeds. No 
significant differences were found between the new and the customary warfarin 
education programs, probably because they both incorporated many similar 
strategies and interventions to target follow-up as a key element. 
Based on the significant deterioration of all patients’ warfarin knowledge 
after three months, a quarterly follow-up scheme is recommended. The long-term 
consequences of patient follow-up on warfarin-related therapeutic outcomes and 
adverse drug events, are difficult to predict from the results of this short-term 
study, so further research is needed.  
 
 
7.8 OTHER INTERESTING RESULTS FOUND IN THE RESEARCH STUDY 
 
7.8.1 Introduction 
 Other interesting results identified in this study will now be discussed. 
Firstly, discussions will focus on the impact of prior warfarin knowledge and 
general practice visits. Secondly, the effects of the new and customary warfarin 
education programs on adverse drug events, hospitalisation and emergency 
department visits will be compared. Lastly, discussion will turn to the impact of 
written information pertaining to drug-to-drug interactions with warfarin, especially 
with regard to complementary medicines.  
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7.8.2 Prior warfarin knowledge 
The research data indicated that the 39.2 percent (40) of participating 
patients (30 percent intervention and 48.1 percent control) who claimed to have 
prior warfarin knowledge, did not achieve higher mean scores for their ‘Self-
Management’, ‘Medication-Taking-Measures’ or ‘Warfarin Knowledge’ 
questionnaires, than the participating patients with no prior knowledge. In other 
words, patients in both groups who claimed to have prior warfarin knowledge did 
not appear to be more confident with their warfarin management and compliance, 
nor did they have a better warfarin knowledge and understanding, than did the 
patients with no prior warfarin knowledge.  
These results have important implications for warfarin education because 
many health professionals perform a quick overview of warfarin information for 
patients whom they believe to have prior warfarin knowledge (Haines 1998). It is 
therefore important for health professionals not to take for granted information 
which has been previously communicated to patients because, despite their best 
efforts, they can and do forget (Ansell, Buttaro et al. 1997). The results of this 
study imply that all patients receiving warfarin therapy - for the first time or not - 
should ideally receive a complete and thorough warfarin education program with 
continuous follow-up, reinforcement and reassurance to help promote good 
warfarin knowledge, management and compliance.  
 
7.8.3 General practitioner visits 
Following discharge from The Ambulatory Care Team (TACT), patient 
participants were cared for by their general practitioners. The data reveal that on 
average the patients in both groups visited their general practitioners 
approximately seven times each, during the three-month follow-up period. The 
intervention group patients who visited their general practitioners more frequently 
were more confident about their warfarin management and had a better warfarin 
knowledge, than did intervention group patients who visited their general 
practitioners less frequently. Conversely, control group patients who visited their 
general practitioners more frequently were less confident about their warfarin 
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management and had poorer warfarin knowledge, than did control group patients 
who visited their general practitioners less frequently. A possible explanation for 
these results given that both groups achieved similar overall therapeutic INR 
scores, is that the control group patients as opposed to the intervention group 
patients were more inclined to let their general practitioners manage their 
warfarin therapy for them. Similar to the results found by Dantas et al (2004), it 
appears that even though the control group patients were satisfied with the 
warfarin information they received and experienced few adverse drug events, 
they were more inclined to accept directives rather than be collaborative with 
their general practitioners. More research is needed to investigate this further.  
 
7.8.4 Warfarin-related adverse drug events, hospitalisation and emergency 
department visits 
 Eighteen percent (9) of the intervention group patients and 21.2 percent 
(11) of the control group patients were hospitalised during the three-month 
follow-up period. Importantly, none of these hospitalisations were due to possible 
warfarin-related adverse drug events. Instead, 5.9 percent (6) in total for both 
groups were due to exacerbations of the disease for which the warfarin was 
initially prescribed. 
Sixteen percent (8) of the intervention group patients and 11.5 percent (6) 
of the control group patients visited the emergency departments during the three-
month follow-up period. In total, only 3.92 percent (4) of these emergency 
department visits were associated with minor bleeds potentially caused by 
warfarin therapy. These results compare well with reports in the literature 
claiming that in anticoagulation clinics, 2.8 percent of patients experience major 
bleeds and 18.3 percent of patients experience minor bleeds, and that in general 
practice settings, 10.9 percent of patients experience major bleeds and 17.6 
percent of patients experience minor bleeds (Ansell, Buttaro et al. 1997). It could 
be argued that as this study was only conducted over a short period of time these 
results are not a true reflection of what may occur in the long-term. Given that 
most warfarin-related adverse events occur within the first few months of therapy 
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(Jackson, Peterson et al. 2004; Levine, Raskob, Landefeld and Kearon 2001; 
White, Beyth, Zhou and Romano 1999), initial indications of this study show that 
both the new and customary education programs are helping to reduce the 
number of such occurrences.  
These results have important implications because not only have both 
programs reduced the incidence of possible warfarin-related adverse events, 
they have also reduced hospitalisation costs. With recent increases in warfarin-
related hospitalisations (AIHW 2002; AIHW 2003), it would be fair to assume that 
current hospitalisation costs are well in excess of the 1992 estimation of $100 
million per annum (Rigby, Clark et al. 1999). Further studies are therefore 
required to analyse the potential reductions in warfarin-related adverse drug 
events and healthcare costs associated with using the new warfarin education 
program. 
The 4.9 percent (5) incidence of minor warfarin-related bleeds in this study 
is much lower than the 18.3 percent average reported in the literature for 
anticoagulation clinics (Ansell, Buttaro et al. 1997). These results and the 
absence of any major bleeds associated with warfarin therapy in this study may 
be a reflection of the small sample size, however they are noteworthy because 
they suggest that both programs potentially reduce the incidence of warfarin 
related adverse drug events. 
 
7.8.5 Warfarin information on possible drug-to-drug interactions (including 
complementary medicines) 
The increasing use of complementary medicines (Harris and Rees 2000; 
Shenfield, Atkin and Kristoffersen 1997; Welch 2001) potentially increases 
possible drug-to-complementary medicine interactions with warfarin (Myers 
2002). This is why participating patients were educated and given the ‘Patient 
information on potential drug-to-drug warfarin interactions sheet’ (APPENDIX 
27). This information sheet also contains information about interactions between 
warfarin and complementary medicines. 
 219 
Upon receipt of the drug-to-drug interaction sheet (APPENDIX 27), 10 
percent (10) of participating patients who had taken complementary medicines 
without their general practitioners’ knowledge either ceased to do so or continued 
after consultation with their general practitioners. Without this information, 
patients would have taken their complementary medicines without their general 
practitioners’ knowledge and potentially caused serious warfarin-to-
complementary medicines interactions. 
An important recommendation for future practice would be to ensure that 
all patients prescribed warfarin, as well as their health professionals, should be 
familiarised with the potential interactions between complementary medicines 
and warfarin. This could be done by ensuring that all patients and their health 
professionals were given relevant education and information such as the ‘Patient 
information on potential drug-to-drug warfarin interactions sheet’ (APPENDIX 
27).  
Current research is identifying an increasing number of potential 
interactions between warfarin and complementary medicines (Myers 2002). 
Future research needs to identify how much health professionals and patients 
need to know about these interactions to achieve optimal warfarin-related 
therapeutic outcomes and minimal adverse drug events.  
 
7.8.6 Summary 
 The research study identified that patients who had prior warfarin 
knowledge did not necessarily have better warfarin knowledge, management, 
compliance and therapeutic outcomes than did those with no prior warfarin 
knowledge. Increased general practitioner visits did not always lead to improved 
warfarin knowledge and management, which confirms the need for regular 
patient follow-up, reinforcement and reassurance. 
Many of the strategies and interventions incorporated in both warfarin 
education programs in this study have successfully contributed to the reduction in 
the incidence of warfarin-related adverse events, as well as in the number of 
emergency department and hospital visits. With the current increase in the use of 
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complementary medicines (Harris and Rees 2000; Shenfield, Atkin et al. 1997; 
Welch 2001), health professionals and patients need to be made fully aware of 
the potential warfarin-to-complementary medicines interactions to prevent further 
possible warfarin-related adverse drug events. The information sheet used in this 
study, ‘Patient information on potential drug-to-drug warfarin interactions sheet’ 
(APPENDIX 27) would be a good starting point. Importantly, each of these 
findings provides valuable information to help reduce the large and unresolved 
problem of warfarin-related adverse drug events (Halstead, Roughead et al. 
1999). 
 
7.9 RECOMMENDATIONS OF THE STUDY 
 
Several recommendations to improve current practice in warfarin education 
arose from the research study. These recommendations include the provision of 
the following to all patients prescribed warfarin: 
 the new warfarin education program should be considered suitable as 
a possible best practice model for effective home-based warfarin 
education program.’ 
 a good quality, simple, easy-to-read warfarin information booklet 
(APPENDIX 12).  
 a warfarin counselling checklist to achieve specific objectives 
(APPENDIX 13). 
 a validated ‘Warfarin Knowledge’ questionnaire to evaluate patients’ 
warfarin knowledge and understanding based on APPENDIX 19.  
 a written information sheet about potential drug-to-drug interactions 
(including warfarin-to-complementary medicines interactions) such as 
the ‘Patient information on potential drug-to-drug warfarin interactions’ 
(APPENDIX 27).  
 regular three-monthly follow-up sessions to reinforce and reassure 
patients about their warfarin information 
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 best practice guidelines for the number of INR blood tests which are 
required to achieve optimal therapeutic control. 
 a best practice model for home-based warfarin self-management 
programs which incorporates the new warfarin education program and 
a structured self-management (self-monitoring) program. 
 
 
The following are recommendations for all health professionals developing and 
producing patient medication education programs: 
 the regular use of readability tests such as SMOG (McLauglin 1969) 
and the Fry Test (Fry 1968) to ensure that patient information is written 
below a grade 8 level or preferably a grade 6 level. 
 the need to develop an easy-to-use healthcare-specific readability 
instrument. 
 the regular use of the ‘Toolkit for producing patient information’ (The 
United Kingdom Department of Health 2002) and the ‘Guidelines for 
writing patient information’ (Doak, Doak et al. 1996b) when developing 
new patient information to ensure that it is written in a simple, easy-to-
read format. 
 evaluation of the quality and suitability of written patient medication 
information by using instruments such as the ‘Suitability Assessment 
Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier Instructional 
Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print 
materials’ (Bidford Maine Area Health Education Center 1996) 
(Appendices 6-8).  
 target the needs of the ‘high risk’ patient population.  
 
These recommendations, in combination with the interventions and strategies 
used in the study to target the five key elements of an effective medication 
education program, should be used to improve current medication education 
practices, including warfarin education programs. The five key elements which 
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need to be improved include: patients/health professional communication and 
partnerships; warfarin compliance; simple, easy-to-read warfarin information; 




7.10 LIMITATIONS OF THE STUDY 
 
There were a number of limitations in the study, many of which have 
already been discussed. The following is a brief overview of these limitations. 
One of the major limitations of the study was that the researcher/TACT 
pharmacist developed both the new and customary warfarin education programs, 
delivered to Illawarra Health’s The Ambulatory Care Team (TACT) patients. This, 
together with the fact that many of the strategies and interventions developed for 
the new warfarin education program were also absorbed into the customary 
warfarin education program during the course of the study, may have affected 
the results and made them less significantly different than expected. In hindsight, 
it would have been better to compare and contrast the new program with another 
home-based warfarin education program available within Australia, because the 
results of this study may have been a better indication of the benefits and/or 
deficits of the new program. 
Another limitation of the study was that it was conducted over a three-
month period and many long-term benefits could not be analysed. Regardless, 
long-term analysis would not have been possible in this study because many of 
the patient participants were diagnosed with a deep venous thrombosis (41.2 
percent). These patients would only have been prescribed warfarin therapy for 
three months, making them ineligible for studies conducted over a longer period 
of time. Future, longer studies would need to be conducted on patients 
diagnosed with an illness such as atrial fibrillation, potentially requiring lifelong 
warfarin therapy.  
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The inclusion of patient participants from the general population could also 
be described as a limitation of this study. As a result, many of the benefits of the 
new warfarin program could not be assessed for their direct impact on the ‘high 
risk’ group – that is, on patients who were elderly, had low literacy skills and/or 
came from non-English speaking backgrounds. It would therefore be useful to 
conduct further studies exclusively on ‘high risk’ patients.  
The use of readability tools such as the SMOG formula (McLauglin 1969), 
the Fry readability formula (Fry 1968) and the Microsoft Word 2000 computerised 
Flesch-Kincaid test, which are not healthcare specific, may also be viewed as a 
limitation of the study. However, in the absence of a simple, easy-to-use 
healthcare specific readability tool there was no alternative in this instance. The 
development of such a tool is highly recommended.  
For non-English speaking background patients, a limitation in the study 
was that the written warfarin information was only available in English. A 
recommendation for future studies is to supply each non-English speaking 
background patient with a booklet translated into their own native language. 
 A final imitation of the study was requiring all patient participants to 
answer follow-up questionnaires when, in some cases, carers and family 
members managed their warfarin therapy for them. Future studies should 
therefore ensure that the person responsible for managing the warfarin therapy 




If current educational practices continue, recent increases in warfarin 
prescribing will almost certainly result in an increased incidence of poor warfarin-
related therapeutic outcomes and adverse drug events (Gurwitz, Field et al. 
2003; Halstead, Roughead et al. 1999). The patients at ‘high risk’ of experiencing 
these poor therapeutic outcomes and adverse events include the elderly and 
those with low literacy skills (Estrada, Martin-Hryniewicz et al. 2004; Tang, Lai et 
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al. 2003), as well as non-English speaking background patients (Lambert and 
Wynne 2003; Nadar, Begum et al. 2003).  
The basis of this thesis is good patient warfarin education, which is the key to 
improving warfarin knowledge, management and compliance (Haines 1998; 
Kagansky, Knobler et al. 2004). These in turn will help to optimise warfarin-
related therapeutic outcomes and minimise adverse drug events by empowering 
patients to make educated decisions, as reported in the literature (Australian 
Council for Safety and Quality in Health Care 2002; Bhasale, Miller et al. 1998). 
The research study focused on developing and evaluating a new warfarin 
education program to improve warfarin knowledge, management and compliance 
in a wider patient population, inclusive of the ‘high risk’ group.  
The new warfarin education program was founded on a conceptual 
framework which targeted five key elements of an effective patient education 
program. These elements were: health professional/patient communication and 
partnerships; warfarin compliance; simple, easy-to-read written warfarin 
information; improved continuity of care between hospital and community 
settings; and patient follow-up. Many similar strategies and interventions 
targeting these key elements were incorporated into both the new and the 
customary warfarin education programs during the course of the study and 
almost certainly affected the results by making them less significantly different 
than expected.  
Overall, however, the trend in the results suggested that the new warfarin 
education program was more effective than the customary warfarin education 
program in educating patients, including ‘high risk’ patients, about their warfarin 
therapy. In other words, patients receiving the new warfarin education program 
had a better warfarin knowledge and understanding, and were more confident 
about their warfarin management and compliance at home. 
Both the new and the customary warfarin education programs used in this 
study appeared to be more effective than other available warfarin education 
programs, achieving better warfarin knowledge scores and therapeutic 
outcomes, with fewer warfarin-related adverse drug events and healthcare visits. 
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It could be argued, therefore, that the interventions and strategies incorporated in 
both programs, which targeted the five key elements in the conceptual 
framework, successfully produced a new more effective warfarin education 
program.  
Throughout the research study, interventions and strategies targeting the five 
key elements of an effective education program were applied to the home-based 
ambulatory care service TACT. There is no reason why this new home-based 
warfarin education program could not be applied to other hospital and 
community-based warfarin education programs, especially since the key to 
effective anticoagulant management is good patient warfarin education (Haines 
1998).  
Based on the success of the results in this study, the researcher contends 
that by targeting the five key elements of an effective warfarin education 
program, a wider patient population, inclusive of those from the ‘high risk’ group, 
will be effectively educated about their warfarin therapy. This in turn will help 
them to achieve optimum warfarin-related therapeutic outcomes and minimum 
adverse drug events.  
One of the major benefits of this study is that the conceptual framework, with 
its five key elements, provides a blueprint for the development of other effective 
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APPENDIX 1 
FLESCH Reading Ease Scale (Flesch 1948) 
Step 1. Count the words. 
Count the words in your piece of writing. Count as single words contractions, 
hyphenated words, abbreviations, figures, symbols and their combinations. 
Step 2. Count the syllables. 
Count the syllables in your piece of writing. Count the syllables in words as they 
are pronounced. Count abbreviations, figures, symbols and their combinations as 
one-syllable words. If a word has two accepted pronunciations, use the one with 
fewer syllables. If in doubt, check a dictionary. 
Step 3. Count the sentences. 
Count the sentences in your piece of writing. Count as a sentence each full unit 
of speech marked off by a period, colon, semicolon, dash, question mark or 
exclamation point. Disregard paragraph breaks, colons, semicolons, dashes or 
initial capitals within a sentence.  
Step 4. Figure the average number of syllables per word. 
Divide the number of syllables by the number of words. 
Step 5. Figure the average number of words per sentence. 
Divide the number of words by the number of sentences. 
Step 6. Find your readability score. 
Find the average sentence length and word length of your piece of writing on the 
chart (below). Take a straightedge or ruler and connect the two figures. The 










You can also use this formula:  
Multiply the average sentence length by 1.015. Multiply the average word length 
by 84.6. Add the two numbers. Subtract this sum from 206.835. The balance is 
your readability score. 
The scale shows scores from 0 to 100. Zero means practically unreadable and 
100 means extremely easy. The minimum score for Plain English is 60, or about 
20 words per sentence and 11/2 syllables per word. Conversational English for 
consumers should score at least 80, or about 15 words per sentence and 1 1/2 
syllables per word. 
Score School Level 
90 to 100 5th grade 
80 to 90 6th grade 
70 to 80 7th grade 
60 to 70 8th and 9th grade 
50 to 60 10th to 12th grade (high school) 
30 to 50 college 
















Toolkit for Producing Patient Information(The United Kingdom 
Department of Health 2002) 
 
To make the text more inviting to read use the following; 
 Short sentences-in general no more than 15 to 20 words long 
 Lower case letters where possible as they are easier to read. Exceptions 
to this are proper names and the first letter in a sentence. 
 Present and active tenses where possible. 
 A question and answer format is helpful to divide up the test. 
 Bulleted or numbered points to divide up complicated information. 
 Small blocks of text. Do not use long paragraphs divide them using 
headings and new paragraphs. 
 White space makes the information easier to read. 
 Large bold font emphasises text. Avoid upper letters, italics and 
underlining as they make the text more difficult to read. 
 Numbers from one to nine are easy to read if they are written in words, 
and numbers from 10 can be represented as numbers. 
 A font size of no less than 12 point. 
 Diagrams and pictures are very effective and should be in line with 
communication principles. Where appropriate, use them to illustrate the 
text, remember to label them and do not print over them. You should not 
use clipart as it does not add to the reputation of the professional 
organisation. 
 
You should apply these principles to all documents, not just those for people with 
sight difficulties. A large number of patients using the NHS will be over 40, and 
clear, legible print with the lines not too close together will make documents 
easier to read. 
 Font size: 12 point (minimum) to 14 point but if you are writing information 
for the elderly or people with sight difficulties always use 14 point or larger. 
 Use a medium weight typeface for example Frutiger Roman. 
 Contrast: use a light background with dark print. 
 It is acceptable to use a dark background with white print (reversed out) 
for headings but not for large sections of the text. 
 Use a sans serif font-Frutiger. 
 Justify the text to the left only. 
 Use one or two colours. 




Guidelines for writing patient information (Doak, Doak and Root 1996)  
1. Write the way you talk; use active voice. 
2. Use common words, and, on average, use short sentences. 
3. Give examples to explain hard words. 
4. Include interaction and reviews. 
 
Guidelines for typography and layout 
a) Type style and size 
 Use serif type and lowercase lettering, except where grammatically 
necessary to use capital letters. 
 Use 12-point type or larger. 
 Do not use large or stylised initial letters. 
 In general, do not use reverse print, that is, white on black. 
b) Line length 
 Try to limit line length to 30 to 50 characters and spaces. 
 Make the left edge of lines rectified. 
 Leave right ends of lines ragged. 
c) Layout of text on the page  
 Leave some white spaces on the page to avoid a look of solid text. 
 Use headers (“road signs”) underlined or in bold print to introduce each 
new topic and to break up the appearance of a page of solid text. 
 Use an eye-catcher, a box or larger font or an indent, to draw readers’ 







SMOG Formula (McLauglin 1969) 
1. Count 10 consecutive sentences near the beginning of the text to be 
assessed, 10 in the middle and 10 near the end. Count as a sentence any string 
of words ending with a period, question mark or exclamation point. 
2. In the 30 selected sentences count every word of three or more 
syllables. Any string of letters or numerals beginning and ending with a space or 
punctuation mark should be counted if you can distinguish at least three syllables 
when you read it aloud in context. If a polysyllabic word is repeated, count each 
repetition. 
3. Estimate the square root of the number of polysyllabic words counted. 
This is done by taking the square root of the nearest perfect square for example 
95 is 100 which yields a square root of 10. If the count lies roughly between two 
perfect squares, choose the lower number. For instance, if the count is 110, take 
the square root of 100 rather than of 121. 
4. Add 3 to the approximate square root. This gives the SMOG GRADE, 
which is the reading grade that a person must have reached if he is to 

















Fry Readability Formula (Fry 1968) 
 
1. Select three one-hundred-word passages from near the beginning, middle 
and end of the book. Skip all proper nouns. 
2. Count the total number of sentences in each hundred-word passage 
(estimating to the nearest tenth of a sentence). Average these three 
numbers. 
3. Count the total number of syllables in each hundred-word sample. There 
is a syllable for each vowel sound; for example car (1), blackbird (2), 
continental (4). Don’t be fooled by word size; for example polio (3), 
through (1). Endings such as –y, -ed, -el, or –le usually make a syllable, 
for example: ready (2), bottle (2). I find it convenient to count every 
syllable over one in each word and add 100. Average the total number of 
syllables for the three samples. 
4. Plot on the graph the average number of sentences per hundred words 
and the average number of syllables per hundred words. Most plot points 
fall near the heavy curved line. Perpendicular lines mark off approximate 
grade level areas. 
 
 





SAM (The Suitability Assessment Materials) (Doak, Doak and Root 1985) 
SAM Scoring Sheet 
2 points for superior rating 
1 point for adequate rating 
0 points for non-suitable rating 
N/A if the factor does not apply to this material. 
FACTOR TO BE RATED   SCORE  COMMENTS  
  
1.CONTENT  
(a) Purpose is evident         
 (b) Content about behaviours        
 (c) Scope is limited         
 (d) Summary or review included        
  
2. LITERACY DEMAND  
(a) Reading grade level         
 (b) Writing style, active voice        
 (c) Vocabulary uses common words       
 (d) Context is given first         
 (e) Learning aids via “road signs”        
 
3.GRAPHICS 
(a) Cover graphic shows purpose       
 (b) Type of graphics         
 (c) Relevance of illustrations        
 (d) Lists, tables, etc, explained        
 (e) Captions used for graphics        
  
4.LAYOUT AND TYPOGRAPHY       
 (a) Layout factors          
(b) Typography          
 (b) Subheads (“chunking”) used        
  
5. LEARNING, STIMULATION, MOTIVATION      
 (a) Interaction used         
 (b) Behaviour are modelled and specific        
 (c) Motivation and self-efficacy          
 
6. CULTURAL APPROPRIATENESS       
 (a) Match in logic, language, experience       
 (b) Cultural image and examples         
. 
Total SAM Score____________ 
Total possible score: ________ 




APPENDIX 7  
Bernier Instructional Design Scale (BIDS) (Bernier 1996) 
 
The rating scale: 
0= Not met 
1= Partially met 
2= Met 
NA= Not applicable 
Principle Scale 0 1 2 NA 
1.There is sufficient contrast between the ink and 
paper to make reading easy. 
    
2.The font or print size can be read easily by the 
target audience. 
    
3.The type style is easy to read.     
4.Drawings/illustrations are recognizable to the target 
group with or without explanatory text. 
    
5.Drawings/illustrations are labeled clearly.     
6.Drawings/illustrations represent racial and ethnic 
groups appropriate to the target audience. 
    
7.Titles and subtitles are clear and informative     
8.The vocabulary of the PEM is one that reflects 
words commonly used by the target group. 
    
9.Necessary health terms are defined.     
10.Terms are used in a consistent manner throughout 
the PEM. 
    
11.The writing style is one that will actively engage 
the reader and stimulate active participation. 
    
12.The active voice is used (e.g. “Many persons with 
colostomies find it beneficial to be a member of an 
ostomy support group” is better than the passive voice 
“Many persons with colostomies have found that they 
benefited from an ostomy support group”). 
    
13.The use of double (or multiple negatives) is 
avoided (e.g. This sentence is confusing: There is no 
reason why a person with diabetes should not 
exercise when they are not ill). 
    
14.The purpose of the PEM is made clear to the 
target group. 
    
15.The relevance of the educational content to the 
target group is clearly stated. 
    
16.The learning objectives that are stated or implied 
and the educational content of the PEM relate to one 
another. 
    
17.The learning objectives that are stated or implied 
relate to the intended learning outcome that is stated 
or implied in the PEM. 
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18.Only the most essential information about the topic 
is presented, using not more than 3-4 main points. 
    
19.The content is accurate.     
20.The content is presented in concrete terms rather 
than abstract ideas and concepts. 
    
21.The content is written in a style that is ‘patient-
centered’ that is, in the perspective of the patient 
foremost. 
    
22.The content is presented in a way that relates and 
integrates the new information to what is already 
known and understood by the target group. 
    
23.Examples are used to bridge the gap between 
what the target group already knows and the content 
that is to be taught and learned. 
    
24.The examples that are used contain the central 
characteristics of the ideas and concepts under 
discussion. 
    
25.The content is presented in a manner, which is 
respectful of the customs and traditions of the target 
group. 
    
26.The information load of the educational material is 
appropriate to the target group (The more unfamiliar 
the information, the smaller the amount to be 
presented at the time). 
    
27.The content focuses on what the target group 
should do as well as know. 
    
28.The main ideas of the PEM are divided into 
meaningful units of content. 
    
29.The educational material moves from simple to 
more complex content in a manner that is organised 
and logical. 
    
30. The educational content is current.     
31.Specific, precise instructions are given if the target 
group is expected to carry out some health or self-
care activity. 
    
32.Important ideas and points of content are repeated 
as reinforcement throughout the PEM. 
    
33.Sentences are kept in logical order and present a 
coherent structure for the information being conveyed 
in the PEM. 
    
34.Summaries/synopses of the educational content 
being delivered are included throughout the PEM. 
    
35.The PEM is written at a readability level that is 
appropriate to the target group (Materials intended for 
the general public should be written at the 6th – 8th 
grade level). 




APPENDIX 8  
 
Checklist For Print Materials (Bidford Maine Area Health Education 
Center 1996) 
 
Title of Material:_____________________________________________ 
 
Directions: Place a check next to each item that meets the described attribute. 
 
ORGANISATION 
1ٱ  . The cover is attractive. It indicates the core content and intended audience. 
2ٱ  . Desired behaviour changes are stressed. ‘Need to know’ information is 
 stressed. 
3ٱ  . Not more than three or four main points are presented. 
4ٱ  . Headers and summaries are used to show organization and provide 
 message repetition. 
5ٱ  . A summary that stresses what to do is included. 
 
WRITING STYLE 
6ٱ  . The writing is in conversational style, active voice. 
7ٱ  . There is little or no technical jargon. 
8ٱ  . Text is vivid and interesting. Tone is friendly. 
 
APPEARANCE 
9ٱ  . Pages or sections appear uncluttered. Ample white spaces. 
10ٱ  . Lowercase letters used (capitals used only when grammatically needed). 
11ٱ  . There is a high degree of contrast between the print and the paper. 
12ٱ  . Print size is at least 12 point, serif type, and no stylized letters. 
13ٱ  . Illustrations are simple - preferably line drawings. 
14ٱ  . Illustrations serve to amplify the text. 
 
APPEAL 
15ٱ  . The material is culturally, gender and age appropriate. 
16ٱ  . The material closely matches the logic, language, and experience of the 
 intended audience. 







Guidelines on the continuum of care of quality use of medicines between 
hospital and community (Australian Pharmaceutical Advisory Council 
1998) 
 
Principle 1:  It is the responsibility of the admitting institution to ensure 
the development and coordination of a medication discharge plan for each 
patient. The person responsible for coordinating the development, 
implementation, and monitoring of the medication discharge plan, including 
medication supply and medication information, should be identified as soon as 
practicable after admission. 
Principle 2:  Hospital staff should obtain an accurate medication history, 
including prescription and over-the-counter medicines and other therapies such 
as herbal products, at the time of admission. 
Principle 3:  Hospital staff should evaluate the current medication at the 
time of admission, in consultation with the patient’s general practitioner, with a 
view to; 
-identifying the appropriateness and effectiveness of current medication  
  and rationalising current medications if appropriate,   
 -paying particular attention to any problems associated with current  drug  
  therapy, including any possible relationship with the current medical 
  condition, and   
 -documenting allergies and any previous adverse drug reactions. 
Principle 4:   During the hospital stay, treatment plans relating to the 
probable medication management during the stay and where applicable at 
discharge should be developed in consultation with the patient and/or carer. 
Hospital staff should negotiate with the patient issues relating to treatment and 
the development of a discharge plan, and these discussions should be 
documented in the patient’s notes. This plan should form part of the overall care 
plan or critical pathway. 
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-The use of interpreters may be required to ensure good communication 
 with people from non-English speaking backgrounds. 
-To enable the discharge process to be successful, there needs to be 
 effective communication and coordination between all relevant 
 parties in the hospital environment. 
-Where appropriate, community health providers, especially the patient’s 
 general practitioner, should be consulted. 
-Carers should also be consulted where appropriate. 
Principle 5:  Prior to discharge, pre-discharge medication review and 
dispensing of adequate medication should take place in a planned and timely 
fashion. Adequate medication means sufficient medication to carry the patient 
through to the next arranged review (by their general practitioner, outpatient 
clinic, or some other arrangement), or to complete the course of treatment.  
If patients are discharged with inadequate supplies of medication, this can 
compromise quality of care for the patient. Supply of the medication from the 
hospital facility must be adequate to ensure continuity of medication is not 
interrupted by the inability to obtain further ongoing supplies if required, within a 
reasonable timeframe. 
Principle 6:  At the time of discharge, each patient should be provided 
with a discharge folio containing relevant information such as Consumer 
Medicine Information, a medication record, patient/carer plan, and information on 
the availability and future supply of medication. 
Principle 7:  No patient should be discharged from hospital until the 
details of the admission, medication changes (including additions/deletions) and 
arrangements for follow-up have been communicated to the healthcare 




Information Required for the Initial New Warfarin Education 
Session 
1. New warfarin information booklet (APPENDIX 12) 
2. Warfarin counselling checklist (APPENDIX 13) 
3. Warfarin pretest questionnaire (APPENDIX 15) 
4. Patient demographic data sheet (APPENDIX 16) 
5. ‘Self-Management’ questionnaire (APPENDIX 17) 
6. ‘Medication-Taking-Measures’ questionnaire    
  (APPENDIX 18) 
7. ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) 
8. ‘Satisfaction with Information about Medicines Scale’ 
 (SIMS)(APPENDIX 20) 
9. NPS medicine information line fridge magnet 
10. Patient information on potential drug-to-drug warfarin 













Typical transcript of the initial new warfarin education session 
Good morning/afternoon, my name is Judy Mullan and I am the pharmacist 
who has come to speak to you about your warfarin medication and to help you 
understand: 
 What warfarin is, how it works and how to take it properly. 
 What to do if you miss a dose. 
 Why regular blood tests are important and what the results mean. 
 What the possible side effects are and when to look for medical help. 
 Why you need to tell other healthcare providers about your warfarin.  
 What other factors such as medicine, food and alcohol can affect your 
warfarin dose. 
 
Remember that we are working in a partnership and if you have any concerns 
or questions please ask me at anytime. Also, remember that if you follow our 
instructions, take your warfarin properly and refer to this booklet, you will help 
stop any problems developing from your warfarin therapy.  
After the education session you will be expected to manage your own 
warfarin therapy at home. It is important for us to know whether you intend to 
take your warfarin tablets regularly and follow the recommendations you are 
about to learn? 
 
 If Yes – continue with the education session 
 If No - explain potential problems and make an appointment for them to  
 speak to the medical practitioners 
 
Before we begin the session, I would like to ask you a few questions about 
what you know about warfarin, so that I can get an idea about how much you 
may or may not already know.  
 
Complete Warfarin pre-test questionnaire (Appendix 15).  
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The purpose of this questionnaire is also to evaluate the patients’ perceptions 
about warfarin and whether or not they have any fears associated with taking 
warfarin medication. If they do, attempts should be made to reduce their negative 
perceptions and/or fears by using encouragement, reassurance and 
reinforcement, as well as providing positive feedback. Giving examples of many 
similar cases to theirs, which have been successfully treated with warfarin 
therapy also often helps relieve anxieties and fears. 
Once the patient is comfortable and confident with the idea of continuing with 
warfarin therapy, the education session resumes with the key points underlined 
in the new warfarin booklet, also provided as a visual guide.  
 
Warfarin and how it works 
Warfarin is an anticoagulant and is sometimes called a ‘blood thinner.’ It 
can save your life because it slows down the clotting process and stops harmful 
clots forming. Blood clots can be harmful because they can travel through blood 
vessels to other parts of the body, such as the lungs and brain. If a blood clot 
reaches the blood supply to the brain, it may cause a stroke. 
Warfarin starts to work 24 hours after taking a dose, but its full effect may 
take between 72 and 96 hours. On the other hand, the effects of a single 
Warfarin dose can last between 2-5 days. 
 
Patients are then informed about why their warfarin has been prescribed for them 
e.g. preventing harmful clots for atrial fibrillation, helping the body to dissolve a 
deep venous thrombosis etc. They are also reminded that although good warfarin 
compliance reduces the development of harmful clots, poor compliance can lead 
to the development of clots. 
 
Warfarin Brands 
Your doctor has ordered your warfarin dose in milligrams (mg). 
In Australia, there are two different brands of warfarin, known as ‘Coumadin’ and 
‘Marevan.’ TACT has given you the ‘Coumadin’ brand (Tick the Coumadin box). 
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However, you need to know that the ‘Marevan’ brand is also available. Unless 
your doctor tells you to changes brands in the future, you are to keep taking the 
‘Coumadin’ brand of warfarin after you are discharged from our service. To make 
sure you are taking the right tablets always check the brand, colour and strength. 
 
Patients are then advised which dose of warfarin to take that night and reminded 
that the dose may vary, depending on the INR blood test results. To ensure that 
patients know how to manage their doses appropriately, they are asked to make 
up possible doses of 9mg, 8mg, 4mg and 3mg, using the warfarin 1mg, 2mg and 
5mg tablets given to them.  
 
How to take warfarin 
You should always take the exact warfarin dose ordered by your doctor at 
the same time every day. We recommend that you take your warfarin tables in 
the evening, swallowed whole with a glass of water, either before or after food, 
whichever you prefer. Don’t stop taking the tablets or change the dose unless 
your doctor tells you to. 
 The most important thing to remember is to take your warfarin every day. 
If you think you will have trouble remembering to take your warfarin, we 
recommend that you use a reminder such as a calendar, an alarm clock, a 
mobile phone alarm or special tablet boxes. 
 
Patients will be asked what time of day they intend to take their warfarin therapy. 
If the patient is unsure or chooses an inappropriate time, then they will be 
encouraged to have an evening dose at approximately 6pm.  
  
What to do if you miss a dose? 
If you forget to take a dose at the normal time but then remember within about 
three hours, you should still take the tablets. However, if you forget for a longer 
time do not take a dose, just take your next normal dose when it is due. Never 
take a double dose because this could thin the blood too much and cause 
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serious bleeding side effects. If this ever happens write down the date and time 
you missed your dose in this booklet and tell your doctor that you missed a dose 
at your next visit or when you have your blood test. Otherwise, contact your 
doctor or pharmacist if you are not sure what to do. 
 
Why are regular blood tests important? 
Different people need different warfarin doses to control their blood’s 
clotting power and the only way we can work out this dose is from your blood test 
results. The blood test is called an INR test or International Normalised Ratio test 
and it shows how long it takes your blood to clot. You will need to have regular 
INR blood tests so that your doctor can prescribe you the correct warfarin dose. 
Generally your INR results should be between 2 and 3. A low INR (below 
2) means that your blood may not be thin enough and clots can continue to grow, 
whereas an INR above 3 (and in some situations above 3.5) may mean that your 
blood is a little too thin and the dose of warfarin needs to be lowered before any 
bleeding side effects occur.  
You must always follow your doctor’s orders for regular INR blood tests, 
as well as writing down your INR blood test results on pages 18-21 of this booklet 
within 24 hours of the test. 
 
Patients are reminded that their dose may need to be adjusted according to their 
INR blood results. Therefore, blood results outside of this therapeutic range 
(generally 2-3) need to be addressed immediately so that dosage adjustments 
can be made and optimal therapeutic outcomes achieved. Also, patients are 
reassured that regular blood tests, visits to the doctor and complying with the 
recommendations in the booklet will help to stop any of these problems 
developing. 
The researcher/pharmacist takes the time to fill in the patient’s first few warfarin 
doses, on pages 18-21 of the new warfarin booklet. She also shows them where 
to fill in their own INR results, warfarin dosage and appointment times in the 
 5 
future. Patients are encouraged to keep these records as valuable information for 
themselves, their medical practitioner and specialists. 
 
Possible side effects and when to look for medical help  
Warfarin does thin the blood and therefore can increase the incidence of 
bleeding and bruising which you will notice straight away. There are, however, 
some very important signs of serious bleeding, which you need to know about. 
 
The early warning signs of serious bleeding include: 
 nosebleeds 
 bleeding gums 
 dark red or dark brown urine 
 red or black faeces (dark stools) 
 cuts that bleed for a much longer time 
 unexplained bruising or other bleeding 
 
If you notice any of these, contact your doctor or local emergency 
department immediately because the earlier a problem is found, the easier it is to 
solve. You will also need to tell your doctor about any of the following symptoms; 
vomiting, diarrhoea, pain, swelling and shortness of breath, because these can 
also affect, or be the effects of, inadequate warfarin therapy. 
 
Patients are reminded that even though the likelihood of serious bleeding 
complications are rare when the recommendations are followed and regular 
blood tests are performed, in the event that they should occur, immediate 
medical attention needs to be sought. 
 
Inform other healthcare providers 
Your will need to inform all your healthcare providers, including: 
specialists; doctors; dentists; pharmacists; nurses; physiotherapists; massage 
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therapists; other healthcare workers; friends and relatives who look after you, 
that you are taking warfarin tablets. 
  
Explain to patients that this is important because these healthcare providers may 
want to undertake a procedure or give medications which could result in an 
adverse event (e.g. bleeding) when used in combination with the warfarin 
therapy. 
 
You might like to consider wearing Medic Alert jewellery (e.g. bracelets or 
pendants) available from your pharmacy, to let others know that you take 
warfarin tablets. 
  
This should especially be encouraged when patients are elderly, live alone 
and/or have any cognitive and physical limitations. 
 
What else can affect your warfarin dose? 
Other medicine(s), food and alcohol can affect how warfarin works. Tell 
your doctor if there are any big changes in the medicine, alcohol or food that you 
normally take because these can affect your warfarin dose. 
 
Patients are then given the ‘Patient information on potential drug-to-drug warfarin 
interactions’ (Appendix 27), which is used as a visual guide while talking about 
the following possible interactions.  
 
Some examples of medicines which can affect the way warfarin works 
include: 
 Prescription medicines - old and new medicines, in particular antibiotics and 
heart medication such as Amiodarone. 
 Non-prescription medicines – medicines bought in the chemist, supermarket 
or health food store.  
 pain relievers (e.g. aspirin and NSAID such as ibuprofen) 
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 cough and cold medicines 
 stomach remedies (e.g. antacids) 
 laxatives 
 some creams for tinea  
 rubs and liniments 
 vitamins  
 
To ensure that patients have understood, the researcher/pharmacist asks them 
which medications they could take and which medications they should definitely 
avoid taking, if they develop a headache or pain while on warfarin therapy.  
 
 Natural and Herbal Preparations 
Many natural or herbal products can affect the way warfarin works. You 
should therefore talk to your doctor or avoid taking: garlic supplements; gingko 
biloba; herbal teas, especially ‘Green Tea’; Chinese herbs, especially “Dong 
Quai”; St. John’s Wort and many other herbal preparations referred to in the 
“Patient information on potential drug-to-drug warfarin interactions” (APPENDIX 
27). 
 
  Vitamin Supplements 
Also talk to your doctor before taking vitamin supplements, because 
vitamins C, E, and K (especially high doses) can affect the way your warfarin 
works. Eating a well-balanced diet will provide you with enough vitamin 
supplements. 
 
Ask the patient whether or not they are taking any of these or any other 
complementary medicines. If the answer is yes, highlight the potential 
interactions on their copy of the ‘Patient information on potential drug-to-drug 
warfarin interactions’ (Appendix 27) and suggest that they either cease taking 
them or talk to their general practitioner about taking them. 
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The researcher/pharmacist should now perform a medication review on all the 
patients’ medications including their complementary medicines, to ensure that 
there are no drug-to-drug interactions with their warfarin therapy. Advice about 
the timing of their doses should subsequently be given to patients to minimise the 
chances of any interactions. Any recommendations for changes in medications 
should be done in collaboration with the patient’s medical practitioners and/or 
other members of The Ambulatory Care Team. 
 
 Alcohol 
Since alcohol can affect the warfarin dose you can drink alcohol in 
moderation (no more than 2 units per day) and avoid binge drinking. 
 
 Your Diet  
Do not crash diet or binge-eat because your warfarin dose will be 
balanced with your eating habits. Most importantly Vitamin K has the opposite 
effect to warfarin, which is why you should eat no more than normal amounts of 
vitamin K rich foods. These foods include: green leafy vegetables (spinach, 
broccoli, lettuce, cabbage, brussels sprouts, alfalfa), canola, soybean and olive 
oils. We highly recommend that you have a well balanced diet and take in 
consistently small amounts of vitamin k rich foods. 
 
Other things to consider 
As already mentioned, warfarin can cause increased bleeding and bruising 
which is why you should avoid contact sports such as basketball, football and 
kick boxing. 
Ask patients if they play any contact sport and advise them accordingly. 
 
Pregnancy must be avoided (Only discuss this when and if appropriate).  
If you decide to go away on a holiday while you are still on your warfarin 
therapy, you will need to check with you doctor. You should always take enough 
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warfarin tablets with you and if you intend to stay for more than two weeks, you 
will need to organise INR blood tests while you are away.  
 
Handy Hints 
These are some handy hints for you while you are on your warfarin therapy: 
 Since warfarin causes increased bleeding and bruising, try to avoid cutting 
yourself or bumping yourself 
 Use a non-slip bath mat when bathing 
 Use a soft bristle toothbrush  
 Use gloves when gardening  
 Use an electric shaver when shaving 
 
We’ve now come to the end of the education session and I was wondering 
whether or not you had any questions or concerns you would like to discuss with 
me. 
 
If “yes”, the patient’s questions are to be answered using positive 
encouragement, reinforcement and reassurance. 
 
If “no”, remind the patient that they can contact the TACT office, seven days a 
week between 8.30am and 9.30pm, if they have any concerns or queries 
regarding their warfarin therapy. The TACT telephone number on the back of the 
TACT information leaflet should be underlined.  
Alternatively, recommend that patients contact the National Prescribing Service 
(NPS) medicines information line on 1300 888 763, Monday to Friday between 
9am to 6pm (The fridge magnets containing these details should now be issued 
to the patients). Also inform patients of the relevant internet sites listed at the 
back of the warfarin information booklets; http://www.nps.org.au; 
http://www.coumadin.com and http://www.warfarininfo.com 
The researcher/pharmacist once again reinforces the key points of the education 
session as per the ‘Warfarin Counselling Checklist’ (APPENDIX 13) offering the 
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reassurance that if the warfarin therapy is taken properly, it will be safe and 
effective. 
 
To make sure that you have understood what you have been taught, I would like 
to ask you a few questions.  
 Why is it important not to miss a dose of warfarin and what should you do 
if you miss a dose? 
 What brand of warfarin have you been given? 
 What dosage of warfarin will you be taking today? 
 Why is it important to have regular INR blood tests and what is your 
expected INR range? 
 
Upon completion of these questions by the patients they are reminded about 
having to complete their questionnaires, both immediately and in three months 
time over the telephone.  
Finally the patients are informed that the new warfarin booklets have been 
especially designed and printed for use in Judy Mullan’s Ph.D. project ‘To 
develop and trial a new warfarin education program to help improve warfarin 
knowledge, management and compliance in a wider warfarin prescribed 
population’ and if they would like further information regarding the project, to 
please contact: 
 
Ms Judy Mullan  
Graduate School of Public Health 
Faculty of Health and Behavioural Science 
University of Wollongong NSW 2500 
Phone 02 4221 4274  
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Warfarin Counselling Checklist (adapted from Witte, Gurwich et al 1980) 
 Reason for anticoagulation (e.g. PE, DVT, AF, others) 
 Explanation about what warfarin is and how it works 
 Patient’s regimen         
 Identification of warfarin brand, colour and strength    
 Dosage, route and frequency of warfarin tablets 
 Importance of compliance 
 What to do if a dose is missed  
 Emphasise the importance of regular INR blood tests 
 Alert patients to warfarin-related side effects 
 Bleeding/bruising 
 Possible signs of warfarin toxicity 
 Proper action to take in case of an emergency 
 Tell all their healthcare practitioners about their warfarin regimen  
 Encourage medical bracelets 
  Inform patients about factors which can affect warfarin dosage  
 Other medications -prescribed 
    -non-prescribed      




 Avoid Pregnancy - when and if applicable 
 Note that patients should use: 
 Non-slip mats in the bath/shower 
 Soft bristle toothbrush 
 Garden gloves 
 Electric razor instead of blades 
 Reassurance 
 Warfarin therapy, when taken properly, is safe and effective 
Careful monitoring is essential: regular INR blood tests; visits to the GP; 







New Warfarin Education Program Objectives (Witte, Gurwich, Anzalone and 
Campagna 1980; Wyness 1990; Haines 1998) 
Overall Goal: The patient takes warfarin effectively and safely. 
1. Understands what the warfarin does 
 1.1 explains the action of the warfarin 
1.2 explains the reason for taking the warfarin 
1.3 explains how quickly the drugs works  
2. Understands how to take the warfarin safely 
2.1 explains how to take the warfarin 
2.2 explains the frequency of taking the warfarin 
 2.3 predicts the optimum time of day for taking the warfarin 
2.4 explains use of an aid (e.g. calendar, alarm device) to remember to take warfarin and  
 to record INR results 
2.5 identifies the action to take if a dose is missed or may have been missed  
2.6 explains that warfarin may be prescribed using generic and trade names 
2.7 explains the reason the same brand of the drug should be used consistently  
 2.8 explains who will prescribe the warfarin and when  
 2.9 explains the importance of identifying the correct tablet by checking the brand, colour 
 and strength in milligrams 
3. Understands facts about the INR test 
 3.1 describes the term INR (International Normalised Ratio) 
 3.2 states the need to go to a laboratory for regular INR tests 
 3.3 explains the reason INR is measured 
 3.4 explains the relationship of INR to amount of drug prescribed 
 3.4 describes the procedure for obtaining INR results and recording them appropriately 
 3.5 explains the goal international normalised ratio 
3.6 explains the reasons accurate drug-taking is essential 
3.7 explains potential consequences associated with a low INR 
 3.8 explains potential consequences associated with a high INR 
4. Understands possible side effects and what should be done if they occur 
4.1 identifies signs of bleeding to report 
 4.2 explains bruises may occur easily and indications for reporting 
 4.3 identifies any symptoms or illness to report 
 4.4 identifies all health care workers e.g. dentist, pharmacist and podiatrist as  
  individuals to notify 
 4.5 identifies the need to inform all health professionals prior to surgery  
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 4.6 identifies the benefits for carrying identification card and wearing Medic Alert tag 
5. Understands factors affecting anticoagulant dosage 
5.1 Other medications 
 5.1.1 identifies prescription medicines new and old can alter the effects of warfarin 
5.1.2 identifies nonprescription medicines (including complementary medicines) can alter 
 the effects of warfarin  
 5.1.3 explains that prior to taking any medication (prescribed or non-prescribed) the  
 patient should check with their doctor or pharmacist  
 5.1.4. explains that many natural and herbal preparations can alter the effects of warfarin 
 5.1.5 explains that vitamin supplements, especially vitamins C; E and K, can alter the 
 effects of warfarin  
 5.1.6 explains the effect of alcohol 
5.2 Diet 
 5.2.1 explains the reason for maintaining a similar day-to-day dietary intake 
 5.2.2 explains the effect of vitamin K on action of warfarin 
 5.2.3 gives examples of foods high in vitamin K 
5.3 Lifestyle 
 5.3.1 explains hazards of physical injury when taking oral anticoagulants 
 5.3.2 identifies activities such as sewing, gardening, kitchen activities, sports, use of  
  power tools, as areas for caution 
 5.3.3 identifies activities of daily living that may need to be modified to prevent injury 
 5.3.4 explains action to take if travel is planned 
 5.3.5 identifies the dangers of pregnancy whilst prescribed warfarin 
6. Demonstrates commitment to ongoing knowledge and safety. 
6.1 proposes adaptations to be made in lifestyle as necessary 
6.2 suggests other possible sites for gathering warfarin information 

















(Circle one response Answered by   patient    carer     patient and carer) 
 
Question 1 
Have you ever taken warfarin before? 
 
Question 2 
Do you know anything about warfarin?          Yes or No. 
 
If No. Go directly to education session 
If Yes. 
 
a. How does warfarin work? 
 
 
b. Does warfarin have any side effects? 
 
 
c. How and when should warfarin be taken? 
 
 









Patients Demographic Data Sheet 
Date………………………………… 
Client ID……………………………Intervention/Control . 
Family Name…………………………….……Given Name …………………………... 
Address……………………………………………………………………………………. 
Suburb…………………………………Telephone……………………………………… 
DOB…………………… Sex     M / F           Weight………………………….. 
Occupation………………………………………Educational Level…………………… 
Allergies…………………………………… 




Referral source……………………………………GP Name………………………… 
Date of Commencement………………………………………………………………… 
Referral Diagnosis……………………………………………………………………. 
Past Medical Surgical History…………………………………………………………... 
……………………………………………………………………………………………… 
Relevant Investigation and results (e.g. Doppler) ………………………………….. 
Next of Kin/Carer……………………Present at Educational Session Yes/No 
Language spoken at home………………………Country of  Birth………………….. 
Interpreter needed Yes/ No 
Aboriginal or Torres Strait Islander Yes / No
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APPENDIX 17 
‘Self-Management’ Questionnaire ( adapted from Lorig, Stewart, Ritter, 
Gonzales, Laurent and Lynch 1996) 
 
(Circle one response Answered by   patient    carer     patient and carer) 
 
1. How confident are you that you can take warfarin tablets correctly? 
 
Not at all confident     1      2      3      4      5 Totally confident 
 
2. How confident are you that you can recognise serious bleeding side 
effects which need medical help? 
 
Not at all confident     1      2      3      4      5  Totally confident 
 
3. How confident are you that you can self-manage your warfarin at 
home? (hint: especially with regard to your diet, alcohol and/or other 
medications)  
 
Not at all confident     1      2      3      4      5  Totally confident 
 
4. How confident are you that you know and understand the information 
given to you about warfarin? 
 
Not at all confident     1      2      3      4      5  Totally confident 
  
5. Are you worried about taking warfarin tablets? 
 
(   ) No       (   ) Yes  
 
If yes  
 
I. What is it about taking warfarin tablets that worries you? 
 
 
II. Has the warfarin education program affected your worries 
about taking warfarin tablets? 
 
 
III. Other comments 
 
 
6. Ask the carer (if present) for any comments about the education 




‘Medication-Taking-Measures’ Questionnaire (Morisky, Green and 
Levine 1986) 
 
(Circle One response Answered by   patient      carer  patient and carer) 
 
 
Please circle “Yes” or “No” for each question: 
 
1. Do you ever forget to take your medicine?    Yes  No 
 
 
2. Are you careless at times about taking medicine?   Yes  No 
 
 
3. When you feel better do you sometimes stop taking your medicine?   
       
Yes   No 
 
 
4. Sometimes if you feel worse when you take the medicine, do you stop taking 
it?        















Scoring: This scale is designed to test medication compliance. To score, 
code “Yes”=0, “No”=1. The sum of the answers is the score. A score of 4 is 





‘Warfarin Knowledge’ Questionnaire (adapted from Scalley, Kearney and 
Jacobs 1979; Witte, Gurwich et al. 1980; Wyness 1990; Horne, Hankins and Jenkins 2001) 
        
(Circle one response Answered by   patient    carer     patient and carer) 
 
Question 1 
Which brand of warfarin is prescribed for you? 
Question 2 
Why is the warfarin prescribed for you? 
Question 3 
How does the warfarin work? 
Question 4 
What are the different strengths and colours of your warfarin tablets? 
Question 5  
How will you know what dose of warfarin to take? 
Question 6 
How and when should you take your dose of warfarin? 
Question 7 
What should you do if you forget to take your dose of warfarin? 
Question 8 
Can you suggest two things which you could use to remind you about taking your 
warfarin tablets if necessary? 
Question 9 
Why should you have regular INR (International Normalised Ratio) blood tests? 
Question 10 
What is your target INR blood test range? 
Question 11 
1. What are FOUR signs of bleeding from too much warfarin? 
2. What should you do if you notice any of these side effects? 
 2 
Question 12 
Why is it necessary to tell your doctor about starting or stopping any other 
medicines, including prescribed medicines (e.g. antibiotics), non-prescribed 
medicines (e.g. cold and flu tablets) and herbal or vitamin preparations? 
Question 13 
1. Do you need to tell your dentist that you are taking warfarin? 
2. Should you tell any of your other healthcare providers that you are taking 
warfarin? 
Question 14 
Which medicine could you take for pain relief (e.g. a headache) while taking 
warfarin? 
Question 15 
Are there any foods that can affect how warfarin works? 
Question 16 
Is it safe to drink alcohol while taking warfarin? 
Question 17 














APPENDIX 20  
Satisfaction with Information About Medicines Scale (SIMS)  
(Horne, Hankins et al. 2001)  
We would like to ask you about the information you have received about your medicines. Please 
rate the information you have received about each of the following aspects of your medicines. If 
you use more than one medicine, please give your overall feeling about information you have 
received about all your medicines.  
(Rated: too much, about right, too little, none received, none needed).  
1. What your medicine is called.  
2. What your medicine is for.  
3. What it does.  
4. How it works.  
5. How long it will take to act.  
6. How you can tell if it is working.  
7. How long you will need to be on your medicine.  
8. How to use your medicine.  
9. How to get a further supply.  
10. Whether the medicine has any unwanted effects (side effects).  
11. What are the risks of you getting side effects?  
12. What you should do if you experience unwanted side effects.  
13. Whether you can drink alcohol whilst taking this medicine.  
14. Whether the medicine interferes with other medicines.  
15. Whether the medication will make you feel drowsy.  
16. Whether the medication will affect your sex life.  
17. What you should do if you forget to take a dose.  
Other information (please specify below)   
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APPENDIX 21  
Outcome Measures Of The Warfarin Education Program Questionnaire  
(adapted from Lorig, Stewart et al. 1996 page 53-55) 
 
1.In the past three months have you tried to find out more information 
about your warfarin therapy?      (   )No   (   )Yes    
If yes:   
i. Where did you go for this information ? e,g. general practitioner, NPS  
  medicines number, internet, etc 
  ii. How many hours did you spend looking for this information?  
      1= None  
2=1 - 5 hours 
3=6 - 10 hours  
4= 11 or more hours 
 
2.In the past three months how many times did you visit your doctor? 
How many visits________________ 
 
3. In the past 3 months how many times did you stay in a hospital overnight 
or longer? 
 
(   ) None         _____times 
 
How many nights in total did you stay in a hospital? 
(   ) None          _____nights 
 
Reason for hospitalisation____________________________________ 
 
4. In the past three months did you visit the emergency department? 
 
    (   ) None          How many visits__________ 
 
Reason for emergency department visit (s)_______________________ 
 
5. In the past three months have you had any warfarin related side effects 








(Charnock, Sheppard et al 1999; Shepperd and Charnock 2002) 
 
SECTION 1: Is the publication reliable? 
1. Are the aims clear? 
  No    Partially   Yes  
  1  2  3  4  5 
Hint: Look for a clear indication at the beginning of the publication: 
 What it is about 
 What it is meant to cover (and what topics are meant to be excluded) 
 Who might find it useful 
If the answer to Question 1 is “No”, go directly to Question 3 
2. Does it achieve its aims? 
 No    Partially   Yes  
  1  2  3  4  5 
Hint: Consider whether the publication provides the information it aimed to as 
 outlined in Question 1 
3. Is it relevant? 
   No    Partially   Yes  
  1  2  3  4  5 
Hint: Consider whether: 
 The publication addresses the questions that readers might ask 
 Recommendations and suggestions concerning treatment choices are realistic or 
appropriate 
4. Is it clear what sources of information were used to compile the publication 
(other than the author or producer)?       
  No    Partially   Yes  
  1  2  3  4  5 
Hint: 
 Check whether the main claims or statements made about treatment choices are 
accompanied by a reference to the sources used as evidence e.g. a research 
study or expert opinion 
 Look for a means of checking the sources used such as a bibliography/reference 
list of the addresses of the experts or organisations quoted, or external links to 
the online sources 
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Rating Note: In order to score a full ‘5’ the publication should fulfill both hints. Lists of 
additional sources of support and information (Question 7) are not necessarily sources 
of evidence for the current publication 
 
5. Is it clear where the information used or reported in the publication was 
produced? 
 No    Partially   Yes  
  1  2  3  4  5 
Hint Look for: 
 Dates of the main sources of information used to compile the publication 
 Dates of any revisions of the publication (but not dates of reprinting in the case of 
print publications) 
 Date of publication (copyright date) 
Rating note: The hints are placed in order of importance - in order to score a full ‘5’ the 
date relating to the first hint should be found 
 
6. Is it balanced and unbiased? 
No    Partially   Yes  
 1  2  3  4  5 
Hint: look for: 
 A clear indication of whether the publication is written from a personal or 
objective point of view 
 Evidence that a range of sources of information were used to compile the 
publication e.g. more than one research study or expert 
 Evidence of an external assessment of the publication 
Be wary if: 
 The publication focuses on the advantages or disadvantages of one particular 
treatment choice without reference to other possible choices 
 The publication relies primarily on evidence from single cases (which may not be 
typical of people with this condition or of responses to a particular treatment) 
 The information is presented in a sensational, emotive or alarmist way 
 
7. Does it provide details of additional sources of support and information? 
No    Partially   Yes  
 1  2  3  4  5 
Hint: look for suggestions for further reading or for details of other organisations 




8. Does it refer to areas of uncertainty? 
  No    Partially   Yes  
  1  2  3  4  5 
Hint: 
 Look for discussion of the gaps in knowledge or differences in expert opinion 
concerning treatment choices 
 Be wary if the publication implies that treatment choice affects everyone in the 
same way, e.g. 100% success rate with a particular treatment 
 
SECTION 2: How good is the quality of information on treatment choices? 
N.B. The questions apply to the treatment (or treatments) described in the publication. 
 Self-care is considered a form of treatment throughout this section. 
 
9. Does it describe how each treatment works? 
No    Partially   Yes  
 1  2  3  4  5 
Hint: Look for a description of how a treatment acts on the body to achieve its effect 
 
10. Does it describe the benefits of each treatment? 
   No    Partially   Yes  
  1  2  3  4  5 
Hint: Benefits can include controlling or getting rid of symptoms, preventing recurrence 
of the condition and eliminating the condition, both short-term and long-term 
 
11. Does it describe the risks of each treatment? 
No    Partially   Yes   
 1  2  3  4  5 
Hint: Risks can include side effects, complications and adverse reactions to treatment, 
both short-term and long-term 
 
12. Does it describe what would happen if no treatment is used? 
No    Partially   Yes   
 1  2  3  4  5 
Hint: Look for a description of the risks and benefits if postponing treatment, of watchful 
waiting (i.e. monitoring how the condition progresses without treatment) or of 




13. Does it describe how the treatment choices affect overall quality of life? 
 No    Partially   Yes   
 1  2  3  4  5 
Hint: Look for 
 Description of the effects of the treatment choices on day-to-day activity 
 Description of the effects of the treatment choices on relationships with family, 
friends and carers 
 
14. Is it clear that there may be more than one possible treatment choice? 
 No    Partially   Yes   
 1  2  3  4  5 
Hint: Look for: 
 A description of who is most likely to benefit from each treatment choice 
mentioned, and under what circumstances 
 Suggestions of alternatives to consider or investigate further (including choices 
not fully described in the publication) before deciding whether to select or reject a 
particular treatment 
 
15. Does it provide support for shared decision-making? 
No    Partially   Yes   
 1  2  3  4  5 
Hint: Look for suggestions of things to discuss with family, friends, doctors or other 
health professionals concerning treatment choices 
 
SECTION 3: Overall rating of the publication 
16. Based on the answers to all of the above questions, rate the overall quality of the 
publication as a source of information about treatment choices 










1 2 3 4 5 
 
Copyright British Library and the University of Oxford 1997
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APPENDIX 23 
UNIVERSITY OF WOLLONGONG  
Research Information Sheet For Illawarra Health Staff 
RESEARCHER:   Judy Mullan (Ph.D. student) 
SUPERVISORS:  Assoc Professor Heather Yeatman    
    Professor Patrick Crookes 
DEPARTMENT:  Graduate School of Public Health 
 
My name is Judy Mullan and I am undertaking research toward my Ph.D. 
in the Graduate School of Public Health at the University of Wollongong. I am 
employed by Illawarra Health as a part-time pharmacist with The Ambulatory 
Care Team (TACT). My background in pharmacy has led to a special interest in 
patient education, especially with regard to warfarin, which is the focus of this 
research. 
The purpose of this research study is to develop and trial a new patient 
warfarin education program based on a conceptual framework, which reflects 
‘best evidence’ with regard to patient medication education programs. The new 
program will be compared and contrasted against the customary warfarin 
education program delivered to TACT patients who are prescribed the oral 
anticoagulant warfarin.  
This comparative analysis will assist with the evaluation of the new 
program and its impact on warfarin knowledge, management and compliance for 
the wider warfarin prescribed population. This population includes the ‘high risk’ 
patient populations such as the elderly, those with low literacy skills and those 
from non-English speaking backgrounds. 
Overview of the Research Study 
 Eligible Participants: Patients admitted to TACT, who are newly prescribed 
warfarin, or who have recommenced on warfarin after at least 15 years, 
will be considered eligible participants. They will be made aware of the fact 
that their participation in the research study is voluntary and that they are 
free to withdraw from the study at any time. They will also be notified that 
their refusal to participate in the study or their withdrawal from the study 
will not detrimentally affect their Illawarra Health TACT service in any way. 
 Participant Demographic Data: Routinely collected by the TACT 
pharmacists from the patients, their notes and the Dracis database will 
provide important patient medical information which can be used to ensure 
optimal therapeutic management and outcome evaluation. An analysis of 
the demographic patient information will also help establish whether or not 
demographic variables have impacted on the outcomes of the different 
patient warfarin education programs. 
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Throughout the research process the patients’ names will be coded and all 
the demographic data will remain confidential and locked in a secured 
cabinet at the University of Wollongong. 
 Warfarin Education Sessions: These will take place in the patients’ homes, 
or at an alternative place specified by the patient. The 50 intervention 
patients will receive the new warfarin education program and the 50 
control patients will receive the customary warfarin education program, 
each of these education sessions will take approximately 30 minutes. 
Evaluation of the Patient Participants 
 Immediately and three months after the initial warfarin education session, 
all consenting patient participants will be asked to complete four 
questionnaires which will take approximately 20 minutes. The initial 
questionnaires will be answered immediately after the education session 
and the three-month follow-up questionnaires will be answered over the 
telephone. These questionnaires relate to warfarin self-management, 
warfarin compliance, warfarin knowledge and understanding, as well as 
satisfaction with the warfarin information provided.  
 During the three-month telephone follow-up, patients will be asked to 
complete their evaluation questionnaires, as well as their outcome 
measures questionnaire. The latter asks questions about INR results and 
health care visits (e.g. general practitioner, hospital and emergency 
department visits.) 
If you have any enquiries about the research, please contact myself or my 
supervisors and we will gladly help with any questions or concerns pertaining to 
this research. 
 
Researcher: Judy Mullan (e-mail jmullan@uow.edu.au, mobile 0412175029) 
Supervisors: Associate Professor Heather Yeatman (02) 4221 3555   
            Professor Patrick Crookes (02) 4221 3123  
 
 






 Suggested Dialogue for Patient Recruitment and Obtaining Consent 
“ Judy Mullan, one of the TACT pharmacists, is currently researching ways in which to improve 
the warfarin education delivered by TACT. This involves obtaining information from our patients 
that will assist with improving the educational services we deliver. If you are interested in 
participating in the research study I will provide you with an information sheet and explain the 
process to you. Would you like me to give you more information?” 
 
If the answer is No –thank them for their kind consideration and inform them that their care will 
not be compromised in any way. 
If the answer is YES- give the patient a ‘Patient Participant Information Sheet’ and proceed. 
 
“This is the information sheet that has all the details of the research study. You can keep this for 
your own reference, however I will now read through the details with you”  (read through and 
explain the information on the sheet). 
 
On completion of reading the ‘Patient Participant Information Sheet’ continue with: 
 
“Because this is a research study, your written consent is required for you to be an active 
participant and so the information you provide can be used. This is the consent form which is 
written in the standard format for Illawarra Health and the University of Wollongong ”  (show 
patients the ‘Patient Participant Consent Form’ and then read through and explain the information 
on the consent form). 
If the patient gives verbal consent, ask them to sign in the space provided, also enter the date. 
Ensure that the patient receives and keeps the ‘Patient Participant Information Sheet’. 
 
“A TACT pharmacist will contact you by telephone to make an appointment for the warfarin 
education session which will take place in your own home, or an alternative place which you 
prefer, at a time that suits you.” 
“Do you have any questions about the research study?”  (Answer if possible, if not assure them 
that the pharmacists will address any of their concerns). 
“Thank you for your support and cooperation.” 
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APPENDIX 25 
   
UNIVERSITY OF WOLLONGONG 
Patient Participant Information Sheet 
RESEARCHER:   Judy Mullan 
SUPERVISORS:    Associate Professor Heather Yeatman     
            Professor Patrick Crookes 
DEPARTMENT:     Graduate School of Public Health,    
 The University of Wollongong 
 
Judy Mullan is a pharmacist working for Illawarra Health’s The Ambulatory 
Care Team (TACT), doing research toward her Ph.D. in the Graduate School of 
Public Health at the University of Wollongong. Her background in pharmacy has 
led to a special interest in patient information, especially with regard to warfarin, 
which is the focus of this research. 
 
The research study aims to provide a new warfarin education program, 
which will help to improve warfarin knowledge, management and compliance for 
a wider warfarin prescribed population. To gain this information, she is inviting 
you to take part in the study where you will be given either the customary or the 
new warfarin education program. The education session will be given at a time 
and place you choose, preferably your own home, and throughout the study your 
name and everything you say and write will remain confidential. 
 
At the completion of the education session you will be asked to complete 
four questionnaires on two separate occasions, immediately and three months 
after the education session. The initial education session and the questionnaires 
will take approximately 30 minutes each and the answers will be recorded and 
evaluated with your approval. You will be contacted by telephone to complete the 
three-month follow-up questionnaires and you will also be asked a few questions 
 2 
relating to your health outcomes. The health outcome questions will be about 
your INR results, general practitioner visits, hospital visits and possible warfarin-
related adverse drug events.  
 
Your participation in this research study is voluntary and you are free to 
withdraw at any time. If you choose to participate in the research study you will 
be asked to give your permission for the researcher to view your medical 
records, including the information available on the Dracis database, as well as 
your blood test results from your pathology service if you do not have your own 
records available. Also, if you choose to withdraw from the research study at any 
time, you will be allowed to withdraw all your personal data if you so wish. Upon 
withdrawal from the research study your refusal to participate or withdrawal of 
consent will not in any way affect the service provided to you by The Ambulatory 
Care Team (TACT). 
 
If you have any enquiries about the study, please contact Judy Mullan or 
her supervisors and they will gladly help you with any queries or concerns you 
may have in relation to this research study. 
 
Researcher/ Pharmacist Judy Mullan  0412175029 (mobile)    
      e-mail jmullan@uow.edu.au 
Supervisors: Associate Professor Heather Yeatman 02 4221 3555   
  Professor Patrick Crookes 02 4221 3123. 
 
If you have any concerns or complaints regarding the way the research study is 
or has been conducted, you can contact the Complaints Officer, Human 
Research Ethics Committee, University of Wollongong on (02) 4221 4457. 
 




UNIVERSITY OF WOLLONGONG 
Patient Participant Consent Form 
RESEARCHER: Judy Mullan (0412175029; e-mail: jmullan@uow.edu.au) 
SUPERVISORS: Associate Professor Heather Yeatman (02 4221 3555) 
   Professor Patrick Crookes (02 4221 3123)   
    
DEPARTMENT: The Graduate School of Public Health 
TITLE: To develop and trial a new warfarin education program which will help to 
improve warfarin knowledge, management and compliance for a wider warfarin 
prescribed population. 
 
I have been given information about the proposed study and have discussed the 
research project ‘To develop and trial a new warfarin education program which 
will help to improve warfarin knowledge, management and compliance for a 
wider warfarin prescribed population’ with a TACT staff member. I understand 
that this research is being conducted as part of a Ph.D. study in the Graduate 
School at the University of Wollongong. 
 
I understand that if I consent to participate in the project, I will be expected to 
participate in a warfarin education program, complete evaluation questionnaires 
and a telephone questionnaire within a 3-month period. I have been informed 
that my responses will be recorded and evaluated. I have also been informed 
that anything I say will be kept confidential and my name will not be revealed to 
anyone. I have been advised of the potential risks and burdens associated with 
this research and have had an opportunity to ask the TACT staff member about 
any questions I may have with regard to the research and my participation. 
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I understand that my participation in this research is voluntary, which means that 
I am free to refuse to participate and I am free to withdraw from the research at 
any time. My refusal to participate or my withdrawal of consent will not affect my 
treatment or health care in any way. 
 
I am aware that if I have any enquiries about the research study, I can contact 
Judy Mullan, Associate Professor Heather Yeatman and Professor Patrick 
Crookes (4221 3555) for further information. Alternatively, if I have any concerns 
or complaints regarding the way the research is or has been conducted, I can 
contact the Complaints Office, Human Research Ethics Committee, University of 
Wollongong on 02 4221 4457. 
 
By signing below I am indicating my consent to participate in the research 
entitled ‘To develop and trial a new warfarin education program which will help to 
improve warfarin knowledge, management and compliance in a wider warfarin 
prescribed population’ conducted by Judy Mullan, as it has been described to me 
in the information sheet and in discussion with me. I understand that the data 
collected from my participation will be used for the purpose of a thesis, 
conference presentations and journal publications, and I consent for it to be used 
in this manner. 
 
Signed………………………………………………Date……………………… 
Name (please print)…………………………………………………………….... 
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APPENDIX 27  
Patient Information on drug-to-drug warfarin interactions 













































 Antiplatelet Agents 
Aspirin (Solprin, Disprin, Astrix) 




 Non-Steroidal Antiinflammatory Drugs (NSAIDs) 









Tiaprofenic Acid (Surgam) 










Please Note: This is not a 
comprehensive or exhaustive 
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↑ Effect of warfarin  
           (↑ INR) 
↓ Effect of warfarin  
           (↓ INR ) 
↑ Bleeding risk 
 Danshen   
 (salvia miltiorrhiza) 
 Devil’s claw    
     (harpagophytum) 
 Dong Quai  
       (angelica sinesis) 
 Garlic  
       (allium sativum) 
 Ginkgo  
        (ginko biloba) 
 Papain  
       (papaya extract) 
 Vitamin E 
 Coenzyme Q10 
 
 Ginseng  
 
 Green Tea 
 
 St John's Wort  
 (hypericum perforatum) 
 
 Vitamin C 
 
 Vitamin K 
 Feverfew  
     (tanecetum parthenium) 
 
 Ginko  
     (ginkgo biloba) 
 
 Ginger  
     (zingiber officinale) 
 
 Korean ginseng  
     (panax ginseng) 
 
 Liquorice  
     (glycyrrhiza glabra) 
Many herbs contain coumarins that may increase the activity of warfarin  
 Alfalfa (medicago sativa) 
 Angelica (angelica archangelica) 
 Aniseed (pimpinella anisum) 
 Arnica (arnica Montana) 
 Asafoetida (ferula spp.) 
 Bedstraw (galium Odoratum) 
 Celery (apium graveolens) 
 Fenugreek (trigonella foenum-graecum) 
 German chamomile (matricaria recutita) 
 Horse chestnut (aesculus hippocastanum) 
 Prickly ash (zanthoxylum americana,z.clava-herculis) 
 Quassia (picrasma excelsa)   Red clover (trifolium pratense) 




Please Note: This is not a comprehensive or 
exhaustive list.  





Transcript of the Customary Warfarin Education Program 
 
Hello my name is Marion Townsend and I am one of the TACT 
pharmacists. I have come to talk to you about your warfarin medication. Firstly, I 
would like to assure you that warfarin has been proven to be effective in 
conditions such as yours, (add in patients diagnosis). These and many other 
people take warfarin and get benefit from it without any problems.  
Warfarin does, however, have some disadvantages in that: 
 it takes a while to have its full effect.  
 blood tests called the INR are necessary to see if it is working 
properly and the dose adjusted accordingly. The tests are done 
daily to start with, after the third dose of warfarin has been taken. 
As the INR stabilises, to between two and three, the frequency of 
blood tests reduces. However, as long as you are on warfarin, the 
INR must be tested at regular times. 
There are two brands of warfarin ‘Coumadin’ and ‘Marevan’ and you have been 
started on the ‘Coumadin’ brand, so we recommend that you do not take the 
‘Marevan’ brand, unless it is recommended by your doctor (put a cross on the 
Marevan page). 
 The dose of Coumadin that will be prescribed for you is in milligrams (mg) 
and as you can see, tablets come in three different strengths and three different 
colours; 5mg is green, 2 mg is lavender and 1 mg light tan. The label on the 
bottle and its lid also match the colour of the tablets to help with identification. 
 You have been given warfarin to take because it stops harmful blood clots 
from forming. Warfarin is an anticoagulant and for warfarin to work properly you 
have to follow our and your doctor’s instructions, and tell us or your doctor about 
any changes in your condition. 
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What is an Anticoagulant 
 Anticoagulant drugs like warfarin help to prevent or treat thrombosis by 
decreasing the clotting power of the blood. The objective of your treatment is only 
to slow down the clotting process; if the blood was prevented from clotting 
altogether this would cause bleeding. 
 In order to do this safely and effectively, a careful check must be kept on 
the effect of the anticoagulant on your blood so that your doctor can prescribe the 
dosage that will keep the clotting process at the correct level. 
 Different people require different amounts of warfarin. Therefore, the 
dosage is tailored to you according to your blood test results and your blood tests 
are very important.  
 While on warfarin your doctor will ask you to have an INR blood test 
regularly. An INR test indicates how long blood takes to clot. A ‘normal’ INR i.e. 
the INR of a person not taking an anticoagulant, is approximately 1. When you 
take anticoagulants, the higher your INR, the longer your blood takes to clot. The 
lower your INR is toward 1, the closer it is to ‘normal’ blood. Changes in your 
warfarin dose will change your INR; however, these changes may not happen 
immediately. It can take four to five days before you have the full impact of a 
dose change on your INR. Your INR levels are very important as they help  
your doctor maintain the dose that suits you. 
 The three things to remember about INR testings are: 
 have the INR test done every time it is ordered by your doctor. 
 call your doctor or laboratory as instructed or within 24 hours of the test in 
case the warfarin dose needs adjusting. 
 record the test results in the record section provided in this book. 
Taking Warfarin 
 You must take your tablets at approximately the same time everyday as 
specified by your doctor. Warfarin can be taken before, during or after meals. By 
getting into the daily routine of marking a calendar after you have taken warfarin 
and not relying on your memory, you will be unlikely to miss a dose. 
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Missing a dose 
If you forget to take a dose and then remember within two to three hours, 
you can still take your tablets. If you forget for a longer time, do not take the 
tablets to catch up, but take your next dose when it is due and tell your doctor or 
laboratory. Do not take a double dose. 
Changes to your INR 
Different things in your life affect how warfarin works on your blood. These 
things include; whether you are eating properly, other medicines you take, the 
amount of alcohol you drink and a new illness. 
The most important thing to remember is that when there is a big change to any 
of these things you must tell your doctor. The times these big changes usually 
occur is when you leave hospital and go home (make sure you arrange for a 
blood test soon after leaving hospital) and when you go away on holidays. 
Other Medicines 
The use of other medicines may interfere with the way warfarin works, 
therefore, keep in mind the following: 
 Before taking any medicines, even prescribed by a doctor (or 
dentist), be certain to check with the doctor who is monitoring your 
warfarin dose. 
 When we talk about medicines, we mean not only prescription 
medicines but anything you might buy (in a chemist or food store) 
for common colds, aches, pains and so on.  
 It is especially important to check with your doctor or pharmacist 
before taking common medicines such as: aspirin; paracetamol or 
other pain medications; rubs and liniments; cold or cough. 
preparations; certain stomach remedies (eg. antacids); laxatives; 
multivitamins containing vitamin K; and herbal medicines.  
 Check with you pharmacist before buying any of these as they may 
affect your INR. 
  If in the past you have been taking any drugs, even prescription 
medications such as the “Pill”, be sure to check with your doctor 
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before taking them now because they might affect your response to 
warfarin. 
Diet Principles 
A well-balanced and varied diet is essential to everyone to maintain health 
and vitality, whether they are taking warfarin or not. This means that your diet 
should include: breads, cereals, fruit, vegetables, milk, cheese, yoghurt, lean 
meat, poultry, fish, legumes, nuts and eggs. Your diet should consist of only 
small amounts of sugar, butter, margarine and oil. 
While taking warfarin you should maintain a well-balanced and consistent 
diet. You should avoid crash dieting and binge eating. As your dosage of warfarin 
has been adjusted to match your current eating pattern and lifestyle, it is 
important that any major changes be talked over with your doctor. You should 
also stabilise your intake of vitamin K because warfarin is affected by vitamin K. 
A high vitamin K intake in your diet can affect your response to warfarin and 
lower your INR significantly. You should therefore keep your intake of vitamin K-
containing food relatively constant. This does not mean cutting these foods out of 
your diet but eating them in small to moderate quantities regularly (about half a 
cup or two to four tablespoons a serve). 
The foods that are highest in vitamin K include the leafy green vegetables  
(not peas or green beans), soya beans, canola and olive oil. 
Vitamin and Herbal Supplements 
If you are taking dietary supplements check to see that they do not contain 
vitamin K. Large amounts of vitamin C (more than 5gms per day) and vitamin E 
greater than 400IU per day can also affect your response to warfarin. Herbal 
supplements and remedies often contain substances which may upset your INR 
balance by increasing your bleeding or increasing your risk of clotting while you 
are taking warfarin. You must discuss taking any supplements or herbal 
remedies with your doctor before starting them. Once you and your doctor decide 
the supplement is suitable for you, it is important that you take it regularly every 
day to maintain a stable INR. It is also important to let your doctor know if you 
stop taking any supplements as this may also affect your INR. 
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Alcohol 
Use in moderation and avoid binge drinking. Discuss with your doctor a safe 
amount to suit you. 
Other important things for you to remember  
 There are several additional things for you to keep in mind while working 
with your doctor to maintain the INR which is best for you.  
 Take the exact number of anticoagulant tablets prescribed by your doctor.  
 Don’t stop taking warfarin or change the dose unless your doctor tells you. 
 Take the prescribed dose at approximately the same time each day. Try to 
connect taking it with something you do regularly e.g. meal time, bed time 
and use your calendar to keep track of the doses you take.  
 If you forget to take a dose, call your doctor for advice. 
 Tell your doctor right away if you develop any illness (for example 
diarrhoea, vomiting, infection or fever) as this may affect your dosage 
requirements. Also tell your doctor if you develop any unusual symptoms 
such as pain, swelling or discomfort. 
 Well before undergoing any treatment, surgery or dental work be certain to 
inform the doctor or dentist performing the procedure that you are taking 
warfarin. This includes emergency treatment following any injury. Also, tell 
the doctor who is supervising your anticoagulation therapy. 
 Remember that because you are taking an anticoagulant you may have 
an increased tendency towards bleeding. Therefore, you should check 
with your doctor before beginning any sport activities. Avoid situations with 
a high risk of injury. 
 Warfarin can seriously affect an unborn baby. All women who may 
become pregnant should discuss with their doctor the possible risks and 
available means of reducing those risks. If a woman becomes pregnant 
she must discuss this with her doctor at the earliest opportunity. However, 
there have been no reports of the sperm from a man taking warfarin 
affecting an unborn child. 
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 Contact your doctor before you start on any extended trips and while 
travelling try to keep your diet and level of activity as close to normal as 
possible. You may need a laboratory test while you are away which is not 
hard to arrange. Ensure the information written on page 20 is up to date 
and take this book with you. Advise the doctor you see while you are away 
of this information. Make sure you take enough tablets with you to last the 
entire trip. 
Handy Hints 
You may need to change some of your activities to minimise the possibility of 
problems occurring. Some changes to consider are: 
 Using a non-slip bath mat when bathing 
 Using a soft bristle toothbrush 
 Using gloves when gardening and having a clean bandage with you in 
case you scratch yourself and begin to bleed. 
 Using an electric shaver when shaving 
Reducing the Chances of Problems 
 In prescribing your warfarin dosage the doctor aims for the level of 
anticoagulation which prevents abnormal clot formation and does not permit 
excessive bleeding. Although people who are not taking anticoagulants can 
ignore occasional slight bleeding (e.g. a nosebleed) in your case this could be 
the result of excessive anticoagulation. Therefore, it’s important for you to be 
extra careful in looking for certain signs. You should therefore look for obvious 
signs of bleeding. These obvious signs of bleeding include: 
 Cuts may bleed for a longer time. 
 Occasional nosebleeds may occur. 
 Heavier bleeding during periods or other vaginal bleeding. 
 Bleeding gums. 
The less obvious signs of bleeding include:  
 Dark red or brown urine. 
 Dark or black bowel movements 
 Bruising 
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A bruise occurs when you bleed under the skin. If you notice you are bruising 
for unknown reasons or more than normal, tell your doctor right away. 
As you continue to take warfarin, it’s very important that you be constantly on the 
lookout for the signs we’ve been talking about and if any of these signs should 
appear, call your doctor immediately. 
 
Remember that the purpose of this booklet and the warfarin therapy is to 
help you lead a normal life. By following your warfarin directions and the 
guidelines given in this booklet, you will reduce the risk of complications. 
If you do experience any problems, tell your doctor immediately so the problems 
can be handled promptly and effectively. 
Finally, use good judgment throughout your therapy program and if you have any 
questions be sure to ask your doctor or pharmacist. 
